
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

38514615
1764
10.1038/s41392-024-01764-w
Review Article
TGF-β signaling in health, disease and therapeutics
Deng Ziqin
Fan Tao
Xiao Chu
Tian He
Zheng Yujia
http://orcid.org/0000-0003-3477-1535
Li Chunxiang lichunxiang@cicams.ac.cn

http://orcid.org/0000-0003-0327-8852
He Jie hejie@cicams.ac.cn

https://ror.org/02drdmm93 grid.506261.6 0000 0001 0706 7839 Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021 China
22 3 2024
22 3 2024
2024
9 617 12 2022
31 8 2023
31 1 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Transforming growth factor (TGF)-β is a multifunctional cytokine expressed by almost every tissue and cell type. The signal transduction of TGF-β can stimulate diverse cellular responses and is particularly critical to embryonic development, wound healing, tissue homeostasis, and immune homeostasis in health. The dysfunction of TGF-β can play key roles in many diseases, and numerous targeted therapies have been developed to rectify its pathogenic activity. In the past decades, a large number of studies on TGF-β signaling have been carried out, covering a broad spectrum of topics in health, disease, and therapeutics. Thus, a comprehensive overview of TGF-β signaling is required for a general picture of the studies in this field. In this review, we retrace the research history of TGF-β and introduce the molecular mechanisms regarding its biosynthesis, activation, and signal transduction. We also provide deep insights into the functions of TGF-β signaling in physiological conditions as well as in pathological processes. TGF-β-targeting therapies which have brought fresh hope to the treatment of relevant diseases are highlighted. Through the summary of previous knowledge and recent updates, this review aims to provide a systematic understanding of TGF-β signaling and to attract more attention and interest to this research area.

Subject terms

Immunology
Diseases
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 81972196 81972196 Li Chunxiang He Jie issue-copyright-statement© West China Hospital, Sichuan University 2024
==== Body
pmcIntroduction

The studies on TGF-β started as early as the 1980s and have developed rapidly ever since. Although TGF-β was first found to be secreted by transformed cells,1 it is widely produced by non-neoplastic tissues such as salivary glands, muscles, kidneys, liver, heart, brain, and embryos as well.2–4 In fact, platelets have been identified as one of the most abundant sources of TGF-β among all normal tissues.5 The ubiquitous expression of TGF-β in health strongly indicates its critical and multiple roles in physiological conditions.

Accumulating evidence has suggested that TGF-β functions diversely among different cell types in a context-dependent manner. Generally, cell survival, metabolism, growth, proliferation, differentiation, adhesion, migration, and death are all under the regulation of TGF-β. Proper TGF-β signaling is critical to the normal functioning and homeostasis of healthy bodies while aberrant TGF-β signaling can lead to diseases of various categories. For this reason, numerous targeted therapies that can remedy dysregulated TGF-β activity have been developed with some demonstrating encouraging safety and efficacy in clinical trials.

In this review, we focus on the mechanism, physiology, pathology, as well as therapeutics of TGF-β signaling, aiming to provide historical, current, and future perspectives on relevant topics.

History of research on TGF-β signaling

TGF-β was first reported in 1978 when De Larco and Todaro discovered the ‘sarcoma growth factors’ which were produced by transformed murine fibroblasts and were able to transform normal fibroblasts to anchorage-independent growth.1 In 1981, Roberts et al. successfully isolated and purified TGF-β from non-neoplastic murine tissues,3 while at about the same time, Moses et al. independently accomplished the purification and characterization of the cytokine as well.6 Both groups also noticed that this relatively acid- and heat-stable polypeptide required disulfide bonds for activity and was sensitive to disulfide-reducing agent dithiothreitol. In 1983, studies by electrophoresis on sodium dodecyl sulfate-polyacrylamide gels indicated that the 25,000-dalton TGF-β molecule in humans was actually composed of two 12,500-dalton subunits cross-linked by disulfide bonds.7,8 Two years later, the amino-acid sequence of human TGF-β1, the first known TGF-β isoform, was revealed by Derynck et al. through direct protein sequencing and complementary deoxyribonucleic acid (DNA) cloning.2 The sequencing established that the 112-amino-acid-long TGF-β1 monomer is initially synthesized as the C-terminal segment of a 390-amino-acid-long precursor polypeptide.2 By the time of 1988, researchers had realized that TGF-β generally remained non-covalently associated with the N-terminal segment of its precursor when it was secreted.9,10 TGF-β cannot bind to its receptors with its receptor-binding site being masked in this inactive form, however, certain treatments such as acidification could convert latent TGF-β complex into active TGF-β ligand.11 In addition, the other two TGF-β isoforms in mammals, TGF-β2 and TGF-β3, were respectively identified in 198712 and 1988.13,14 Although the three TGF-β isoforms are encoded by three different genes, their mature ligands show strong conservation of amino acid sequences.

The effects of TGF-β signaling in cell proliferation,15,16 cell differentiation,17,18 embryonic development,19 wound healing,20 immune regulation,21,22 tissue fibrosis,23,24 and tumor development25,26 have been studied shortly after the discovery of the cytokine. Meanwhile, the receptors in TGF-β signaling known as TGF-β receptor I (TβRI) and TβRII were also identified and characterized in the 1980s.27–29 But it was not until the discovery of signaling mediators small (Sma) in Caenorhabditis elegans and mothers against decapentaplegic (Mad) in Drosophila melanogaster that the homologous small mothers against decapentaplegic (SMAD) proteins were identified as the canonical signal transducers of TGF-β signaling in humans in 1996.30–32 Since then, the development of TGF-β research has been largely accelerated. In recent times, as studies on TGF-β signaling in both health and disease going deeper and further, a lot of TGF-β-targeting therapies have been developed and assessed for the treatment of various diseases,33–39 revealing a promising future for the studies in this area (Fig. 1).Fig. 1 History of research on TGF-β signaling

Biosynthesis and activation of TGF-β

During the biosynthesis of TGF-β, the precursor undergoes post-translational processing to become a latent complex which is the secretory form of TGF-β. The latent TGF-β complex still requires further activation to eventually become a mature cytokine before it can trigger signal transduction in cells (Fig. 2).Fig. 2 Biosynthesis and activation of TGF-β. Each TGF-β monomer is initially synthesized as a precursor polypeptide. In the endoplasmic reticulum, TGF-β precursors lose their signal peptides and dimerize through disulfide bonds. The dimers then transit into the Golgi where they are cleaved by protease furin into mature cytokine segments and latency-associated peptides (LAPs) to form small latent complexes (SLCs). The secreted SLCs can further link to latent TGF-β-binding proteins (LTBPs) which target them into the extracellular matrix (ECM) for storage, or they can link to glycoprotein-A repetitions predominant protein (GARP) or leucine-rich repeat-containing protein 33 (LRRC33) which tethers them to the cell surface. Numerous factors such as acids, bases, reactive oxygen species (ROS), thrombospondin-1 (TSP-1), certain proteases, and integrins can release the mature cytokines from the latent complexes and thus are known as TGF-β activators

TGF-β biosynthesis and latency

Each TGF-β monomer is initially synthesized as a precursor polypeptide composed of a mature cytokine as its C-terminal segment, a signal peptide at the N-terminus, and a latency-associated peptide (LAP) in between.2 The signal peptide leads the precursor into the endoplasmic reticulum lumen and promptly gets removed. The remainder of the precursor then dimerizes through three disulfide bonds and transits into the Golgi where it gets cleaved between the mature cytokine and LAP by protease furin.40 However, the cytokine segment is still unable to bind its receptors after the cleavage, for it remains associated with LAP in a non-covalent way that masks its receptor-binding site and forms a small latent complex (SLC).41 In most cases, LAP is linked to latent TGF-β-binding protein (LTBP) through a disulfide bond, making the SLC into a large latent complex (LLC) when secreted.42 LTBP can further bind to fibrillin to target the LLC into the extracellular matrix (ECM) for storage.43 Alternatively, LAP can also form disulfide linkage with leucine-rich repeat-containing protein 32 (LRRC32) or LRRC33 to tether SLC to the cell surface. Unlike LTBP which is widely expressed by many cell types, LRRC32, also known as glycoprotein-A repetitions predominant protein (GARP), is specifically detected in regulatory T cells (Tregs), platelets, and endothelium,44 whereas high expression of LRRC33 is found in macrophages, dendritic cells (DCs), and B cells.45

TGF-β activation

The bioactivity of TGF-β is based on ligand-receptor interaction which requires the exposure of its receptor-binding site. Thus, the activation of TGF-β represents the release of mature cytokine from the latent complex. Numerous factors have been identified as TGF-β activators as introduced below. Notably, integrin-dependent activation is so far the best described and likely the most important mechanism, while TGF-β activation mediated by acids, bases, reactive oxygen species (ROS), thrombospondin-1 (TSP-1), proteases, and other TGF-β activators is collectively known as integrin-independent activation.

TGF-β activation by integrins

Integrins are heterodimeric transmembrane receptors each consisting of an α-subunit and a β-subunit. TGF-β activation by integrins requires the binding of the integrins to an RGD sequence in the LAP of TGF-β1 and TGF-β3. Therefore, latent TGF-β2 without the RGD motif is excluded from integrin-dependent activation.46

Among all integrins, αVβ6 and αVβ8 integrins are the best studied TGF-β activators. The expression of αVβ6 integrin is nearly restricted to epithelial cells and is upregulated in response to morphogenesis, wounding, inflammation, and tumorigenesis.47 In contrast, αVβ8 integrin is widely expressed by epithelial cells,48 fibroblasts,49 macrophages,50 DCs,51 Tregs,52 and different kinds of tumor cells.53 The lack of αVβ6 and αVβ8 integrin activity reproduces the phenotypes of TGF-β1- and TGF-β3-null mice, indicating the central importance of integrin-dependent activation.54,55

Upon binding to the RGD motif in LAP, the mechanisms by which αVβ6 and αVβ8 integrins activate TGF-β are quite different. With latent TGF-β being tethered to ECM or cell membrane (through the binding of LAP to LTBP, GARP, or LRRC33 as mentioned before) and the cytoplasmic domain of integrin β6 subunit linking to the actin cytoskeleton, αVβ6 integrin can transmit contractile force which changes the conformation of LAP to release TGF-β ligand.56,57 However, the cytoplasmic domain of integrin β8 subunit does not link to the actin cytoskeleton. One effective mechanism for αVβ8 integrin-mediated TGF-β activation requires the proteolytic activity of membrane type 1-matrix metalloproteinase (MT1-MMP, also known as MMP14).48 Alternatively, membrane molecules such as GARP and LRRC33 which bind and present latent TGF-β on the surface of one cell can cooperate with the αVβ8 integrin expressed on a different cell to activate TGF-β in trans.45,58,59 A recent study reveals that upon binding to αVβ8 integrin, the flexible membrane-presented latent complex can expose the active domain of the TGF-β ligand to its receptors for binding and signaling without the need to release diffusible cytokine.60

TGF-β activation by acids and bases

It has long been noticed that acidification can unmask the activity of freshly secreted TGF-β.61 Sharply defined parameters for human TGF-β activation by acids and bases show that the transition from latency of all three isoforms occurred between pH 2.5 and 4, and between pH 10 and 12.62 Thus, extremely acidic environments such as the microenvironments in tumor tissues and the resorption lacunae of osteoclasts are possibly conducive to local TGF-β activation.63,64 A study on lung fibrosis even suggests that physiologic concentrations of lactic acid are sufficient enough to activate TGF-β in a pH-dependent manner.65

TGF-β activation by ROS

TGF-β1 is the only isoform that can be directly activated by ROS, for a unique methionine residue at the amino acid position 253 of its LAP is required for oxidation-triggered conformational change.66 However, ROS can induce other TGF-β activators such as TSP-167 and MMPs68 to activate all three isoforms in an indirect manner. ROS-mediated TGF-β activation prevails in tissues exposed to asbestos,69,70 ultraviolet,68 and ionizing radiation.71 High glucose intake can also induce ROS production and consequentially increase TGF-β activation to play roles in the development of fibrotic diseases and inflammatory diseases.72,73 Moreover, in T cells, ROS can be elevated during apoptosis or upon stimulation by T cell receptor (TCR) and cluster of differentiation 28 (CD28) to contribute to the immunosuppression mediated by activated TGF-β.74,75

TGF-β activation by TSP-1

TSP-1 is a multi-functional ECM protein not only abundant in platelet α-granules but also secreted by fibroblasts, endothelial cells, macrophages, T cells, and many other cell types.76 The KRFK sequence in TSP-1 can recognize the LSKL sequence in LAP to competitively disrupt its interaction with the receptor-binding site of the TGF-β ligand. Since the LSKL sequence in LAP is conserved among TGF-β isoforms, it is suggested that the direct binding of TSP-1 to latent complex is capable of activating all three TGF-β isoforms through this protease- and cell-independent mechanism.77 Interestingly, TSP-1 can also bind to the mature TGF-β ligand to form a complex that retains the biological activity of the cytokine.78 ROS,67 glucose,79 angiotensin II,80 hypoxia,81 wounding,82 inflammation,83 pathogens,84–86 and many other factors can all induce TSP-1 to function as a TGF-β activator in wound healing,67,82 cardiovascular diseases,81,86 renal diseases,79 fibrotic diseases,87,88 inflammatory diseases,83 infectious diseases,89 and tumors.90

TGF-β activation by proteases

Many proteases have been proved capable of directly activating TGF-β in vitro. However, the function of an individual protease seems redundant in vivo, as deficiency of a single species generally leads to no significant signs of impaired TGF-β activation.91 Among these proteases, MMPs such as MMP-2, MMP-9, and MMP-13 are conducive to the TGF-β activation in wound healing,92 cardiovascular diseases,93 renal diseases,94 fibrotic diseases,95 and tumors.96 Interestingly, although the activation by MMPs works for all three TGF-β isoforms, latent TGF-β2 and TGF-β3 appear much more sensitive to MMP-9 treatment than latent TGF-β1.96 Moreover, a serine protease known as plasmin plays an important role in the TGF-β activation mediated by macrophages97,98 and endothelial cells.99,100

Signal transduction of TGF-β

TGF-β signal is transmitted into the cells by TβRI (also known as activin receptor-like kinase 5, ALK5) and TβRII both of which are enzyme-linked receptors with dual specificity of serine/threonine kinase and tyrosine kinase. Studies have revealed that TGF-β1 and TGF-β3 bind TβRII prior to TβRI due to higher affinity, while TGF-β2 binds poorly to both receptors.12,101,102 TβRIII, also known as β-glycan, lacks the motifs to directly mediate TGF-β signal transduction. However, TβRIII is able to bind TGF-β especially TGF-β2 with high affinity and thus acts as a co-receptor that presents the ligand to the receptors and further enhances their binding.101,103–107 The ligand-receptor interaction subsequently activates the intracellular signaling of TGF-β through a canonical pathway and several non-canonical pathways.

Canonical TGF-β signaling

The canonical TGF-β signaling is mediated by transcription factors SMADs and thus is also known as the SMAD signaling. Notably, the canonical pathway is under the regulation of various factors that can control the intensity and manner of cellular responses at different levels (Fig. 3).Fig. 3 Canonical TGF-β signaling. TGF-β can initially bind to its co-receptor TGF-β receptor III (TβRIII) or directly bind to its receptor TβRII which subsequently recruits TβRI to form a TGF-β-TβRI-TβRII complex. TβRII then actives TβRI through phosphorylation, leading to its dissociation with signaling inhibitor FK506-binding protein 1A (FKBP12) and interaction with signaling effectors receptor-activated SMADs (R-SMADs). R-SMADs which are presented to TβRI by adaptor protein SMAD anchor for receptor activation (SARA) get activated through phosphorylation and undergo oligomerization with common-partner SMAD (co-SMAD). The SMAD oligomers then translocate into the nucleus where they function as transcription factors (TFs), mediating the transcriptional activation or repression of target genes by binding to specific DNA sequences known as SMAD-binding elements (SBEs) and generally in cooperation with other TFs as well as transcriptional cofactors. In this way, TGF-β signaling can activate the expression of inhibitory SMADs (I-SMADs) which in turn function to attenuate the transcriptional regulation mediated by TGF-β signaling through several mechanisms. Moreover, many protein kinases (PKs), protein phosphatases (PPs), and (E3) ubiquitin ligases can also modulate canonical TGF-β signaling through various post-translational modifications of SMADs. (TFBS, TF-binding site)

TGF-β-activated SMAD signaling

TGF-β ligand initially binds to TβRII monomer to promote its homodimerization or directly binds to pre-existing TβRII homodimer to recruit TβRI for assembly.108–111 This forms a heteromeric TGF-β-TβRI-TβRII complex in which low-affinity TβRI requires high-affinity TβRII to bind TGF-β ligand and constitutively active TβRII requires phosphorylating TβRI to transduce intracellular signal.112 The phosphorylation of TβRI occurs in its juxtamembrane GS domain at several serine and threonine residues, triggering conformational changes that transform the GS domain from a site that binds the signaling inhibitor known as immunophilin FK506-binding protein 1A (FKBP12) into a binding site for the signaling effectors known as receptor-activated SMADs (R-SMADs).113

R-SMADs, including SMAD2 and SMAD3, consist of a globular Mad homology 1 (MH1) domain at the N-terminus, a globular MH2 domain at the C-terminus, and a highly flexible long linker region in between. R-SMADs are retained in cytoplasm and presented to TβRI by the adaptor protein known as SMAD anchor for receptor activation (SARA).114 The R-SMAD MH2 domain then gets phosphorylated at two serine residues in the extreme C-terminal SXS motif by the TβRI kinase domain which is located immediately downstream of the TβRI GS domain.113 Activated R-SMADs undergo homo-oligomerization or hetero-oligomerization through their MH2 domains upon phosphorylation, and they can also oligomerize with SMAD4, the common-partner SMAD (co-SMAD) which lacks the SXS motif for phosphorylation by TβRI kinase. Notably, studies have suggested that SMAD heterotrimers containing two R-SMADs and one SMAD4 are likely more common and stable than other SMAD oligomers.115–119 Although different SMAD oligomers can vary in function, they all act to regulate the transcription of target genes by binding to DNA after translocating into the nucleus. The MH1 domains of SMAD4, SMAD3, and a specific SMAD2 splicing variant recognize the nucleic acid sequence GTCT or its reverse complement AGAC in double-stranded DNA which are known as the canonical SMAD-binding elements (SBEs).120 Other SBEs such as the 5GC SBEs including GGCGC and GGCCG have also been discovered, indicating a relatively loose DNA-binding specificity of the SMAD oligomers.121 However, the binding to a single SBE is so weak that SMAD oligomers generally require interacting with replications of SBE copies as well as other DNA-binding sequence-specific transcription factors to function.119,120,122 In fact, many SBE repeats are enriched at the binding sites for SMAD-interacting transcription factors, exactly increasing the binding accessibility, specificity, and affinity of SMAD oligomers associated with specific transcription factors.123–125 Despite a large number of SMAD-interacting transcription factors indicating a huge amount of potential gene targets for canonical TGF-β signaling, the dominant effects are generally determined by the master transcription factors in specific cell types and contexts which contribute to the complexity and variability of cellular responses to TGF-β.125

Regulation of SMAD signaling by inhibitory SMADs (I-SMADs)

TGF-β and many other factors can induce the expression of SMAD6 and SMAD7 which function to inhibit TGF-β signaling and thus are known as I-SMADs.126,127 Unlike R-SMADs, I-SMADs lack the N-terminal MH1 domain and the C-terminal SXS motif, however, they retain the C-terminal MH2 domain which can competitively bind to activated receptor TβRI to inhibit the phosphorylation of R-SMADs.128,129 Through some extra mechanisms, SMAD7 confers greater abilities in suppressing TGF-β signaling than SMAD6 does.130 For example, SMAD7 recruits E3 ubiquitin ligases such as SMAD ubiquitination regulatory factors (SMURFs) and neural precursor cell expressed, developmentally downregulated 4-like (NEDD4L) to TβRI, R-SMADs, and co-SMAD to mediate the proteasomal and lysosomal degradation of these TGF-β signaling components.131–135 SMAD7 can also trigger the dephosphorylation of TβRI by recruiting protein phosphatase 1 (PP1) to the receptor.136 Moreover, with its MH2 domain, SMAD7 can oligomerize with R-SMADs to compete with co-SMAD133 and can bind to specific DNA sequences to disrupt the formation of the transcriptional SMAD-DNA complex.137 Taken together, TGF-β signaling induces I-SMADs to form a negative feedback loop of itself.

Regulation of SMAD signaling by transcriptional cofactors

Transcriptional cofactors are actively recruited to the transcriptional SMAD complex to regulate its activity. Notably, many of these transcriptional cofactors have histone modification activity and thus enable TGF-β signaling to trigger epigenetic changes. Histone acetyltransferases (HATs) such as p300, cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB)-binding protein (CBP), p300/CBP-associated factor (PCAF), and general control non‐repressed protein 5 (GCN5) act as the transcriptional coactivators of SMADs by increasing the accessibility to DNA.138–141 The interaction between p300/CBP and doubly phosphorylated R-SMADs requires SMAD4 for stabilization and is critical for SMAD-mediated transcriptional activation. Other SMAD coactivators include melanocyte-specific gene 1 (MSG1),142 zinc finger E-box-binding homeobox 1 (ZEB1),143,144 and the histone methyltransferase (HMT) known as SET domain-containing protein 7 (SETD7).145 Contrary to HATs, histone deacetylases (HDACs) generally act as the transcriptional corepressors of SMADs by decreasing the accessibility to DNA. SMAD3 can directly recruit HDAC4 and HDAC5 to gene promoters to inhibit the function of transcription factors via histone deacetylation.146 SMADs can also associate with HDACs through interaction with other corepressors such as TGF-β-induced factor (TGIF),147 ecotropic viral integration site 1 (EVI1),148,149 Sloan-Kettering Institute proto-oncogene (SKI),150–152 as well as SKI-related novel gene N (SNO).153 Other transcriptional corepressors of SMADs include cellular-myelocytomatosis viral oncogene (MYC),154 SMAD nuclear-interacting protein 1 (SNIP1),155 ZEB2,143,156 and HMTs such as suppressor of variegation 3-9 homolog 1 (SUV39H1) and SET domain bifurcated 1 (SETDB1) which can both trigger the methylation of histone 3 lysine 9 (H3K9) at gene promoters.157,158

Regulation of SMAD signaling by SMAD modifications

Post-translational modifications can also regulate the functions of SMADs. Apart from TβRI kinase which phosphorylates R-SMADs in their C-terminal SXS motif to mediate their activation, many other protein kinases such as mitogen-activated protein kinase kinase kinase 1 (MAPKKK1),159 p38 MAPK,160 c-Jun N-terminal kinase (JNK),161 extracellular signal-regulated kinase (ERK),162–164 rat sarcoma (RAS) homolog (Rho)-associated coiled-coil-containing protein kinase (ROCK),160 glycogen synthase kinase (GSK)-3β,165–167 calcium/calmodulin-dependent protein kinase II (CAMK2),168 protein kinase C (PKC),169 PKG,170 and several cyclin-dependent kinases (CDKs)167,171,172 can phosphorylate R-SMADs as well as co-SMAD at many different sites to enhance or attenuate SMAD activity. Meanwhile, the various phosphorylation of SMADs can be reversed by phosphatases. Several nuclear phosphatases known as the small C-terminal domain phosphatases (SCPs) can specifically dephosphorylate the linker region and MH1 domain of R-SMADs,173,174 whereas protein phosphatase, magnesium/manganese-dependent 1A (PPM1A),175 myotubularin-related protein 4 (MTMR4),176 and protein phosphatase 2A (PP2A)177 catalyze the dephosphorylation of the C-terminal SXS motif to terminate the signaling and promote the dissociation and cytoplasmic localization of SMADs.

Furthermore, SMADs can be ubiquitinated and deubiquitinated respectively by E3 ubiquitin ligases and deubiquitylating enzymes (DUBs). The E3 ubiquitin ligases that can mediate SMAD ubiquitination include SMURFs,135,178–180 NEDD4L,134,181 WW domain-containing proteins (WWPs),182–184 really interesting new gene (RING) finger protein 111 (RNF111),185 C-terminus of heat shock protein (HSP) 70-interacting protein (CHIP),186 itchy (ITCH) E3 ubiquitin ligase,187 and S-phase kinase-associated protein (SKP)-cullin-F-box (SCF) E3 ubiquitin ligase complex.188,189 The ubiquitination generally leads to the proteasomal degradation of SMADs, but in some cases, it also exerts non-degradative effects on SMAD activity.190 Notably, the degradative ubiquitination of R-SMADs by NEDD4L requires the phosphorylation of the R-SMAD linker by CDK8/9 and GSK-3 in sequence to create binding sites for the E3 ubiquitin ligase.171,181,191

Non-canonical TGF-β signaling

Apart from the SMAD-dependent pathway, TGF-β can also signal through SMAD-independent pathways to activate ERK signaling, Rho guanosine triphosphatase (GTPase) signaling, p38 MAPK signaling, JNK signaling, nuclear factor-κB (NF-κB) signaling, phosphatidylinositol 3-kinase (PI3K)/AKR mouse thymoma proto-oncogene (AKT) signaling, as well as Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling. These non-canonical TGF-β signaling pathways are involved in an extensive range of cellular events, greatly expanding the participation of TGF-β signaling in health and disease (Fig. 4).Fig. 4 Non-canonical TGF-β signaling. TGF-β can signal through non-canonical pathways to activate extracellular signal-regulated kinase (ERK) signaling, rat sarcoma (RAS) homolog (Rho)-guanosine triphosphatase (GTPase) signaling, p38 mitogen-activated protein kinase (MAPK) signaling, c-Jun N-terminal kinase (JNK) signaling, nuclear factor-κB (NF-κB) signaling, phosphatidylinositol 3-kinase (PI3K)/AKR mouse thymoma proto-oncogene (AKT) signaling, as well as Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling. These non-canonical TGF-β signaling pathways are actively involved in an extensive range of cellular events. (RAF, RAS-associated factor; MEK, MAPK/ERK kinase; ROCK1, Rho-associated coiled-coil-containing protein kinase 1; LIMK2, LIM domain kinase 2; TRAF, tumor necrosis factor (TNF) receptor-associated factor; TAK1, TGF-β-activated kinase 1; MKK, MAPK kinase; IKK, NF-κB inhibitor (IκB) kinase; GSK-3β, glycogen synthase kinase-3β; MTOR, mechanistic target of rapamycin; FOXO, forkhead box O; S6K, S6 kinase; 4EBP1, 4E-binding protein 1)

TGF-β-activated ERK signaling

As a dual-specificity kinase, TβRI can phosphorylate at its tyrosine residues to activate ERK signaling upon TGF-β stimulation.192 In this case, TβRI with tyrosine kinase activity initially phosphorylates the adapter protein known as sarcoma (SRC) homology and collagen A (SHCA) which subsequently forms a complex with growth factor receptor-bound protein 2 (GRB2) and son of sevenless homolog (SOS). The SHCA-GRB2-SOS complex then initiates a canonical MAPK signaling cascade which involves the sequential activation of RAS, the MAPKKK known as RAS-associated factor (RAF), the MAPKK known as MAPK/ERK kinase (MEK), and eventually, the ERK MAPK. Activated ERK is known to regulate various biological events including cell survival, proliferation, differentiation, adhesion, migration, as well as metabolism, and is implicated in a spectrum of diseases such as developmental disorders, chronic inflammation, neurodegeneration, obesity, and cancers.193,194

TGF-β-activated Rho GTPase signaling

Rho GTPases such as RHO, RAS-related C3 botulinum toxin substrate 1 (RAC1), and cell division cycle 42 (CDC42) play a central role in the organization and dynamics of the actin cytoskeleton. They are activated by guanine nucleotide exchange factors (GEFs) through the exchange of a bound GDP for GTP.195 TGF-β can trigger RHO activation in a rapid SMAD-independent manner or by inducing a GEF known as neuroepithelial cell transforming 1 (NET1) through SMAD and MEK/ERK pathways.196–200 RHO then activates its key effector ROCK1 which further mediates the phosphorylation of LIM domain kinase 2 (LIMK2). Activated LIMK2 subsequently phosphorylates cofilin to inhibit its function as a constitutive actin-depolymerizing factor, leading to the reorganization of the actin cytoskeleton in the end.201–203 Additionally, TGF-β-triggered RHO/ROCK1 signaling can contribute to ERK phosphorylation,204,205 and besides RHO, TGF-β can also activate the signaling of other Rho GTPases such as RAC1202 and CDC42.206 Besides the regulation of cell morphogenesis, adhesion, and movement, Rho GTPase signaling is also known to participate in transcriptional regulation, cell cycle progression, vesicular trafficking, and pathological processes such as fibrosis, inflammation, wound repair, and tumor development.207,208

TGF-β-activated p38, JNK, and NF-κB signaling

TGF-β can activate the signaling of another two MAPKs known as p38 and JNK through a receptor kinase-independent mechanism which is different from that of ERK signaling. TGF-β-activated TβR complex can recruit tumor necrosis factor (TNF) receptor-associated factor 4 (TRAF4) and TRAF6 to trigger their lysine 63 (K63)-linked polyubiquitination. With E3 ubiquitin ligase activity, polyubiquitinated TRAF then attaches the polyubiquitin chain on the MAPKKK known as TGF-β-activated kinase 1 (TAK1) which subsequently gets activated and phosphorylates several MAPKKs (MKKs).209–211 As a result, MKK3 and MKK6 specifically trigger the activation of p38 while MKK4 mediates the phosphorylation of both p38 and JNK. TGF-β-activated Rho GTPases such as RHOA, RAC1, and CDC42 can also contribute to p38 and JNK activation.204,212–216 Both the two MAPKs regulate a series of biological events to respond to all kinds of environmental and intracellular stresses, meanwhile, they engage actively in embryonic development, metabolic regulation, neuronal functions, immunological actions, as well as tumor development.217–220

Additionally, TGF-β-activated TRAF/TAK1 signaling, RHO/ROCK1 signaling, and PI3K/AKT signaling can also lead to the phosphorylation of NF-κB inhibitor (IκB) kinase (IKK).221–224 Activated IKK then triggers the phosphorylation of IκB which subsequently gets polyubiquitinated and degraded while releasing active NF-κB for nuclear translocation.221 NF-κB as a transcription factor can regulate hundreds of genes involved in cell survival, proliferation, metabolism, and immunity in particular.225–227

TGF-β-activated PI3K/AKT signaling

The TβR complex can activate the lipid kinase PI3K upon TGF-β stimulation, either via the kinase activity of TβRI or through the recruitment of TRAF6, which polyubiquitylates PI3K regulatory subunit p85α independent of the receptor kinase.228,229 Activated PI3K then phosphorylates phosphoinositide phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinositol-3,4,5-trisphosphate (PIP3) which further triggers the phosphorylation of AKT.228,230 Activated AKT targets plenty of substrates, including mechanistic target of rapamycin (MTOR),231,232 GSK-3β,233 and several forkhead box O (FOXO) transcription factors.234Among them, MTOR is the most common downstream effector of AKT, and ribosomal protein S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein 1 (4EBP1) are the best-characterized downstream effectors of MTOR. In general, the consequences of PI3K/AKT signaling include diverse cellular responses such as survival, metabolism, growth, proliferation, and differentiation.235

TGF-β-activated JAK/STAT signaling

TGF-β is found to induce JAK1 and JAK2 activation respectively in hepatic stellate cells (HSCs) and fibroblasts. In these cases, activated JAK triggers the phosphorylation of STAT3 which functions to mediate the fibrogenic effects of TGF-β, including increased cell proliferation, myofibroblast (MF) differentiation, ECM production, α-smooth muscle actin (α-SMA) expression, and stress fiber formation.236–238 Like other signaling pathways, JAK/STAT signaling can also drive many physiological and pathological events, including development, metabolism, immunity, wounding, and cancers.239

TGF-β signaling in health

In physiological conditions, TGF-β signaling is greatly required by multiple biological processes and is particularly critical to embryonic development, wound healing, tissue homeostasis, and immune homeostasis (Fig. 5).Fig. 5 TGF-β signaling in health. TGF-β signaling plays a critical role in physiological conditions. a During embryonic development, TGF-β regulates cell differentiation, epithelial/endothelial-mesenchymal transition (EMT/EndMT), and apoptosis to ensure proper histogenesis and organogenesis. b TGF-β promotes wound healing by participating in inflammation, re-epithelialization, angiogenesis, and fibroblast activation. c TGF-β is indispensable for tissue homeostasis as it generally suppresses cell proliferation and induces cell apoptosis through various mechanisms. d TGF-β functions to suppress the activity of multiple immunocompetent cells while inducing the phenotypes of several immune immunosuppressive cells to maintain immune homeostasis. (SMC, smooth muscle cell; VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinase; TIMP tissue inhibitor of MMP, PAI plasminogen activator inhibitor, CDK cyclin-dependent kinase, CKI CDK inhibitor, ID inhibitor of DNA binding, MYC cellular-myelocytomatosis viral oncogene, CDC25A cell division cycle 25A, BCL-2 B-cell lymphoma-2, BAX BCL-2-associated X protein, BIM BCL-2-interacting mediator of cell death, BCL-XL BCL-extra-large, GADD45β growth arrest and DNA damage-inducible β, SHIP sarcoma (SRC) homology 2 (SH2) domain-containing inositol 5’-phosphatase, TIEG TGF-β-inducible early gene, CTL cytotoxic T lymphocyte, Th T helper, Treg regulatory T cell, Breg regulatory B cell, NK natural killer, DC dendritic cell)

Embryonic development

In situ hybridization and immunohistochemical staining reveal overlapping but distinct expression patterns of the three TGF-β isoforms at different developmental stages of murine embryos. TGF-β is expressed in nearly all kinds of embryonic tissues such as heart, vessels, lungs, kidneys, liver, gut, bones, teeth, cartilages, muscles, skin, thymus, thyroid, suprarenal glands, salivary glands, nervous system, and craniofacial tissues.19,240–244 In particular, mesenchymal and epithelial components undergoing organogenesis and morphogenesis which involve active cell differentiation and epithelial-mesenchymal interactions generally express high levels of TGF-β.19,240–243

TGF-β has a significant impact on cell differentiation. Studies on Xenopus embryos reveal that TGF-β can induce mesoderm formation which is a primary patterning event in early vertebrate development.245,246 TGF-β can further regulate the development of hemangioblasts from mesoderm as well as subsequent differentiation of hematopoietic stem and progenitor cells (HSPCs) to participate in hematopoiesis and vasculogenesis.240,247–250 Mesenchymal stem cells (MSCs) which are derived from the mesoderm as well also respond actively to TGF-β signaling during their differentiation into several connective tissue cell lineages such as osteocytes, chondrocytes, myocytes, and adipocytes.251,252 TGF-β inhibits osteogenic differentiation by inducing the nuclear translocation of β-catenin and repressing the transcriptional activity of core-binding factor subunit α-1 (CBFA1) in a SMAD3-dependent manner.252,253 TGF-β-induced SMAD signaling also inhibits myogenesis and adipogenesis by respectively repressing the transcriptional activity of myogenic differentiation (MYOD) family members254–257 and CCAAT/enhancer-binding proteins (C/EBPs).17,258,259 However, the differentiation of MSCs into smooth muscle cells (SMCs) is promoted by TGF-β through mechanisms involving the activation of SMAD signaling, RHO signaling, and NOTCH signaling.260 Moreover, TGF-β stimulates chondrogenesis by inducing mesenchymal cells to differentiate into chondrocytes and produce cartilage-specific proteoglycan and type II collagen.18,261,262 As for other cell types, TGF-β signaling also regulates the differentiation and development in epidermis,263 lungs,264,265 kidneys,266 pancreas,267,268 teeth,269 and nervous system.270–276

Especially for epithelial cells, TGF-β can induce a reversible de-differentiation process known as epithelial-mesenchymal transition (EMT) which is critical to embryonic development.277 During EMT, epithelial cells lose their cellular polarity, intercellular junctions, and epithelial markers such as E-cadherin, but turn to acquire mesenchymal or fibroblastic phenotype with increased cell migratory motility, ECM proteolytic activity, and expression of mesenchymal markers such as fibronectin.278 This process is generally mediated by transcription factors such as SNAIL, SLUG, ZEB, and TWIST, involving both SMAD-dependent and SMAD-independent pathways in the case of TGF-β signaling.198,200,219,230–232,279,280 The developmental functions of TGF-β-induced EMT have been well studied in embryonic palate formation during which the expression of TGF-β is significantly elevated.19,243 Among the three TGF-β isoforms expressed in developing murine palate,281,282 only TGF-β3 is indispensable to the fusion of palatal shelves which is a crucial step during palatogenesis.283 Mechanically, TGF-β3 induces the EMT of palatal midline epithelial seam (MES) cells, leading to the disintegration of the epithelium and subsequent confluence of the mesenchyme.279,280 Interestingly, endothelial cells can undergo a similar process known as endothelial-mesenchymal transition (EndMT) which is crucial for cardiovascular development. In humans, TGF-β2 is the most potent inducer of EndMT, while TGF-β1 and TGF-β3 at least partially rely on the induction of TGF-β2 to trigger this process.284 Consistently, although all three TGF-β isoforms are differentially expressed during murine cardiogenesis,19,240,242,243,285–287 only TGF-β2 is obligatory to the EndMT during the endocardial cushion development in the atrioventricular canal which is necessary to valvular formation.288–291 Moreover, TGF-β1 and TGF-β2 can trigger EndMT in the epicardium to contribute to coronary vessel formation.292,293 In fact, TGF-β signaling is essential to vasculogenesis in many developing tissues by promoting the proliferation and migration of endothelial cells.19,294

Furthermore, TGF-β can induce apoptosis of unnecessary cells during embryonic development to ensure proper histogenesis and organogenesis. During murine palatogenesis, the disintegration of MES not only relies on TGF-β3-induced EMT as introduced above but also requires TGF-β3-induced apoptosis of MES cells to complete palatal confluency.295 In murine limb buds, highly expressed TGF-β triggers massive cell death in the mesenchyme of interdigital spaces to induce the regression of interdigital webs and the formation of free digits.19,243,296 Endogenous TGF-β also mediates the apoptotic death of certain neuron types in chick embryos to contribute to nervous system development.297 Notably, TGF-β2 and TGF-β3 presenting in the central part of the developing chick retina are essentially required to trigger retinal cell apoptosis, which can create space for incoming axons of retinal ganglion cells to form optic nerve.298,299 In mice, however, TGF-β signaling also protects retinal neurons from excessive apoptosis to ensure proper development of eyes.300

Wound healing

Wound healing which happens after tissue injuries generally involves four orderly and overlapping stages known as hemostasis, inflammation, proliferation, and remodeling.301 Throughout the healing of cutaneous wounds, all TGF-β isoforms and TβR types are induced in a distinct spatial and temporal pattern.302,303 During hemostasis, platelets provide an immediate and abundant supply of TGF-β after wounding, contributing largely to subsequent healing stages by promoting the influx of inflammatory cells and fibroblasts into the wounds due to its chemotactic activity.302,304–307 Interestingly, many of the cell types recruited by TGF-β are also active in secreting TGF-β, leading to even higher TGF-β concentrations in the wounds. In ovine skin, all three TGF-β isoforms increase dramatically only one day after wounding, attributed to the expression by epithelial cells, endothelial cells, fibroblasts, and inflammatory cells such as neutrophils, macrophages, and lymphocytes.302 During the stage of proliferation and remodeling, TGF-β is implicated in wound re-epithelialization, tissue angiogenesis, and fibroblast activation.308,309 Upon cutaneous injury, TGF-β1 is initially expressed by all epidermal keratinocytes adjacent to the wounds but gradually gets excluded from the basal keratinocytes, corresponding to the transient block and subsequent burst of basal keratinocyte proliferation after wounding.310 TGF-β1 also contributes to the migration of epithelial sheets at the leading edges of cutaneous wounds through the regulation of integrins and the activation of PI3K.310–312 Other TGF-β isoforms such as TGF-β3 can have similar impacts on cell migration during cutaneous wound healing.313 As for angiogenesis, TGF-β regulates the proliferation and migration of endothelial cells in vitro and shows potent angiogenic activity when overexpressed or directly applied in vivo.307,314–321 A possible mechanism of TGF-β-induced angiogenesis involves the induction of vascular endothelial growth factor (VEGF) in epithelial cells and fibroblasts.322,323 Moreover, TGF-β can stimulate fibroblasts to proliferate and produce bioactive factors such as collagen, fibronectin, MMPs, tissue inhibitor of MMPs (TIMPs), and plasminogen activator inhibitor 1 (PAI-1) which contribute to the deposition and remodeling of wound ECM.304,306,307,315,317,321,324–334 It can also promote fibroblast-mediated wound contraction through MF differentiation and RHO activation.335–337

Apart from the skin, TGF-β also functions in the repair and regeneration of many other tissues. During rat liver regeneration, all TGF-β isoforms are induced in non-parenchymal cells rather than hepatocytes, which however, exhibit upregulation of all TβR types to enhance the responsiveness to TGF-β, which may help to prevent uncontrolled cell proliferation.338–342 Similarly, the marked increase in TGF-β and TβR expression following acute pancreatitis suggests the role of TGF-β signaling in pancreatic repair.343–345 Upon vascular injury, TGF-β mobilizes MSCs to peripheral blood and further recruits them to the injured sites for vascular repair.346 As for cardiac repair after myocardial injury, TGF-β triggers the EndMT of epicardial cells, which then migrate into the injured myocardium to generate various cardiac cell types.347 TGF-β also plays a role in cartilage repair by stimulating proteoglycan synthesis in chondrocytes.348,349 Moreover, after injury in the nervous system, neurons, astrocytes, microglia, as well as recruited macrophages all upregulate the expression of TGF-β which may contribute to the healing process of the nervous tissues.350,351

Tissue homeostasis

Tissue homeostasis is maintained by the balance between cell proliferation and cell death in which TGF-β acts as a key regulator.

Cell proliferation is generally driven by CDKs through a series of events collectively known as the cell cycle. For most cells, TGF-β inhibits their proliferation, or in other words, triggers their cytostasis by inducing cell cycle arrest in the gap 1 (G1) phase. In epithelial cells and glial cells, TGF-β suppresses the activity of CDKs by activating the transcription of CDK inhibitors (CKIs) such as p15 and p21 to induce cytostasis.352–355 The transcriptional activation of CKIs in response to TGF-β is likely mediated by SMADs in cooperation with transcription factor FOXO355,356 or specificity protein 1 (SP1).357,358 Notably, the SMAD-FOXO complex additionally requires transcription factor C/EBPβ for the induction of p15 but not of p21.356 In epithelial cells, TGF-β-mediated upregulation of p15 also prevents the non-inhibitory binding of CKI p27 to CDK4. As a result, p15 and p27 turn to bind their own targets which are respectively CDK4 and CDK2 to exert their inhibitory effects.359,360 Interestingly, in murine B cells, TGF-β increases the expression of p27 instead of p21 to trigger cytostasis,361 while in human hematopoietic cells, p57 is likely the only TGF-β-induced CKI for cell cycle arrest.362 Besides CKIs, TGF-β can also target other proliferative factors such as MYC, inhibitors of DNA binding (IDs), and CDC25A to inhibit cell proliferation as mostly shown in epithelial cells. TGF-β induces the transcriptional repression of MYC through a complex containing SMADs, transcription factors E2F4/5 and C/EBPβ, as well as transcriptional corepressor p107.356,363,364 It also inhibits ID1 expression through SMADs which mediate the induction and recruitment of transcriptional repressor activating transcription factor 3 (ATF3) to target ID1 promoter.365 As for ID2 which can be induced by MYC at the transcriptional level, its suppression by TGF-β is attributed to the downregulation of MYC or the upregulation of antagonistic MYC repressors known as MYC-associated factor X (MAX) dimerization proteins (MADs).366,367 By these means, TGF-β is able to relieve the transcriptional repression on CKIs exerted by MYC and IDs to facilitate the induction of cytostasis.368–371 Furthermore, TGF-β can downregulate the activity of the CDK-activating phosphatase CDC25A through several mechanisms such as the transcriptional repression by E2F4-p130-HDAC1 complex,372 the inhibitory phosphorylation by RHOA/ROCK1 signaling,373 as well as the SMAD3-dependent degradative ubiquitination by E3 ubiquitin ligase complex SCF.374 Notably, TGF-β can also stimulate the proliferation of certain cell types, including SMCs, fibroblasts, and chondrocytes, likely due to the induction of autocrine growth factors such as fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF).324,325,375

As for cell death, TGF-β can trigger apoptosis which is one of the most common forms of cell death in a wide range of cell types including lymphocytes, hepatocytes, podocytes, glial cells, hematopoietic cells, and epithelial cells. Such effect is generally attributed to SMAD-dependent regulation of B-cell lymphoma-2 (BCL-2) family members. More specifically, TGF-β can upregulate pro-apoptotic BCL-2 family members such as BCL-2-associated X protein (BAX) and BCL-2-interacting mediator of cell death (BIM),376–379 meanwhile, it can also downregulate anti-apoptotic BCL-2 family members such as BCL-2 and BCL-extra-large (BCL-XL).378,380,381 Apart from BCL-2 family members, many other effectors and pathways are also involved in TGF-β-induced cell apoptosis. A septin-like protein known as apoptosis-related protein in the TGF-β signaling pathway (ARTS) undergoes mitochondrial-to-nuclear translocation to promote cell apoptosis in response to TGF-β.382 Death domain-associated protein (DAXX) interacts with TβRII as an intermediary to convey pro-apoptotic TGF-β signal to downstream machinery.383 In B cells and hepatocytes, TGF-β triggers the transient activation of TAK1/IKK/NF-κB pathway, sequentially leading to the transcriptional activation of IκB-α, the post-repression of NF-κB, the upregulation of JNK signaling, the increase of activator protein 1 (AP-1) complex activity, and finally, the apoptotic death of cells.384–386 In hepatocytes, TGF-β also promotes the expression of growth arrest and DNA damage-inducible β (GADD45β), which functions as a positive mediator of cell apoptosis by acting upstream of p38 MAPK.387 As for podocytes, TGF-β can activate both pro-apoptotic p38 signaling and anti-apoptotic PI3K/AKT signaling to regulate their survival and death.379,388 In fact, AKT, especially when phosphorylated, can bind to unphosphorylated SMAD3 to inhibit its activity and thus protect several cell types from SMAD-dependent apoptosis. In contrast, TGF-β can prevent the AKT-SMAD3 interaction by triggering SMAD3 phosphorylation to facilitate the cell death program.389,390 Moreover, in hematopoietic cells, SMAD-dependent TGF-β signaling induces the expression of a central regulator of phospholipid metabolism known as SRC homology 2 (SH2) domain-containing inositol 5’-phosphatase (SHIP) to inhibit AKT phosphorylation as well as cell survival.391 Furthermore, TGF-β triggers the apoptosis of oligodendrocytes and epithelial cells by inducing transcription factors TGF-β-inducible early genes (TIEGs) to downregulate BCL-XL expression.392–394 Notably, TGF-β is also found to promote cell survival in certain cases.300,395–398 Related mechanisms involve the AKT-dependent inhibition of FOXO3 as in epithelial cells,399 the suppression of AKT and the induction of BCL-2 as in pre-B lymphocytes,400 the early induction and phosphorylation of c-Jun and consequential attenuation of JNK as in lung carcinoma cells,401 the downregulation of CD95L and p53 as well as the upregulation of NF-κB, BCL-XL, and p21 as in HSCs.402

Immune homeostasis

Generally, TGF-β functions to suppress the activity of multiple immunocompetent cells while inducing the phenotypes of several immune immunosuppressive cells. For this reason, it is regarded as one of the most potent immunosuppressive cytokines which are of vital importance to the maintenance of immune homeostasis and self-immune tolerance.403

Cytotoxic T lymphocytes (CTLs), T helper type 1 (Th1), and Th2 cells

TGF-β prevents naïve T cells from differentiating into classical effecter T cells through numerous mechanisms. For CD8+ T cells which can develop into CTLs upon activation, TGF-β inhibits their functions by suppressing the expression of cytolytic factors such as perforin, granzyme A, granzyme B, Fas ligand, and interferon (IFN)-γ. Mechanically, the encoding genes of granzyme B and IFN-γ are directly recognized by SMADs and transcription factor ATF1 which both bind to the gene promoter regions to mediate transcriptional repression in response to TGF-β signaling.404 The suppression of IFN-γ release is also correlated to the reduction of transcription factor T-box expressed in T cells (T-BET)405 while the decrease in Fas ligand expression is partially attributed to the downregulation of MYC.406 In CD4+ T cells, TGF-β inhibits the phosphorylation of T-cell kinase (ITK) to decrease the influx of calcium ion and subsequent activation of nuclear factor of activated T cells (NFATC) which are both critical events for Th1 and Th2 cell differentiation.407 TGF-β also suppresses the expression of transcription factors T-BET and GATA-3 in CD4+ T cells which act as master transcriptional activators during Th1 and Th2 cell development respectively.408–410

Tregs, Th9, and Th17 cells

TGF-β induces the expression of transcription factor forkhead box P3 (FOXP3) in an interleukin (IL)-2-dependent manner in CD4+ CD25− naïve T cells to convert them into CD4+ CD25+ Tregs which can express TGF-β and inhibit other T cell proliferation with potent immunosuppressive activity.411–414 Similarly, TGF-β can induce the generation of Tregs from CD8+ T cells through the expression of FOXP3.415,416 Interestingly, IL-4 inhibits the induction of FOXP3 by TGF-β in naïve CD4+ T cells, instead, both cytokines cooperate to drive the differentiation of another Th cell subset known as Th9 cells by inducing the expression of transcription factor purine-rich box-1 (PU.1).417–419 Unlike the immunosuppressive Tregs, these IL-9- and IL-10-secreting cells can potently promote tissue inflammation.417–420 In addition, inflammatory cytokines such as IL-1β, IL-6, IL-21, and IL-23 also suppress TGF-β-induced FOXP3 in naïve CD4+ T cells, meanwhile, they elevate the activity of a TGF-β-induced transcription factor known as retinoic acid receptor-related orphan receptor γt (RORγt) to contribute to the generation of Th17 cells. This pro-inflammatory Th cell subset characterized by IL-17 expression plays important roles in anti-microbial defense and autoimmunity.421,422

B cells

As critical effectors of humoral immune responses, B cells mainly function by secreting antibodies which are also known as immunoglobulins (Igs). TGF-β decreases B cell Ig secretion by inhibiting the synthesis and the switch from the membrane form to the secreted form of Ig messenger ribonucleic acids (mRNAs).423 More specifically, TGF-β selectively inhibits the expression of Ig λ light chains while inducing less pronounced reductions in Ig κ light chains,423,424 moreover, it suppresses the production of isotypes IgM and IgG but enhances the class switching to isotype IgA.423,425,426 Notably, TGF-β-induced IgA with poor specificity is considered insufficient to mediate immune responses such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).427,428 Furthermore, TGF-β can convert B cells into regulatory B cells (Bregs) which produce numerous factors such as TGF-β, IL-10, IL-35, Fas-L, and programmed death-ligand 1 (PD-L1) to mediate immunosuppression.429–432

Natural killer (NK) cells

NK cells are cytotoxic lymphocytes of the innate immunity. TGF-β suppresses NK cell development by downregulating transcription factor E4 promoter-binding protein 4 (E4BP4) in a SMAD3-dependent manner.433 The SMAD3 also decreases NK cell IFN-γ secretion through the inhibition of E4BP4 and T-BET.433,434 Moreover, TGF-β downregulates the surface expression of NK triggering receptors such as NKP30 and NK group 2 member D (NKG2D) which are responsible for the recognition and killing of target cells.435,436 It also negatively regulates the expression of cytolytic factors such as granzyme A, granzyme B, and perforin through SMAD signaling to further impair NK cytotoxicity.434,436

DCs, macrophages, and neutrophils

DCs, macrophages, and neutrophils can function as antigen-presenting cells (APCs), which are the keys to the activation of adaptive immune responses. TGF-β can impair antigen presentation through the downregulation of major histocompatibility complex (MHC) molecules.437–439 It also reduces the expression of IL-12 and co-stimulatory molecules such as CD40 in macrophages and CD80, CD83, and CD86 in DCs to interfere in APC-mediated immune cell activation.440,441 Apart from antigen presentation, TGF-β also inhibits the cytotoxicity of macrophages, on one hand, through the downregulation of cytotoxic factors, such as TNF-α and nitric oxide (NO),442–446 on the other hand, by suppressing the activity of Fcγ receptors (FcγRs) which function to mediate the ADCC and ADCP of macrophages.447 Moreover, TGF-β can trigger the polarization of macrophages and neutrophils from classical M1 macrophages and N1 neutrophils to alternative M2 macrophages and N2 neutrophils which are characterized by multiple immunosuppressive properties.439,448–450

TGF-β signaling in disease

Dysfunctional TGF-β signaling can play key roles in numerous pathological processes, contributing to the disorders of developmental defects, aberrant healing, fibrotic diseases, inflammatory diseases, infectious diseases, as well as tumors (Fig. 6).Fig. 6 TGF-β signaling in disease. Dysfunctional TGF-β signaling is involved in numerous pathological processes. a Mutations that lead to decreased or increased TGF-β signaling can cause various developmental defects. b Deficient TGF-β signaling contributes to wound chronicity while excess TGF-β signaling leads to wound scarring and tissue fibrosis by stimulating ECM deposition through fibroblast activation and EMT/EndMT. c Dysfunctional TGF-β signaling exacerbates tissue injuries in inflammatory diseases and infectious diseases by promoting inflammation, pathogen infection, and tissue remodeling. d Aberrant TGF-β signaling is implicated in all aspects of tumor development including tumorigenesis, tumor growth, tumor invasion, tumor metastasis, as well as tumor microenvironment (TME) remodeling. (CTGF, connective tissue growth factor; IFN-γ, interferon-γ; IL-6, interleukin-6; solid arrows from TGF-β indicate excessive TGF-β signaling, dashed arrows from TGF-β indicate deficient TGF-β signaling)

Developmental defects

Loss of TβRI or TβRII functions due to homozygous mutations generally results in embryonic lethality in mice due to defects in the hematopoiesis and vasculogenesis of yolk sac.451,452 However, the lack of different TGF-β isoforms can lead to distinct phenotypes in mice, consistent with the isoform-specific roles of TGF-β in embryonic development. TGF-β1-knockout mice show no gross developmental abnormalities in spite of the defective hematopoiesis and vasculogenesis in yolk sac during embryonic development.452–454 In contrast, TGF-β2-knockout mice exhibit perinatal mortality and a wide range of developmental defects in heart, lungs, bones, eyes, inner ears, craniofacial structures, urogenital organs, and hair follicles.290,455–458 TGF-β3-knockout mice also die shortly after birth but show no detectable abnormalities except for cleft palate and abnormal lung development.459,460 Notably, palatal shelves that fail to elevate in TGF-β2-knockout mice undergo elevation in TGF-β3-knockout mice but still fail in fusion.455,459,460 Also, branching morphogenesis and respiratory epithelial cell differentiation which appear normal in the lungs of TGF-β2-knockout mice are defective in TGF-β3-knockout mice.455,459 In humans, loss-of-function mutations of a single TGF-β signaling component such as TGF-β2,461–463 TGF-β3,464–466 TβRI,467–469 TβRII,470–472 SMAD2,473–475 or SMAD3476–478 can cause Loeys-Dietz syndrome (LDS), an autosomal dominant connective tissue disorder with a range of cardiovascular, skeletal, craniofacial, and cutaneous manifestations. LDS patients typically present with features including congenital heart defects, aneurysms, arterial tortuosity and dissections, skeletal overgrowth, cervical spine instability, clubfoot deformity, craniosynostosis, hypertelorism, bifid uvula, cleft palate, thin skin, and mental retardation. Dermal fibroblasts derived from LDS patients demonstrate impaired deposition of extracellular collagen and elastin, suggesting a possible mechanism of the connective tissue defects of the patients.479,480 However, the aortic tissues of LDS patients show increased accumulation of collagen, elevated expression of connective tissue growth factor (CTGF), and enhanced activity of non-mutant TGF-β signaling components.461–463,465,467,468,475,476,481,482 Therefore, primary downregulation and compensatory upregulation of TGF-β signaling are both responsible for the abnormalities of LDS.

Excessive TGF-β signaling can also act as a primary pathogenic factor in developmental defects. In mice, overexpression of TGF-β or SMAD can lead to developmental abnormalities in several tissues, such as skin,483,484 bones,485 eyes,486 lungs,487,488 mammary glands,489–491 salivary glands,492 and central nervous system.493 In humans, Camurati-Engelmann disease (CED), a progressive bone dysplasia inherited in an autosomal dominant manner, is ascribed to mutations of TGF-β1, which lead to increased TGF-β1 activation and signaling.494,495 This disease is characterized by hyperostosis and sclerosis of the long bones and the skull.496,497 Studies on CED have suggested that hyperactive TGF-β1 in the bone microenvironment can induce osteoclasts and osteoblasts to increase but cluster in separated areas, uncoupling bone resorption and formation to cause bone remodeling defects.494,498,499

Aberrant healing and fibrotic diseases

Dysregulated TGF-β signaling can contribute to the tissue damage in aberrant healing and fibrotic diseases which are caused by all kinds of injuries such as wounding, burns, radiation, infection, and inflammation.

Aberrant healing

The lack of TGF-β and TβR expression is commonly found in the chronic wounds in patients, indicating that deficient TGF-β signaling may lead to wound chronicity and even unhealing.500–505 However, in vivo studies in mice have reported quite complicated findings. An activating mutation of TβRI can lead to a regenerative healing phenotype which enables rapid regeneration of normal tissues with differentiated structures instead of scar formation in ear punch wounds.506 Paradoxically, overexpression of TGF-β1 in keratinocytes accelerates the re-epithelialization in partial-thickness cutaneous wounds but slows that of full-thickness cutaneous wounds.507,508 In TGF-β1-deficient mice, the healing of full-thickness cutaneous wounds is initially normal but ultimately damaged by severe inflammatory diseases.509 In immunodeficient mice without inflammatory diseases, the lack of TGF-β1 still leads to significant delays in each healing stage of full-thickness cutaneous wounds.510 However, loss of TGF-β signaling in keratinocytes due to expression of dominant negative TβRII leads to increased proliferation and reduced apoptosis, thus facilitating the re-epithelialization in full-thickness cutaneous wounds.511 Furthermore, cutaneous wound healing is accelerated in mice lacking SMAD3 but is aberrant in mice lacking SMAD4 exclusively in keratinocytes.512,513

In contrast to chronic wounds, hypertrophic scars and keloids both characterized by overabundant ECM deposition are the results of hyperactive cutaneous wound healing. In fact, the expression of TGF-β and TβR which decreases eventually in normal cutaneous wounds remains elevated in hypertrophic scars and keloids.514–518 In contrast to normal cutaneous fibroblasts, both keloid fibroblasts and hypertrophic scar fibroblasts are significantly higher in collagen production, however, only keloid fibroblasts exhibit increased sensitivity to TGF-β stimulation.519 For keloid fibroblasts, overexpressed TGF-β can promote the resistance to apoptosis, the ability of proliferation, the conversion to MFs, and the expression of CTGF and VEGF, thus contributing to the ECM deposition, focal adhesion, fibrous growth, and angiogenesis in keloid tissues.518,520–523

Fibrotic diseases

Besides wounding, other forms of injurious stimulation can also cause excessive ECM deposition in different kinds of tissues, leading to fibrotic diseases, which are closely associated with the hyperactivity of TGF-β signaling.

TGF-β expression is significantly elevated in fibrotic lungs in various cases such as idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF).524–528 In situ hybridization and immunohistochemical staining suggest that alveolar macrophages and epithelial cells are likely the major sources of TGF-β which contribute to the fibrosis of lungs.526–528 In vitro studies show that TGF-β1 can trigger the EMT of alveolar epithelial cells and enhance the activity of lung fibroblasts to mediate fibrogenic effects.529–532 Transgenic expression of TGF-β1 in murine and rat lungs induces pulmonary fibrosis which is accompanied by alveolar EMT, MF differentiation, and mononuclear-rich inflammation.532–535 Interestingly, the suppression of TGF-β1, the deletion of TβRII, the ablation of SMAD3, the upregulation of SMAD7, but the administration of TGF-β3 can all significantly protect mice from experimentally induced pulmonary fibrosis.535–539

Similarly, the fibrotic kidneys of human glomerulonephritis, IgA nephropathy, diabetic nephropathy, lupus nephritis, as well as renal allografts in chronic rejection all show significant increases in three TGF-β isoforms in the glomeruli and tubulointerstitium where ECM deposition and PAI-1 production is closely related to the expression of TGF-β1 isoform in particular.540–543 In vitro, TGF-β1 stimulates kidney fibroblasts, mesangial cells, glomerular epithelial cells, and tubular epithelial cells to produce several ECM components and remodelers such as collagen, fibronectin, laminin, proteoglycan, MMP, and TIMP.544–550 TGF-β1 also contributes to the EMT induction and MF differentiation in renal fibrosis.550 Transgenic mice that have increased levels of TGF-β1 in plasma develop progressive renal disease characterized by glomerulosclerosis and tubulointerstitial fibrosis with TIMP overexpression and ECM deposition in sub-endothelial and mesangial locations.551,552

In fibrotic livers, TGF-β1 expression increases markedly with fibrogenic activity.553–556 Induction of TGF-β1 expression in murine livers leads to hepatic fibrosis characterized by prominent ECM deposition in peri-sinusoidal areas with activation of HSCs and apoptosis of hepatocytes.557,558 Notably, activated HSCs which play a major role in hepatic fibrosis can provide an important source of TGF-β,559 while overproduced TGF-β can in turn activate several signaling pathways such as those of SMAD, MEK, JNK, PI3K, and JAK/STAT in HSCs to contribute to their functions.236,237

As for the cardiovascular system, TGF-β is also elevated during myocardial fibrosis, valve fibrosis, and arteriosclerosis, generally attributed to the expression by SMCs, fibroblasts, endothelial cells, and inflammatory cells such as macrophages.560–569 On one hand, TGF-β can stimulate cardiovascular fibroblasts to differentiate into MFs and produce ECM components and remodelers,562,563,570–573 on the other hand, it can also stimulate endothelial cells to undergo EndMT to induce their fibrogenic phenotype.569,574,575

Furthermore, TGF-β is widely involved in the fibrosis of many other tissues and diseases as in the cases of cutaneous fibrosis,576,577 muscular fibrosis,578 pancreatic fibrosis,579–582 myelofibrosis,583,584 adenomyosis,585 autoimmune diseases,238,527,573,586–589 and infectious diseases.590–593

Inflammatory diseases and infectious diseases

Inflammatory diseases and infectious diseases can demonstrate aberrant immune responses and various tissue injuries which usually implicate the dysfunction of TGF-β signaling.

Inflammatory diseases

Since TGF-β acts as a negative regulator to maintain immune homeostasis, deficient TGF-β signaling can lead to hyperactive immune responses, contributing to the pathology of numerous inflammatory diseases. TGF-β1-null mice initially appear normal after birth but soon develop a rapid wasting syndrome accompanied by a multifocal inflammatory disease which leads to organ failure and early death by 3-4 weeks of age.453,594–596 Many organs in these mice, including heart, lungs, stomach, liver, pancreas, and muscles, all exhibit massive infiltration of inflammatory cells such as lymphocytes, macrophages, and granulocytes. Moreover, their total numbers of blood leukocytes increase mainly due to the elevated absolute numbers of neutrophils and monocytes, while their levels of autoantibodies, MHC molecules, and inflammatory cytokines such as IFN-γ, TNF-α, and CCL3 also rise correspondingly in serum or tissues.

In the absence of any pathogens, the inflammatory diseases in TGF-β1-knockout mice actually resemble a special group of inflammatory diseases known as autoimmune diseases, which are characterized by dysregulated immune responses attacking self-tissues. In fact, even cell type-specific loss of TGF-β signaling can lead to the development of various autoimmune diseases in mice.597–604 In patients with autoimmune diseases such as systemic lupus erythematosus (SLE),605–607 systemic sclerosis (SSc),608–611 rheumatoid arthritis (RA),612–614 Sjögren’s syndrome,586,614–616 Crohn’s disease,587,617–619 ulcerative colitis (UC),617–622 autoimmune hepatitis (AIH),623,624 and Hashimoto’s thyroiditis (HT),606,625,626 the levels of TGF-β or TβR in tissues or circulation are associated with the presence, activity, and severity of the diseases. Notably, although all these diseases show correlations with dysregulated TGF-β signaling, their correlations with TGF-β levels can be either positive or negative. Some cases of the diseases are likely caused by insufficient TGF-β expression and thus exhibit decreased TGF-β production.619,622,627–630 In other cases, however, the autoimmune inflammation is likely attributed to impaired cell responsiveness to TGF-β especially due to deficient TβR functions, therefore, TGF-β production is elevated as a compensatory response.624,628,631–635

Allergic diseases, including asthma, allergic rhinitis, food allergy, and atopic dermatitis, are another group of inflammatory diseases that are caused by aberrant immune responses to harmless environmental antigens. TGF-β production is increased in the airways and serum of asthmatic patients and is further increased after allergen exposure, disease progression, or certain treatments.636–646 Bronchial epithelial cells, fibroblasts, SMCs, eosinophils, neutrophils, and macrophages can all contribute to the excessive TGF-β production in asthmatic patients.641–650 However, the functions of TGF-β are seemingly contradictory in the context of allergic airway inflammation, for TGF-β can either enhance or suppress the activity of eosinophils, lymphocytes, macrophages, and mast cells in asthma.648,651–661 Nevertheless, it is clear that TGF-β can promote asthmatic airway remodeling by inducing airway EMT,662,663 ECM production,649,650 MF differentiation,664,665 and smooth muscle hyperplasia.647 In patients with allergic rhinitis, TGF-β levels in serum are found dependent on allergen exposure, while TGF-β and TβR expression in nasal mucosa is noticed correlated with intra-epithelial mast cell abundance.666–668 In fact, allergen challenge can activate TGF-β signaling in the mast cells and epithelial cells in nasal mucosa which may contribute to the mast cell accumulation and goblet cell hyperplasia in allergic rhinitis.669,670 Allergen challenge can also induce the loss of TGF-β1-expressing Bregs and Tregs which function to suppress the inflammatory Th2 responses of allergic rhinitis. However, with prolonged challenging time, the proportion of TGF-β1-expressing Bregs and Tregs can gradually recover to reconstitute the immune homeostasis in nasal mucosa.671 Similarly, TGF-β can inhibit the Th2 responses of food allergy by promoting Treg activity in the intestines.603,672,673 Therefore, reduced TGF-β1 expression in the intestinal epithelial cells and mononuclear cells of patients with food allergy can partially account for the development of the disease.603,674 Moreover, TGF-β can inhibit the pathology of atopic dermatitis by suppressing B cell maturation, mast cell activation, eosinophil infiltration, as well as the secretion of IgE, TNF-α, and histamine by those cells.675–677 Aberrant TGF-β expression or attenuated cell responsiveness discovered in patients with atopic dermatitis may play a key role in the disorder.678–680

Furthermore, TGF-β signaling is implicated in the pathology of other inflammatory diseases and inflammation-related diseases such as bronchitis,642 pancreatitis,681–683 glomerulonephritis,684,685 osteomyelitis,686 arthritis,687 diabetes,688 and Alzheimer’s disease (AD).689,690

Infectious diseases

Infectious diseases caused by different kinds of pathogenic organisms can result in tissue damage due to diverse pathogen virulence and dysregulated host responses.

TGF-β can function to reduce pathogen burdens as well as tissue injuries in some cases of infection. In patients with H1N1 influenza A virus sepsis, blood TGF-β levels are negatively correlated with clinical severity scores on admission.691 Consistently, increased TGF-β activity in mice confers resistance against lethal influenza infection due to reductions in both viral titers and pulmonary inflammation.692,693 TGF-β expression also prevents mice from coxsackievirus-induced myocarditis and type 1 diabetes in a Treg-dependent manner.694,695 Moreover, TGF-β acts as a pro-survival factor to protect murine neurons and intestinal epithelial cells against cell death during reovirus infection.696,697 As for bacterial infection, TGF-β can attenuate sepsis-induced tissue injuries through mechanisms involving the induction of Tregs.698 It also enhances the pathogen clearance and host resistance of mice during the infection of Streptococcus pneumoniae,699 Streptococcus pyogenes,700 Listeria monocytogenes,701 and Yersinia enterocolitica,702 likely, by suppressing IFN-γ, TNF-α, and IL-6 production while promoting Th17 and Treg responses. In rats with pulmonary cryptococcosis, TGF-β reduces fungal burdens by promoting the lysozyme secretion of macrophages, meanwhile, it also limits inflammation by inhibiting macrophage phagocytosis, chemokine production, and oxidative burst.703 Moreover, TGF-β can be protective during parasitic infection. The lack of TGF-β exacerbates the severity of murine malaria infection, whereas TGF-β treatment, in contrast, suppresses plasmodium proliferation and prolongs mice survival with decreased TNF-α and increased IL-10 in serum.704 During Trypanosoma congolense infection, exogenous TGF-β1 confers early protection against parasitemia, anemia, splenomegaly, and mortality due to enhanced macrophage activity and Th1 responses which are characterized by increased NO, IFN-γ, TNF-α, IL-12, and IgG2a production.705 During Toxoplasma infection, TGF-β can prevent tissue damage by reducing inflammatory cell infiltration and cytokine production, while it can also improve the outcomes of infection-related abnormal pregnancy by promoting Treg functions and suppressing NK cytotoxicity.706–709 Furthermore, TGF-β can prevent the lung injuries during hookworm infection by inducing the immunosuppressive activity of myeloid cells to reduce Th2 responses.710

In other cases of infection, however, TGF-β can turn to facilitate pathogen infection and tissue injuries. In clinical patients, circulating TGF-β1 levels are positively correlated with the severity and mortality of severe community-acquired pneumonia (CAP)711 and sepsis-induced acute respiratory distress syndrome (ARDS).712 Increased TGF-β production can impair the anti-bacterial functions of neutrophils, uncouple the cytokine production and glycolysis of macrophages, and suppress the IL-2 expression and proliferation of T cells to participate in the pathology of sepsis.713–715 As for bacterial infection in local tissues, on one hand, TGF-β can upregulate fibronectin and integrins in hosts to promote bacterial adhesion and invasion,716,717 on the other hand, it can attenuate anti-infectious innate responses and Th1 responses while inducing immunotolerant Treg responses to facilitate the immune escape of the pathogens.718–722 TGF-β-mediated immunosuppression can also contribute to viral infection, as elevated TGF-β expression during viral infection not only impairs early innate immunity such as IFN responses, NK functions, and macrophage activity but also suppresses the adaptive immune responses of T cells and B cells.428,723–731 Notably, TGF-β can also enhance viral infection through certain pathogen-specific mechanisms as in the cases of human immunodeficiency virus type 1 (HIV-1) infection,732–734 human T-cell leukemia virus type I (HTLV-I) infection,735 hepatitis C virus (HCV) infection,736 Zika virus (ZIKV) infection,737 as well as rubella virus (RuV) infection.738 Furthermore, TGF-β can promote the survival and growth of parasites in hosts through downregulation of NO, IFN-γ, TNF-α, IL-6, IL-17, and Th17 cells as well as upregulation of IL-4, IL-10, and Treg cells, contributing to the infection of Fasciola hepatica,739 Echinococcus multilocularis,740 Toxoplasma gondii,741 Leishmania,742 and Plasmodium.743,744

Tumors

It is generally accepted that TGF-β acts as a tumor suppressor during the early stages of tumorigenesis but turns into a tumor promotor at later stages of tumor development.

Tumorigenesis

Evidence from animal models firmly establishes the suppressor role of TGF-β signaling in early tumorigenesis. TGF-β and its receptors can be strongly induced in the murine epidermis upon exposure to carcinogens that tend to disrupt tissue homeostasis and cause oncogenic transformation.745,746 Increased TGF-β expression in murine epidermis can potently attenuate cell proliferation and confer resistance to hyperproliferation induced by carcinogens.316,746,747 Similarly, in murine mammary epithelia, the overexpression of TGF-β or TβR can result in remarkable protection from carcinogen-induced tumorigenesis with reduced premalignant lesions, prolonged tumor latency, and decreased cancer incidence.25,491,748–750 Such tumor-inhibitory effects by TGF-β signaling are attributed to the early apoptosis of differentiating cells and, more importantly, the premature senescence of stem cells which reduces the reproductive capacity of the mammary epithelia and thus decreases the frequency with which transforming mutations may occur and be fixed in the cell population.491,748

In contrast, loss of TGF-β signaling can be an early event that contributes to tumorigenesis. In clinical patients, heterogeneous patterns of TβRII expression in normal breast lobular units as well as loss of TβRII expression in breast epithelial hyperplastic lesions are both associated with increased risks of invasive breast cancer.751 More convincing evidence is provided by germline mutations of TGF-β signaling components which show strong correlations with increased risks of tumorigenesis. Loss-of-function TβRI mutations can result in an autosomal dominant skin cancer condition known as multiple self-healing squamous epithelioma (MSSE) or Ferguson-Smith disease (FSD) which is characterized by multiple squamous-carcinoma-like skin tumors that invade locally and then regress spontaneously after several months.752,753 Inactivating TβRII mutations are considered causative of some cases of hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome, an autosomal dominant cancer predisposition syndrome, by impairing cell growth inhibition in response to TGF-β.754 Moreover, germline mutations of SMAD4 are responsible for juvenile polyposis, an autosomal dominant syndrome predisposing to gastrointestinal hamartomatous polyps and cancers.755,756 Mechanically, impaired TGF-β signaling can cause serious disturbance to tissue homeostasis, thus largely facilitating the development of pre-neoplastic lesions, as well as subsequent tumors, as shown in different murine tissues with deficiencies in the activity of TGF-β,757,758 TβR,749,759–770 or SMAD.657,771–776 Among them, TβR-deleted murine epithelia exhibit significant reductions in p15 and p21 and remarkable increases in MYC expression and RAS/ERK signaling, accompanied by elevated cell proliferation, reduced cell apoptosis, and enhanced cell malignant transformation to become tumorigenic.762–765

Furthermore, TGF-β can provide additional protection against tumorigenesis by controlling pathogen infection,777 inhibiting excessive inflammation,778–781 reducing genomic instability,782 inducing replicative senescence,783 and regulating epithelial-mesenchymal interaction.784

Tumor growth

TGF-β can inhibit tumor growth by triggering cytostasis and apoptosis through similar mechanisms as it does in cells from normal tissues. In tumor cells, TGF-β signaling induces cell cycle arrest by targeting effectors, such as p15,354,356 p21,355,785,786 p27,361 MYC,363 ID,787 and CDC25A,374,786 while it also induces apoptotic cell death through effectors including CTGF,788 programmed cell death 4 (PDCD4),789 Fas receptor,790 death-associated protein kinase (DAPK),791 DAXX,383 IκB-α,384,386 sex-determining region Y (SRY)-box 4 (SOX4),792 ARTS,382 TIEGs,793 as well as several BCL-2 family members.794–800 Consistently, primary tumors induced from murine tissues with intact TGF-β signaling pathways are initially responsive to TGF-β-mediated inhibitory effects.491,749,759,764,801,802

On the contrary, deficient TGF-β signaling can potently promote the growth of tumors. The downregulation of tumor TGF-β signaling in many cases is attributed to reduced expression or inactivating mutations of TβR or SMAD, as shown in various tumor types such as leukemia,772 lymphoma,803,804 esophageal cancer,805–807 gastric cancer,808 colorectal cancer,30,807,809–811 pancreatic cancer,32,812,813 biliary cancer,812 ampullary cancer,814 thyroid cancer,815 prostate cancer,816,817 breast cancer,818 ovarian cancer,819 endometrial cancer,808 genital squamous cell carcinomas (SCC),764 head and neck SCC,820–823 etc. These changes are able to confer resistance to the tumor-inhibitory effects of TGF-β. In mouse models, tumors developed from tissues with deletion or inactivation of TβR exhibit increased cell proliferation and decreased cell apoptosis, accompanied by reduction in p15, p21, and p27, the elevation of MYC, cyclin D1, and epidermal growth factor receptor (EGFR), as well as activation of STAT3 and PI3K/AKT pathways.761–765 Interestingly, reconstituted expression of TβRII in tumor cells with corresponding deficiency not only restores the inhibitory responses to TGF-β but also significantly attenuates the tumorigenicity of these cells.824

Notably, TGF-β can fail to suppress the growth of tumors where there is likely no loss of functional TGF-β signaling components, and even formerly inhibited tumor cells can subsequently resume proliferating in vitro and develop larger tumor masses in vivo.354,825,826 On one hand, such resistance may result from the dysfunction of the downstream targets of TGF-β signaling such as CKIs.354 On the other hand, the tumor-suppressive signaling of TGF-β can be offset or interfered by enhanced I-SMAD activity827 or potent oncogenic factors such as E1A,828,829 EVI1,148,830 SKI,150,152 SNO,153 MYC,831 ID2,832 mutant p53,833 as well as RAS/RAF/ERK signaling.162,834 Moreover, TGF-β-mediated tumor-promoting effects can also account for the enhanced tumor growth in vivo, as discussed in a later section.

Tumor invasion and metastasis

Contrary to its role as a suppressor of tumor growth, TGF-β generally acts as a promoter of tumor invasion and metastasis especially in advanced tumors. Upregulation of TGF-β as well as its receptors is associated with disease progression and poor prognosis in some patients with tumors such as breast cancer,835,836 pancreatic cancer,837,838 and gastric cancer.839 Consistently, TGF-β overexpression or pre-treatment enables tumor cells to form increased metastases in vivo,825,840 while loss of TGF-β responsiveness due to the introduction of dominant negative TβRII decreases the metastatic efficiency of high-grade tumor cells.841,842 Moreover, tumors derived from transgenic murine epithelia that overexpress TGF-β or TβR are significantly more malignant and more invasive.491,749,750,802,843 Notably, these TGF-β-overexpressing tumor cells are more likely to undergo the transition from epithelial cell phenotype into spindle cell phenotype which is the most malignant and invasive cell type.802,843 This indicates that TGF-β can facilitate the progression of epithelial-derived tumors through the induction of EMT which is inoperative in tumors with deficiencies in TβR or SMAD.761,770,774,842,843 Similar to the EMT of normal cells, TGF-β-induced EMT of tumor cells is characterized by changes in keratin, integrin, cadherin, catenin, claudin, vimentin, occludin, fibronectin, and MMP expression which can contribute to the invasive and metastatic capacity of tumors.197,198,200,203,230,232,750,774,802,843–848

However, loss of functional TGF-β signaling components can occur in tumor cells during disease progression.759,809 In fact, reduced TGF-β signaling can also contribute to tumor invasion and metastasis. For some patients, decreased expression of TβR is correlated with higher tumor grades, later clinical stages, and worse clinical prognosis.805,816,818 A large number of cell models and mouse models also demonstrate that tumors lacking TGF-β signaling tend to be more malignant and more aggressive.758,760–762,764,801,841,843,849–852 Relevant mechanisms in these cases involve the loss of E-cadherin,761 the reduction in PAI,849 the increase in RHO/RAC signaling,843 the activation of integrin/focal adhesion kinase (FAK)/SRC/MAPK pathway,764 and more importantly, the overexpression of various pro-invasive and pro-metastatic factors. In mouse models, deficient TGF-β signaling can stimulate tumor cells and stromal cells to produce high levels of TGF-β and other tumor-promoting factors such as CTGF, VEGF, IL-1β, C-X-C motif chemokine ligand (CXCL8), CXCL12, cyclooxygenase(COX)-2, MMPs, collagen, and tenascin C (TNC) which can strongly promote tumor angiogenesis, fibroblasts activation, immune infiltration, and ECM remodeling.760–764,774,843,850

Tumor microenvironment (TME) remodeling

TGF-β can stimulate tumor progression even when its signaling pathways are unavailable in the tumor cells, indicating its additional tumor-promoting effects exerted on tumor stroma.760–764,843 Fibroblasts, endothelial cells, and immune cells are the major stromal cell types in TME and can all be manipulated by TGF-β in favor of tumor progression.

Actively produced TGF-β in the TME can stimulate the chemotactic migration of fibroblasts and convert them into MFs which are also known as cancer-associated fibroblasts (CAFs) in terms of tumors.305,853 Activated CAFs can in turn repay TME with more TGF-β as well as other tumor-promoting factors such as TGF-α, FGF, HGF, PDGF, and CTGF to exert a strong stimulation on tumor growth.324,853–857 Moreover, TGF-β regulates the production of various ECM components and remodelers by CAFs to facilitate the migration of tumor cells during invasion and metastasis.855,858 Interestingly, fibroblasts with the loss of TβRII can also contribute to tumor development through the production of TGF-α, HGF, and macrophage-stimulating protein (MSP).859

Endothelial cells can also be converted into CAFs through TGF-β-mediated EndMT.860 More importantly, TGF-β promotes the angiogenesis of endothelial cells by inducing VEGF production in tumor cells and fibroblasts.323,354,750,861,862 TGF-β also disrupts inter-endothelial junctions to increase the vascular permeability in TME through the process of EndMT and the induction of angiopoietin-like 4 (ANGPTL4).863 Therefore, TGF-β-mediated angiogenesis not only increases the blood supply to tumors to favor their growth but also provides tumors with more accessible entrances into the circulation to form metastasis.

Furthermore, TGF-β can modulate immune cell activity to facilitate tumor survival and development. TGF-β inhibits the tumoricidal activity of macrophages and neutrophils and polarizes them into tumor-promoting M2 macrophages and N2 neutrophils, which are also known as tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) in terms of tumors.439,442,444,448,449,864 It also promotes the functions of Tregs while suppressing the cytotoxicity of CTLs and NK cells to facilitate tumor evasion from immune surveillance.865–869 Moreover, TGF-β can inhibit the expression of MHC antigens in tumor cells to further attenuate their recognition by adaptive anti-tumor immunity.870,871 However, TGF-β-mediated downregulation of MHC antigens and NKG2D ligands can increase tumor susceptibility to NK cytotoxicity to some extent.233,872

TGF-β-targeting therapies

To rectify the dysfunction of TGF-β in different kinds of diseases, several targeted therapies have been developed to regulate TGF-β activity at the levels of biosynthesis, activation, and signaling. Many completed clinical trials have preliminarily confirmed the safety and efficacy of some therapeutic strategies, while there are still numerous clinical trials ongoing at present (Table 1).Table 1 Ongoing clinical trials of TGF-β-targeting therapies

Targets	Strategies	Treatments	Diseases	Clinical trials	
TGF-β2 mRNA	Antisense oligonucleotide	Trabedersen	Pancreatic ductal adenocarcinoma and malignant pleural mesothelioma	NCT06079346 (phase 2/3) and NCT05425576 (phase 2)	
TGF-β2 mRNA	Antisense oligonucleotide	TASO-001	Solid tumors	NCT04862767 (phase 1)	
Furin	ShRNA	Vigil	Ovarian cancer	NCT02346747 (phase 2)	
Latent TGF-β complex	Monoclonal antibody	SRK-181	Solid tumors	NCT04291079 (phase 1)	
GARP	Monoclonal antibody	HLX60	Solid tumors and lymphoma	NCT05483530 (phase 1) and NCT05606380 (phase 1)	
TGF-β2	Dietary supplement	Modulen	IBD	NCT04921033 (phase 3), NCT04777656 (phase 3), and RBR-955md27	
TGF-β	Monoclonal antibody	NIS793	Pancreatic cancer, colorectal cancer, and MDS	NCT04935359 (phase 3), NCT04390763 (phase 2), NCT04952753 (phase 2), NCT05417386 (phase 1), and NCT04810611 (phase 1)	
TGF-β	Monoclonal antibody	SAR439459	Multiple myeloma and osteogenesis imperfecta	NCT04643002 (phase 1/2) and NCT05231668 (phase 1)	
TGF-β	Ligand trap	Bintrafusp alfa	Solid tumors	NCT05061823 (phase 3), NCT03436563 (phase 2), NCT04396886 (phase 2), NCT05005429 (phase 2), NCT04708470 (phase 1/2), NCT04574583 (phase 1/2), etc.	
TβR	Dominant-negative TβR	TGF-β-resistant cytotoxic T lymphocytes	Lymphoma	NCT00368082 (phase 1)	
TβRI	Kinase inhibitor	Galunisertib	Nasopharyngeal carcinoma, prostate cancer, colorectal cancer, and glioma	NCT04605562 (phase 2), NCT02452008 (phase 2), NCT02688712 (phase 2), NCT01582269 (phase 2), NCT05700656 (phase 1/2), and NCT01682187 (phase 1)	
TβRI	Kinase inhibitor	Vactosertib	Solid tumors and myeloproliferative neoplasm	NCT04515979 (phase 2), NCT04064190 (phase 2), NCT05436990 (phase 2), NCT04103645 (phase 2), NCT05588648 (phase 1/2), NCT03802084 (phase 1/2), etc.	
TβRI	Kinase inhibitor	LY3200882	Solid tumors	NCT02937272 (phase 1)	

Alteration of TGF-β biosynthesis

Targeting TGF-β mRNAs

Trabedersen (AP 12009 or OT-101) is an antisense oligonucleotide complementary to human TGF-β2 mRNA and can specifically inhibit TGF-β2 biosynthesis. It is hypothesized that trabedersen mainly acts by reversing TGF-β2-mediated immunosuppression to facilitate immune responses against tumors. A phase 2b clinical trial showed no advantage in early tumor control rate but in long-term survival rate for glioma patients treated with trabedersen in comparison with standard chemotherapy. Tumor responses which continued to increase long after discontinuation in the study suggested that the clinically relevant beneficial effects of trabedersen might increase over time. Moreover, compared with the standard chemotherapy group, drug-related or possibly drug-related adverse events in the trabedersen group were less common and mostly nervous system disorders. The study also indicated that the optimal dose of trabedersen is 10 µM, as both its efficacy and safety tended to be superior to the 80 µM dose, although the mechanism for this counterintuitive result has not been fully understood.873 TGF-β1 antisense oligonucleotides or small interfering RNAs (siRNAs) were also developed and evaluated in different pre-clinical models, suggested as potential therapeutic strategies for tuberculosis,874,875 wound scarring,876,877 and several renal diseases.878–881

TGF-β antisense gene-modified tumor cell vaccines are designed to exhibit increased immunogenicity due to reduced TGF-β expression in the tumor cells that comprise the vaccines. Vaccine Lucanix (belagenpumatucel-L) made from allogeneic non-small cell lung cancer (NSCLC) cell lines was well tolerated and brought survival advantages to NSCLC patients who were randomized within 12 weeks of completion of platinum-based chemotherapy and in those who had received prior radiation, as shown in a phase 3 trial which, however, failed to demonstrate a significant increase in survival in the overall patient population.882 TGF-β antisense-modified autologous tumor cell vaccines have also been tested in advanced glioma and other solid tumors, respectively, in two phase 1 studies in which enhanced anti-tumor activity and improved survival were observed.34,883 Notably, in the study among glioma patients, the most common treatment-related adverse events were delayed-type hypersensitivity-like reactions observed at the sites of the second and subsequent vaccinations in all patients. Some of these patients also experienced transient, flu-like symptoms consisting of musculoskeletal aches and pains and fatigue during the course of treatment.34

Targeting furin

Convertase furin is a therapeutic target participating in the post-translational processing of TGF-β. Vigil (FANG or Gemogenovatucel-T) is an autologous tumor cell vaccine incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GMCSF) and a bifunctional short-hairpin RNA (shRNA) targeting the expression of furin. A phase 1 study confirmed its safety and efficacy in various advanced solid tumors, with significant survival differences noted between patients who received less than four vaccinations and those who received no less than four vaccinations.884 A later phase 2b trial also demonstrated significant clinical benefit in homologous recombination proficient ovarian cancer (NCT02346747).885 Both studies reported no treatment-related serious adverse events, while the most common grade one and two adverse events related to study medication were local reactions at the injection site.

Alteration of TGF-β activation

Targeting latent TGF-β complex

SRK-181 is an antibody that selectively binds to latent TGF-β1 to inhibit its activation. Co-administration of SRK-181 and anti-PD-1 antibody induced profound anti-tumor responses and survival benefit in mice, with increased infiltrating CD8+ T cells and decreased immunosuppressive myeloid cells observed in tumors refractory to anti-PD-1 treatment.886 The selective blockade of TGF-β1 by SRK-181 neither caused cardiac valvulopathy in rats as pan-TGFβ inhibitors might do nor did it induce cytokine release in human peripheral blood. Moreover, SRK-181 showed no effect on human platelet aggregation, activation, and binding.886,887 The favorable safety profile displayed in these preclinical assessments supports the ongoing phase 1 trial of SRK-181 in patients with advanced cancers (NCT04291079).

Targeting GARP

GARP expressed by Tregs, platelets, and endothelium functions to tether latent TGF-β complex to the cell surface for activation. Anti-GARP monoclonal antibody PIIO-1 proved to be an effective and safe strategy to block TGF-β activation in preclinical models, for it specifically bound to ligand-free GARP on Tregs but lacked recognition of GARP-latent TGF-β complex on platelets, actually avoiding the risk of platelet-related toxicities such as thrombocytopenia. More importantly, PIIO-1 showed therapeutic efficacy against both GARP+ and GARP- cancers alone or in combination with anti-PD-1 antibody, by preventing T cell exhaustion and enhancing CD8+ T cell migration into the TME in a C-X-C motif chemokine receptor 3 (CXCR3)-dependent manner.888

Targeting αV integrins

Integrins are regarded as the most important activators of TGF-β. Abituzumab (EMD 525797 or DI17E6) is an antibody against pan-αV integrins. In a phase 1/2 trial on KRAS wild-type metastatic colorectal cancer (NCT01008475), the progression-free survival (PFS) and response rates were similar among all groups in the intent-to-treat population comprising all patients randomized, although a trend toward improved overall survival (OS) was observed in the groups that received abituzumab treatment. However, exploratory analysis suggested that in patients with high αVβ6 expression, PFS and response rates might be increased with abituzumab therapy.889 This pan-αV integrin inhibitor was also found to inhibit prostate cancer-associated bone lesion formation in a randomized phase 2 trial (NCT01360840), although PFS was not significantly extended.890 Recently, abituzumab has been investigated in SSc-associated interstitial lung disease in a phase 2 trial (NCT02745145). However, the study was terminated prematurely due to slow enrollment and no meaningful conclusions could be drawn due to a small sample size.891 The most commonly reported treatment-related adverse events of abituzumab included fatigue, headache, gastrointestinal disorders, as well as abnormal biochemistry and hematology values.889,890,892

Cilengitide (EMD 121974, NSC 707544) is a selective αvβ3 and αvβ5 integrin inhibitor which has been evaluated for therapeutic efficacy in NSCLC (NCT00842712),893,894 head and neck SCC (NCT00705016),895 glioblastoma (NCT00689221, NCT00813943, and NCT01124240),896–903 melanoma,904 pancreatic cancer,905 and prostate cancer906,907 in a series of phase 2 studies and one phase 3 study. Although cilengitide failed to demonstrate significant clinical benefits in these studies on tumors, it might be a novel treatment for fibrotic diseases as relevant preclinical studies suggested.908,909 Notably, the adverse events possibly related to cilengitide treatment included fatigue, arthralgia, lymphopenia, and gastrointestinal disorders.893,897,899,900,904,906,907 Furthermore, an inhibitor of pan-integrins and TGF-β known as GLPG-0187 was proved to enhance T cell killing of colorectal cancer cells in vitro, possibly by suppressing TGF-β-mediated PD-L1 upregulation.910,911

Targeting TSP-1

TSP-1 can directly activate all three TGF-β isoforms independent of other activators or cellular activity. The conserved LSKL sequence in LAP which is recognized by TSP-1 can be synthesized as peptides to block TSP-1-mediated TGF-β activation. Pre-clinical studies suggested that treatment of LSKL or relevant tripeptide SRI31277 could be novel therapeutic strategies for various cardiovascular diseases,912 pulmonary diseases,913 renal diseases,914–916 nervous diseases,917,918 fibrotic diseases,919–921 wound healing,922,923 and tumors.924–926 Moreover, TSP-1 antisense oligonucleotides were successfully developed and applied to inhibit TGF-β activation in a rat model of mesangial proliferative glomerulonephritis, demonstrating a remarkable prevention against renal fibrosis.927

Alteration of TGF-β signaling

Targeting TGF-β ligands

A TGF-β2-enriched polymeric dietary supplement known as Modulen (CT3211) was effective in inducing earlier remission of inflammatory bowel diseases (IBDs) including both Crohn’s disease and UC with significant improvements in endoscopic and histologic appearances, mucosal cytokine parameters, C-reactive protein (CRP) values, erythrocyte sedimentation rates (ESRs), serum albumin levels, as well as weight and height scores in the patients.928–931 Notably, an exclusive Modulen diet was more efficient than steroids to induce mucosal healing in children with Crohn’s disease, possibly due to its additional advantage in regulating intestinal microbiota (NCT00265772).932,933 Moreover, a pre-operative polymeric diet enriched with TGF-β2 was able to decrease post-operative complications after surgery for complicated ileocolonic Crohn’s disease.934 The side effects of Modulen were mild, including abdominal pain, flatulence, nausea, and vomiting.928,932,934 In mouse models, oral TGF-β supplementation also showed beneficial effects on food allergy prevention.935–937 In fact, it is believed that the presence of TGF-β in breast milk can protect the progeny from several allergic diseases such as asthma,938 eczema,939 and food allergy.940

Recombinant human TGF-β3 known as avotermin (Juvista) is a potential therapy for the improvement of cutaneous scarring. In a series of phase 1/2 studies (NCT00847925, NCT00847795, NCT00629811, NCT00432211, NCT00594581, and NCT00430326), visual assessment of scar formation revealed that, in contrast to placebo, intradermal avotermin could significantly improve total scar scores which were derived from a visual analog scale to assess how closely scars resembled normal skin. The results were further confirmed by histological assessments that scars treated with avotermin showed better organized ECM of the papillary and reticular dermis. The incidence of adverse events at wound sites, including infection, exudate, erythema, pain, burning, itching, and thickening was low and similar for avotermin and controls.941–944 Although the other two TGF-β isoforms, TGF-β1 and TGF-β2, showed no therapeutic activity of scarring, they were found to improve and accelerate the healing of cutaneous wounds in animal models as well as clinical patients.304,306,307,317,321,334,945 Moreover, TGF-β also showed therapeutic potential for tissue regeneration,329,946,947 inflammatory diseases,676,687,948 and influenza949 as shown in relevant preclinical models.

TGF-β neutralizing antibodies and ligand traps can block the binding of TGF-β to its receptors. Fresolimumab (GC1008), a monoclonal antibody that neutralizes all three TGF-β isoforms demonstrated acceptable safety and preliminary evidence of anti-tumor activity in a phase 1 study on advanced malignant melanoma and renal cell carcinoma (NCT00356460).950 In a phase 2 trial (NCT01401062), a higher dose of fresolimumab is associated with longer median OS as well as improved peripheral blood mononuclear cell counts and boosted central memory CD8+ T cell levels in metastatic breast cancer patients receiving radiotherapy.951 Fresolimumab also showed therapeutic effects on SSc with decreased biomarkers of skin fibrosis and improved clinical symptoms in the patients in a phase 1 study (NCT01284322).952 Moreover, a phase 1 study evaluated the safety of fresolimumab in patients with treatment-resistant primary focal segmental glomerulosclerosis and the good tolerability supported additional evaluation in larger randomized dose-ranging clinical trials.953 Notably, the major drug-related adverse events of fresolimumab were skin disorders, bleeding episodes, and anemia. Skin toxicity was particularly significant and tumor patients assigned to high doses of treatment even developed skin tumors, including keratoacanthoma, basal cell carcinoma, and SCC.950–954 Another anti-TGF-β monoclonal antibody known as NIS793 was well tolerated alone or in combination with anti-PD-1 antibody in patients with advanced solid tumors in a phase 1 study (NCT02947165). Treatment-related adverse events of all patients in the study were mostly skin toxicity and gastrointestinal events, and no dose-limiting toxicities were observed during dose escalation. Notably, biomarker analyses in the study showed evidence of systemic target engagement, local signaling inhibition, and tumor immune activation.955 Apart from tumors, a recombinant human anti-TGF-β1 antibody known as CAT-192 was evaluated in the treatment of early-stage diffuse cutaneous SSc but showed no evidence of efficacy in the pilot phase 1/2 study. The most commonly reported adverse events in the study affected the gastrointestinal, musculoskeletal, respiratory, and skin systems, but none of them were considered to be related to the treatment.956 Moreover, a phase 2 study assessing the safety and efficacy of TGF-β1 monoclonal antibody in patients with diabetic nephropathy was terminated early for futility (NCT01113801). The frequencies of the various categories of adverse effects in this study were generally similar between the treatment and placebo groups.957 Furthermore, monotherapy of a selective TGF-β1/3 trap known as AVID200 in a population of patients with an advanced stage of myelofibrosis in a phase 1b trial resulted in limited toxicity as well as improvements in spleen size, symptom benefit, and platelet counts (NCT03895112). Remarkably, platelet count increase was a therapeutic effect not observed with other myelofibrosis therapies, suggesting a potential advantage of AVID200 treatment. Adverse events that occurred during the study regardless of attribution mainly included pruritus, fatigue, abdominal pain, anemia, and thrombocytopenia.958 Additionally, other potential applications of neutralizing TGF-β antibodies suggested by pre-clinical studies include wound healing,334,959,960 prostatic hyperplasia,961 pulmonary diseases,962,963 cardiovascular diseases,564,964 musculoskeletal diseases,965–968 inflammatory diseases,969,970 and Chagas disease (Trypanosoma cruzi infection).971

Bifunctional antibody-ligand traps containing the extracellular domain of TβRII can target both TGF-β and immune checkpoints. In preclinical studies, both the anti-CTL associated protein (CTLA)-4-TβRII chimera and the anti-PD-L1-TβRII chimera exhibited superior anti-tumor efficacy compared with their parent immune checkpoint inhibitors.972 Bintrafusp alfa (M7824), a bifunctional fusion protein targeting both TGF-β and PD-L1 was assessed in several phase 1 trials (NCT02699515, NCT02517398, NCT02699515, and NCT04247282). The results showed that bintrafusp alfa had encouraging efficacy in NSCLC,973 gastric cancer,974 biliary tract cancer,975 as well as human papillomavirus (HPV)-unrelated head and neck cancer in which enhanced tumor antigen-specific immunity has been observed.976 Similar to fresolimumab, the treatment-related adverse events of bintrafusp alfa included fatigue, colitis, bleeding, anemia, hypokalemia, lipase increase, hepatic function abnormalities, as well as several skin disorders from rash, hyperkeratosis, to keratoacanthoma and SCC.973–977 BR102 is another bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. The efficacy and safety of BR102 demonstrated in preclinical characterization supported its further clinical development for anti-cancer therapy.978 Notably, the bifunctional antibody-ligand traps have inspired the development of chimeric antigen receptor (CAR)-T cells secreting bispecific trap protein, which co-targets PD-1 and TGF-β to enhance anti-tumor efficacy as shown in mouse models.979

Furthermore, LAP, TβRIII (β-glycan), and decorin can bind to TGF-β as natural inhibitors. They have shown treatment effects in preclinical models of wound healing,980–983 cardiovascular diseases,984–989 nervous diseases,990–992 renal diseases,993–996 fibrotic diseases,997–1000 tuberculosis,1001 and tumors1002–1005 and thus warrant further development.

Targeting TβRs

TGF-β-insensitive CAR-T cells armored with dominant-negative TβRII showed preliminary evidence for early anti-tumor function in prostate cancer, including a biomarker decline among approximately 30% of the patients in a phase 1 trial (NCT03089203). This strategy which is considered generally feasible, despite no partial response being observed in the study, and safe, with study-related serious adverse events mostly being cytokine release syndrome, warrants further validation and investigation.1006 Dominant-negative TβRII can also enhance the anti-tumor efficacy of DC vaccines, manifested by powerful tumor-specific CTL responses, inhibited tumor development, and prolonged survival times in mouse models.1007,1008 Moreover, dominant-negative TβRII showed great potential for reducing hypertrophic scars as in rabbit ear models.1009

Many small-molecule inhibitors have been developed to suppress the kinase activity of TβRI. In a series of phase 2 studies, a TβRI kinase inhibitor known as galunisertib (LY2157299) showed preliminary efficacy in patients with myelodysplastic syndromes (MDS) (NCT02008318),1010 NSCLC (NCT02423343),1011 hepatocellular carcinoma (NCT01246986),1012,1013 rectal cancer (NCT02688712),1014 and pancreatic cancer,1015 but failed to demonstrate clinical benefit in patients with glioma (NCT01582269 and NCT01220271).1016,1017 The most common adverse events related to galunisertib treatment included fatigue, pyrexia, anemia, nausea, vomiting, diarrhea, and abdominal pain.1010,1013,1017 Despite comprehensive cardiovascular monitoring for galunisertib did not detect medically relevant cardiac toxicity in cancer patients,1018 galunisertib-related uncontrolled cytokine release was reported in patients with advanced solid tumors in a phase 1 trial (NCT01646203).1019 Other TβRI kinase inhibitors such as SM16, SD-208, NP-40208, SB-431542, LY3200882, LY364947, and vactosertib (EW-7197) also showed therapeutic potential in pre-clinical studies on tumors1020–1026 as well as many other diseases such as cardiovascular diseases,565,1027–1030 renal diseases,1031 ophthalmic diseases,1032 skeletal diseases,1033 fibrotic diseases,1034–1036 inflammatory diseases,1037–1039 Chagas disease,1040,1041 coronavirus disease 2019 (COVID-19),1042 and wound healing.1043–1045

Targeting SMADs

An oral SMAD7 antisense oligonucleotide known as mongersen (GED-0301) showed promising results in patients with active Crohn’s disease in phase 1 and 2 phase trials, but further phase 3 study failed due to lack of clinical benefit (EudraCT 2009-012465-66, EudraCT 2011-002640-27, and NCT02596893).1046–1048 Meanwhile, SMAD3 antisense oligonucleotide treatment was found to improve flexor tendon repair in mice and might have possible therapeutic applications in clinical practice.877

Moreover, a small-molecule SMAD3 inhibitor known as specific inhibitor of SMAD3 (SIS3) has shown pre-clinical therapeutic efficacy in wound healing,1049 cardiovascular diseases,569,1050,1051 nervous diseases,1052 renal diseases,1053,1054 skeletal diseases,1055 fibrotic diseases,1056,1057 inflammatory diseases,1039,1058 type 2 diabetes,1059,1060 and tumors,1061,1062 suggesting a novel approach that could be further tested to treat clinical patients.

Furthermore, several SMAD-binding peptide aptamers have been developed to selectively inhibit the binding between SMADs and their interacting factors.1063 An aptamer containing the SMAD-binding domain of transcription factor lymphoid enhancer-binding factor 1 (LEF1) can suppress tumor cell proliferation by inhibiting the interaction between SMAD4 and LEF/T cell-specific factor (TCF) to suppress MYC expression.1064 Other aptamers that bind specifically to R-SMADs through the SMAD-binding domain from SARA can impair the formation of functional SMAD oligomers to inhibit TGF-β-induced EMT.1065,1066 Moreover, aptamers that disrupt the interaction between SMAD and transcription coactivator yes-associated protein (YAP) have been designed for bone tumor therapy.1067

Conclusions and future perspectives

TGF-β signaling is so extensively and indispensably involved in a large number of biological processes that it has attracted great interest and attention over the past decades during which relevant knowledge has exploded in the fields of health, disease, and therapeutics. However, there are still some specific issues that have not been fully elucidated, while some previous knowledge is facing updates and challenges.

Studies on embryonic development and wound healing have revealed the isoform-specific roles of TGF-β which remain poorly aware in other fields of research, as studies on immune homeostasis, fibrotic diseases, and tumor development so far have focused on the most abundant TGF-β1 isoform in particular. Since all TGF-β isoforms are believed to signal through the same receptors and downstream pathways, the causes of the differences in biological effects between isotypes have not been fully understood. Moreover, since a natural TGF-β heterodimer containing one TGF-β1 monomer and one TGF-β2 monomer has long been discovered,12,1068 it would be very interesting to identify and characterize novel TGF-β heterodimers in the future. Furthermore, with the discovery and study of TGF-β superfamily which also includes polypeptides structurally similar to TGF-β such as nodal, myostatin, inhibins, activins, Müllerian-inhibiting substance (MIS), bone morphogenetic proteins (BMPs), and growth and differentiation factors (GDFs), researchers have realized that TGF-β can also signal through pathways ‘specific’ to other TGF-β superfamily members, for example, via receptors ALK1/2/3 and transcription factors SMAD1/5/8.1069–1073 The significance of the signaling crosstalk within the TGF-β superfamily also warrants future exploration. Notably, Reblozyl (luspatercept or ACE-536), a ligand trap that contains the extracellular domain of human activin receptor type IIB (ActRIIB) to inhibit GDF11-mediated SMAD2/3 signaling has been approved by the US Federal Drug Agency (FDA) for the treatment of anemia in adult patients with β-thalassemia or with MDS.

As for TGF-β-targeting therapy, the efficacy and safety of treatment are always issues of concern. The current lack of systematic studies on the dural roles of TGF-β in wound healing, infectious diseases, and tumor development may hinder the development of related therapeutics. Given the extensive impacts of TGF-β on a lot of biological processes, the development of TGF-β isoform-specific therapies and SMAD-binding peptide aptamers is expected to cause less adverse effects through more precise targeting. Moreover, the identification of the applicable population for each therapeutic approach is also important for better efficacy and less toxicity. Serum and tissue levels of TGF-β have shown potential as predictors or indicators of the development,1074–1077 complication,1078–1080 response,1081–1084 recurrence,1085–1087 and outcomes1088–1090 of various kinds of diseases, meanwhile, bioinformatic tools of TGF-β signaling-related gene expression signatures have also been developed for patient stratification.863,1091 But so far, TGF-β or related factors as clinical biomarkers still need further development and assessment.

To summarize, this review focuses on the multiple roles of TGF-β in health and disease while emphasizing the mechanisms of TGF-β production, activation, signaling, as well as corresponding therapeutic strategies. These understandings might be instructive for the basic and applied research of relevant topics in the future.

Acknowledgements

Not applicable.

Author contributions

J.H. supervised the project. J.H., C.L., and T.F. conceived the idea. Z.D., T.F., and C.L. drafted the manuscript. Z.D., C.X., H.T., and Y.Z. polished the language. All authors read and approved the final manuscript.

Funding

This work was supported by the National Key R&D Program of China (2021YFF1201303), the Beijing Natural Science Foundation (BJNSF) (7242119), and the CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-012).

Data availability

Not applicable.

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

These authors contributed equally: Ziqin Deng, Tao Fan.
==== Refs
References

1. de Larco JE Todaro GJ Growth factors from murine sarcoma virus-transformed cells Proc. Natl Acad. Sci. USA 1978 75 4001 4005 10.1073/pnas.75.8.4001 211512
de Larco, J. E. & Todaro, G. J. Growth factors from murine sarcoma virus-transformed cells. Proc. Natl Acad. Sci. USA 75, 4001–4005 (1978).211512 10.1073/pnas.75.8.4001
2. Derynck R Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells Nature 1985 316 701 705 10.1038/316701a0 3861940
Derynck, R. et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 316, 701–705 (1985).3861940 10.1038/316701a0
3. Roberts AB Anzano MA Lamb LC Smith JM Sporn MB New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues Proc. Natl Acad. Sci. USA 1981 78 5339 5343 10.1073/pnas.78.9.5339 6975480
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M. & Sporn, M. B. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc. Natl Acad. Sci. USA 78, 5339–5343 (1981).6975480 10.1073/pnas.78.9.5339
4. Proper JA Bjornson CL Moses HL Mouse embryos contain polypeptide growth factor(s) capable of inducing a reversible neoplastic phenotype in nontransformed cells in culture J. Cell Physiol. 1982 110 169 174 10.1002/jcp.1041100210 6279682
Proper, J. A., Bjornson, C. L. & Moses, H. L. Mouse embryos contain polypeptide growth factor(s) capable of inducing a reversible neoplastic phenotype in nontransformed cells in culture. J. Cell Physiol. 110, 169–174 (1982).6279682 10.1002/jcp.1041100210
5. Childs CB Proper JA Tucker RF Moses HL Serum contains a platelet-derived transforming growth factor Proc. Natl Acad. Sci. USA 1982 79 5312 5316 10.1073/pnas.79.17.5312 6957865
Childs, C. B., Proper, J. A., Tucker, R. F. & Moses, H. L. Serum contains a platelet-derived transforming growth factor. Proc. Natl Acad. Sci. USA 79, 5312–5316 (1982).6957865 10.1073/pnas.79.17.5312
6. Moses HL Branum EL Proper JA Robinson RA Transforming growth factor production by chemically transformed cells Cancer Res 1981 41 2842 2848 6265069
Moses, H. L., Branum, E. L., Proper, J. A. & Robinson, R. A. Transforming growth factor production by chemically transformed cells. Cancer Res 41, 2842–2848 (1981).6265069
7. Assoian RK Komoriya A Meyers CA Miller DM Sporn MB Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization J. Biol. Chem. 1983 258 7155 7160 10.1016/S0021-9258(18)32345-7 6602130
Assoian, R. K., Komoriya, A., Meyers, C. A., Miller, D. M. & Sporn, M. B. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J. Biol. Chem. 258, 7155–7160 (1983).6602130 10.1016/S0021-9258(18)32345-7
8. Roberts AB Purification and properties of a type beta transforming growth factor from bovine kidney Biochemistry 1983 22 5692 5698 10.1021/bi00294a002 6607069
Roberts, A. B. et al. Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry 22, 5692–5698 (1983).6607069 10.1021/bi00294a002
9. Miyazono K Hellman U Wernstedt C Heldin CH Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization J. Biol. Chem. 1988 263 6407 6415 10.1016/S0021-9258(18)68800-3 3162913
Miyazono, K., Hellman, U., Wernstedt, C. & Heldin, C. H. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J. Biol. Chem. 263, 6407–6415 (1988).3162913 10.1016/S0021-9258(18)68800-3
10. Wakefield LM Smith DM Flanders KC Sporn MB Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences J. Biol. Chem. 1988 263 7646 7654 10.1016/S0021-9258(18)68547-3 3163692
Wakefield, L. M., Smith, D. M., Flanders, K. C. & Sporn, M. B. Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. J. Biol. Chem. 263, 7646–7654 (1988).3163692 10.1016/S0021-9258(18)68547-3
11. Lawrence DA Pircher R Jullien P Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions Biochem Biophys. Res Commun. 1985 133 1026 1034 10.1016/0006-291X(85)91239-2 3866579
Lawrence, D. A., Pircher, R. & Jullien, P. Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys. Res Commun. 133, 1026–1034 (1985).3866579 10.1016/0006-291X(85)91239-2
12. Cheifetz S The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors Cell 1987 48 409 415 10.1016/0092-8674(87)90192-9 2879635
Cheifetz, S. et al. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48, 409–415 (1987).2879635 10.1016/0092-8674(87)90192-9
13. ten Dijke P Hansen P Iwata KK Pieler C Foulkes JG Identification of another member of the transforming growth factor type beta gene family Proc. Natl Acad. Sci. USA 1988 85 4715 4719 10.1073/pnas.85.13.4715 3164476
ten Dijke, P., Hansen, P., Iwata, K. K., Pieler, C. & Foulkes, J. G. Identification of another member of the transforming growth factor type beta gene family. Proc. Natl Acad. Sci. USA 85, 4715–4719 (1988).3164476 10.1073/pnas.85.13.4715
14. Derynck R A new type of transforming growth factor-beta, TGF-beta 3 EMBO J. 1988 7 3737 3743 10.1002/j.1460-2075.1988.tb03257.x 3208746
Derynck, R. et al. A new type of transforming growth factor-beta, TGF-beta 3. EMBO J. 7, 3737–3743 (1988).3208746 10.1002/j.1460-2075.1988.tb03257.x
15. Tucker RF Shipley GD Moses HL Holley RW Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor Science 1984 226 705 707 10.1126/science.6093254 6093254
Tucker, R. F., Shipley, G. D., Moses, H. L. & Holley, R. W. Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science 226, 705–707 (1984).6093254 10.1126/science.6093254
16. Holley RW Armour R Baldwin JH Density-dependent regulation of growth of BSC-1 cells in cell culture: growth inhibitors formed by the cells Proc. Natl Acad. Sci. USA 1978 75 1864 1866 10.1073/pnas.75.4.1864 273914
Holley, R. W., Armour, R. & Baldwin, J. H. Density-dependent regulation of growth of BSC-1 cells in cell culture: growth inhibitors formed by the cells. Proc. Natl Acad. Sci. USA 75, 1864–1866 (1978).273914 10.1073/pnas.75.4.1864
17. Ignotz RA Massague J Type beta transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts Proc. Natl Acad. Sci. USA 1985 82 8530 8534 10.1073/pnas.82.24.8530 3001708
Ignotz, R. A. & Massague, J. Type beta transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts. Proc. Natl Acad. Sci. USA 82, 8530–8534 (1985).3001708 10.1073/pnas.82.24.8530
18. Seyedin SM Thomas TC Thompson AY Rosen DM Piez KA Purification and characterization of two cartilage-inducing factors from bovine demineralized bone Proc. Natl Acad. Sci. USA 1985 82 2267 2271 10.1073/pnas.82.8.2267 3857579
Seyedin, S. M., Thomas, T. C., Thompson, A. Y., Rosen, D. M. & Piez, K. A. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc. Natl Acad. Sci. USA 82, 2267–2271 (1985).3857579 10.1073/pnas.82.8.2267
19. Heine U Role of transforming growth factor-beta in the development of the mouse embryo J. Cell Biol. 1987 105 2861 2876 10.1083/jcb.105.6.2861 3320058
Heine, U. et al. Role of transforming growth factor-beta in the development of the mouse embryo. J. Cell Biol. 105, 2861–2876 (1987).3320058 10.1083/jcb.105.6.2861
20. Sporn MB Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo Science 1983 219 1329 1331 10.1126/science.6572416 6572416
Sporn, M. B. et al. Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science 219, 1329–1331 (1983).6572416 10.1126/science.6572416
21. Rook AH Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness J. Immunol. 1986 136 3916 3920 10.4049/jimmunol.136.10.3916 2871107
Rook, A. H. et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136, 3916–3920 (1986).2871107 10.4049/jimmunol.136.10.3916
22. Kehrl JH Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes J. Immunol. 1986 137 3855 3860 10.4049/jimmunol.137.12.3855 2878044
Kehrl, J. H. et al. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J. Immunol. 137, 3855–3860 (1986).2878044 10.4049/jimmunol.137.12.3855
23. Border WA Okuda S Languino LR Sporn MB Ruoslahti E Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1 Nature 1990 346 371 374 10.1038/346371a0 2374609
Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B. & Ruoslahti, E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346, 371–374 (1990).2374609 10.1038/346371a0
24. Connor TB Jr. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye J. Clin. Invest 1989 83 1661 1666 10.1172/JCI114065 2708527
Connor, T. B. Jr. et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J. Clin. Invest 83, 1661–1666 (1989).2708527 10.1172/JCI114065
25. Pierce DF Jr. Mammary tumor suppression by transforming growth factor beta 1 transgene expression Proc. Natl Acad. Sci. USA 1995 92 4254 4258 10.1073/pnas.92.10.4254 7753792
Pierce, D. F. Jr. et al. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc. Natl Acad. Sci. USA 92, 4254–4258 (1995).7753792 10.1073/pnas.92.10.4254
26. Markowitz S Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability Science 1995 268 1336 1338 10.1126/science.7761852 7761852
Markowitz, S. et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268, 1336–1338 (1995).7761852 10.1126/science.7761852
27. Massague J Czech MP Iwata K DeLarco JE Todaro GJ Affinity labeling of a transforming growth factor receptor that does not interact with epidermal growth factor Proc. Natl Acad. Sci. USA 1982 79 6822 6826 10.1073/pnas.79.22.6822 6294655
Massague, J., Czech, M. P., Iwata, K., DeLarco, J. E. & Todaro, G. J. Affinity labeling of a transforming growth factor receptor that does not interact with epidermal growth factor. Proc. Natl Acad. Sci. USA 79, 6822–6826 (1982).6294655 10.1073/pnas.79.22.6822
28. Frolik CA Wakefield LM Smith DM Sporn MB Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts J. Biol. Chem. 1984 259 10995 11000 10.1016/S0021-9258(18)90612-5 6088525
Frolik, C. A., Wakefield, L. M., Smith, D. M. & Sporn, M. B. Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. J. Biol. Chem. 259, 10995–11000 (1984).6088525 10.1016/S0021-9258(18)90612-5
29. Massagué J Like B Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines J. Biol. Chem. 1985 260 2636 2645 10.1016/S0021-9258(18)89408-X 2982829
Massagué, J. & Like, B. Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J. Biol. Chem. 260, 2636–2645 (1985).2982829 10.1016/S0021-9258(18)89408-X
30. Eppert K MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma Cell 1996 86 543 552 10.1016/S0092-8674(00)80128-2 8752209
Eppert, K. et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86, 543–552 (1996).8752209 10.1016/S0092-8674(00)80128-2
31. Zhang Y Feng X We R Derynck R Receptor-associated Mad homologues synergize as effectors of the TGF-beta response Nature 1996 383 168 172 10.1038/383168a0 8774881
Zhang, Y., Feng, X., We, R. & Derynck, R. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature 383, 168–172 (1996).8774881 10.1038/383168a0
32. Hahn SA DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1 Science 1996 271 350 353 10.1126/science.271.5247.350 8553070
Hahn, S. A. et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350–353 (1996).8553070 10.1126/science.271.5247.350
33. Schlingensiepen KH Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009 Cytokine Growth Factor Rev. 2006 17 129 139 10.1016/j.cytogfr.2005.09.002 16377233
Schlingensiepen, K. H. et al. Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17, 129–139 (2006).16377233 10.1016/j.cytogfr.2005.09.002
34. Fakhrai H Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma Cancer Gene Ther. 2006 13 1052 1060 10.1038/sj.cgt.7700975 16826191
Fakhrai, H. et al. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. 13, 1052–1060 (2006).16826191 10.1038/sj.cgt.7700975
35. Nemunaitis J Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J. Clin. Oncol. 2006 24 4721 4730 10.1200/JCO.2005.05.5335 16966690
Nemunaitis, J. et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24, 4721–4730 (2006).16966690 10.1200/JCO.2005.05.5335
36. Trachtman H A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis Kidney Int 2011 79 1236 1243 10.1038/ki.2011.33 21368745
Trachtman, H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79, 1236–1243 (2011).21368745 10.1038/ki.2011.33
37. Rodon J First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma Clin. Cancer Res 2015 21 553 560 10.1158/1078-0432.CCR-14-1380 25424852
Rodon, J. et al. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin. Cancer Res 21, 553–560 (2015).25424852 10.1158/1078-0432.CCR-14-1380
38. Rodón J Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer Invest N. Drugs 2015 33 357 370 10.1007/s10637-014-0192-4
Rodón, J. et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest N. Drugs 33, 357–370 (2015).10.1007/s10637-014-0192-4
39. Strauss J Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors Clin. Cancer Res 2018 24 1287 1295 10.1158/1078-0432.CCR-17-2653 29298798
Strauss, J. et al. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Clin. Cancer Res 24, 1287–1295 (2018).29298798 10.1158/1078-0432.CCR-17-2653
40. Dubois CM Laprise MH Blanchette F Gentry LE Leduc R Processing of transforming growth factor beta 1 precursor by human furin convertase J. Biol. Chem. 1995 270 10618 10624 10.1074/jbc.270.18.10618 7737999
Dubois, C. M., Laprise, M. H., Blanchette, F., Gentry, L. E. & Leduc, R. Processing of transforming growth factor beta 1 precursor by human furin convertase. J. Biol. Chem. 270, 10618–10624 (1995).7737999 10.1074/jbc.270.18.10618
41. Shi M Latent TGF-beta structure and activation Nature 2011 474 343 349 10.1038/nature10152 21677751
Shi, M. et al. Latent TGF-beta structure and activation. Nature 474, 343–349 (2011).21677751 10.1038/nature10152
42. Miyazono K Olofsson A Colosetti P Heldin CH A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1 EMBO J. 1991 10 1091 1101 10.1002/j.1460-2075.1991.tb08049.x 2022183
Miyazono, K., Olofsson, A., Colosetti, P. & Heldin, C. H. A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J. 10, 1091–1101 (1991).2022183 10.1002/j.1460-2075.1991.tb08049.x
43. Lockhart-Cairns MP Latent TGFbeta complexes are transglutaminase cross-linked to fibrillin to facilitate TGFbeta activation Matrix Biol. 2022 107 24 39 10.1016/j.matbio.2022.01.005 35122964
Lockhart-Cairns, M. P. et al. Latent TGFbeta complexes are transglutaminase cross-linked to fibrillin to facilitate TGFbeta activation. Matrix Biol. 107, 24–39 (2022).35122964 10.1016/j.matbio.2022.01.005
44. Tran DQ GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells Proc. Natl Acad. Sci. USA 2009 106 13445 13450 10.1073/pnas.0901944106 19651619
Tran, D. Q. et al. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc. Natl Acad. Sci. USA 106, 13445–13450 (2009).19651619 10.1073/pnas.0901944106
45. Qin Y A Milieu Molecule for TGF-beta Required for Microglia Function in the Nervous System Cell 2018 174 156 171.e116 10.1016/j.cell.2018.05.027 29909984
Qin, Y. et al. A Milieu Molecule for TGF-beta Required for Microglia Function in the Nervous System. Cell 174, 156–171.e116 (2018).29909984 10.1016/j.cell.2018.05.027
46. Annes JP Rifkin DB Munger JS The integrin alphaVbeta6 binds and activates latent TGFbeta3 FEBS Lett. 2002 511 65 68 10.1016/S0014-5793(01)03280-X 11821050
Annes, J. P., Rifkin, D. B. & Munger, J. S. The integrin alphaVbeta6 binds and activates latent TGFbeta3. FEBS Lett. 511, 65–68 (2002).11821050 10.1016/S0014-5793(01)03280-X
47. Breuss JM Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling J. Cell Sci. 1995 108 2241 2251 10.1242/jcs.108.6.2241 7673344
Breuss, J. M. et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J. Cell Sci. 108, 2241–2251 (1995).7673344 10.1242/jcs.108.6.2241
48. Mu D The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1 J. Cell Biol. 2002 157 493 507 10.1083/jcb.200109100 11970960
Mu, D. et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J. Cell Biol. 157, 493–507 (2002).11970960 10.1083/jcb.200109100
49. Kitamura H Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin alphavbeta8-mediated activation of TGF-beta J. Clin. Invest 2011 121 2863 2875 10.1172/JCI45589 21646718
Kitamura, H. et al. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin alphavbeta8-mediated activation of TGF-beta. J. Clin. Invest 121, 2863–2875 (2011).21646718 10.1172/JCI45589
50. Kelly A Human monocytes and macrophages regulate immune tolerance via integrin alphavbeta8-mediated TGFbeta activation J. Exp. Med 2018 215 2725 2736 10.1084/jem.20171491 30355614
Kelly, A. et al. Human monocytes and macrophages regulate immune tolerance via integrin alphavbeta8-mediated TGFbeta activation. J. Exp. Med 215, 2725–2736 (2018).30355614 10.1084/jem.20171491
51. Worthington JJ Czajkowska BI Melton AC Travis MA Intestinal dendritic cells specialize to activate transforming growth factor-beta and induce Foxp3+ regulatory T cells via integrin alphavbeta8 Gastroenterology 2011 141 1802 1812 10.1053/j.gastro.2011.06.057 21723222
Worthington, J. J., Czajkowska, B. I., Melton, A. C. & Travis, M. A. Intestinal dendritic cells specialize to activate transforming growth factor-beta and induce Foxp3+ regulatory T cells via integrin alphavbeta8. Gastroenterology 141, 1802–1812 (2011).21723222 10.1053/j.gastro.2011.06.057
52. Laine A Regulatory T cells promote cancer immune-escape through integrin alphavbeta8-mediated TGF-beta activation Nat. Commun. 2021 12 6228 10.1038/s41467-021-26352-2 34711823
Laine, A. et al. Regulatory T cells promote cancer immune-escape through integrin alphavbeta8-mediated TGF-beta activation. Nat. Commun. 12, 6228 (2021).34711823 10.1038/s41467-021-26352-2
53. Takasaka N Integrin alphavbeta8-expressing tumor cells evade host immunity by regulating TGF-beta activation in immune cells JCI Insight 2018 3 e122591 10.1172/jci.insight.122591 30333313
Takasaka, N. et al. Integrin alphavbeta8-expressing tumor cells evade host immunity by regulating TGF-beta activation in immune cells. JCI Insight 3, e122591 (2018).30333313 10.1172/jci.insight.122591
54. Yang Z Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice J. Cell Biol. 2007 176 787 793 10.1083/jcb.200611044 17353357
Yang, Z. et al. Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J. Cell Biol. 176, 787–793 (2007).17353357 10.1083/jcb.200611044
55. Aluwihare P Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice J. Cell Sci. 2009 122 227 232 10.1242/jcs.035246 19118215
Aluwihare, P. et al. Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J. Cell Sci. 122, 227–232 (2009).19118215 10.1242/jcs.035246
56. Dong X Force interacts with macromolecular structure in activation of TGF-beta Nature 2017 542 55 59 10.1038/nature21035 28117447
Dong, X. et al. Force interacts with macromolecular structure in activation of TGF-beta. Nature 542, 55–59 (2017).28117447 10.1038/nature21035
57. Wang R GARP regulates the bioavailability and activation of TGFbeta Mol. Biol. Cell 2012 23 1129 1139 10.1091/mbc.e11-12-1018 22278742
Wang, R. et al. GARP regulates the bioavailability and activation of TGFbeta. Mol. Biol. Cell 23, 1129–1139 (2012).22278742 10.1091/mbc.e11-12-1018
58. Edwards JP Regulation of the expression of GARP/latent TGF-beta1 complexes on mouse T cells and their role in regulatory T cell and Th17 differentiation J. Immunol. 2013 190 5506 5515 10.4049/jimmunol.1300199 23645881
Edwards, J. P. et al. Regulation of the expression of GARP/latent TGF-beta1 complexes on mouse T cells and their role in regulatory T cell and Th17 differentiation. J. Immunol. 190, 5506–5515 (2013).23645881 10.4049/jimmunol.1300199
59. Stockis J Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin alphaVbeta8 Proc. Natl Acad. Sci. USA 2017 114 E10161 E10168 10.1073/pnas.1710680114 29109269
Stockis, J. et al. Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin alphaVbeta8. Proc. Natl Acad. Sci. USA 114, E10161–E10168 (2017).29109269 10.1073/pnas.1710680114
60. Campbell MG Cryo-EM Reveals Integrin-Mediated TGF-beta Activation without Release from Latent TGF-beta Cell 2020 180 490 501.e416 10.1016/j.cell.2019.12.030 31955848
Campbell, M. G. et al. Cryo-EM Reveals Integrin-Mediated TGF-beta Activation without Release from Latent TGF-beta. Cell 180, 490–501.e416 (2020).31955848 10.1016/j.cell.2019.12.030
61. Lawrence DA Pircher R Krycève-Martinerie C Jullien P Normal embryo fibroblasts release transforming growth factors in a latent form J. Cell Physiol. 1984 121 184 188 10.1002/jcp.1041210123 6090474
Lawrence, D. A., Pircher, R., Krycève-Martinerie, C. & Jullien, P. Normal embryo fibroblasts release transforming growth factors in a latent form. J. Cell Physiol. 121, 184–188 (1984).6090474 10.1002/jcp.1041210123
62. Brown PD Wakefield LM Levinson AD Sporn MB Physicochemical activation of recombinant latent transforming growth factor-beta’s 1, 2, and 3 Growth Factors 1990 3 35 43 10.3109/08977199009037500 2200452
Brown, P. D., Wakefield, L. M., Levinson, A. D. & Sporn, M. B. Physicochemical activation of recombinant latent transforming growth factor-beta’s 1, 2, and 3. Growth Factors 3, 35–43 (1990).2200452 10.3109/08977199009037500
63. Jullien P Berg TM Lawrence DA Acidic cellular environments: activation of latent TGF-beta and sensitization of cellular responses to TGF-beta and EGF Int J. Cancer 1989 43 886 891 10.1002/ijc.2910430525 2785508
Jullien, P., Berg, T. M. & Lawrence, D. A. Acidic cellular environments: activation of latent TGF-beta and sensitization of cellular responses to TGF-beta and EGF. Int J. Cancer 43, 886–891 (1989).2785508 10.1002/ijc.2910430525
64. Silver IA Murrills RJ Etherington DJ Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts Exp. Cell Res 1988 175 266 276 10.1016/0014-4827(88)90191-7 3360056
Silver, I. A., Murrills, R. J. & Etherington, D. J. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp. Cell Res 175, 266–276 (1988).3360056 10.1016/0014-4827(88)90191-7
65. Kottmann RM Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-beta Am. J. Respir. Crit. Care Med 2012 186 740 751 10.1164/rccm.201201-0084OC 22923663
Kottmann, R. M. et al. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-beta. Am. J. Respir. Crit. Care Med 186, 740–751 (2012).22923663 10.1164/rccm.201201-0084OC
66. Jobling MF Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species Radiat. Res 2006 166 839 848 10.1667/RR0695.1 17149983
Jobling, M. F. et al. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat. Res 166, 839–848 (2006).17149983 10.1667/RR0695.1
67. Hayashi H Sakai K Baba H Sakai T Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in mice Hepatology 2012 55 1562 1573 10.1002/hep.24800 22105716
Hayashi, H., Sakai, K., Baba, H. & Sakai, T. Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in mice. Hepatology 55, 1562–1573 (2012).22105716 10.1002/hep.24800
68. Wang H Kochevar IE Involvement of UVB-induced reactive oxygen species in TGF-beta biosynthesis and activation in keratinocytes Free Radic. Biol. Med 2005 38 890 897 10.1016/j.freeradbiomed.2004.12.005 15749385
Wang, H. & Kochevar, I. E. Involvement of UVB-induced reactive oxygen species in TGF-beta biosynthesis and activation in keratinocytes. Free Radic. Biol. Med 38, 890–897 (2005).15749385 10.1016/j.freeradbiomed.2004.12.005
69. Pociask DA Sime PJ Brody AR Asbestos-derived reactive oxygen species activate TGF-beta1 Lab Invest 2004 84 1013 1023 10.1038/labinvest.3700109 15122306
Pociask, D. A., Sime, P. J. & Brody, A. R. Asbestos-derived reactive oxygen species activate TGF-beta1. Lab Invest 84, 1013–1023 (2004).15122306 10.1038/labinvest.3700109
70. Sullivan DE Ferris M Pociask D Brody AR The latent form of TGFbeta(1) is induced by TNFalpha through an ERK specific pathway and is activated by asbestos-derived reactive oxygen species in vitro and in vivo J. Immunotoxicol. 2008 5 145 149 10.1080/15476910802085822 18569384
Sullivan, D. E., Ferris, M., Pociask, D. & Brody, A. R. The latent form of TGFbeta(1) is induced by TNFalpha through an ERK specific pathway and is activated by asbestos-derived reactive oxygen species in vitro and in vivo. J. Immunotoxicol. 5, 145–149 (2008).18569384 10.1080/15476910802085822
71. Barcellos-Hoff MH Dix TA Redox-mediated activation of latent transforming growth factor-beta 1 Mol. Endocrinol. 1996 10 1077 1083 8885242
Barcellos-Hoff, M. H. & Dix, T. A. Redox-mediated activation of latent transforming growth factor-beta 1. Mol. Endocrinol. 10, 1077–1083 (1996).8885242
72. Ning W Effect of high glucose supplementation on pulmonary fibrosis involving reactive oxygen species and TGF-beta Front Nutr. 2022 9 998662 10.3389/fnut.2022.998662 36304232
Ning, W. et al. Effect of high glucose supplementation on pulmonary fibrosis involving reactive oxygen species and TGF-beta. Front Nutr. 9, 998662 (2022).36304232 10.3389/fnut.2022.998662
73. Zhang D High Glucose Intake Exacerbates Autoimmunity through Reactive-Oxygen-Species-Mediated TGF-beta Cytokine Activation Immunity 2019 51 671 681.e675 10.1016/j.immuni.2019.08.001 31451397
Zhang, D. et al. High Glucose Intake Exacerbates Autoimmunity through Reactive-Oxygen-Species-Mediated TGF-beta Cytokine Activation. Immunity 51, 671–681.e675 (2019).31451397 10.1016/j.immuni.2019.08.001
74. Chen W Frank ME Jin W Wahl SM TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu Immunity 2001 14 715 725 10.1016/S1074-7613(01)00147-9 11420042
Chen, W., Frank, M. E., Jin, W. & Wahl, S. M. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14, 715–725 (2001).11420042 10.1016/S1074-7613(01)00147-9
75. Amarnath S Dong L Li J Wu Y Chen W Endogenous TGF-beta activation by reactive oxygen species is key to Foxp3 induction in TCR-stimulated and HIV-1-infected human CD4+CD25- T cells Retrovirology 2007 4 57 10.1186/1742-4690-4-57 17688698
Amarnath, S., Dong, L., Li, J., Wu, Y. & Chen, W. Endogenous TGF-beta activation by reactive oxygen species is key to Foxp3 induction in TCR-stimulated and HIV-1-infected human CD4+CD25- T cells. Retrovirology 4, 57 (2007).17688698 10.1186/1742-4690-4-57
76. Sweetwyne MT Murphy-Ullrich JE Thrombospondin1 in tissue repair and fibrosis: TGF-beta-dependent and independent mechanisms Matrix Biol. 2012 31 178 186 10.1016/j.matbio.2012.01.006 22266026
Sweetwyne, M. T. & Murphy-Ullrich, J. E. Thrombospondin1 in tissue repair and fibrosis: TGF-beta-dependent and independent mechanisms. Matrix Biol. 31, 178–186 (2012).22266026 10.1016/j.matbio.2012.01.006
77. Murphy-Ullrich JE Suto MJ Thrombospondin-1 regulation of latent TGF-beta activation: A therapeutic target for fibrotic disease Matrix Biol. 2018 68-69 28 43 10.1016/j.matbio.2017.12.009 29288716
Murphy-Ullrich, J. E. & Suto, M. J. Thrombospondin-1 regulation of latent TGF-beta activation: A therapeutic target for fibrotic disease. Matrix Biol. 68-69, 28–43 (2018).29288716 10.1016/j.matbio.2017.12.009
78. Murphy-Ullrich JE Schultz-Cherry S Hook M Transforming growth factor-beta complexes with thrombospondin Mol. Biol. Cell 1992 3 181 188 10.1091/mbc.3.2.181 1550960
Murphy-Ullrich, J. E., Schultz-Cherry, S. & Hook, M. Transforming growth factor-beta complexes with thrombospondin. Mol. Biol. Cell 3, 181–188 (1992).1550960 10.1091/mbc.3.2.181
79. Yung S Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways Nephrol. Dial. Transpl. 2006 21 1504 1513 10.1093/ndt/gfl017
Yung, S. et al. Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways. Nephrol. Dial. Transpl. 21, 1504–1513 (2006).10.1093/ndt/gfl017
80. Naito T Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1 Am. J. Physiol. Ren. Physiol. 2004 286 F278 F287 10.1152/ajprenal.00139.2003
Naito, T. et al. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am. J. Physiol. Ren. Physiol. 286, F278–F287 (2004).10.1152/ajprenal.00139.2003
81. Kumar R Interstitial macrophage-derived thrombospondin-1 contributes to hypoxia-induced pulmonary hypertension Cardiovasc Res 2020 116 2021 2030 10.1093/cvr/cvz304 31710666
Kumar, R. et al. Interstitial macrophage-derived thrombospondin-1 contributes to hypoxia-induced pulmonary hypertension. Cardiovasc Res 116, 2021–2030 (2020).31710666 10.1093/cvr/cvz304
82. Matsuba M Hutcheon AE Zieske JD Localization of thrombospondin-1 and myofibroblasts during corneal wound repair Exp. Eye Res 2011 93 534 540 10.1016/j.exer.2011.06.018 21749870
Matsuba, M., Hutcheon, A. E. & Zieske, J. D. Localization of thrombospondin-1 and myofibroblasts during corneal wound repair. Exp. Eye Res 93, 534–540 (2011).21749870 10.1016/j.exer.2011.06.018
83. Doyen V Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation J. Exp. Med 2003 198 1277 1283 10.1084/jem.20030705 14568985
Doyen, V. et al. Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J. Exp. Med 198, 1277–1283 (2003).14568985 10.1084/jem.20030705
84. McMaken S Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity PLoS One 2011 6 e19654 10.1371/journal.pone.0019654 21573017
McMaken, S. et al. Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity. PLoS One 6, e19654 (2011).21573017 10.1371/journal.pone.0019654
85. Presser LD Haskett A Waris G Hepatitis C virus-induced furin and thrombospondin-1 activate TGF-beta1: role of TGF-beta1 in HCV replication Virology 2011 412 284 296 10.1016/j.virol.2010.12.051 21296375
Presser, L. D., Haskett, A. & Waris, G. Hepatitis C virus-induced furin and thrombospondin-1 activate TGF-beta1: role of TGF-beta1 in HCV replication. Virology 412, 284–296 (2011).21296375 10.1016/j.virol.2010.12.051
86. Kumar R TGF-beta activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension Nat. Commun. 2017 8 15494 10.1038/ncomms15494 28555642
Kumar, R. et al. TGF-beta activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension. Nat. Commun. 8, 15494 (2017).28555642 10.1038/ncomms15494
87. Zhou Y Poczatek MH Berecek KH Murphy-Ullrich JE Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions Biochem Biophys. Res Commun. 2006 339 633 641 10.1016/j.bbrc.2005.11.060 16310163
Zhou, Y., Poczatek, M. H., Berecek, K. H. & Murphy-Ullrich, J. E. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys. Res Commun. 339, 633–641 (2006).16310163 10.1016/j.bbrc.2005.11.060
88. Atanasova VS Thrombospondin-1 Is a Major Activator of TGF-beta Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts J. Invest Dermatol 2019 139 1497 1505.e1495 10.1016/j.jid.2019.01.011 30684555
Atanasova, V. S. et al. Thrombospondin-1 Is a Major Activator of TGF-beta Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts. J. Invest Dermatol 139, 1497–1505.e1495 (2019).30684555 10.1016/j.jid.2019.01.011
89. Presser LD Haskett A Waris G Hepatitis C virus-induced furin and thrombospondin-1 activate TGF-β1: role of TGF-β1 in HCV replication Virology 2011 412 284 296 10.1016/j.virol.2010.12.051 21296375
Presser, L. D., Haskett, A. & Waris, G. Hepatitis C virus-induced furin and thrombospondin-1 activate TGF-β1: role of TGF-β1 in HCV replication. Virology 412, 284–296 (2011).21296375 10.1016/j.virol.2010.12.051
90. Matsumura K Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-beta signal activation in pancreatic ductal adenocarcinoma Transl. Oncol. 2022 26 101533 10.1016/j.tranon.2022.101533 36115074
Matsumura, K. et al. Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-beta signal activation in pancreatic ductal adenocarcinoma. Transl. Oncol. 26, 101533 (2022).36115074 10.1016/j.tranon.2022.101533
91. Jenkins G The role of proteases in transforming growth factor-beta activation Int J. Biochem. Cell Biol. 2008 40 1068 1078 10.1016/j.biocel.2007.11.026 18243766
Jenkins, G. The role of proteases in transforming growth factor-beta activation. Int J. Biochem. Cell Biol. 40, 1068–1078 (2008).18243766 10.1016/j.biocel.2007.11.026
92. Lu L Restoration of intrahepatic regulatory T cells through MMP-9/13-dependent activation of TGF-beta is critical for immune homeostasis following acute liver injury J. Mol. Cell Biol. 2013 5 369 379 10.1093/jmcb/mjt042 24280647
Lu, L. et al. Restoration of intrahepatic regulatory T cells through MMP-9/13-dependent activation of TGF-beta is critical for immune homeostasis following acute liver injury. J. Mol. Cell Biol. 5, 369–379 (2013).24280647 10.1093/jmcb/mjt042
93. Bai P Macrophage-Derived Legumain Promotes Pulmonary Hypertension by Activating the MMP (Matrix Metalloproteinase)-2/TGF (Transforming Growth Factor)-β1 Signaling Arterioscler Thromb. Vasc. Biol. 2019 39 e130 e145 10.1161/ATVBAHA.118.312254 30676070
Bai, P. et al. Macrophage-Derived Legumain Promotes Pulmonary Hypertension by Activating the MMP (Matrix Metalloproteinase)-2/TGF (Transforming Growth Factor)-β1 Signaling. Arterioscler Thromb. Vasc. Biol. 39, e130–e145 (2019).30676070 10.1161/ATVBAHA.118.312254
94. Feng W Matrix metalloproteinase-9 regulates afferent arteriolar remodeling and function in hypertension-induced kidney disease Kidney Int 2023 104 740 753 10.1016/j.kint.2023.06.031 37423509
Feng, W. et al. Matrix metalloproteinase-9 regulates afferent arteriolar remodeling and function in hypertension-induced kidney disease. Kidney Int 104, 740–753 (2023).37423509 10.1016/j.kint.2023.06.031
95. Espindola MS Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med 2021 203 458 470 10.1164/rccm.201910-1977OC 33052708
Espindola, M. S. et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med 203, 458–470 (2021).33052708 10.1164/rccm.201910-1977OC
96. Yu Q Stamenkovic I Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis Genes Dev. 2000 14 163 176 10.1101/gad.14.2.163 10652271
Yu, Q. & Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163–176 (2000).10652271 10.1101/gad.14.2.163
97. Yehualaeshet T Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36 Am. J. Pathol. 1999 155 841 851 10.1016/S0002-9440(10)65183-8 10487979
Yehualaeshet, T. et al. Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am. J. Pathol. 155, 841–851 (1999).10487979 10.1016/S0002-9440(10)65183-8
98. Nunes I Shapiro RL Rifkin DB Characterization of latent TGF-beta activation by murine peritoneal macrophages J. Immunol. 1995 155 1450 1459 10.4049/jimmunol.155.3.1450 7636210
Nunes, I., Shapiro, R. L. & Rifkin, D. B. Characterization of latent TGF-beta activation by murine peritoneal macrophages. J. Immunol. 155, 1450–1459 (1995).7636210 10.4049/jimmunol.155.3.1450
99. Kojima S Rifkin DB Mechanism of retinoid-induced activation of latent transforming growth factor-beta in bovine endothelial cells J. Cell Physiol. 1993 155 323 332 10.1002/jcp.1041550213 8482724
Kojima, S. & Rifkin, D. B. Mechanism of retinoid-induced activation of latent transforming growth factor-beta in bovine endothelial cells. J. Cell Physiol. 155, 323–332 (1993).8482724 10.1002/jcp.1041550213
100. Sato Y Rifkin DB Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture J. Cell Biol. 1989 109 309 315 10.1083/jcb.109.1.309 2526131
Sato, Y. & Rifkin, D. B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J. Cell Biol. 109, 309–315 (1989).2526131 10.1083/jcb.109.1.309
101. Sankar S Mahooti-Brooks N Centrella M McCarthy TL Madri JA Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2 J. Biol. Chem. 1995 270 13567 13572 10.1074/jbc.270.22.13567 7768960
Sankar, S., Mahooti-Brooks, N., Centrella, M., McCarthy, T. L. & Madri, J. A. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J. Biol. Chem. 270, 13567–13572 (1995).7768960 10.1074/jbc.270.22.13567
102. Cheifetz S Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms J. Biol. Chem. 1990 265 20533 20538 10.1016/S0021-9258(17)30535-5 1700790
Cheifetz, S. et al. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J. Biol. Chem. 265, 20533–20538 (1990).1700790 10.1016/S0021-9258(17)30535-5
103. Wang XF Expression cloning and characterization of the TGF-beta type III receptor Cell 1991 67 797 805 10.1016/0092-8674(91)90074-9 1657407
Wang, X. F. et al. Expression cloning and characterization of the TGF-beta type III receptor. Cell 67, 797–805 (1991).1657407 10.1016/0092-8674(91)90074-9
104. Lopez-Casillas F Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system Cell 1991 67 785 795 10.1016/0092-8674(91)90073-8 1657406
Lopez-Casillas, F. et al. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 67, 785–795 (1991).1657406 10.1016/0092-8674(91)90073-8
105. Lopez-Casillas F Wrana JL Massague J Betaglycan presents ligand to the TGF beta signaling receptor Cell 1993 73 1435 1444 10.1016/0092-8674(93)90368-Z 8391934
Lopez-Casillas, F., Wrana, J. L. & Massague, J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 73, 1435–1444 (1993).8391934 10.1016/0092-8674(93)90368-Z
106. Esparza-Lopez J Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A J. Biol. Chem. 2001 276 14588 14596 10.1074/jbc.M008866200 11278442
Esparza-Lopez, J. et al. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J. Biol. Chem. 276, 14588–14596 (2001).11278442 10.1074/jbc.M008866200
107. Madamanchi A Ingle M Hinck AP Umulis DM Computational modeling of TGF-β2:TβRI:TβRII receptor complex assembly as mediated by the TGF-β coreceptor betaglycan Biophys. J. 2023 122 1342 1354 10.1016/j.bpj.2023.02.030 36869592
Madamanchi, A., Ingle, M., Hinck, A. P. & Umulis, D. M. Computational modeling of TGF-β2:TβRI:TβRII receptor complex assembly as mediated by the TGF-β coreceptor betaglycan. Biophys. J. 122, 1342–1354 (2023).36869592 10.1016/j.bpj.2023.02.030
108. Zhang W Single-molecule imaging reveals transforming growth factor-beta-induced type II receptor dimerization Proc. Natl Acad. Sci. USA 2009 106 15679 15683 10.1073/pnas.0908279106 19720988
Zhang, W. et al. Single-molecule imaging reveals transforming growth factor-beta-induced type II receptor dimerization. Proc. Natl Acad. Sci. USA 106, 15679–15683 (2009).19720988 10.1073/pnas.0908279106
109. Gilboa L Wells RG Lodish HF Henis YI Oligomeric structure of type I and type II transforming growth factor beta receptors: homodimers form in the ER and persist at the plasma membrane J. Cell Biol. 1998 140 767 777 10.1083/jcb.140.4.767 9472030
Gilboa, L., Wells, R. G., Lodish, H. F. & Henis, Y. I. Oligomeric structure of type I and type II transforming growth factor beta receptors: homodimers form in the ER and persist at the plasma membrane. J. Cell Biol. 140, 767–777 (1998).9472030 10.1083/jcb.140.4.767
110. Chen RH Derynck R Homomeric interactions between type II transforming growth factor-beta receptors J. Biol. Chem. 1994 269 22868 22874 10.1016/S0021-9258(17)31725-8 7521335
Chen, R. H. & Derynck, R. Homomeric interactions between type II transforming growth factor-beta receptors. J. Biol. Chem. 269, 22868–22874 (1994).7521335 10.1016/S0021-9258(17)31725-8
111. Groppe J Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding Mol. Cell 2008 29 157 168 10.1016/j.molcel.2007.11.039 18243111
Groppe, J. et al. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol. Cell 29, 157–168 (2008).18243111 10.1016/j.molcel.2007.11.039
112. Wrana JL TGF beta signals through a heteromeric protein kinase receptor complex Cell 1992 71 1003 1014 10.1016/0092-8674(92)90395-S 1333888
Wrana, J. L. et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71, 1003–1014 (1992).1333888 10.1016/0092-8674(92)90395-S
113. Huse M The TGF beta receptor activation process: an inhibitor- to substrate-binding switch Mol. Cell 2001 8 671 682 10.1016/S1097-2765(01)00332-X 11583628
Huse, M. et al. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol. Cell 8, 671–682 (2001).11583628 10.1016/S1097-2765(01)00332-X
114. Tsukazaki T Chiang TA Davison AF Attisano L Wrana JL SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor Cell 1998 95 779 791 10.1016/S0092-8674(00)81701-8 9865696
Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L. & Wrana, J. L. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95, 779–791 (1998).9865696 10.1016/S0092-8674(00)81701-8
115. Wu JW Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling Mol. Cell 2001 8 1277 1289 10.1016/S1097-2765(01)00421-X 11779503
Wu, J. W. et al. Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. Mol. Cell 8, 1277–1289 (2001).11779503 10.1016/S1097-2765(01)00421-X
116. Kawabata M Inoue H Hanyu A Imamura T Miyazono K Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors Embo j. 1998 17 4056 4065 10.1093/emboj/17.14.4056 9670020
Kawabata, M., Inoue, H., Hanyu, A., Imamura, T. & Miyazono, K. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. Embo j. 17, 4056–4065 (1998).9670020 10.1093/emboj/17.14.4056
117. Chacko BM The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization Nat. Struct. Biol. 2001 8 248 253 10.1038/84995 11224571
Chacko, B. M. et al. The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization. Nat. Struct. Biol. 8, 248–253 (2001).11224571 10.1038/84995
118. Lucarelli P Resolving the Combinatorial Complexity of Smad Protein Complex Formation and Its Link to Gene Expression Cell Syst. 2018 6 75 89.e11 10.1016/j.cels.2017.11.010 29248373
Lucarelli, P. et al. Resolving the Combinatorial Complexity of Smad Protein Complex Formation and Its Link to Gene Expression. Cell Syst. 6, 75–89.e11 (2018).29248373 10.1016/j.cels.2017.11.010
119. Inman GJ Hill CS Stoichiometry of active smad-transcription factor complexes on DNA J. Biol. Chem. 2002 277 51008 51016 10.1074/jbc.M208532200 12374795
Inman, G. J. & Hill, C. S. Stoichiometry of active smad-transcription factor complexes on DNA. J. Biol. Chem. 277, 51008–51016 (2002).12374795 10.1074/jbc.M208532200
120. Shi Y Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling Cell 1998 94 585 594 10.1016/S0092-8674(00)81600-1 9741623
Shi, Y. et al. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 94, 585–594 (1998).9741623 10.1016/S0092-8674(00)81600-1
121. Martin-Malpartida P Structural basis for genome wide recognition of 5-bp GC motifs by SMAD transcription factors Nat. Commun. 2017 8 2070 10.1038/s41467-017-02054-6 29234012
Martin-Malpartida, P. et al. Structural basis for genome wide recognition of 5-bp GC motifs by SMAD transcription factors. Nat. Commun. 8, 2070 (2017).29234012 10.1038/s41467-017-02054-6
122. Zawel L Human Smad3 and Smad4 are sequence-specific transcription activators Mol. Cell 1998 1 611 617 10.1016/S1097-2765(00)80061-1 9660945
Zawel, L. et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1, 611–617 (1998).9660945 10.1016/S1097-2765(00)80061-1
123. Liu Z Global identification of SMAD2 target genes reveals a role for multiple co-regulatory factors in zebrafish early gastrulas J. Biol. Chem. 2011 286 28520 28532 10.1074/jbc.M111.236307 21669877
Liu, Z. et al. Global identification of SMAD2 target genes reveals a role for multiple co-regulatory factors in zebrafish early gastrulas. J. Biol. Chem. 286, 28520–28532 (2011).21669877 10.1074/jbc.M111.236307
124. Koinuma D Promoter-wide analysis of Smad4 binding sites in human epithelial cells Cancer Sci. 2009 100 2133 2142 10.1111/j.1349-7006.2009.01299.x 19686287
Koinuma, D. et al. Promoter-wide analysis of Smad4 binding sites in human epithelial cells. Cancer Sci. 100, 2133–2142 (2009).19686287 10.1111/j.1349-7006.2009.01299.x
125. Mullen AC Master transcription factors determine cell-type-specific responses to TGF-β signaling Cell 2011 147 565 576 10.1016/j.cell.2011.08.050 22036565
Mullen, A. C. et al. Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell 147, 565–576 (2011).22036565 10.1016/j.cell.2011.08.050
126. Afrakhte M Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members Biochem Biophys. Res Commun. 1998 249 505 511 10.1006/bbrc.1998.9170 9712726
Afrakhte, M. et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys. Res Commun. 249, 505–511 (1998).9712726 10.1006/bbrc.1998.9170
127. Denissova NG Pouponnot C Long J He D Liu F Transforming growth factor beta -inducible independent binding of SMAD to the Smad7 promoter Proc. Natl Acad. Sci. USA 2000 97 6397 6402 10.1073/pnas.090099297 10823886
Denissova, N. G., Pouponnot, C., Long, J., He, D. & Liu, F. Transforming growth factor beta -inducible independent binding of SMAD to the Smad7 promoter. Proc. Natl Acad. Sci. USA 97, 6397–6402 (2000).10823886 10.1073/pnas.090099297
128. Imamura T Smad6 inhibits signalling by the TGF-beta superfamily Nature 1997 389 622 626 10.1038/39355 9335505
Imamura, T. et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 389, 622–626 (1997).9335505 10.1038/39355
129. Kamiya Y Miyazono K Miyazawa K Smad7 inhibits transforming growth factor-beta family type i receptors through two distinct modes of interaction J. Biol. Chem. 2010 285 30804 30813 10.1074/jbc.M110.166140 20663871
Kamiya, Y., Miyazono, K. & Miyazawa, K. Smad7 inhibits transforming growth factor-beta family type i receptors through two distinct modes of interaction. J. Biol. Chem. 285, 30804–30813 (2010).20663871 10.1074/jbc.M110.166140
130. Hanyu A The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling J. Cell Biol. 2001 155 1017 1027 10.1083/jcb.200106023 11739411
Hanyu, A. et al. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling. J. Cell Biol. 155, 1017–1027 (2001).11739411 10.1083/jcb.200106023
131. Suzuki C Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane J. Biol. Chem. 2002 277 39919 39925 10.1074/jbc.M201901200 12151385
Suzuki, C. et al. Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J. Biol. Chem. 277, 39919–39925 (2002).12151385 10.1074/jbc.M201901200
132. Kavsak P Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation Mol. Cell 2000 6 1365 1375 10.1016/S1097-2765(00)00134-9 11163210
Kavsak, P. et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol. Cell 6, 1365–1375 (2000).11163210 10.1016/S1097-2765(00)00134-9
133. Yan X Smad7 Protein Interacts with Receptor-regulated Smads (R-Smads) to Inhibit Transforming Growth Factor-β (TGF-β)/Smad Signaling J. Biol. Chem. 2016 291 382 392 10.1074/jbc.M115.694281 26555259
Yan, X. et al. Smad7 Protein Interacts with Receptor-regulated Smads (R-Smads) to Inhibit Transforming Growth Factor-β (TGF-β)/Smad Signaling. J. Biol. Chem. 291, 382–392 (2016).26555259 10.1074/jbc.M115.694281
134. Kuratomi G NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor Biochem J. 2005 386 461 470 10.1042/BJ20040738 15496141
Kuratomi, G. et al. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem J. 386, 461–470 (2005).15496141 10.1042/BJ20040738
135. Morén A Imamura T Miyazono K Heldin CH Moustakas A Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases J. Biol. Chem. 2005 280 22115 22123 10.1074/jbc.M414027200 15817471
Morén, A., Imamura, T., Miyazono, K., Heldin, C. H. & Moustakas, A. Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J. Biol. Chem. 280, 22115–22123 (2005).15817471 10.1074/jbc.M414027200
136. Shi W GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor J. Cell Biol. 2004 164 291 300 10.1083/jcb.200307151 14718519
Shi, W. et al. GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor. J. Cell Biol. 164, 291–300 (2004).14718519 10.1083/jcb.200307151
137. Zhang S Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation Mol. Cell Biol. 2007 27 4488 4499 10.1128/MCB.01636-06 17438144
Zhang, S. et al. Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol. Cell Biol. 27, 4488–4499 (2007).17438144 10.1128/MCB.01636-06
138. Ross S Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription Embo j. 2006 25 4490 4502 10.1038/sj.emboj.7601332 16990801
Ross, S. et al. Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription. Embo j. 25, 4490–4502 (2006).16990801 10.1038/sj.emboj.7601332
139. Feng XH Zhang Y Wu RY Derynck R The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation Genes Dev. 1998 12 2153 2163 10.1101/gad.12.14.2153 9679060
Feng, X. H., Zhang, Y., Wu, R. Y. & Derynck, R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev. 12, 2153–2163 (1998).9679060 10.1101/gad.12.14.2153
140. Itoh S Ericsson J Nishikawa J Heldin CH ten Dijke P The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling Nucleic Acids Res 2000 28 4291 4298 10.1093/nar/28.21.4291 11058129
Itoh, S., Ericsson, J., Nishikawa, J., Heldin, C. H. & ten Dijke, P. The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling. Nucleic Acids Res 28, 4291–4298 (2000).11058129 10.1093/nar/28.21.4291
141. Kahata K Regulation of transforming growth factor-beta and bone morphogenetic protein signalling by transcriptional coactivator GCN5 Genes Cells 2004 9 143 151 10.1111/j.1365-2443.2004.00706.x 15009097
Kahata, K. et al. Regulation of transforming growth factor-beta and bone morphogenetic protein signalling by transcriptional coactivator GCN5. Genes Cells 9, 143–151 (2004).15009097 10.1111/j.1365-2443.2004.00706.x
142. Yahata T The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors J. Biol. Chem. 2000 275 8825 8834 10.1074/jbc.275.12.8825 10722728
Yahata, T. et al. The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors. J. Biol. Chem. 275, 8825–8834 (2000).10722728 10.1074/jbc.275.12.8825
143. Postigo AA Opposing functions of ZEB proteins in the regulation of the TGFbeta/BMP signaling pathway Embo j. 2003 22 2443 2452 10.1093/emboj/cdg225 12743038
Postigo, A. A. Opposing functions of ZEB proteins in the regulation of the TGFbeta/BMP signaling pathway. Embo j. 22, 2443–2452 (2003).12743038 10.1093/emboj/cdg225
144. Postigo AA Depp JL Taylor JJ Kroll KL Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins Embo j. 2003 22 2453 2462 10.1093/emboj/cdg226 12743039
Postigo, A. A., Depp, J. L., Taylor, J. J. & Kroll, K. L. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. Embo j. 22, 2453–2462 (2003).12743039 10.1093/emboj/cdg226
145. Shuttleworth VG The methyltransferase SET9 regulates TGFB1 activation of renal fibroblasts via interaction with SMAD3 J. Cell Sci. 2018 131 jcs207761 10.1242/jcs.207761 29222115
Shuttleworth, V. G. et al. The methyltransferase SET9 regulates TGFB1 activation of renal fibroblasts via interaction with SMAD3. J. Cell Sci. 131, jcs207761 (2018).29222115 10.1242/jcs.207761
146. Kang JS Alliston T Delston R Derynck R Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3 Embo j. 2005 24 2543 2555 10.1038/sj.emboj.7600729 15990875
Kang, J. S., Alliston, T., Delston, R. & Derynck, R. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. Embo j. 24, 2543–2555 (2005).15990875 10.1038/sj.emboj.7600729
147. Wotton D Lo RS Lee S Massagué J A Smad transcriptional corepressor Cell 1999 97 29 39 10.1016/S0092-8674(00)80712-6 10199400
Wotton, D., Lo, R. S., Lee, S. & Massagué, J. A Smad transcriptional corepressor. Cell 97, 29–39 (1999).10199400 10.1016/S0092-8674(00)80712-6
148. Alliston T Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1 J. Biol. Chem. 2005 280 24227 24237 10.1074/jbc.M414305200 15849193
Alliston, T. et al. Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1. J. Biol. Chem. 280, 24227–24237 (2005).15849193 10.1074/jbc.M414305200
149. Izutsu K The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling Blood 2001 97 2815 2822 10.1182/blood.V97.9.2815 11313276
Izutsu, K. et al. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 97, 2815–2822 (2001).11313276 10.1182/blood.V97.9.2815
150. Luo K The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling Genes Dev. 1999 13 2196 2206 10.1101/gad.13.17.2196 10485843
Luo, K. et al. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev. 13, 2196–2206 (1999).10485843 10.1101/gad.13.17.2196
151. Akiyoshi S c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads J. Biol. Chem. 1999 274 35269 35277 10.1074/jbc.274.49.35269 10575014
Akiyoshi, S. et al. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J. Biol. Chem. 274, 35269–35277 (1999).10575014 10.1074/jbc.274.49.35269
152. Sun Y Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling Mol. Cell 1999 4 499 509 10.1016/S1097-2765(00)80201-4 10549282
Sun, Y. et al. Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling. Mol. Cell 4, 499–509 (1999).10549282 10.1016/S1097-2765(00)80201-4
153. Stroschein SL Wang W Zhou S Zhou Q Luo K Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein Science 1999 286 771 774 10.1126/science.286.5440.771 10531062
Stroschein, S. L., Wang, W., Zhou, S., Zhou, Q. & Luo, K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 286, 771–774 (1999).10531062 10.1126/science.286.5440.771
154. Feng XH Liang YY Liang M Zhai W Lin X Direct Interaction of c-Myc with Smad2 and Smad3 to Inhibit TGF-β-Mediated Induction of the CDK Inhibitor p15(Ink4B) Mol. Cell 2016 63 1089 10.1016/j.molcel.2016.08.027 27618489
Feng, X. H., Liang, Y. Y., Liang, M., Zhai, W. & Lin, X. Direct Interaction of c-Myc with Smad2 and Smad3 to Inhibit TGF-β-Mediated Induction of the CDK Inhibitor p15(Ink4B). Mol. Cell 63, 1089 (2016).27618489 10.1016/j.molcel.2016.08.027
155. Kim RH A novel smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-beta signal transduction Genes Dev. 2000 14 1605 1616 10.1101/gad.14.13.1605 10887155
Kim, R. H. et al. A novel smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-beta signal transduction. Genes Dev. 14, 1605–1616 (2000).10887155 10.1101/gad.14.13.1605
156. Verschueren K SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5’-CACCT sequences in candidate target genes J. Biol. Chem. 1999 274 20489 20498 10.1074/jbc.274.29.20489 10400677
Verschueren, K. et al. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5’-CACCT sequences in candidate target genes. J. Biol. Chem. 274, 20489–20498 (1999).10400677 10.1074/jbc.274.29.20489
157. Wakabayashi Y Histone 3 lysine 9 (H3K9) methyltransferase recruitment to the interleukin-2 (IL-2) promoter is a mechanism of suppression of IL-2 transcription by the transforming growth factor-β-Smad pathway J. Biol. Chem. 2011 286 35456 35465 10.1074/jbc.M111.236794 21862595
Wakabayashi, Y. et al. Histone 3 lysine 9 (H3K9) methyltransferase recruitment to the interleukin-2 (IL-2) promoter is a mechanism of suppression of IL-2 transcription by the transforming growth factor-β-Smad pathway. J. Biol. Chem. 286, 35456–35465 (2011).21862595 10.1074/jbc.M111.236794
158. Du D Smad3-mediated recruitment of the methyltransferase SETDB1/ESET controls Snail1 expression and epithelial-mesenchymal transition EMBO Rep. 2018 19 135 155 10.15252/embr.201744250 29233829
Du, D. et al. Smad3-mediated recruitment of the methyltransferase SETDB1/ESET controls Snail1 expression and epithelial-mesenchymal transition. EMBO Rep. 19, 135–155 (2018).29233829 10.15252/embr.201744250
159. Brown JD DiChiara MR Anderson KR Gimbrone MA Jr. Topper JN MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells J. Biol. Chem. 1999 274 8797 8805 10.1074/jbc.274.13.8797 10085121
Brown, J. D., DiChiara, M. R., Anderson, K. R., Gimbrone, M. A. Jr. & Topper, J. N. MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J. Biol. Chem. 274, 8797–8805 (1999).10085121 10.1074/jbc.274.13.8797
160. Kamaraju AK Roberts AB Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo J. Biol. Chem. 2005 280 1024 1036 10.1074/jbc.M403960200 15520018
Kamaraju, A. K. & Roberts, A. B. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 280, 1024–1036 (2005).15520018 10.1074/jbc.M403960200
161. Mori S TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions Oncogene 2004 23 7416 7429 10.1038/sj.onc.1207981 15326485
Mori, S. et al. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 23, 7416–7429 (2004).15326485 10.1038/sj.onc.1207981
162. Lehmann K Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells Genes Dev. 2000 14 2610 2622 10.1101/gad.181700 11040215
Lehmann, K. et al. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev. 14, 2610–2622 (2000).11040215 10.1101/gad.181700
163. Funaba M Zimmerman CM Mathews LS Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase J. Biol. Chem. 2002 277 41361 41368 10.1074/jbc.M204597200 12193595
Funaba, M., Zimmerman, C. M. & Mathews, L. S. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J. Biol. Chem. 277, 41361–41368 (2002).12193595 10.1074/jbc.M204597200
164. Roelen BA Phosphorylation of threonine 276 in Smad4 is involved in transforming growth factor-beta-induced nuclear accumulation Am. J. Physiol. Cell Physiol. 2003 285 C823 C830 10.1152/ajpcell.00053.2003 12801888
Roelen, B. A. et al. Phosphorylation of threonine 276 in Smad4 is involved in transforming growth factor-beta-induced nuclear accumulation. Am. J. Physiol. Cell Physiol. 285, C823–C830 (2003).12801888 10.1152/ajpcell.00053.2003
165. Guo X Axin and GSK3- control Smad3 protein stability and modulate TGF- signaling Genes Dev. 2008 22 106 120 10.1101/gad.1590908 18172167
Guo, X. et al. Axin and GSK3- control Smad3 protein stability and modulate TGF- signaling. Genes Dev. 22, 106–120 (2008).18172167 10.1101/gad.1590908
166. Millet C A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204 J. Biol. Chem. 2009 284 19808 19816 10.1074/jbc.M109.016667 19458083
Millet, C. et al. A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204. J. Biol. Chem. 284, 19808–19816 (2009).19458083 10.1074/jbc.M109.016667
167. Wang G Matsuura I He D Liu F Transforming growth factor-{beta}-inducible phosphorylation of Smad3 J. Biol. Chem. 2009 284 9663 9673 10.1074/jbc.M809281200 19218245
Wang, G., Matsuura, I., He, D. & Liu, F. Transforming growth factor-{beta}-inducible phosphorylation of Smad3. J. Biol. Chem. 284, 9663–9673 (2009).19218245 10.1074/jbc.M809281200
168. Wicks SJ Lui S Abdel-Wahab N Mason RM Chantry A Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II Mol. Cell Biol. 2000 20 8103 8111 10.1128/.20.21.8103-8111.2000 11027280
Wicks, S. J., Lui, S., Abdel-Wahab, N., Mason, R. M. & Chantry, A. Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II. Mol. Cell Biol. 20, 8103–8111 (2000).11027280 10.1128/.20.21.8103-8111.2000
169. Yakymovych I Ten Dijke P Heldin CH Souchelnytskyi S Regulation of Smad signaling by protein kinase C Faseb j. 2001 15 553 555 10.1096/fj.00-0474fje 11259364
Yakymovych, I., Ten Dijke, P., Heldin, C. H. & Souchelnytskyi, S. Regulation of Smad signaling by protein kinase C. Faseb j. 15, 553–555 (2001).11259364 10.1096/fj.00-0474fje
170. Saura M Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells Circ. Res 2005 97 1115 1123 10.1161/01.RES.0000191538.76771.66 16239590
Saura, M. et al. Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells. Circ. Res 97, 1115–1123 (2005).16239590 10.1161/01.RES.0000191538.76771.66
171. Alarcón C Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways Cell 2009 139 757 769 10.1016/j.cell.2009.09.035 19914168
Alarcón, C. et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 139, 757–769 (2009).19914168 10.1016/j.cell.2009.09.035
172. Matsuura I Cyclin-dependent kinases regulate the antiproliferative function of Smads Nature 2004 430 226 231 10.1038/nature02650 15241418
Matsuura, I. et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430, 226–231 (2004).15241418 10.1038/nature02650
173. Sapkota G Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways J. Biol. Chem. 2006 281 40412 40419 10.1074/jbc.M610172200 17085434
Sapkota, G. et al. Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. J. Biol. Chem. 281, 40412–40419 (2006).17085434 10.1074/jbc.M610172200
174. Wrighton KH Small C-terminal domain phosphatases dephosphorylate the regulatory linker regions of Smad2 and Smad3 to enhance transforming growth factor-beta signaling J. Biol. Chem. 2006 281 38365 38375 10.1074/jbc.M607246200 17035229
Wrighton, K. H. et al. Small C-terminal domain phosphatases dephosphorylate the regulatory linker regions of Smad2 and Smad3 to enhance transforming growth factor-beta signaling. J. Biol. Chem. 281, 38365–38375 (2006).17035229 10.1074/jbc.M607246200
175. Lin X PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling Cell 2006 125 915 928 10.1016/j.cell.2006.03.044 16751101
Lin, X. et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell 125, 915–928 (2006).16751101 10.1016/j.cell.2006.03.044
176. Yu J MTMR4 attenuates transforming growth factor beta (TGFbeta) signaling by dephosphorylating R-Smads in endosomes J. Biol. Chem. 2010 285 8454 8462 10.1074/jbc.M109.075036 20061380
Yu, J. et al. MTMR4 attenuates transforming growth factor beta (TGFbeta) signaling by dephosphorylating R-Smads in endosomes. J. Biol. Chem. 285, 8454–8462 (2010).20061380 10.1074/jbc.M109.075036
177. Heikkinen PT Hypoxia-activated Smad3-specific dephosphorylation by PP2A J. Biol. Chem. 2010 285 3740 3749 10.1074/jbc.M109.042978 19951945
Heikkinen, P. T. et al. Hypoxia-activated Smad3-specific dephosphorylation by PP2A. J. Biol. Chem. 285, 3740–3749 (2010).19951945 10.1074/jbc.M109.042978
178. Lin X Liang M Feng XH Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling J. Biol. Chem. 2000 275 36818 36822 10.1074/jbc.C000580200 11016919
Lin, X., Liang, M. & Feng, X. H. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J. Biol. Chem. 275, 36818–36822 (2000).11016919 10.1074/jbc.C000580200
179. Zhang Y Chang C Gehling DJ Hemmati-Brivanlou A Derynck R Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase Proc. Natl Acad. Sci. USA 2001 98 974 979 10.1073/pnas.98.3.974 11158580
Zhang, Y., Chang, C., Gehling, D. J., Hemmati-Brivanlou, A. & Derynck, R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl Acad. Sci. USA 98, 974–979 (2001).11158580 10.1073/pnas.98.3.974
180. Tang LY Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3 Embo j. 2011 30 4777 4789 10.1038/emboj.2011.393 22045334
Tang, L. Y. et al. Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3. Embo j. 30, 4777–4789 (2011).22045334 10.1038/emboj.2011.393
181. Gao S Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling Mol. Cell 2009 36 457 468 10.1016/j.molcel.2009.09.043 19917253
Gao, S. et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol. Cell 36, 457–468 (2009).19917253 10.1016/j.molcel.2009.09.043
182. Komuro A Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1) Oncogene 2004 23 6914 6923 10.1038/sj.onc.1207885 15221015
Komuro, A. et al. Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene 23, 6914–6923 (2004).15221015 10.1038/sj.onc.1207885
183. Seo SR The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation Embo j. 2004 23 3780 3792 10.1038/sj.emboj.7600398 15359284
Seo, S. R. et al. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. Embo j. 23, 3780–3792 (2004).15359284 10.1038/sj.emboj.7600398
184. Soond SM Chantry A Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGFβ signalling and EMT Oncogene 2011 30 2451 2462 10.1038/onc.2010.617 21258410
Soond, S. M. & Chantry, A. Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGFβ signalling and EMT. Oncogene 30, 2451–2462 (2011).21258410 10.1038/onc.2010.617
185. Mavrakis KJ Arkadia enhances Nodal/TGF-beta signaling by coupling phospho-Smad2/3 activity and turnover PLoS Biol. 2007 5 e67 10.1371/journal.pbio.0050067 17341133
Mavrakis, K. J. et al. Arkadia enhances Nodal/TGF-beta signaling by coupling phospho-Smad2/3 activity and turnover. PLoS Biol. 5, e67 (2007).17341133 10.1371/journal.pbio.0050067
186. Xin H CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation J. Biol. Chem. 2005 280 20842 20850 10.1074/jbc.M412275200 15781469
Xin, H. et al. CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation. J. Biol. Chem. 280, 20842–20850 (2005).15781469 10.1074/jbc.M412275200
187. Bai Y Yang C Hu K Elly C Liu YC Itch E3 ligase-mediated regulation of TGF-beta signaling by modulating smad2 phosphorylation Mol. Cell 2004 15 825 831 10.1016/j.molcel.2004.07.021 15350225
Bai, Y., Yang, C., Hu, K., Elly, C. & Liu, Y. C. Itch E3 ligase-mediated regulation of TGF-beta signaling by modulating smad2 phosphorylation. Mol. Cell 15, 825–831 (2004).15350225 10.1016/j.molcel.2004.07.021
188. Fukuchi M Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins Mol. Biol. Cell 2001 12 1431 1443 10.1091/mbc.12.5.1431 11359933
Fukuchi, M. et al. Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Mol. Biol. Cell 12, 1431–1443 (2001).11359933 10.1091/mbc.12.5.1431
189. Wan M Smad4 protein stability is regulated by ubiquitin ligase SCF beta-TrCP1 J. Biol. Chem. 2004 279 14484 14487 10.1074/jbc.C400005200 14988407
Wan, M. et al. Smad4 protein stability is regulated by ubiquitin ligase SCF beta-TrCP1. J. Biol. Chem. 279, 14484–14487 (2004).14988407 10.1074/jbc.C400005200
190. Tang LY Zhang YE Non-degradative ubiquitination in Smad-dependent TGF-β signaling Cell Biosci. 2011 1 43 10.1186/2045-3701-1-43 22204598
Tang, L. Y. & Zhang, Y. E. Non-degradative ubiquitination in Smad-dependent TGF-β signaling. Cell Biosci. 1, 43 (2011).22204598 10.1186/2045-3701-1-43
191. Aragón E A Smad action turnover switch operated by WW domain readers of a phosphoserine code Genes Dev. 2011 25 1275 1288 10.1101/gad.2060811 21685363
Aragón, E. et al. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev. 25, 1275–1288 (2011).21685363 10.1101/gad.2060811
192. Lee MK TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA Embo j. 2007 26 3957 3967 10.1038/sj.emboj.7601818 17673906
Lee, M. K. et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. Embo j. 26, 3957–3967 (2007).17673906 10.1038/sj.emboj.7601818
193. Lavoie H Gagnon J Therrien M ERK signalling: a master regulator of cell behaviour, life and fate Nat. Rev. Mol. Cell Biol. 2020 21 607 632 10.1038/s41580-020-0255-7 32576977
Lavoie, H., Gagnon, J. & Therrien, M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat. Rev. Mol. Cell Biol. 21, 607–632 (2020).32576977 10.1038/s41580-020-0255-7
194. Lu N Malemud CJ Extracellular Signal-Regulated Kinase: A Regulator of Cell Growth, Inflammation, Chondrocyte and Bone Cell Receptor-Mediated Gene Expression Int J. Mol. Sci. 2019 20 3792 10.3390/ijms20153792 31382554
Lu, N. & Malemud, C. J. Extracellular Signal-Regulated Kinase: A Regulator of Cell Growth, Inflammation, Chondrocyte and Bone Cell Receptor-Mediated Gene Expression. Int J. Mol. Sci. 20, 3792 (2019).31382554 10.3390/ijms20153792
195. Schmidt A Hall A Guanine nucleotide exchange factors for Rho GTPases: turning on the switch Genes Dev. 2002 16 1587 1609 10.1101/gad.1003302 12101119
Schmidt, A. & Hall, A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev. 16, 1587–1609 (2002).12101119 10.1101/gad.1003302
196. Papadimitriou E Kardassis D Moustakas A Stournaras C TGFβ-induced early activation of the small GTPase RhoA is Smad2/3-independent and involves Src and the guanine nucleotide exchange factor Vav2 Cell Physiol. Biochem 2011 28 229 238 10.1159/000331734 21865730
Papadimitriou, E., Kardassis, D., Moustakas, A. & Stournaras, C. TGFβ-induced early activation of the small GTPase RhoA is Smad2/3-independent and involves Src and the guanine nucleotide exchange factor Vav2. Cell Physiol. Biochem 28, 229–238 (2011).21865730 10.1159/000331734
197. Lu X Effect of RhoC on the epithelial-mesenchymal transition process induced by TGF-β1 in lung adenocarcinoma cells Oncol. Rep. 2016 36 3105 3112 10.3892/or.2016.5146 27748883
Lu, X. et al. Effect of RhoC on the epithelial-mesenchymal transition process induced by TGF-β1 in lung adenocarcinoma cells. Oncol. Rep. 36, 3105–3112 (2016).27748883 10.3892/or.2016.5146
198. Bhowmick NA Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism Mol. Biol. Cell 2001 12 27 36 10.1091/mbc.12.1.27 11160820
Bhowmick, N. A. et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 12, 27–36 (2001).11160820 10.1091/mbc.12.1.27
199. Shen X The activity of guanine exchange factor NET1 is essential for transforming growth factor-beta-mediated stress fiber formation J. Biol. Chem. 2001 276 15362 15368 10.1074/jbc.M009534200 11278519
Shen, X. et al. The activity of guanine exchange factor NET1 is essential for transforming growth factor-beta-mediated stress fiber formation. J. Biol. Chem. 276, 15362–15368 (2001).11278519 10.1074/jbc.M009534200
200. Papadimitriou E Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF-β and miR-24: role in epithelial-to-mesenchymal transition Oncogene 2012 31 2862 2875 10.1038/onc.2011.457 21986943
Papadimitriou, E. et al. Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF-β and miR-24: role in epithelial-to-mesenchymal transition. Oncogene 31, 2862–2875 (2012).21986943 10.1038/onc.2011.457
201. Vardouli L Moustakas A Stournaras C LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta J. Biol. Chem. 2005 280 11448 11457 10.1074/jbc.M402651200 15647284
Vardouli, L., Moustakas, A. & Stournaras, C. LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. J. Biol. Chem. 280, 11448–11457 (2005).15647284 10.1074/jbc.M402651200
202. Lee J Ko M Joo CK Rho plays a key role in TGF-beta1-induced cytoskeletal rearrangement in human retinal pigment epithelium J. Cell Physiol. 2008 216 520 526 10.1002/jcp.21424 18314880
Lee, J., Ko, M. & Joo, C. K. Rho plays a key role in TGF-beta1-induced cytoskeletal rearrangement in human retinal pigment epithelium. J. Cell Physiol. 216, 520–526 (2008).18314880 10.1002/jcp.21424
203. Sousa-Squiavinato ACM Rocha MR Barcellos-de-Souza P de Souza WF Morgado-Diaz JA Cofilin-1 signaling mediates epithelial-mesenchymal transition by promoting actin cytoskeleton reorganization and cell-cell adhesion regulation in colorectal cancer cells Biochim Biophys. Acta Mol. Cell Res 2019 1866 418 429 10.1016/j.bbamcr.2018.10.003 30296500
Sousa-Squiavinato, A. C. M., Rocha, M. R., Barcellos-de-Souza, P., de Souza, W. F. & Morgado-Diaz, J. A. Cofilin-1 signaling mediates epithelial-mesenchymal transition by promoting actin cytoskeleton reorganization and cell-cell adhesion regulation in colorectal cancer cells. Biochim Biophys. Acta Mol. Cell Res 1866, 418–429 (2019).30296500 10.1016/j.bbamcr.2018.10.003
204. Wei YH Liao SL Wang SH Wang CC Yang CH Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves’ Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways Front Endocrinol. (Lausanne) 2020 11 607968 10.3389/fendo.2020.607968 33597925
Wei, Y. H., Liao, S. L., Wang, S. H., Wang, C. C. & Yang, C. H. Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves’ Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways. Front Endocrinol. (Lausanne) 11, 607968 (2020).33597925 10.3389/fendo.2020.607968
205. Matoba K Rho-Kinase Blockade Attenuates Podocyte Apoptosis by Inhibiting the Notch Signaling Pathway in Diabetic Nephropathy Int J. Mol. Sci. 2017 18 1795 10.3390/ijms18081795 28820432
Matoba, K. et al. Rho-Kinase Blockade Attenuates Podocyte Apoptosis by Inhibiting the Notch Signaling Pathway in Diabetic Nephropathy. Int J. Mol. Sci. 18, 1795 (2017).28820432 10.3390/ijms18081795
206. Edlund S Landström M Heldin CH Aspenström P Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA Mol. Biol. Cell 2002 13 902 914 10.1091/mbc.01-08-0398 11907271
Edlund, S., Landström, M., Heldin, C. H. & Aspenström, P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol. Biol. Cell 13, 902–914 (2002).11907271 10.1091/mbc.01-08-0398
207. Jaffe AB Hall A Rho GTPases: biochemistry and biology Annu Rev. Cell Dev. Biol. 2005 21 247 269 10.1146/annurev.cellbio.21.020604.150721 16212495
Jaffe, A. B. & Hall, A. Rho GTPases: biochemistry and biology. Annu Rev. Cell Dev. Biol. 21, 247–269 (2005).16212495 10.1146/annurev.cellbio.21.020604.150721
208. Nomikou E Livitsanou M Stournaras C Kardassis D Transcriptional and post-transcriptional regulation of the genes encoding the small GTPases RhoA, RhoB, and RhoC: implications for the pathogenesis of human diseases Cell Mol. Life Sci. 2018 75 2111 2124 10.1007/s00018-018-2787-y 29500478
Nomikou, E., Livitsanou, M., Stournaras, C. & Kardassis, D. Transcriptional and post-transcriptional regulation of the genes encoding the small GTPases RhoA, RhoB, and RhoC: implications for the pathogenesis of human diseases. Cell Mol. Life Sci. 75, 2111–2124 (2018).29500478 10.1007/s00018-018-2787-y
209. Zhang L TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis Mol. Cell 2013 51 559 572 10.1016/j.molcel.2013.07.014 23973329
Zhang, L. et al. TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. Mol. Cell 51, 559–572 (2013).23973329 10.1016/j.molcel.2013.07.014
210. Sorrentino A The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner Nat. Cell Biol. 2008 10 1199 1207 10.1038/ncb1780 18758450
Sorrentino, A. et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 10, 1199–1207 (2008).18758450 10.1038/ncb1780
211. Yamashita M TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta Mol. Cell 2008 31 918 924 10.1016/j.molcel.2008.09.002 18922473
Yamashita, M. et al. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol. Cell 31, 918–924 (2008).18922473 10.1016/j.molcel.2008.09.002
212. Engel ME McDonnell MA Law BK Moses HL Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription J. Biol. Chem. 1999 274 37413 37420 10.1074/jbc.274.52.37413 10601313
Engel, M. E., McDonnell, M. A., Law, B. K. & Moses, H. L. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J. Biol. Chem. 274, 37413–37420 (1999).10601313 10.1074/jbc.274.52.37413
213. Atfi A Djelloul S Chastre E Davis R Gespach C Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling J. Biol. Chem. 1997 272 1429 1432 10.1074/jbc.272.3.1429 8999807
Atfi, A., Djelloul, S., Chastre, E., Davis, R. & Gespach, C. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J. Biol. Chem. 272, 1429–1432 (1997).8999807 10.1074/jbc.272.3.1429
214. Minden A Lin A Claret FX Abo A Karin M Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs Cell 1995 81 1147 1157 10.1016/S0092-8674(05)80019-4 7600582
Minden, A., Lin, A., Claret, F. X., Abo, A. & Karin, M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81, 1147–1157 (1995).7600582 10.1016/S0092-8674(05)80019-4
215. Coso OA The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway Cell 1995 81 1137 1146 10.1016/S0092-8674(05)80018-2 7600581
Coso, O. A. et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 81, 1137–1146 (1995).7600581 10.1016/S0092-8674(05)80018-2
216. Mazars A Differential roles of JNK and Smad2 signaling pathways in the inhibition of c-Myc-induced cell death by TGF-beta Oncogene 2000 19 1277 1287 10.1038/sj.onc.1203420 10713669
Mazars, A. et al. Differential roles of JNK and Smad2 signaling pathways in the inhibition of c-Myc-induced cell death by TGF-beta. Oncogene 19, 1277–1287 (2000).10713669 10.1038/sj.onc.1203420
217. Hocevar BA Brown TL Howe PH TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway Embo j. 1999 18 1345 1356 10.1093/emboj/18.5.1345 10064600
Hocevar, B. A., Brown, T. L. & Howe, P. H. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. Embo j. 18, 1345–1356 (1999).10064600 10.1093/emboj/18.5.1345
218. Zeke A Misheva M Reményi A Bogoyevitch MA JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships Microbiol Mol. Biol. Rev. 2016 80 793 835 10.1128/MMBR.00043-14 27466283
Zeke, A., Misheva, M., Reményi, A. & Bogoyevitch, M. A. JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships. Microbiol Mol. Biol. Rev. 80, 793–835 (2016).27466283 10.1128/MMBR.00043-14
219. Yu L Hébert MC Zhang YE TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses Embo j. 2002 21 3749 3759 10.1093/emboj/cdf366 12110587
Yu, L., Hébert, M. C. & Zhang, Y. E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. Embo j. 21, 3749–3759 (2002).12110587 10.1093/emboj/cdf366
220. Canovas B Nebreda AR Diversity and versatility of p38 kinase signalling in health and disease Nat. Rev. Mol. Cell Biol. 2021 22 346 366 10.1038/s41580-020-00322-w 33504982
Canovas, B. & Nebreda, A. R. Diversity and versatility of p38 kinase signalling in health and disease. Nat. Rev. Mol. Cell Biol. 22, 346–366 (2021).33504982 10.1038/s41580-020-00322-w
221. Hamidi A Polyubiquitination of transforming growth factor β (TGFβ)-associated kinase 1 mediates nuclear factor-κB activation in response to different inflammatory stimuli J. Biol. Chem. 2012 287 123 133 10.1074/jbc.M111.285122 22069318
Hamidi, A. et al. Polyubiquitination of transforming growth factor β (TGFβ)-associated kinase 1 mediates nuclear factor-κB activation in response to different inflammatory stimuli. J. Biol. Chem. 287, 123–133 (2012).22069318 10.1074/jbc.M111.285122
222. Kim HJ Kim JG Moon MY Park SH Park JB IκB kinase γ/nuclear factor-κB-essential modulator (IKKγ/NEMO) facilitates RhoA GTPase activation, which, in turn, activates Rho-associated KINASE (ROCK) to phosphorylate IKKβ in response to transforming growth factor (TGF)-β1 J. Biol. Chem. 2014 289 1429 1440 10.1074/jbc.M113.520130 24240172
Kim, H. J., Kim, J. G., Moon, M. Y., Park, S. H. & Park, J. B. IκB kinase γ/nuclear factor-κB-essential modulator (IKKγ/NEMO) facilitates RhoA GTPase activation, which, in turn, activates Rho-associated KINASE (ROCK) to phosphorylate IKKβ in response to transforming growth factor (TGF)-β1. J. Biol. Chem. 289, 1429–1440 (2014).24240172 10.1074/jbc.M113.520130
223. Rodriguez PL Sahay S Olabisi OO Whitehead IP ROCK I-mediated activation of NF-kappaB by RhoB Cell Signal 2007 19 2361 2369 10.1016/j.cellsig.2007.07.021 17728102
Rodriguez, P. L., Sahay, S., Olabisi, O. O. & Whitehead, I. P. ROCK I-mediated activation of NF-kappaB by RhoB. Cell Signal 19, 2361–2369 (2007).17728102 10.1016/j.cellsig.2007.07.021
224. Zhu X TGF-beta1-induced PI3K/Akt/NF-kappaB/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts J. Biochem 2011 149 405 414 10.1093/jb/mvr016 21288887
Zhu, X. et al. TGF-beta1-induced PI3K/Akt/NF-kappaB/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts. J. Biochem 149, 405–414 (2011).21288887 10.1093/jb/mvr016
225. Capece D NF-κB: blending metabolism, immunity, and inflammation Trends Immunol. 2022 43 757 775 10.1016/j.it.2022.07.004 35965153
Capece, D. et al. NF-κB: blending metabolism, immunity, and inflammation. Trends Immunol. 43, 757–775 (2022).35965153 10.1016/j.it.2022.07.004
226. Zinatizadeh MR The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases Genes Dis. 2021 8 287 297 10.1016/j.gendis.2020.06.005 33997176
Zinatizadeh, M. R. et al. The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases. Genes Dis. 8, 287–297 (2021).33997176 10.1016/j.gendis.2020.06.005
227. Liu D Zhong Z Karin M NF-κB: A Double-Edged Sword Controlling Inflammation Biomedicines 2022 10 1250 10.3390/biomedicines10061250 35740272
Liu, D., Zhong, Z. & Karin, M. NF-κB: A Double-Edged Sword Controlling Inflammation. Biomedicines 10, 1250 (2022).35740272 10.3390/biomedicines10061250
228. Yi JY Shin I Arteaga CL Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase J. Biol. Chem. 2005 280 10870 10876 10.1074/jbc.M413223200 15657037
Yi, J. Y., Shin, I. & Arteaga, C. L. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J. Biol. Chem. 280, 10870–10876 (2005).15657037 10.1074/jbc.M413223200
229. Hamidi A TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α Sci. Signal 2017 10 eaal4186 10.1126/scisignal.aal4186 28676490
Hamidi, A. et al. TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α. Sci. Signal 10, eaal4186 (2017).28676490 10.1126/scisignal.aal4186
230. Bakin AV Tomlinson AK Bhowmick NA Moses HL Arteaga CL Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration J. Biol. Chem. 2000 275 36803 36810 10.1074/jbc.M005912200 10969078
Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L. & Arteaga, C. L. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275, 36803–36810 (2000).10969078 10.1074/jbc.M005912200
231. Lamouille S Derynck R Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway J. Cell Biol. 2007 178 437 451 10.1083/jcb.200611146 17646396
Lamouille, S. & Derynck, R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J. Cell Biol. 178, 437–451 (2007).17646396 10.1083/jcb.200611146
232. Lamouille S Connolly E Smyth JW Akhurst RJ Derynck R TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion J. Cell Sci. 2012 125 1259 1273 10.1242/jcs.095299 22399812
Lamouille, S., Connolly, E., Smyth, J. W., Akhurst, R. J. & Derynck, R. TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J. Cell Sci. 125, 1259–1273 (2012).22399812 10.1242/jcs.095299
233. Chen XH The TGF-β-induced up-regulation of NKG2DLs requires AKT/GSK-3β-mediated stabilization of SP1 J. Cell Mol. Med 2017 21 860 870 10.1111/jcmm.13025 28165192
Chen, X. H. et al. The TGF-β-induced up-regulation of NKG2DLs requires AKT/GSK-3β-mediated stabilization of SP1. J. Cell Mol. Med 21, 860–870 (2017).28165192 10.1111/jcmm.13025
234. Kato M Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease J. Am. Soc. Nephrol. 2006 17 3325 3335 10.1681/ASN.2006070754 17082237
Kato, M. et al. Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J. Am. Soc. Nephrol. 17, 3325–3335 (2006).17082237 10.1681/ASN.2006070754
235. Franke TF PI3K/Akt: getting it right matters Oncogene 2008 27 6473 6488 10.1038/onc.2008.313 18955974
Franke, T. F. PI3K/Akt: getting it right matters. Oncogene 27, 6473–6488 (2008).18955974 10.1038/onc.2008.313
236. Liu Y Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation J. Biol. Chem. 2013 288 30708 30719 10.1074/jbc.M113.478685 24005672
Liu, Y. et al. Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J. Biol. Chem. 288, 30708–30719 (2013).24005672 10.1074/jbc.M113.478685
237. Tang LY Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway J. Biol. Chem. 2017 292 4302 4312 10.1074/jbc.M116.773085 28154170
Tang, L. Y. et al. Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway. J. Biol. Chem. 292, 4302–4312 (2017).28154170 10.1074/jbc.M116.773085
238. Dees C JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis Arthritis Rheum. 2012 64 3006 3015 10.1002/art.34500 22549363
Dees, C. et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheum. 64, 3006–3015 (2012).22549363 10.1002/art.34500
239. Philips RL The JAK-STAT pathway at 30: Much learned, much more to do Cell 2022 185 3857 3876 10.1016/j.cell.2022.09.023 36240739
Philips, R. L. et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell 185, 3857–3876 (2022).36240739 10.1016/j.cell.2022.09.023
240. Lehnert SA Akhurst RJ Embryonic expression pattern of TGF beta type-1 RNA suggests both paracrine and autocrine mechanisms of action Development 1988 104 263 273 10.1242/dev.104.2.263 2474426
Lehnert, S. A. & Akhurst, R. J. Embryonic expression pattern of TGF beta type-1 RNA suggests both paracrine and autocrine mechanisms of action. Development 104, 263–273 (1988).2474426 10.1242/dev.104.2.263
241. Pelton RW Nomura S Moses HL Hogan BL Expression of transforming growth factor beta 2 RNA during murine embryogenesis Development 1989 106 759 767 10.1242/dev.106.4.759 2485246
Pelton, R. W., Nomura, S., Moses, H. L. & Hogan, B. L. Expression of transforming growth factor beta 2 RNA during murine embryogenesis. Development 106, 759–767 (1989).2485246 10.1242/dev.106.4.759
242. Pelton RW Dickinson ME Moses HL Hogan BL In situ hybridization analysis of TGF beta 3 RNA expression during mouse development: comparative studies with TGF beta 1 and beta 2 Development 1990 110 609 620 10.1242/dev.110.2.609 1723948
Pelton, R. W., Dickinson, M. E., Moses, H. L. & Hogan, B. L. In situ hybridization analysis of TGF beta 3 RNA expression during mouse development: comparative studies with TGF beta 1 and beta 2. Development 110, 609–620 (1990).1723948 10.1242/dev.110.2.609
243. Millan FA Denhez F Kondaiah P Akhurst RJ Embryonic gene expression patterns of TGF beta 1, beta 2 and beta 3 suggest different developmental functions in vivo Development 1991 111 131 143 10.1242/dev.111.1.131 1707784
Millan, F. A., Denhez, F., Kondaiah, P. & Akhurst, R. J. Embryonic gene expression patterns of TGF beta 1, beta 2 and beta 3 suggest different developmental functions in vivo. Development 111, 131–143 (1991).1707784 10.1242/dev.111.1.131
244. Pelton RW Saxena B Jones M Moses HL Gold LI Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development J. Cell Biol. 1991 115 1091 1105 10.1083/jcb.115.4.1091 1955457
Pelton, R. W., Saxena, B., Jones, M., Moses, H. L. & Gold, L. I. Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J. Cell Biol. 115, 1091–1105 (1991).1955457 10.1083/jcb.115.4.1091
245. Rosa F Mesoderm induction in amphibians: the role of TGF-beta 2-like factors Science 1988 239 783 785 10.1126/science.3422517 3422517
Rosa, F. et al. Mesoderm induction in amphibians: the role of TGF-beta 2-like factors. Science 239, 783–785 (1988).3422517 10.1126/science.3422517
246. Kimelman D Kirschner M Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo Cell 1987 51 869 877 10.1016/0092-8674(87)90110-3 3479265
Kimelman, D. & Kirschner, M. Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell 51, 869–877 (1987).3479265 10.1016/0092-8674(87)90110-3
247. Bai H Xie YL Gao YX Cheng T Wang ZZ The balance of positive and negative effects of TGF-β signaling regulates the development of hematopoietic and endothelial progenitors in human pluripotent stem cells Stem Cells Dev. 2013 22 2765 2776 10.1089/scd.2013.0008 23758278
Bai, H., Xie, Y. L., Gao, Y. X., Cheng, T. & Wang, Z. Z. The balance of positive and negative effects of TGF-β signaling regulates the development of hematopoietic and endothelial progenitors in human pluripotent stem cells. Stem Cells Dev. 22, 2765–2776 (2013).23758278 10.1089/scd.2013.0008
248. Zhang CY Transforming growth factor-β1 regulates the nascent hematopoietic stem cell niche by promoting gluconeogenesis Leukemia 2018 32 479 491 10.1038/leu.2017.198 28642593
Zhang, C. Y. et al. Transforming growth factor-β1 regulates the nascent hematopoietic stem cell niche by promoting gluconeogenesis. Leukemia 32, 479–491 (2018).28642593 10.1038/leu.2017.198
249. Challen GA Boles NC Chambers SM Goodell MA Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1 Cell Stem Cell 2010 6 265 278 10.1016/j.stem.2010.02.002 20207229
Challen, G. A., Boles, N. C., Chambers, S. M. & Goodell, M. A. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell 6, 265–278 (2010).20207229 10.1016/j.stem.2010.02.002
250. Xie Y Cooperative Effect of Erythropoietin and TGF-β Inhibition on Erythroid Development in Human Pluripotent Stem Cells J. Cell Biochem 2015 116 2735 2743 10.1002/jcb.25233 26012423
Xie, Y. et al. Cooperative Effect of Erythropoietin and TGF-β Inhibition on Erythroid Development in Human Pluripotent Stem Cells. J. Cell Biochem 116, 2735–2743 (2015).26012423 10.1002/jcb.25233
251. Ng F PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages Blood 2008 112 295 307 10.1182/blood-2007-07-103697 18332228
Ng, F. et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 112, 295–307 (2008).18332228 10.1182/blood-2007-07-103697
252. Jian H Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells Genes Dev. 2006 20 666 674 10.1101/gad.1388806 16543220
Jian, H. et al. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev. 20, 666–674 (2006).16543220 10.1101/gad.1388806
253. Alliston T Choy L Ducy P Karsenty G Derynck R TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation Embo j. 2001 20 2254 2272 10.1093/emboj/20.9.2254 11331591
Alliston, T., Choy, L., Ducy, P., Karsenty, G. & Derynck, R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. Embo j. 20, 2254–2272 (2001).11331591 10.1093/emboj/20.9.2254
254. Liu D Black BL Derynck R TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3 Genes Dev. 2001 15 2950 2966 10.1101/gad.925901 11711431
Liu, D., Black, B. L. & Derynck, R. TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15, 2950–2966 (2001).11711431 10.1101/gad.925901
255. Massagué J Cheifetz S Endo T Nadal-Ginard B Type beta transforming growth factor is an inhibitor of myogenic differentiation Proc. Natl Acad. Sci. USA 1986 83 8206 8210 10.1073/pnas.83.21.8206 3022285
Massagué, J., Cheifetz, S., Endo, T. & Nadal-Ginard, B. Type beta transforming growth factor is an inhibitor of myogenic differentiation. Proc. Natl Acad. Sci. USA 83, 8206–8210 (1986).3022285 10.1073/pnas.83.21.8206
256. Florini JR Transforming growth factor-beta. A very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells J. Biol. Chem. 1986 261 16509 16513 10.1016/S0021-9258(18)66595-0 3465726
Florini, J. R. et al. Transforming growth factor-beta. A very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells. J. Biol. Chem. 261, 16509–16513 (1986).3465726 10.1016/S0021-9258(18)66595-0
257. Zhu S Goldschmidt-Clermont PJ Dong C Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability Circ. Res 2004 94 617 625 10.1161/01.RES.0000118599.25944.D5 14739161
Zhu, S., Goldschmidt-Clermont, P. J. & Dong, C. Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. Circ. Res 94, 617–625 (2004).14739161 10.1161/01.RES.0000118599.25944.D5
258. Choy L Derynck R Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function J. Biol. Chem. 2003 278 9609 9619 10.1074/jbc.M212259200 12524424
Choy, L. & Derynck, R. Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. J. Biol. Chem. 278, 9609–9619 (2003).12524424 10.1074/jbc.M212259200
259. Choy L Skillington J Derynck R Roles of autocrine TGF-beta receptor and Smad signaling in adipocyte differentiation J. Cell Biol. 2000 149 667 682 10.1083/jcb.149.3.667 10791980
Choy, L., Skillington, J. & Derynck, R. Roles of autocrine TGF-beta receptor and Smad signaling in adipocyte differentiation. J. Cell Biol. 149, 667–682 (2000).10791980 10.1083/jcb.149.3.667
260. Kurpinski K Transforming growth factor-beta and notch signaling mediate stem cell differentiation into smooth muscle cells Stem Cells 2010 28 734 742 10.1002/stem.319 20146266
Kurpinski, K. et al. Transforming growth factor-beta and notch signaling mediate stem cell differentiation into smooth muscle cells. Stem Cells 28, 734–742 (2010).20146266 10.1002/stem.319
261. Seyedin SM Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta J. Biol. Chem. 1986 261 5693 5695 10.1016/S0021-9258(17)38436-3 3754555
Seyedin, S. M. et al. Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta. J. Biol. Chem. 261, 5693–5695 (1986).3754555 10.1016/S0021-9258(17)38436-3
262. Leonard CM Role of transforming growth factor-beta in chondrogenic pattern formation in the embryonic limb: stimulation of mesenchymal condensation and fibronectin gene expression by exogenenous TGF-beta and evidence for endogenous TGF-beta-like activity Dev. Biol. 1991 145 99 109 10.1016/0012-1606(91)90216-P 2019328
Leonard, C. M. et al. Role of transforming growth factor-beta in chondrogenic pattern formation in the embryonic limb: stimulation of mesenchymal condensation and fibronectin gene expression by exogenenous TGF-beta and evidence for endogenous TGF-beta-like activity. Dev. Biol. 145, 99–109 (1991).2019328 10.1016/0012-1606(91)90216-P
263. Reiss M Sartorelli AC Regulation of growth and differentiation of human keratinocytes by type beta transforming growth factor and epidermal growth factor Cancer Res 1987 47 6705 6709 2445478
Reiss, M. & Sartorelli, A. C. Regulation of growth and differentiation of human keratinocytes by type beta transforming growth factor and epidermal growth factor. Cancer Res 47, 6705–6709 (1987).2445478
264. Masui T Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells Proc. Natl Acad. Sci. USA 1986 83 2438 2442 10.1073/pnas.83.8.2438 2871553
Masui, T. et al. Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc. Natl Acad. Sci. USA 83, 2438–2442 (1986).2871553 10.1073/pnas.83.8.2438
265. Yu X The Cytokine TGF-β Promotes the Development and Homeostasis of Alveolar Macrophages Immunity 2017 47 903 912.e904 10.1016/j.immuni.2017.10.007 29126797
Yu, X. et al. The Cytokine TGF-β Promotes the Development and Homeostasis of Alveolar Macrophages. Immunity 47, 903–912.e904 (2017).29126797 10.1016/j.immuni.2017.10.007
266. Clark AT Young RJ Bertram JF In vitro studies on the roles of transforming growth factor-beta 1 in rat metanephric development Kidney Int 2001 59 1641 1653 10.1046/j.1523-1755.2001.0590051641.x 11318934
Clark, A. T., Young, R. J. & Bertram, J. F. In vitro studies on the roles of transforming growth factor-beta 1 in rat metanephric development. Kidney Int 59, 1641–1653 (2001).11318934 10.1046/j.1523-1755.2001.0590051641.x
267. Sanvito F TGF-beta 1 influences the relative development of the exocrine and endocrine pancreas in vitro Development 1994 120 3451 3462 10.1242/dev.120.12.3451 7821214
Sanvito, F. et al. TGF-beta 1 influences the relative development of the exocrine and endocrine pancreas in vitro. Development 120, 3451–3462 (1994).7821214 10.1242/dev.120.12.3451
268. Böttinger EP Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas Embo j. 1997 16 2621 2633 10.1093/emboj/16.10.2621 9184209
Böttinger, E. P. et al. Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas. Embo j. 16, 2621–2633 (1997).9184209 10.1093/emboj/16.10.2621
269. Huojia M TGF-beta3 induces ectopic mineralization in fetal mouse dental pulp during tooth germ development Dev. Growth Differ. 2005 47 141 152 10.1111/j.1440-169x.2005.00790.x 15839999
Huojia, M. et al. TGF-beta3 induces ectopic mineralization in fetal mouse dental pulp during tooth germ development. Dev. Growth Differ. 47, 141–152 (2005).15839999 10.1111/j.1440-169x.2005.00790.x
270. Yi JJ Barnes AP Hand R Polleux F Ehlers MD TGF-beta signaling specifies axons during brain development Cell 2010 142 144 157 10.1016/j.cell.2010.06.010 20603020
Yi, J. J., Barnes, A. P., Hand, R., Polleux, F. & Ehlers, M. D. TGF-beta signaling specifies axons during brain development. Cell 142, 144–157 (2010).20603020 10.1016/j.cell.2010.06.010
271. Stipursky J Gomes FC TGF-beta1/SMAD signaling induces astrocyte fate commitment in vitro: implications for radial glia development Glia 2007 55 1023 1033 10.1002/glia.20522 17549683
Stipursky, J. & Gomes, F. C. TGF-beta1/SMAD signaling induces astrocyte fate commitment in vitro: implications for radial glia development. Glia 55, 1023–1033 (2007).17549683 10.1002/glia.20522
272. Farkas LM Dünker N Roussa E Unsicker K Krieglstein K Transforming growth factor-beta(s) are essential for the development of midbrain dopaminergic neurons in vitro and in vivo J. Neurosci. 2003 23 5178 5186 10.1523/JNEUROSCI.23-12-05178.2003 12832542
Farkas, L. M., Dünker, N., Roussa, E., Unsicker, K. & Krieglstein, K. Transforming growth factor-beta(s) are essential for the development of midbrain dopaminergic neurons in vitro and in vivo. J. Neurosci. 23, 5178–5186 (2003).12832542 10.1523/JNEUROSCI.23-12-05178.2003
273. Chleilat E TGF-β Signaling Regulates Development of Midbrain Dopaminergic and Hindbrain Serotonergic Neuron Subgroups Neuroscience 2018 381 124 137 10.1016/j.neuroscience.2018.04.019 29689292
Chleilat, E. et al. TGF-β Signaling Regulates Development of Midbrain Dopaminergic and Hindbrain Serotonergic Neuron Subgroups. Neuroscience 381, 124–137 (2018).29689292 10.1016/j.neuroscience.2018.04.019
274. Araujo AP Effects of Transforming Growth Factor Beta 1 in Cerebellar Development: Role in Synapse Formation Front Cell Neurosci. 2016 10 104 10.3389/fncel.2016.00104 27199658
Araujo, A. P. et al. Effects of Transforming Growth Factor Beta 1 in Cerebellar Development: Role in Synapse Formation. Front Cell Neurosci. 10, 104 (2016).27199658 10.3389/fncel.2016.00104
275. Morris AD Lewis GM Kucenas S Perineurial Glial Plasticity and the Role of TGF-β in the Development of the Blood-Nerve Barrier J. Neurosci. 2017 37 4790 4807 10.1523/JNEUROSCI.2875-16.2017 28389474
Morris, A. D., Lewis, G. M. & Kucenas, S. Perineurial Glial Plasticity and the Role of TGF-β in the Development of the Blood-Nerve Barrier. J. Neurosci. 37, 4790–4807 (2017).28389474 10.1523/JNEUROSCI.2875-16.2017
276. de Sampaio e Spohr TC Martinez R da Silva EF Neto VM Gomes FC Neuro-glia interaction effects on GFAP gene: a novel role for transforming growth factor-beta1 Eur. J. Neurosci. 2002 16 2059 2069 10.1046/j.1460-9568.2002.02283.x 12473073
de Sampaio e Spohr, T. C., Martinez, R., da Silva, E. F., Neto, V. M. & Gomes, F. C. Neuro-glia interaction effects on GFAP gene: a novel role for transforming growth factor-beta1. Eur. J. Neurosci. 16, 2059–2069 (2002).12473073 10.1046/j.1460-9568.2002.02283.x
277. Miettinen PJ Ebner R Lopez AR Derynck R TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors J. Cell Biol. 1994 127 2021 2036 10.1083/jcb.127.6.2021 7806579
Miettinen, P. J., Ebner, R., Lopez, A. R. & Derynck, R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol. 127, 2021–2036 (1994).7806579 10.1083/jcb.127.6.2021
278. Lamouille S Xu J Derynck R Molecular mechanisms of epithelial-mesenchymal transition Nat. Rev. Mol. Cell Biol. 2014 15 178 196 10.1038/nrm3758 24556840
Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014).24556840 10.1038/nrm3758
279. Jalali A Zhu X Liu C Nawshad A Induction of palate epithelial mesenchymal transition by transforming growth factor β3 signaling Dev. Growth Differ. 2012 54 633 648 10.1111/j.1440-169X.2012.01364.x 22775504
Jalali, A., Zhu, X., Liu, C. & Nawshad, A. Induction of palate epithelial mesenchymal transition by transforming growth factor β3 signaling. Dev. Growth Differ. 54, 633–648 (2012).22775504 10.1111/j.1440-169X.2012.01364.x
280. Nawshad A Hay ED TGFbeta3 signaling activates transcription of the LEF1 gene to induce epithelial mesenchymal transformation during mouse palate development J. Cell Biol. 2003 163 1291 1301 10.1083/jcb.200306024 14691138
Nawshad, A. & Hay, E. D. TGFbeta3 signaling activates transcription of the LEF1 gene to induce epithelial mesenchymal transformation during mouse palate development. J. Cell Biol. 163, 1291–1301 (2003).14691138 10.1083/jcb.200306024
281. Pelton RW Hogan BL Miller DA Moses HL Differential expression of genes encoding TGFs beta 1, beta 2, and beta 3 during murine palate formation Dev. Biol. 1990 141 456 460 10.1016/0012-1606(90)90401-4 1698672
Pelton, R. W., Hogan, B. L., Miller, D. A. & Moses, H. L. Differential expression of genes encoding TGFs beta 1, beta 2, and beta 3 during murine palate formation. Dev. Biol. 141, 456–460 (1990).1698672 10.1016/0012-1606(90)90401-4
282. Fitzpatrick DR Denhez F Kondaiah P Akhurst RJ Differential expression of TGF beta isoforms in murine palatogenesis Development 1990 109 585 595 10.1242/dev.109.3.585 2401212
Fitzpatrick, D. R., Denhez, F., Kondaiah, P. & Akhurst, R. J. Differential expression of TGF beta isoforms in murine palatogenesis. Development 109, 585–595 (1990).2401212 10.1242/dev.109.3.585
283. Brunet CL Sharpe PM Ferguson MW Inhibition of TGF-beta 3 (but not TGF-beta 1 or TGF-beta 2) activity prevents normal mouse embryonic palate fusion Int J. Dev. Biol. 1995 39 345 355 7669547
Brunet, C. L., Sharpe, P. M. & Ferguson, M. W. Inhibition of TGF-beta 3 (but not TGF-beta 1 or TGF-beta 2) activity prevents normal mouse embryonic palate fusion. Int J. Dev. Biol. 39, 345–355 (1995).7669547
284. Sabbineni H Verma A Somanath PR Isoform-specific effects of transforming growth factor beta on endothelial-to-mesenchymal transition J. Cell Physiol. 2018 233 8418 8428 10.1002/jcp.26801 29856065
Sabbineni, H., Verma, A. & Somanath, P. R. Isoform-specific effects of transforming growth factor beta on endothelial-to-mesenchymal transition. J. Cell Physiol. 233, 8418–8428 (2018).29856065 10.1002/jcp.26801
285. Molin DG Expression patterns of Tgfbeta1-3 associate with myocardialisation of the outflow tract and the development of the epicardium and the fibrous heart skeleton Dev. Dyn. 2003 227 431 444 10.1002/dvdy.10314 12815630
Molin, D. G. et al. Expression patterns of Tgfbeta1-3 associate with myocardialisation of the outflow tract and the development of the epicardium and the fibrous heart skeleton. Dev. Dyn. 227, 431–444 (2003).12815630 10.1002/dvdy.10314
286. Dickson MC Slager HG Duffie E Mummery CL Akhurst RJ RNA and protein localisations of TGF beta 2 in the early mouse embryo suggest an involvement in cardiac development Development 1993 117 625 639 10.1242/dev.117.2.625 7687212
Dickson, M. C., Slager, H. G., Duffie, E., Mummery, C. L. & Akhurst, R. J. RNA and protein localisations of TGF beta 2 in the early mouse embryo suggest an involvement in cardiac development. Development 117, 625–639 (1993).7687212 10.1242/dev.117.2.625
287. Akhurst RJ Lehnert SA Faissner A Duffie E TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis Development 1990 108 645 656 10.1242/dev.108.4.645 1696875
Akhurst, R. J., Lehnert, S. A., Faissner, A. & Duffie, E. TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. Development 108, 645–656 (1990).1696875 10.1242/dev.108.4.645
288. Camenisch TD Temporal and distinct TGFbeta ligand requirements during mouse and avian endocardial cushion morphogenesis Dev. Biol. 2002 248 170 181 10.1006/dbio.2002.0731 12142029
Camenisch, T. D. et al. Temporal and distinct TGFbeta ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev. Biol. 248, 170–181 (2002).12142029 10.1006/dbio.2002.0731
289. Potts JD Runyan RB Epithelial-mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor beta Dev. Biol. 1989 134 392 401 10.1016/0012-1606(89)90111-5 2744239
Potts, J. D. & Runyan, R. B. Epithelial-mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor beta. Dev. Biol. 134, 392–401 (1989).2744239 10.1016/0012-1606(89)90111-5
290. Azhar M Ligand-specific function of transforming growth factor beta in epithelial-mesenchymal transition in heart development Dev. Dyn. 2009 238 431 442 10.1002/dvdy.21854 19161227
Azhar, M. et al. Ligand-specific function of transforming growth factor beta in epithelial-mesenchymal transition in heart development. Dev. Dyn. 238, 431–442 (2009).19161227 10.1002/dvdy.21854
291. Nakajima Y Yamagishi T Nakamura H Markwald RR Krug EL An autocrine function for transforming growth factor (TGF)-beta3 in the transformation of atrioventricular canal endocardium into mesenchyme during chick heart development Dev. Biol. 1998 194 99 113 10.1006/dbio.1997.8807 9473335
Nakajima, Y., Yamagishi, T., Nakamura, H., Markwald, R. R. & Krug, E. L. An autocrine function for transforming growth factor (TGF)-beta3 in the transformation of atrioventricular canal endocardium into mesenchyme during chick heart development. Dev. Biol. 194, 99–113 (1998).9473335 10.1006/dbio.1997.8807
292. Compton LA Potash DA Mundell NA Barnett JV Transforming growth factor-beta induces loss of epithelial character and smooth muscle cell differentiation in epicardial cells Dev. Dyn. 2006 235 82 93 10.1002/dvdy.20629 16258965
Compton, L. A., Potash, D. A., Mundell, N. A. & Barnett, J. V. Transforming growth factor-beta induces loss of epithelial character and smooth muscle cell differentiation in epicardial cells. Dev. Dyn. 235, 82–93 (2006).16258965 10.1002/dvdy.20629
293. Austin AF Compton LA Love JD Brown CB Barnett JV Primary and immortalized mouse epicardial cells undergo differentiation in response to TGFbeta Dev. Dyn. 2008 237 366 376 10.1002/dvdy.21421 18213583
Austin, A. F., Compton, L. A., Love, J. D., Brown, C. B. & Barnett, J. V. Primary and immortalized mouse epicardial cells undergo differentiation in response to TGFbeta. Dev. Dyn. 237, 366–376 (2008).18213583 10.1002/dvdy.21421
294. Liu M Transforming Growth Factor-induced Protein Promotes NF-κB-mediated Angiogenesis during Postnatal Lung Development Am. J. Respir. Cell Mol. Biol. 2021 64 318 330 10.1165/rcmb.2020-0153OC 33264084
Liu, M. et al. Transforming Growth Factor-induced Protein Promotes NF-κB-mediated Angiogenesis during Postnatal Lung Development. Am. J. Respir. Cell Mol. Biol. 64, 318–330 (2021).33264084 10.1165/rcmb.2020-0153OC
295. Ahmed S Liu CC Nawshad A Mechanisms of palatal epithelial seam disintegration by transforming growth factor (TGF) beta3 Dev. Biol. 2007 309 193 207 10.1016/j.ydbio.2007.06.018 17698055
Ahmed, S., Liu, C. C. & Nawshad, A. Mechanisms of palatal epithelial seam disintegration by transforming growth factor (TGF) beta3. Dev. Biol. 309, 193–207 (2007).17698055 10.1016/j.ydbio.2007.06.018
296. Dunker N Schmitt K Krieglstein K TGF-beta is required for programmed cell death in interdigital webs of the developing mouse limb Mech. Dev. 2002 113 111 120 10.1016/S0925-4773(02)00015-1 11960699
Dunker, N., Schmitt, K. & Krieglstein, K. TGF-beta is required for programmed cell death in interdigital webs of the developing mouse limb. Mech. Dev. 113, 111–120 (2002).11960699 10.1016/S0925-4773(02)00015-1
297. Krieglstein K Reduction of endogenous transforming growth factors beta prevents ontogenetic neuron death Nat. Neurosci. 2000 3 1085 1090 10.1038/80598 11036264
Krieglstein, K. et al. Reduction of endogenous transforming growth factors beta prevents ontogenetic neuron death. Nat. Neurosci. 3, 1085–1090 (2000).11036264 10.1038/80598
298. Dunker N Schuster N Krieglstein K TGF-beta modulates programmed cell death in the retina of the developing chick embryo Development 2001 128 1933 1942 10.1242/dev.128.11.1933 11493517
Dunker, N., Schuster, N. & Krieglstein, K. TGF-beta modulates programmed cell death in the retina of the developing chick embryo. Development 128, 1933–1942 (2001).11493517 10.1242/dev.128.11.1933
299. Schuster N Dunker N Krieglstein K Transforming growth factor-beta induced cell death in the developing chick retina is mediated via activation of c-jun N-terminal kinase and downregulation of the anti-apoptotic protein Bcl-X(L) Neurosci. Lett. 2002 330 239 242 10.1016/S0304-3940(02)00801-7 12270637
Schuster, N., Dunker, N. & Krieglstein, K. Transforming growth factor-beta induced cell death in the developing chick retina is mediated via activation of c-jun N-terminal kinase and downregulation of the anti-apoptotic protein Bcl-X(L). Neurosci. Lett. 330, 239–242 (2002).12270637 10.1016/S0304-3940(02)00801-7
300. Braunger BM TGF-β signaling protects retinal neurons from programmed cell death during the development of the mammalian eye J. Neurosci. 2013 33 14246 14258 10.1523/JNEUROSCI.0991-13.2013 23986258
Braunger, B. M. et al. TGF-β signaling protects retinal neurons from programmed cell death during the development of the mammalian eye. J. Neurosci. 33, 14246–14258 (2013).23986258 10.1523/JNEUROSCI.0991-13.2013
301. Ruiz-Canada C Bernabe-Garcia A Liarte S Rodriguez-Valiente M Nicolas FJ Chronic Wound Healing by Amniotic Membrane: TGF-beta and EGF Signaling Modulation in Re-epithelialization Front Bioeng. Biotechnol. 2021 9 689328 10.3389/fbioe.2021.689328 34295882
Ruiz-Canada, C., Bernabe-Garcia, A., Liarte, S., Rodriguez-Valiente, M. & Nicolas, F. J. Chronic Wound Healing by Amniotic Membrane: TGF-beta and EGF Signaling Modulation in Re-epithelialization. Front Bioeng. Biotechnol. 9, 689328 (2021).34295882 10.3389/fbioe.2021.689328
302. McMullen H Spatial and temporal expression of transforming growth factor-beta isoforms during ovine excisional and incisional wound repair Wound Repair Regen. 1995 3 141 156 10.1046/j.1524-475X.1995.30206.x 17173643
McMullen, H. et al. Spatial and temporal expression of transforming growth factor-beta isoforms during ovine excisional and incisional wound repair. Wound Repair Regen. 3, 141–156 (1995).17173643 10.1046/j.1524-475X.1995.30206.x
303. Gold LI Sung JJ Siebert JW Longaker MT Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair Am. J. Pathol. 1997 150 209 222 9006337
Gold, L. I., Sung, J. J., Siebert, J. W. & Longaker, M. T. Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair. Am. J. Pathol. 150, 209–222 (1997).9006337
304. Mustoe TA Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta Science 1987 237 1333 1336 10.1126/science.2442813 2442813
Mustoe, T. A. et al. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science 237, 1333–1336 (1987).2442813 10.1126/science.2442813
305. Postlethwaite AE Keski-Oja J Moses HL Kang AH Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta J. Exp. Med 1987 165 251 256 10.1084/jem.165.1.251 3491869
Postlethwaite, A. E., Keski-Oja, J., Moses, H. L. & Kang, A. H. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J. Exp. Med 165, 251–256 (1987).3491869 10.1084/jem.165.1.251
306. Pierce GF Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms J. Cell Biol. 1989 109 429 440 10.1083/jcb.109.1.429 2745556
Pierce, G. F. et al. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. J. Cell Biol. 109, 429–440 (1989).2745556 10.1083/jcb.109.1.429
307. Puolakkainen PA Acceleration of wound healing in aged rats by topical application of transforming growth factor-beta(1) Wound Repair Regen. 1995 3 330 339 10.1046/j.1524-475X.1995.t01-1-30314.x 17173560
Puolakkainen, P. A. et al. Acceleration of wound healing in aged rats by topical application of transforming growth factor-beta(1). Wound Repair Regen. 3, 330–339 (1995).17173560 10.1046/j.1524-475X.1995.t01-1-30314.x
308. Wahl SM Transforming growth factor type beta induces monocyte chemotaxis and growth factor production Proc. Natl Acad. Sci. USA 1987 84 5788 5792 10.1073/pnas.84.16.5788 2886992
Wahl, S. M. et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc. Natl Acad. Sci. USA 84, 5788–5792 (1987).2886992 10.1073/pnas.84.16.5788
309. Rappolee DA Mark D Banda MJ Werb Z Wound macrophages express TGF-alpha and other growth factors in vivo: analysis by mRNA phenotyping Science 1988 241 708 712 10.1126/science.3041594 3041594
Rappolee, D. A., Mark, D., Banda, M. J. & Werb, Z. Wound macrophages express TGF-alpha and other growth factors in vivo: analysis by mRNA phenotyping. Science 241, 708–712 (1988).3041594 10.1126/science.3041594
310. Kane CJ Hebda PA Mansbridge JN Hanawalt PC Direct evidence for spatial and temporal regulation of transforming growth factor beta 1 expression during cutaneous wound healing J. Cell Physiol. 1991 148 157 173 10.1002/jcp.1041480119 1907288
Kane, C. J., Hebda, P. A., Mansbridge, J. N. & Hanawalt, P. C. Direct evidence for spatial and temporal regulation of transforming growth factor beta 1 expression during cutaneous wound healing. J. Cell Physiol. 148, 157–173 (1991).1907288 10.1002/jcp.1041480119
311. Zambruno G Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing J. Cell Biol. 1995 129 853 865 10.1083/jcb.129.3.853 7537276
Zambruno, G. et al. Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. J. Cell Biol. 129, 853–865 (1995).7537276 10.1083/jcb.129.3.853
312. Jeong HW Kim IS TGF-beta1 enhances betaig-h3-mediated keratinocyte cell migration through the alpha3beta1 integrin and PI3K J. Cell Biochem 2004 92 770 780 10.1002/jcb.20110 15211574
Jeong, H. W. & Kim, I. S. TGF-beta1 enhances betaig-h3-mediated keratinocyte cell migration through the alpha3beta1 integrin and PI3K. J. Cell Biochem 92, 770–780 (2004).15211574 10.1002/jcb.20110
313. Bandyopadhyay B A “traffic control” role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing J. Cell Biol. 2006 172 1093 1105 10.1083/jcb.200507111 16549496
Bandyopadhyay, B. et al. A “traffic control” role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing. J. Cell Biol. 172, 1093–1105 (2006).16549496 10.1083/jcb.200507111
314. Heimark RL Twardzik DR Schwartz SM Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets Science 1986 233 1078 1080 10.1126/science.3461562 3461562
Heimark, R. L., Twardzik, D. R. & Schwartz, S. M. Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science 233, 1078–1080 (1986).3461562 10.1126/science.3461562
315. Roberts AB Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro Proc. Natl Acad. Sci. USA 1986 83 4167 4171 10.1073/pnas.83.12.4167 2424019
Roberts, A. B. et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl Acad. Sci. USA 83, 4167–4171 (1986).2424019 10.1073/pnas.83.12.4167
316. Wang XJ Liefer KM Tsai S O’Malley BW Roop DR Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis Proc. Natl Acad. Sci. USA 1999 96 8483 8488 10.1073/pnas.96.15.8483 10411901
Wang, X. J., Liefer, K. M., Tsai, S., O’Malley, B. W. & Roop, D. R. Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis. Proc. Natl Acad. Sci. USA 96, 8483–8488 (1999).10411901 10.1073/pnas.96.15.8483
317. Lynch SE Colvin RB Antoniades HN Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds J. Clin. Invest 1989 84 640 646 10.1172/JCI114210 2788174
Lynch, S. E., Colvin, R. B. & Antoniades, H. N. Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. J. Clin. Invest 84, 640–646 (1989).2788174 10.1172/JCI114210
318. Madri JA Pratt BM Tucker AM Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix J. Cell Biol. 1988 106 1375 1384 10.1083/jcb.106.4.1375 3283153
Madri, J. A., Pratt, B. M. & Tucker, A. M. Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. J. Cell Biol. 106, 1375–1384 (1988).3283153 10.1083/jcb.106.4.1375
319. Iruela-Arispe ML Sage EH Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGF-beta 1 J. Cell Biochem 1993 52 414 430 10.1002/jcb.240520406 7693728
Iruela-Arispe, M. L. & Sage, E. H. Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGF-beta 1. J. Cell Biochem 52, 414–430 (1993).7693728 10.1002/jcb.240520406
320. Lu SL Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation Cancer Res 2004 64 4405 4410 10.1158/0008-5472.CAN-04-1032 15231647
Lu, S. L. et al. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 64, 4405–4410 (2004).15231647 10.1158/0008-5472.CAN-04-1032
321. Cox DA Kunz S Cerletti N McMaster GK Burk RR Wound healing in aged animals-effects of locally applied transforming growth factor beta 2 in different model systems Exs 1992 61 287 295 1377545
Cox, D. A., Kunz, S., Cerletti, N., McMaster, G. K. & Burk, R. R. Wound healing in aged animals-effects of locally applied transforming growth factor beta 2 in different model systems. Exs 61, 287–295 (1992).1377545
322. Frank S Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing J. Biol. Chem. 1995 270 12607 12613 10.1074/jbc.270.21.12607 7759509
Frank, S. et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J. Biol. Chem. 270, 12607–12613 (1995).7759509 10.1074/jbc.270.21.12607
323. Pertovaara L Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells J. Biol. Chem. 1994 269 6271 6274 10.1016/S0021-9258(17)37365-9 8119973
Pertovaara, L. et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J. Biol. Chem. 269, 6271–6274 (1994).8119973 10.1016/S0021-9258(17)37365-9
324. Strutz F TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2) Kidney Int 2001 59 579 592 10.1046/j.1523-1755.2001.059002579.x 11168939
Strutz, F. et al. TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). Kidney Int 59, 579–592 (2001).11168939 10.1046/j.1523-1755.2001.059002579.x
325. Battegay EJ Raines EW Seifert RA Bowen-Pope DF Ross R TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop Cell 1990 63 515 524 10.1016/0092-8674(90)90448-N 2171777
Battegay, E. J., Raines, E. W., Seifert, R. A., Bowen-Pope, D. F. & Ross, R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63, 515–524 (1990).2171777 10.1016/0092-8674(90)90448-N
326. Ignotz RA Massagué J Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix J. Biol. Chem. 1986 261 4337 4345 10.1016/S0021-9258(17)35666-1 3456347
Ignotz, R. A. & Massagué, J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 261, 4337–4345 (1986).3456347 10.1016/S0021-9258(17)35666-1
327. Clark RA McCoy GA Folkvord JM McPherson JM TGF-beta 1 stimulates cultured human fibroblasts to proliferate and produce tissue-like fibroplasia: a fibronectin matrix-dependent event J. Cell Physiol. 1997 170 69 80 10.1002/(SICI)1097-4652(199701)170:1<69::AID-JCP8>3.0.CO;2-J 9012786
Clark, R. A., McCoy, G. A., Folkvord, J. M. & McPherson, J. M. TGF-beta 1 stimulates cultured human fibroblasts to proliferate and produce tissue-like fibroplasia: a fibronectin matrix-dependent event. J. Cell Physiol. 170, 69–80 (1997).9012786 10.1002/(SICI)1097-4652(199701)170:1<69::AID-JCP8>3.0.CO;2-J
328. Murata H TGF-beta3 stimulates and regulates collagen synthesis through TGF-beta1-dependent and independent mechanisms J. Invest Dermatol 1997 108 258 262 10.1111/1523-1747.ep12286451 9036921
Murata, H. et al. TGF-beta3 stimulates and regulates collagen synthesis through TGF-beta1-dependent and independent mechanisms. J. Invest Dermatol 108, 258–262 (1997).9036921 10.1111/1523-1747.ep12286451
329. Tyrone JW Transforming growth factor beta3 promotes fascial wound healing in a new animal model Arch. Surg. 2000 135 1154 1159 10.1001/archsurg.135.10.1154 11030871
Tyrone, J. W. et al. Transforming growth factor beta3 promotes fascial wound healing in a new animal model. Arch. Surg. 135, 1154–1159 (2000).11030871 10.1001/archsurg.135.10.1154
330. Edwards DR Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor Embo j. 1987 6 1899 1904 10.1002/j.1460-2075.1987.tb02449.x 2820711
Edwards, D. R. et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. Embo j. 6, 1899–1904 (1987).2820711 10.1002/j.1460-2075.1987.tb02449.x
331. Lund LR Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts Embo j. 1987 6 1281 1286 10.1002/j.1460-2075.1987.tb02365.x 3111844
Lund, L. R. et al. Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. Embo j. 6, 1281–1286 (1987).3111844 10.1002/j.1460-2075.1987.tb02365.x
332. Overall CM Wrana JL Sodek J Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta J. Biol. Chem. 1989 264 1860 1869 10.1016/S0021-9258(18)94267-5 2536374
Overall, C. M., Wrana, J. L. & Sodek, J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. J. Biol. Chem. 264, 1860–1869 (1989).2536374 10.1016/S0021-9258(18)94267-5
333. Wright JK Cawston TE Hazleman BL Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts Biochim. Biophys. Acta 1991 1094 207 210 10.1016/0167-4889(91)90010-U 1654118
Wright, J. K., Cawston, T. E. & Hazleman, B. L. Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim. Biophys. Acta 1094, 207–210 (1991).1654118 10.1016/0167-4889(91)90010-U
334. Shah M Foreman DM Ferguson MW Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring J. Cell Sci. 1995 108 985 1002 10.1242/jcs.108.3.985 7542672
Shah, M., Foreman, D. M. & Ferguson, M. W. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J. Cell Sci. 108, 985–1002 (1995).7542672 10.1242/jcs.108.3.985
335. Montesano R Orci L Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing Proc. Natl Acad. Sci. USA 1988 85 4894 4897 10.1073/pnas.85.13.4894 3164478
Montesano, R. & Orci, L. Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc. Natl Acad. Sci. USA 85, 4894–4897 (1988).3164478 10.1073/pnas.85.13.4894
336. Meckmongkol TT Harmon R McKeown-Longo P Van De Water L The fibronectin synergy site modulates TGF-beta-dependent fibroblast contraction Biochem Biophys. Res Commun. 2007 360 709 714 10.1016/j.bbrc.2007.06.121 17631278
Meckmongkol, T. T., Harmon, R., McKeown-Longo, P. & Van De Water, L. The fibronectin synergy site modulates TGF-beta-dependent fibroblast contraction. Biochem Biophys. Res Commun. 360, 709–714 (2007).17631278 10.1016/j.bbrc.2007.06.121
337. Desmoulière A Geinoz A Gabbiani F Gabbiani G Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts J. Cell Biol. 1993 122 103 111 10.1083/jcb.122.1.103 8314838
Desmoulière, A., Geinoz, A., Gabbiani, F. & Gabbiani, G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 122, 103–111 (1993).8314838 10.1083/jcb.122.1.103
338. Jakowlew SB Transforming growth factor-beta (TGF-beta) isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-beta Cell Regul. 1991 2 535 548 10.1091/mbc.2.7.535 1782214
Jakowlew, S. B. et al. Transforming growth factor-beta (TGF-beta) isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-beta. Cell Regul. 2, 535–548 (1991).1782214 10.1091/mbc.2.7.535
339. Armendariz-Borunda J Transforming growth factor beta gene expression is transiently enhanced at a critical stage during liver regeneration after CCl4 treatment Lab Invest 1993 69 283 294 8377471
Armendariz-Borunda, J. et al. Transforming growth factor beta gene expression is transiently enhanced at a critical stage during liver regeneration after CCl4 treatment. Lab Invest 69, 283–294 (1993).8377471
340. Braun L Transforming growth factor beta mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation Proc. Natl Acad. Sci. USA 1988 85 1539 1543 10.1073/pnas.85.5.1539 3422749
Braun, L. et al. Transforming growth factor beta mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc. Natl Acad. Sci. USA 85, 1539–1543 (1988).3422749 10.1073/pnas.85.5.1539
341. Nishikawa Y Wang M Carr BI Changes in TGF-beta receptors of rat hepatocytes during primary culture and liver regeneration: increased expression of TGF-beta receptors associated with increased sensitivity to TGF-beta-mediated growth inhibition J. Cell Physiol. 1998 176 612 623 10.1002/(SICI)1097-4652(199809)176:3<612::AID-JCP18>3.0.CO;2-0 9699514
Nishikawa, Y., Wang, M. & Carr, B. I. Changes in TGF-beta receptors of rat hepatocytes during primary culture and liver regeneration: increased expression of TGF-beta receptors associated with increased sensitivity to TGF-beta-mediated growth inhibition. J. Cell Physiol. 176, 612–623 (1998).9699514 10.1002/(SICI)1097-4652(199809)176:3<612::AID-JCP18>3.0.CO;2-0
342. Grasl-Kraupp B Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia Hepatology 1998 28 717 726 10.1002/hep.510280318 9731564
Grasl-Kraupp, B. et al. Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia. Hepatology 28, 717–726 (1998).9731564 10.1002/hep.510280318
343. Riesle E Increased expression of transforming growth factor beta s after acute oedematous pancreatitis in rats suggests a role in pancreatic repair Gut 1997 40 73 79 10.1136/gut.40.1.73 9155579
Riesle, E. et al. Increased expression of transforming growth factor beta s after acute oedematous pancreatitis in rats suggests a role in pancreatic repair. Gut 40, 73–79 (1997).9155579 10.1136/gut.40.1.73
344. Friess H Enhanced expression of TGF-betas and their receptors in human acute pancreatitis Ann. Surg. 1998 227 95 104 10.1097/00000658-199801000-00014 9445116
Friess, H. et al. Enhanced expression of TGF-betas and their receptors in human acute pancreatitis. Ann. Surg. 227, 95–104 (1998).9445116 10.1097/00000658-199801000-00014
345. Gress T Enhancement of transforming growth factor beta 1 expression in the rat pancreas during regeneration from caerulein-induced pancreatitis Eur. J. Clin. Invest 1994 24 679 685 10.1111/j.1365-2362.1994.tb01060.x 7851468
Gress, T. et al. Enhancement of transforming growth factor beta 1 expression in the rat pancreas during regeneration from caerulein-induced pancreatitis. Eur. J. Clin. Invest 24, 679–685 (1994).7851468 10.1111/j.1365-2362.1994.tb01060.x
346. Wan M Injury-activated transforming growth factor β controls mobilization of mesenchymal stem cells for tissue remodeling Stem Cells 2012 30 2498 2511 10.1002/stem.1208 22911900
Wan, M. et al. Injury-activated transforming growth factor β controls mobilization of mesenchymal stem cells for tissue remodeling. Stem Cells 30, 2498–2511 (2012).22911900 10.1002/stem.1208
347. Bax NA In vitro epithelial-to-mesenchymal transformation in human adult epicardial cells is regulated by TGFβ-signaling and WT1 Basic Res Cardiol. 2011 106 829 847 10.1007/s00395-011-0181-0 21516490
Bax, N. A. et al. In vitro epithelial-to-mesenchymal transformation in human adult epicardial cells is regulated by TGFβ-signaling and WT1. Basic Res Cardiol. 106, 829–847 (2011).21516490 10.1007/s00395-011-0181-0
348. Redini F Galera P Mauviel A Loyau G Pujol JP Transforming growth factor beta stimulates collagen and glycosaminoglycan biosynthesis in cultured rabbit articular chondrocytes FEBS Lett. 1988 234 172 176 10.1016/0014-5793(88)81327-9 3164687
Redini, F., Galera, P., Mauviel, A., Loyau, G. & Pujol, J. P. Transforming growth factor beta stimulates collagen and glycosaminoglycan biosynthesis in cultured rabbit articular chondrocytes. FEBS Lett. 234, 172–176 (1988).3164687 10.1016/0014-5793(88)81327-9
349. Malemud CJ Killeen W Hering TM Purchio AF Enhanced sulfated-proteoglycan core protein synthesis by incubation of rabbit chondrocytes with recombinant transforming growth factor-beta 1 J. Cell Physiol. 1991 149 152 159 10.1002/jcp.1041490119 1939343
Malemud, C. J., Killeen, W., Hering, T. M. & Purchio, A. F. Enhanced sulfated-proteoglycan core protein synthesis by incubation of rabbit chondrocytes with recombinant transforming growth factor-beta 1. J. Cell Physiol. 149, 152–159 (1991).1939343 10.1002/jcp.1041490119
350. Buss A TGF-beta1 and TGF-beta2 expression after traumatic human spinal cord injury Spinal Cord. 2008 46 364 371 10.1038/sj.sc.3102148 18040277
Buss, A. et al. TGF-beta1 and TGF-beta2 expression after traumatic human spinal cord injury. Spinal Cord. 46, 364–371 (2008).18040277 10.1038/sj.sc.3102148
351. Lehrmann E Microglia and macrophages are major sources of locally produced transforming growth factor-beta1 after transient middle cerebral artery occlusion in rats Glia 1998 24 437 448 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X 9814824
Lehrmann, E. et al. Microglia and macrophages are major sources of locally produced transforming growth factor-beta1 after transient middle cerebral artery occlusion in rats. Glia 24, 437–448 (1998).9814824 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X
352. Hannon GJ Beach D p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest Nature 1994 371 257 261 10.1038/371257a0 8078588
Hannon, G. J. & Beach, D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371, 257–261 (1994).8078588 10.1038/371257a0
353. Datto MB Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism Proc. Natl Acad. Sci. USA 1995 92 5545 5549 10.1073/pnas.92.12.5545 7777546
Datto, M. B. et al. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl Acad. Sci. USA 92, 5545–5549 (1995).7777546 10.1073/pnas.92.12.5545
354. Rich JN Zhang M Datto MB Bigner DD Wang XF Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines J. Biol. Chem. 1999 274 35053 35058 10.1074/jbc.274.49.35053 10574984
Rich, J. N., Zhang, M., Datto, M. B., Bigner, D. D. & Wang, X. F. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J. Biol. Chem. 274, 35053–35058 (1999).10574984 10.1074/jbc.274.49.35053
355. Seoane J Le HV Shen L Anderson SA Massagué J Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation Cell 2004 117 211 223 10.1016/S0092-8674(04)00298-3 15084259
Seoane, J., Le, H. V., Shen, L., Anderson, S. A. & Massagué, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211–223 (2004).15084259 10.1016/S0092-8674(04)00298-3
356. Gomis RR Alarcón C Nadal C Van Poznak C Massagué J C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells Cancer Cell 2006 10 203 214 10.1016/j.ccr.2006.07.019 16959612
Gomis, R. R., Alarcón, C., Nadal, C., Van Poznak, C. & Massagué, J. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10, 203–214 (2006).16959612 10.1016/j.ccr.2006.07.019
357. Feng XH Lin X Derynck R Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta Embo j. 2000 19 5178 5193 10.1093/emboj/19.19.5178 11013220
Feng, X. H., Lin, X. & Derynck, R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. Embo j. 19, 5178–5193 (2000).11013220 10.1093/emboj/19.19.5178
358. Pardali K Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta J. Biol. Chem. 2000 275 29244 29256 10.1074/jbc.M909467199 10878024
Pardali, K. et al. Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J. Biol. Chem. 275, 29244–29256 (2000).10878024 10.1074/jbc.M909467199
359. Reynisdóttir I Polyak K Iavarone A Massagué J Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta Genes Dev. 1995 9 1831 1845 10.1101/gad.9.15.1831 7649471
Reynisdóttir, I., Polyak, K., Iavarone, A. & Massagué, J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9, 1831–1845 (1995).7649471 10.1101/gad.9.15.1831
360. Reynisdóttir I Massagué J The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2 Genes Dev. 1997 11 492 503 10.1101/gad.11.4.492 9042862
Reynisdóttir, I. & Massagué, J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 11, 492–503 (1997).9042862 10.1101/gad.11.4.492
361. Kamesaki H Nishizawa K Michaud GY Cossman J Kiyono T TGF-beta 1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells J. Immunol. 1998 160 770 777 10.4049/jimmunol.160.2.770 9551912
Kamesaki, H., Nishizawa, K., Michaud, G. Y., Cossman, J. & Kiyono, T. TGF-beta 1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells. J. Immunol. 160, 770–777 (1998).9551912 10.4049/jimmunol.160.2.770
362. Scandura JM Boccuni P Massagué J Nimer SD Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation Proc. Natl Acad. Sci. USA 2004 101 15231 15236 10.1073/pnas.0406771101 15477587
Scandura, J. M., Boccuni, P., Massagué, J. & Nimer, S. D. Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc. Natl Acad. Sci. USA 101, 15231–15236 (2004).15477587 10.1073/pnas.0406771101
363. Chen CR Kang Y Siegel PM Massagué J E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression Cell 2002 110 19 32 10.1016/S0092-8674(02)00801-2 12150994
Chen, C. R., Kang, Y., Siegel, P. M. & Massagué, J. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 110, 19–32 (2002).12150994 10.1016/S0092-8674(02)00801-2
364. Yagi K c-myc is a downstream target of the Smad pathway J. Biol. Chem. 2002 277 854 861 10.1074/jbc.M104170200 11689553
Yagi, K. et al. c-myc is a downstream target of the Smad pathway. J. Biol. Chem. 277, 854–861 (2002).11689553 10.1074/jbc.M104170200
365. Kang Y Chen CR Massagué J A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells Mol. Cell 2003 11 915 926 10.1016/S1097-2765(03)00109-6 12718878
Kang, Y., Chen, C. R. & Massagué, J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol. Cell 11, 915–926 (2003).12718878 10.1016/S1097-2765(03)00109-6
366. Lasorella A Noseda M Beyna M Yokota Y Iavarone A Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins Nature 2000 407 592 598 10.1038/35036504 11034201
Lasorella, A., Noseda, M., Beyna, M., Yokota, Y. & Iavarone, A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407, 592–598 (2000).11034201 10.1038/35036504
367. Siegel PM Shu W Massagué J Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-beta-mediated epithelial cell growth suppression J. Biol. Chem. 2003 278 35444 35450 10.1074/jbc.M301413200 12824180
Siegel, P. M., Shu, W. & Massagué, J. Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-beta-mediated epithelial cell growth suppression. J. Biol. Chem. 278, 35444–35450 (2003).12824180 10.1074/jbc.M301413200
368. Seoane J TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b Nat. Cell Biol. 2001 3 400 408 10.1038/35070086 11283614
Seoane, J. et al. TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat. Cell Biol. 3, 400–408 (2001).11283614 10.1038/35070086
369. Seoane J Le HV Massagué J Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage Nature 2002 419 729 734 10.1038/nature01119 12384701
Seoane, J., Le, H. V. & Massagué, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729–734 (2002).12384701 10.1038/nature01119
370. Prabhu S Ignatova A Park ST Sun XH Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins Mol. Cell Biol. 1997 17 5888 5896 10.1128/MCB.17.10.5888 9315646
Prabhu, S., Ignatova, A., Park, S. T. & Sun, X. H. Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol. Cell Biol. 17, 5888–5896 (1997).9315646 10.1128/MCB.17.10.5888
371. Asirvatham AJ Carey JP Chaudhary J ID1-, ID2-, and ID3-regulated gene expression in E2A positive or negative prostate cancer cells Prostate 2007 67 1411 1420 10.1002/pros.20633 17639499
Asirvatham, A. J., Carey, J. P. & Chaudhary, J. ID1-, ID2-, and ID3-regulated gene expression in E2A positive or negative prostate cancer cells. Prostate 67, 1411–1420 (2007).17639499 10.1002/pros.20633
372. Iavarone A Massagué J E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest Mol. Cell Biol. 1999 19 916 922 10.1128/MCB.19.1.916 9858615
Iavarone, A. & Massagué, J. E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. Mol. Cell Biol. 19, 916–922 (1999).9858615 10.1128/MCB.19.1.916
373. Bhowmick NA TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest Proc. Natl Acad. Sci. USA 2003 100 15548 15553 10.1073/pnas.2536483100 14657354
Bhowmick, N. A. et al. TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc. Natl Acad. Sci. USA 100, 15548–15553 (2003).14657354 10.1073/pnas.2536483100
374. Ray D Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner Mol. Cell Biol. 2005 25 3338 3347 10.1128/MCB.25.8.3338-3347.2005 15798217
Ray, D. et al. Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol. Cell Biol. 25, 3338–3347 (2005).15798217 10.1128/MCB.25.8.3338-3347.2005
375. Leof EB Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity Proc. Natl Acad. Sci. USA 1986 83 2453 2457 10.1073/pnas.83.8.2453 3010310
Leof, E. B. et al. Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. Proc. Natl Acad. Sci. USA 83, 2453–2457 (1986).3010310 10.1073/pnas.83.8.2453
376. Wildey GM Patil S Howe PH Smad3 potentiates transforming growth factor beta (TGFbeta)-induced apoptosis and expression of the BH3-only protein Bim in WEHI 231 B lymphocytes J. Biol. Chem. 2003 278 18069 18077 10.1074/jbc.M211958200 12637528
Wildey, G. M., Patil, S. & Howe, P. H. Smad3 potentiates transforming growth factor beta (TGFbeta)-induced apoptosis and expression of the BH3-only protein Bim in WEHI 231 B lymphocytes. J. Biol. Chem. 278, 18069–18077 (2003).12637528 10.1074/jbc.M211958200
377. Ramjaun AR Tomlinson S Eddaoudi A & Downward, J. Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis Oncogene 2007 26 970 981 10.1038/sj.onc.1209852 16909112
Ramjaun, A. R., Tomlinson, S. & Eddaoudi, A. & Downward, J. Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis. Oncogene 26, 970–981 (2007).16909112 10.1038/sj.onc.1209852
378. Yoshimoto T Involvement of smad2 and Erk/Akt cascade in TGF-β1-induced apoptosis in human gingival epithelial cells Cytokine 2015 75 165 173 10.1016/j.cyto.2015.03.011 25882870
Yoshimoto, T. et al. Involvement of smad2 and Erk/Akt cascade in TGF-β1-induced apoptosis in human gingival epithelial cells. Cytokine 75, 165–173 (2015).25882870 10.1016/j.cyto.2015.03.011
379. Schiffer M Apoptosis in podocytes induced by TGF-beta and Smad7 J. Clin. Invest 2001 108 807 816 10.1172/JCI200112367 11560950
Schiffer, M. et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J. Clin. Invest 108, 807–816 (2001).11560950 10.1172/JCI200112367
380. Francis JM Transforming growth factor-beta 1 induces apoptosis independently of p53 and selectively reduces expression of Bcl-2 in multipotent hematopoietic cells J. Biol. Chem. 2000 275 39137 39145 10.1074/jbc.M007212200 10993901
Francis, J. M. et al. Transforming growth factor-beta 1 induces apoptosis independently of p53 and selectively reduces expression of Bcl-2 in multipotent hematopoietic cells. J. Biol. Chem. 275, 39137–39145 (2000).10993901 10.1074/jbc.M007212200
381. Schulz R Vogel T Dressel R Krieglstein K TGF-beta superfamily members, ActivinA and TGF-beta1, induce apoptosis in oligodendrocytes by different pathways Cell Tissue Res 2008 334 327 338 10.1007/s00441-008-0714-5 19002501
Schulz, R., Vogel, T., Dressel, R. & Krieglstein, K. TGF-beta superfamily members, ActivinA and TGF-beta1, induce apoptosis in oligodendrocytes by different pathways. Cell Tissue Res 334, 327–338 (2008).19002501 10.1007/s00441-008-0714-5
382. Larisch S A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif Nat. Cell Biol. 2000 2 915 921 10.1038/35046566 11146656
Larisch, S. et al. A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat. Cell Biol. 2, 915–921 (2000).11146656 10.1038/35046566
383. Perlman R Schiemann WP Brooks MW Lodish HF Weinberg RA TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation Nat. Cell Biol. 2001 3 708 714 10.1038/35087019 11483955
Perlman, R., Schiemann, W. P., Brooks, M. W., Lodish, H. F. & Weinberg, R. A. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat. Cell Biol. 3, 708–714 (2001).11483955 10.1038/35087019
384. Arsura M Wu M Sonenshein GE TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha Immunity 1996 5 31 40 10.1016/S1074-7613(00)80307-6 8758892
Arsura, M., Wu, M. & Sonenshein, G. E. TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity 5, 31–40 (1996).8758892 10.1016/S1074-7613(00)80307-6
385. Arsura M FitzGerald MJ Fausto N Sonenshein GE Nuclear factor-kappaB/Rel blocks transforming growth factor beta1-induced apoptosis of murine hepatocyte cell lines Cell Growth Differ. 1997 8 1049 1059 9342183
Arsura, M., FitzGerald, M. J., Fausto, N. & Sonenshein, G. E. Nuclear factor-kappaB/Rel blocks transforming growth factor beta1-induced apoptosis of murine hepatocyte cell lines. Cell Growth Differ. 8, 1049–1059 (1997).9342183
386. Arsura M Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation Oncogene 2003 22 412 425 10.1038/sj.onc.1206132 12545162
Arsura, M. et al. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene 22, 412–425 (2003).12545162 10.1038/sj.onc.1206132
387. Yoo J Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation J. Biol. Chem. 2003 278 43001 43007 10.1074/jbc.M307869200 12933797
Yoo, J. et al. Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. J. Biol. Chem. 278, 43001–43007 (2003).12933797 10.1074/jbc.M307869200
388. Schiffer M Mundel P Shaw AS Böttinger EP A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis J. Biol. Chem. 2004 279 37004 37012 10.1074/jbc.M403534200 15213232
Schiffer, M., Mundel, P., Shaw, A. S. & Böttinger, E. P. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J. Biol. Chem. 279, 37004–37012 (2004).15213232 10.1074/jbc.M403534200
389. Conery AR Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis Nat. Cell Biol. 2004 6 366 372 10.1038/ncb1117 15104092
Conery, A. R. et al. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat. Cell Biol. 6, 366–372 (2004).15104092 10.1038/ncb1117
390. Remy I Montmarquette A Michnick SW PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3 Nat. Cell Biol. 2004 6 358 365 10.1038/ncb1113 15048128
Remy, I., Montmarquette, A. & Michnick, S. W. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat. Cell Biol. 6, 358–365 (2004).15048128 10.1038/ncb1113
391. Valderrama-Carvajal H Activin/TGF-beta induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP Nat. Cell Biol. 2002 4 963 969 10.1038/ncb885 12447389
Valderrama-Carvajal, H. et al. Activin/TGF-beta induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nat. Cell Biol. 4, 963–969 (2002).12447389 10.1038/ncb885
392. Bender H Wang Z Schuster N Krieglstein K TIEG1 facilitates transforming growth factor-beta-mediated apoptosis in the oligodendroglial cell line OLI-neu J. Neurosci. Res 2004 75 344 352 10.1002/jnr.10856 14743447
Bender, H., Wang, Z., Schuster, N. & Krieglstein, K. TIEG1 facilitates transforming growth factor-beta-mediated apoptosis in the oligodendroglial cell line OLI-neu. J. Neurosci. Res 75, 344–352 (2004).14743447 10.1002/jnr.10856
393. Wang Z Spittau B Behrendt M Peters B Krieglstein K Human TIEG2/KLF11 induces oligodendroglial cell death by downregulation of Bcl-XL expression J. Neural Transm. (Vienna) 2007 114 867 875 10.1007/s00702-007-0635-6 17308981
Wang, Z., Spittau, B., Behrendt, M., Peters, B. & Krieglstein, K. Human TIEG2/KLF11 induces oligodendroglial cell death by downregulation of Bcl-XL expression. J. Neural Transm. (Vienna) 114, 867–875 (2007).17308981 10.1007/s00702-007-0635-6
394. Chalaux E A zinc-finger transcription factor induced by TGF-beta promotes apoptotic cell death in epithelial Mv1Lu cells FEBS Lett. 1999 457 478 482 10.1016/S0014-5793(99)01051-0 10471833
Chalaux, E. et al. A zinc-finger transcription factor induced by TGF-beta promotes apoptotic cell death in epithelial Mv1Lu cells. FEBS Lett. 457, 478–482 (1999).10471833 10.1016/S0014-5793(99)01051-0
395. Poulsen KT TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons Neuron 1994 13 1245 1252 10.1016/0896-6273(94)90062-0 7946360
Poulsen, K. T. et al. TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons. Neuron 13, 1245–1252 (1994).7946360 10.1016/0896-6273(94)90062-0
396. Roussa E Farkas LM Krieglstein K TGF-beta promotes survival on mesencephalic dopaminergic neurons in cooperation with Shh and FGF-8 Neurobiol. Dis. 2004 16 300 310 10.1016/j.nbd.2004.03.006 15193287
Roussa, E., Farkas, L. M. & Krieglstein, K. TGF-beta promotes survival on mesencephalic dopaminergic neurons in cooperation with Shh and FGF-8. Neurobiol. Dis. 16, 300–310 (2004).15193287 10.1016/j.nbd.2004.03.006
397. Krieglstein K Farkas L Unsicker K TGF-beta regulates the survival of ciliary ganglionic neurons synergistically with ciliary neurotrophic factor and neurotrophins J. Neurobiol. 1998 37 563 572 10.1002/(SICI)1097-4695(199812)37:4<563::AID-NEU5>3.0.CO;2-A 9858258
Krieglstein, K., Farkas, L. & Unsicker, K. TGF-beta regulates the survival of ciliary ganglionic neurons synergistically with ciliary neurotrophic factor and neurotrophins. J. Neurobiol. 37, 563–572 (1998).9858258 10.1002/(SICI)1097-4695(199812)37:4<563::AID-NEU5>3.0.CO;2-A
398. Bye N Zieba M Wreford NG Nichols NR Resistance of the dentate gyrus to induced apoptosis during ageing is associated with increases in transforming growth factor-beta1 messenger RNA Neuroscience 2001 105 853 862 10.1016/S0306-4522(01)00236-6 11530223
Bye, N., Zieba, M., Wreford, N. G. & Nichols, N. R. Resistance of the dentate gyrus to induced apoptosis during ageing is associated with increases in transforming growth factor-beta1 messenger RNA. Neuroscience 105, 853–862 (2001).11530223 10.1016/S0306-4522(01)00236-6
399. Shin I Bakin AV Rodeck U Brunet A Arteaga CL Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1 Mol. Biol. Cell 2001 12 3328 3339 10.1091/mbc.12.11.3328 11694570
Shin, I., Bakin, A. V., Rodeck, U., Brunet, A. & Arteaga, C. L. Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol. Biol. Cell 12, 3328–3339 (2001).11694570 10.1091/mbc.12.11.3328
400. Lanvin O TGF-beta1 modulates Fas (APO-1/CD95)-mediated apoptosis of human pre-B cell lines Eur. J. Immunol. 2003 33 1372 1381 10.1002/eji.200323761 12731064
Lanvin, O. et al. TGF-beta1 modulates Fas (APO-1/CD95)-mediated apoptosis of human pre-B cell lines. Eur. J. Immunol. 33, 1372–1381 (2003).12731064 10.1002/eji.200323761
401. Huang Y Transforming growth factor-beta 1 suppresses serum deprivation-induced death of A549 cells through differential effects on c-Jun and JNK activities J. Biol. Chem. 2000 275 18234 18242 10.1074/jbc.M909431199 10748131
Huang, Y. et al. Transforming growth factor-beta 1 suppresses serum deprivation-induced death of A549 cells through differential effects on c-Jun and JNK activities. J. Biol. Chem. 275, 18234–18242 (2000).10748131 10.1074/jbc.M909431199
402. Saile B Matthes N El Armouche H Neubauer K Ramadori G The bcl, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells Eur. J. Cell Biol. 2001 80 554 561 10.1078/0171-9335-00182 11561906
Saile, B., Matthes, N., El Armouche, H., Neubauer, K. & Ramadori, G. The bcl, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. Eur. J. Cell Biol. 80, 554–561 (2001).11561906 10.1078/0171-9335-00182
403. Letterio JJ Roberts AB Regulation of immune responses by TGF-beta Annu Rev. Immunol. 1998 16 137 161 10.1146/annurev.immunol.16.1.137 9597127
Letterio, J. J. & Roberts, A. B. Regulation of immune responses by TGF-beta. Annu Rev. Immunol. 16, 137–161 (1998).9597127 10.1146/annurev.immunol.16.1.137
404. Thomas DA Massagué J TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance Cancer Cell 2005 8 369 380 10.1016/j.ccr.2005.10.012 16286245
Thomas, D. A. & Massagué, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369–380 (2005).16286245 10.1016/j.ccr.2005.10.012
405. Ahmadzadeh M Rosenberg SA TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells J. Immunol. 2005 174 5215 5223 10.4049/jimmunol.174.9.5215 15843517
Ahmadzadeh, M. & Rosenberg, S. A. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J. Immunol. 174, 5215–5223 (2005).15843517 10.4049/jimmunol.174.9.5215
406. Genestier L Kasibhatla S Brunner T Green DR Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc J. Exp. Med 1999 189 231 239 10.1084/jem.189.2.231 9892606
Genestier, L., Kasibhatla, S., Brunner, T. & Green, D. R. Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J. Exp. Med 189, 231–239 (1999).9892606 10.1084/jem.189.2.231
407. Chen CH Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation J. Exp. Med 2003 197 1689 1699 10.1084/jem.20021170 12810687
Chen, C. H. et al. Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J. Exp. Med 197, 1689–1699 (2003).12810687 10.1084/jem.20021170
408. Gorelik L Constant S Flavell RA Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation J. Exp. Med 2002 195 1499 1505 10.1084/jem.20012076 12045248
Gorelik, L., Constant, S. & Flavell, R. A. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J. Exp. Med 195, 1499–1505 (2002).12045248 10.1084/jem.20012076
409. Gorelik L Fields PE Flavell RA Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression J. Immunol. 2000 165 4773 4777 10.4049/jimmunol.165.9.4773 11045997
Gorelik, L., Fields, P. E. & Flavell, R. A. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J. Immunol. 165, 4773–4777 (2000).11045997 10.4049/jimmunol.165.9.4773
410. Heath VL Murphy EE Crain C Tomlinson MG O’Garra A TGF-beta1 down-regulates Th2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression Eur. J. Immunol. 2000 30 2639 2649 10.1002/1521-4141(200009)30:9<2639::AID-IMMU2639>3.0.CO;2-7 11009098
Heath, V. L., Murphy, E. E., Crain, C., Tomlinson, M. G. & O’Garra, A. TGF-beta1 down-regulates Th2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression. Eur. J. Immunol. 30, 2639–2649 (2000).11009098 10.1002/1521-4141(200009)30:9<2639::AID-IMMU2639>3.0.CO;2-7
411. Chen W Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 J. Exp. Med 2003 198 1875 1886 10.1084/jem.20030152 14676299
Chen, W. et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med 198, 1875–1886 (2003).14676299 10.1084/jem.20030152
412. Fantini MC Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7 J. Immunol. 2004 172 5149 5153 10.4049/jimmunol.172.9.5149 15100250
Fantini, M. C. et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172, 5149–5153 (2004).15100250 10.4049/jimmunol.172.9.5149
413. Zheng SG Wang J Wang P Gray JD Horwitz DA IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells J. Immunol. 2007 178 2018 2027 10.4049/jimmunol.178.4.2018 17277105
Zheng, S. G., Wang, J., Wang, P., Gray, J. D. & Horwitz, D. A. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J. Immunol. 178, 2018–2027 (2007).17277105 10.4049/jimmunol.178.4.2018
414. Davidson TS DiPaolo RJ Andersson J Shevach EM Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells J. Immunol. 2007 178 4022 4026 10.4049/jimmunol.178.7.4022 17371955
Davidson, T. S., DiPaolo, R. J., Andersson, J. & Shevach, E. M. Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J. Immunol. 178, 4022–4026 (2007).17371955 10.4049/jimmunol.178.7.4022
415. Sawamukai N Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD Blood 2012 119 5575 5583 10.1182/blood-2011-07-367987 22496155
Sawamukai, N. et al. Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD. Blood 119, 5575–5583 (2012).22496155 10.1182/blood-2011-07-367987
416. Rich S Seelig M Lee HM Lin J Transforming growth factor beta 1 costimulated growth and regulatory function of staphylococcal enterotoxin B-responsive CD8+ T cells J. Immunol. 1995 155 609 618 10.4049/jimmunol.155.2.609 7608539
Rich, S., Seelig, M., Lee, H. M. & Lin, J. Transforming growth factor beta 1 costimulated growth and regulatory function of staphylococcal enterotoxin B-responsive CD8+ T cells. J. Immunol. 155, 609–618 (1995).7608539 10.4049/jimmunol.155.2.609
417. Dardalhon V IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells Nat. Immunol. 2008 9 1347 1355 10.1038/ni.1677 18997793
Dardalhon, V. et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat. Immunol. 9, 1347–1355 (2008).18997793 10.1038/ni.1677
418. Chang HC The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation Nat. Immunol. 2010 11 527 534 10.1038/ni.1867 20431622
Chang, H. C. et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat. Immunol. 11, 527–534 (2010).20431622 10.1038/ni.1867
419. Goswami R STAT6-dependent regulation of Th9 development J. Immunol. 2012 188 968 975 10.4049/jimmunol.1102840 22180613
Goswami, R. et al. STAT6-dependent regulation of Th9 development. J. Immunol. 188, 968–975 (2012).22180613 10.4049/jimmunol.1102840
420. Veldhoen M Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset Nat. Immunol. 2008 9 1341 1346 10.1038/ni.1659 18931678
Veldhoen, M. et al. Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9, 1341–1346 (2008).18931678 10.1038/ni.1659
421. Manel N Unutmaz D Littman DR The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat Nat. Immunol. 2008 9 641 649 10.1038/ni.1610 18454151
Manel, N., Unutmaz, D. & Littman, D. R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 9, 641–649 (2008).18454151 10.1038/ni.1610
422. Volpe E A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses Nat. Immunol. 2008 9 650 657 10.1038/ni.1613 18454150
Volpe, E. et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9, 650–657 (2008).18454150 10.1038/ni.1613
423. Kehrl JH Thevenin C Rieckmann P Fauci AS Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA J. Immunol. 1991 146 4016 4023 10.4049/jimmunol.146.11.4016 1903417
Kehrl, J. H., Thevenin, C., Rieckmann, P. & Fauci, A. S. Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J. Immunol. 146, 4016–4023 (1991).1903417 10.4049/jimmunol.146.11.4016
424. Rehmann JA LeBien TW Transforming growth factor-beta regulates normal human pre-B cell differentiation Int Immunol. 1994 6 315 322 10.1093/intimm/6.2.315 8155604
Rehmann, J. A. & LeBien, T. W. Transforming growth factor-beta regulates normal human pre-B cell differentiation. Int Immunol. 6, 315–322 (1994).8155604 10.1093/intimm/6.2.315
425. Bouchard C Fridman WH Sautès C Mechanism of inhibition of lipopolysaccharide-stimulated mouse B-cell responses by transforming growth factor-beta 1 Immunol. Lett. 1994 40 105 110 10.1016/0165-2478(94)90180-5 8088868
Bouchard, C., Fridman, W. H. & Sautès, C. Mechanism of inhibition of lipopolysaccharide-stimulated mouse B-cell responses by transforming growth factor-beta 1. Immunol. Lett. 40, 105–110 (1994).8088868 10.1016/0165-2478(94)90180-5
426. Lebman DA Lee FD Coffman RL Mechanism for transforming growth factor beta and IL-2 enhancement of IgA expression in lipopolysaccharide-stimulated B cell cultures J. Immunol. 1990 144 952 959 10.4049/jimmunol.144.3.952 2295822
Lebman, D. A., Lee, F. D. & Coffman, R. L. Mechanism for transforming growth factor beta and IL-2 enhancement of IgA expression in lipopolysaccharide-stimulated B cell cultures. J. Immunol. 144, 952–959 (1990).2295822 10.4049/jimmunol.144.3.952
427. Zhong Z Pro- and Anti- Effects of Immunoglobulin A- Producing B Cell in Tumors and Its Triggers Front Immunol. 2021 12 765044 10.3389/fimmu.2021.765044 34868013
Zhong, Z. et al. Pro- and Anti- Effects of Immunoglobulin A- Producing B Cell in Tumors and Its Triggers. Front Immunol. 12, 765044 (2021).34868013 10.3389/fimmu.2021.765044
428. Ferreira-Gomes M SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself Nat. Commun. 2021 12 1961 10.1038/s41467-021-22210-3 33785765
Ferreira-Gomes, M. et al. SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself. Nat. Commun. 12, 1961 (2021).33785765 10.1038/s41467-021-22210-3
429. Balkwill F Montfort A Capasso M B regulatory cells in cancer Trends Immunol. 2013 34 169 173 10.1016/j.it.2012.10.007 23206438
Balkwill, F., Montfort, A. & Capasso, M. B regulatory cells in cancer. Trends Immunol. 34, 169–173 (2013).23206438 10.1016/j.it.2012.10.007
430. Catalan D Immunosuppressive Mechanisms of Regulatory B Cells Front Immunol. 2021 12 611795 10.3389/fimmu.2021.611795 33995344
Catalan, D. et al. Immunosuppressive Mechanisms of Regulatory B Cells. Front Immunol. 12, 611795 (2021).33995344 10.3389/fimmu.2021.611795
431. Shang J Zha H Sun Y Phenotypes, Functions, and Clinical Relevance of Regulatory B Cells in Cancer Front Immunol. 2020 11 582657 10.3389/fimmu.2020.582657 33193391
Shang, J., Zha, H. & Sun, Y. Phenotypes, Functions, and Clinical Relevance of Regulatory B Cells in Cancer. Front Immunol. 11, 582657 (2020).33193391 10.3389/fimmu.2020.582657
432. Wang L Fu Y Chu Y Regulatory B Cells Adv. Exp. Med. Biol. 2020 1254 87 103 10.1007/978-981-15-3532-1_8 32323272
Wang, L., Fu, Y. & Chu, Y. Regulatory B Cells. Adv. Exp. Med. Biol. 1254, 87–103 (2020).32323272 10.1007/978-981-15-3532-1_8
433. Tang PM Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development Nat. Commun. 2017 8 14677 10.1038/ncomms14677 28262747
Tang, P. M. et al. Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development. Nat. Commun. 8, 14677 (2017).28262747 10.1038/ncomms14677
434. Trotta R TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells J. Immunol. 2008 181 3784 3792 10.4049/jimmunol.181.6.3784 18768831
Trotta, R. et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol. 181, 3784–3792 (2008).18768831 10.4049/jimmunol.181.6.3784
435. Castriconi R Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells Proc. Natl Acad. Sci. USA 2003 100 4120 4125 10.1073/pnas.0730640100 12646700
Castriconi, R. et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl Acad. Sci. USA 100, 4120–4125 (2003).12646700 10.1073/pnas.0730640100
436. Fujii R An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression Cancer Immunol. Immunother. 2018 67 675 689 10.1007/s00262-018-2121-4 29392336
Fujii, R. et al. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression. Cancer Immunol. Immunother. 67, 675–689 (2018).29392336 10.1007/s00262-018-2121-4
437. Piskurich JF Wang Y Linhoff MW White LC Ting JP Identification of distinct regions of 5’ flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene J. Immunol. 1998 160 233 240 10.4049/jimmunol.160.1.233 9551976
Piskurich, J. F., Wang, Y., Linhoff, M. W., White, L. C. & Ting, J. P. Identification of distinct regions of 5’ flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. J. Immunol. 160, 233–240 (1998).9551976 10.4049/jimmunol.160.1.233
438. Nandan D Reiner NE TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action J. Immunol. 1997 158 1095 1101 10.4049/jimmunol.158.3.1095 9013947
Nandan, D. & Reiner, N. E. TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. J. Immunol. 158, 1095–1101 (1997).9013947 10.4049/jimmunol.158.3.1095
439. Shaul ME Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs Oncoimmunology 2016 5 e1232221 10.1080/2162402X.2016.1232221 27999744
Shaul, M. E. et al. Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs. Oncoimmunology 5, e1232221 (2016).27999744 10.1080/2162402X.2016.1232221
440. Geissmann F TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells J. Immunol. 1999 162 4567 4575 10.4049/jimmunol.162.8.4567 10201996
Geissmann, F. et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162, 4567–4575 (1999).10201996 10.4049/jimmunol.162.8.4567
441. Takeuchi M Alard P Streilein JW TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells J. Immunol. 1998 160 1589 1597 10.4049/jimmunol.160.4.1589 9469414
Takeuchi, M., Alard, P. & Streilein, J. W. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J. Immunol. 160, 1589–1597 (1998).9469414 10.4049/jimmunol.160.4.1589
442. Espevik T Inhibition of cytokine production by cyclosporin A and transforming growth factor beta J. Exp. Med 1987 166 571 576 10.1084/jem.166.2.571 3110354
Espevik, T. et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J. Exp. Med 166, 571–576 (1987).3110354 10.1084/jem.166.2.571
443. Bogdan C Paik J Vodovotz Y Nathan C Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10 J. Biol. Chem. 1992 267 23301 23308 10.1016/S0021-9258(18)50091-0 1429677
Bogdan, C., Paik, J., Vodovotz, Y. & Nathan, C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J. Biol. Chem. 267, 23301–23308 (1992).1429677 10.1016/S0021-9258(18)50091-0
444. Nelson BJ Ralph P Green SJ Nacy CA Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1 J. Immunol. 1991 146 1849 1857 10.4049/jimmunol.146.6.1849 1900875
Nelson, B. J., Ralph, P., Green, S. J. & Nacy, C. A. Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1. J. Immunol. 146, 1849–1857 (1991).1900875 10.4049/jimmunol.146.6.1849
445. Vodovotz Y Bogdan C Paik J Xie QW Nathan C Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta J. Exp. Med 1993 178 605 613 10.1084/jem.178.2.605 7688028
Vodovotz, Y., Bogdan, C., Paik, J., Xie, Q. W. & Nathan, C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J. Exp. Med 178, 605–613 (1993).7688028 10.1084/jem.178.2.605
446. Oswald IP Gazzinelli RT Sher A James SL IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity J. Immunol. 1992 148 3578 3582 10.4049/jimmunol.148.11.3578 1588047
Oswald, I. P., Gazzinelli, R. T., Sher, A. & James, S. L. IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. J. Immunol. 148, 3578–3582 (1992).1588047 10.4049/jimmunol.148.11.3578
447. Tridandapani S TGF-beta 1 suppresses [correction of supresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit J. Immunol. 2003 170 4572 4577 10.4049/jimmunol.170.9.4572 12707335
Tridandapani, S. et al. TGF-beta 1 suppresses [correction of supresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit. J. Immunol. 170, 4572–4577 (2003).12707335 10.4049/jimmunol.170.9.4572
448. Mantovani A Sozzani S Locati M Allavena P Sica A Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends Immunol. 2002 23 549 555 10.1016/S1471-4906(02)02302-5 12401408
Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549–555 (2002).12401408 10.1016/S1471-4906(02)02302-5
449. Fridlender ZG Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN Cancer Cell 2009 16 183 194 10.1016/j.ccr.2009.06.017 19732719
Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16, 183–194 (2009).19732719 10.1016/j.ccr.2009.06.017
450. Sagiv JY Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer Cell Rep. 2015 10 562 573 10.1016/j.celrep.2014.12.039 25620698
Sagiv, J. Y. et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 10, 562–573 (2015).25620698 10.1016/j.celrep.2014.12.039
451. Larsson J Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice Embo j. 2001 20 1663 1673 10.1093/emboj/20.7.1663 11285230
Larsson, J. et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. Embo j. 20, 1663–1673 (2001).11285230 10.1093/emboj/20.7.1663
452. Oshima M Oshima H Taketo MM TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis Dev. Biol. 1996 179 297 302 10.1006/dbio.1996.0259 8873772
Oshima, M., Oshima, H. & Taketo, M. M. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol. 179, 297–302 (1996).8873772 10.1006/dbio.1996.0259
453. Shull MM Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease Nature 1992 359 693 699 10.1038/359693a0 1436033
Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359, 693–699 (1992).1436033 10.1038/359693a0
454. McLennan IS Poussart Y Koishi K Development of skeletal muscles in transforming growth factor-beta 1 (TGF-beta1) null-mutant mice Dev. Dyn. 2000 217 250 256 10.1002/(SICI)1097-0177(200003)217:3<250::AID-DVDY3>3.0.CO;2-F 10741419
McLennan, I. S., Poussart, Y. & Koishi, K. Development of skeletal muscles in transforming growth factor-beta 1 (TGF-beta1) null-mutant mice. Dev. Dyn. 217, 250–256 (2000).10741419 10.1002/(SICI)1097-0177(200003)217:3<250::AID-DVDY3>3.0.CO;2-F
455. Sanford LP TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes Development 1997 124 2659 2670 10.1242/dev.124.13.2659 9217007
Sanford, L. P. et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124, 2659–2670 (1997).9217007 10.1242/dev.124.13.2659
456. Foitzik K Paus R Doetschman T Dotto GP The TGF-beta2 isoform is both a required and sufficient inducer of murine hair follicle morphogenesis Dev. Biol. 1999 212 278 289 10.1006/dbio.1999.9325 10433821
Foitzik, K., Paus, R., Doetschman, T. & Dotto, G. P. The TGF-beta2 isoform is both a required and sufficient inducer of murine hair follicle morphogenesis. Dev. Biol. 212, 278–289 (1999).10433821 10.1006/dbio.1999.9325
457. Bartram U Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice Circulation 2001 103 2745 2752 10.1161/01.CIR.103.22.2745 11390347
Bartram, U. et al. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation 103, 2745–2752 (2001).11390347 10.1161/01.CIR.103.22.2745
458. Jiao K Tgfbeta signaling is required for atrioventricular cushion mesenchyme remodeling during in vivo cardiac development Development 2006 133 4585 4593 10.1242/dev.02597 17050629
Jiao, K. et al. Tgfbeta signaling is required for atrioventricular cushion mesenchyme remodeling during in vivo cardiac development. Development 133, 4585–4593 (2006).17050629 10.1242/dev.02597
459. Kaartinen V Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction Nat. Genet 1995 11 415 421 10.1038/ng1295-415 7493022
Kaartinen, V. et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat. Genet 11, 415–421 (1995).7493022 10.1038/ng1295-415
460. Proetzel G Transforming growth factor-beta 3 is required for secondary palate fusion Nat. Genet 1995 11 409 414 10.1038/ng1295-409 7493021
Proetzel, G. et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat. Genet 11, 409–414 (1995).7493021 10.1038/ng1295-409
461. Lindsay ME Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm Nat. Genet 2012 44 922 927 10.1038/ng.2349 22772368
Lindsay, M. E. et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat. Genet 44, 922–927 (2012).22772368 10.1038/ng.2349
462. Boileau C TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome Nat. Genet 2012 44 916 921 10.1038/ng.2348 22772371
Boileau, C. et al. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat. Genet 44, 916–921 (2012).22772371 10.1038/ng.2348
463. Al Maskari R A missense TGFB2 variant p.(Arg320Cys) causes a paradoxical and striking increase in aortic TGFB1/2 expression Eur. J. Hum. Genet 2016 25 157 160 10.1038/ejhg.2016.143 27782106
Al Maskari, R. et al. A missense TGFB2 variant p.(Arg320Cys) causes a paradoxical and striking increase in aortic TGFB1/2 expression. Eur. J. Hum. Genet 25, 157–160 (2016).27782106 10.1038/ejhg.2016.143
464. Rienhoff HY Jr A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome Am. J. Med Genet A 2013 161a 2040 2046 10.1002/ajmg.a.36056 23824657
Rienhoff, H. Y. Jr. et al. A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome. Am. J. Med Genet A 161a, 2040–2046 (2013).23824657 10.1002/ajmg.a.36056
465. Bertoli-Avella AM Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections J. Am. Coll. Cardiol. 2015 65 1324 1336 10.1016/j.jacc.2015.01.040 25835445
Bertoli-Avella, A. M. et al. Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections. J. Am. Coll. Cardiol. 65, 1324–1336 (2015).25835445 10.1016/j.jacc.2015.01.040
466. Kuechler A Exome sequencing identifies a novel heterozygous TGFB3 mutation in a disorder overlapping with Marfan and Loeys-Dietz syndrome Mol. Cell Probes 2015 29 330 334 10.1016/j.mcp.2015.07.003 26184463
Kuechler, A. et al. Exome sequencing identifies a novel heterozygous TGFB3 mutation in a disorder overlapping with Marfan and Loeys-Dietz syndrome. Mol. Cell Probes 29, 330–334 (2015).26184463 10.1016/j.mcp.2015.07.003
467. Loeys BL Aneurysm syndromes caused by mutations in the TGF-beta receptor N. Engl. J. Med 2006 355 788 798 10.1056/NEJMoa055695 16928994
Loeys, B. L. et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N. Engl. J. Med 355, 788–798 (2006).16928994 10.1056/NEJMoa055695
468. Hara H Activation of TGF-β signaling in an aortic aneurysm in a patient with Loeys-Dietz syndrome caused by a novel loss-of-function variant of TGFBR1 Hum. Genome Var. 2019 6 6 10.1038/s41439-019-0038-x 30701076
Hara, H. et al. Activation of TGF-β signaling in an aortic aneurysm in a patient with Loeys-Dietz syndrome caused by a novel loss-of-function variant of TGFBR1. Hum. Genome Var. 6, 6 (2019).30701076 10.1038/s41439-019-0038-x
469. Tran-Fadulu V Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations J. Med Genet 2009 46 607 613 10.1136/jmg.2008.062844 19542084
Tran-Fadulu, V. et al. Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations. J. Med Genet 46, 607–613 (2009).19542084 10.1136/jmg.2008.062844
470. Kirmani S Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome Am. J. Med Genet A 2010 152a 1016 1019 10.1002/ajmg.a.33356 20358619
Kirmani, S. et al. Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome. Am. J. Med Genet A 152a, 1016–1019 (2010).20358619 10.1002/ajmg.a.33356
471. Cousin MA Functional validation reveals the novel missense V419L variant in TGFBR2 associated with Loeys-Dietz syndrome (LDS) impairs canonical TGF-β signaling Cold Spring Harb. Mol. Case Stud. 2017 3 a001727 10.1101/mcs.a001727 28679693
Cousin, M. A. et al. Functional validation reveals the novel missense V419L variant in TGFBR2 associated with Loeys-Dietz syndrome (LDS) impairs canonical TGF-β signaling. Cold Spring Harb. Mol. Case Stud. 3, a001727 (2017).28679693 10.1101/mcs.a001727
472. Luo X Identification of a Pathogenic TGFBR2 Variant in a Patient With Loeys-Dietz Syndrome Front Genet 2020 11 479 10.3389/fgene.2020.00479 32528524
Luo, X. et al. Identification of a Pathogenic TGFBR2 Variant in a Patient With Loeys-Dietz Syndrome. Front Genet 11, 479 (2020).32528524 10.3389/fgene.2020.00479
473. Cannaerts E Novel pathogenic SMAD2 variants in five families with arterial aneurysm and dissection: further delineation of the phenotype J. Med Genet 2019 56 220 227 10.1136/jmedgenet-2018-105304 29967133
Cannaerts, E. et al. Novel pathogenic SMAD2 variants in five families with arterial aneurysm and dissection: further delineation of the phenotype. J. Med Genet 56, 220–227 (2019).29967133 10.1136/jmedgenet-2018-105304
474. Granadillo JL Variable cardiovascular phenotypes associated with SMAD2 pathogenic variants Hum. Mutat. 2018 39 1875 1884 10.1002/humu.23627 30157302
Granadillo, J. L. et al. Variable cardiovascular phenotypes associated with SMAD2 pathogenic variants. Hum. Mutat. 39, 1875–1884 (2018).30157302 10.1002/humu.23627
475. Schepers D A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3 Hum. Mutat. 2018 39 621 634 10.1002/humu.23407 29392890
Schepers, D. et al. A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3. Hum. Mutat. 39, 621–634 (2018).29392890 10.1002/humu.23407
476. van de Laar IM Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis Nat. Genet 2011 43 121 126 10.1038/ng.744 21217753
van de Laar, I. M. et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat. Genet 43, 121–126 (2011).21217753 10.1038/ng.744
477. van de Laar IM Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome J. Med Genet 2012 49 47 57 10.1136/jmedgenet-2011-100382 22167769
van de Laar, I. M. et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J. Med Genet 49, 47–57 (2012).22167769 10.1136/jmedgenet-2011-100382
478. Aubart M Early-onset osteoarthritis, Charcot-Marie-Tooth like neuropathy, autoimmune features, multiple arterial aneurysms and dissections: an unrecognized and life threatening condition PLoS One 2014 9 e96387 10.1371/journal.pone.0096387 24804794
Aubart, M. et al. Early-onset osteoarthritis, Charcot-Marie-Tooth like neuropathy, autoimmune features, multiple arterial aneurysms and dissections: an unrecognized and life threatening condition. PLoS One 9, e96387 (2014).24804794 10.1371/journal.pone.0096387
479. Chung BH Hand and fibrillin-1 deposition abnormalities in Loeys-Dietz syndrome-expanding the clinical spectrum Am. J. Med Genet A 2014 164a 461 466 10.1002/ajmg.a.36246 24194458
Chung, B. H. et al. Hand and fibrillin-1 deposition abnormalities in Loeys-Dietz syndrome-expanding the clinical spectrum. Am. J. Med Genet A 164a, 461–466 (2014).24194458 10.1002/ajmg.a.36246
480. Barnett CP Chitayat D Bradley TJ Wang Y Hinek A Dexamethasone normalizes aberrant elastic fiber production and collagen 1 secretion by Loeys-Dietz syndrome fibroblasts: a possible treatment? Eur. J. Hum. Genet 2011 19 624 633 10.1038/ejhg.2010.259 21267002
Barnett, C. P., Chitayat, D., Bradley, T. J., Wang, Y. & Hinek, A. Dexamethasone normalizes aberrant elastic fiber production and collagen 1 secretion by Loeys-Dietz syndrome fibroblasts: a possible treatment? Eur. J. Hum. Genet 19, 624–633 (2011).21267002 10.1038/ejhg.2010.259
481. Loeys BL A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 Nat. Genet 2005 37 275 281 10.1038/ng1511 15731757
Loeys, B. L. et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet 37, 275–281 (2005).15731757 10.1038/ng1511
482. Maleszewski JJ Miller DV Lu J Dietz HC Halushka MK Histopathologic findings in ascending aortas from individuals with Loeys-Dietz syndrome (LDS) Am. J. Surg. Pathol. 2009 33 194 201 10.1097/PAS.0b013e31817f3661 18852674
Maleszewski, J. J., Miller, D. V., Lu, J., Dietz, H. C. & Halushka, M. K. Histopathologic findings in ascending aortas from individuals with Loeys-Dietz syndrome (LDS). Am. J. Surg. Pathol. 33, 194–201 (2009).18852674 10.1097/PAS.0b013e31817f3661
483. Sellheyer K Inhibition of skin development by overexpression of transforming growth factor beta 1 in the epidermis of transgenic mice Proc. Natl Acad. Sci. USA 1993 90 5237 5241 10.1073/pnas.90.11.5237 7685120
Sellheyer, K. et al. Inhibition of skin development by overexpression of transforming growth factor beta 1 in the epidermis of transgenic mice. Proc. Natl Acad. Sci. USA 90, 5237–5241 (1993).7685120 10.1073/pnas.90.11.5237
484. Ito Y Overexpression of Smad2 reveals its concerted action with Smad4 in regulating TGF-beta-mediated epidermal homeostasis Dev. Biol. 2001 236 181 194 10.1006/dbio.2001.0332 11456453
Ito, Y. et al. Overexpression of Smad2 reveals its concerted action with Smad4 in regulating TGF-beta-mediated epidermal homeostasis. Dev. Biol. 236, 181–194 (2001).11456453 10.1006/dbio.2001.0332
485. Erlebacher A Derynck R Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype J. Cell Biol. 1996 132 195 210 10.1083/jcb.132.1.195 8567723
Erlebacher, A. & Derynck, R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132, 195–210 (1996).8567723 10.1083/jcb.132.1.195
486. Flügel-Koch C Ohlmann A Piatigorsky J Tamm ER Disruption of anterior segment development by TGF-beta1 overexpression in the eyes of transgenic mice Dev. Dyn. 2002 225 111 125 10.1002/dvdy.10144 12242711
Flügel-Koch, C., Ohlmann, A., Piatigorsky, J. & Tamm, E. R. Disruption of anterior segment development by TGF-beta1 overexpression in the eyes of transgenic mice. Dev. Dyn. 225, 111–125 (2002).12242711 10.1002/dvdy.10144
487. Vicencio AG Conditional overexpression of bioactive transforming growth factor-beta1 in neonatal mouse lung: a new model for bronchopulmonary dysplasia? Am. J. Respir. Cell Mol. Biol. 2004 31 650 656 10.1165/rcmb.2004-0092OC 15333328
Vicencio, A. G. et al. Conditional overexpression of bioactive transforming growth factor-beta1 in neonatal mouse lung: a new model for bronchopulmonary dysplasia? Am. J. Respir. Cell Mol. Biol. 31, 650–656 (2004).15333328 10.1165/rcmb.2004-0092OC
488. Zeng X Gray M Stahlman MT Whitsett JA TGF-beta1 perturbs vascular development and inhibits epithelial differentiation in fetal lung in vivo Dev. Dyn. 2001 221 289 301 10.1002/dvdy.1140 11458389
Zeng, X., Gray, M., Stahlman, M. T. & Whitsett, J. A. TGF-beta1 perturbs vascular development and inhibits epithelial differentiation in fetal lung in vivo. Dev. Dyn. 221, 289–301 (2001).11458389 10.1002/dvdy.1140
489. Jhappan C Targeting expression of a transforming growth factor beta 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation Embo j. 1993 12 1835 1845 10.1002/j.1460-2075.1993.tb05832.x 8491177
Jhappan, C. et al. Targeting expression of a transforming growth factor beta 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. Embo j. 12, 1835–1845 (1993).8491177 10.1002/j.1460-2075.1993.tb05832.x
490. Pierce DF Jr Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1 Genes Dev. 1993 7 2308 2317 10.1101/gad.7.12a.2308 8253379
Pierce, D. F. Jr. et al. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev. 7, 2308–2317 (1993).8253379 10.1101/gad.7.12a.2308
491. Buggiano V Impairment of mammary lobular development induced by expression of TGFbeta1 under the control of WAP promoter does not suppress tumorigenesis in MMTV-infected transgenic mice Int J. Cancer 2001 92 568 576 10.1002/ijc.1232 11304693
Buggiano, V. et al. Impairment of mammary lobular development induced by expression of TGFbeta1 under the control of WAP promoter does not suppress tumorigenesis in MMTV-infected transgenic mice. Int J. Cancer 92, 568–576 (2001).11304693 10.1002/ijc.1232
492. Hall BE Conditional overexpression of TGF-beta1 disrupts mouse salivary gland development and function Lab Invest 2010 90 543 555 10.1038/labinvest.2010.5 20142803
Hall, B. E. et al. Conditional overexpression of TGF-beta1 disrupts mouse salivary gland development and function. Lab Invest 90, 543–555 (2010).20142803 10.1038/labinvest.2010.5
493. Wyss-Coray T Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1 Am. J. Pathol. 1995 147 53 67 7604885
Wyss-Coray, T. et al. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Am. J. Pathol. 147, 53–67 (1995).7604885
494. Saito T Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta 1 J. Biol. Chem. 2001 276 11469 11472 10.1074/jbc.C000859200 11278244
Saito, T. et al. Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta 1. J. Biol. Chem. 276, 11469–11472 (2001).11278244 10.1074/jbc.C000859200
495. Janssens K ten Dijke P Ralston SH Bergmann C Van Hul W Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein J. Biol. Chem. 2003 278 7718 7724 10.1074/jbc.M208857200 12493741
Janssens, K., ten Dijke, P., Ralston, S. H., Bergmann, C. & Van Hul, W. Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J. Biol. Chem. 278, 7718–7724 (2003).12493741 10.1074/jbc.M208857200
496. Wallace, S. E. & Wilcox, W. R. In GeneReviews(®) (eds. M. P. Adam et al.) (University of Washington, Seattle Copyright © 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., 1993).
497. Janssens K Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease Nat. Genet 2000 26 273 275 10.1038/81563 11062463
Janssens, K. et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat. Genet 26, 273–275 (2000).11062463 10.1038/81563
498. McGowan NW A mutation affecting the latency-associated peptide of TGFbeta1 in Camurati-Engelmann disease enhances osteoclast formation in vitro J. Clin. Endocrinol. Metab. 2003 88 3321 3326 10.1210/jc.2002-020564 12843182
McGowan, N. W. et al. A mutation affecting the latency-associated peptide of TGFbeta1 in Camurati-Engelmann disease enhances osteoclast formation in vitro. J. Clin. Endocrinol. Metab. 88, 3321–3326 (2003).12843182 10.1210/jc.2002-020564
499. Tang Y TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation Nat. Med 2009 15 757 765 10.1038/nm.1979 19584867
Tang, Y. et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med 15, 757–765 (2009).19584867 10.1038/nm.1979
500. Schmid P TGF-beta s and TGF-beta type II receptor in human epidermis: differential expression in acute and chronic skin wounds J. Pathol. 1993 171 191 197 10.1002/path.1711710307 8277368
Schmid, P. et al. TGF-beta s and TGF-beta type II receptor in human epidermis: differential expression in acute and chronic skin wounds. J. Pathol. 171, 191–197 (1993).8277368 10.1002/path.1711710307
501. Pastar I Attenuation of the transforming growth factor beta-signaling pathway in chronic venous ulcers Mol. Med 2010 16 92 101 10.2119/molmed.2009.00149 20069132
Pastar, I. et al. Attenuation of the transforming growth factor beta-signaling pathway in chronic venous ulcers. Mol. Med 16, 92–101 (2010).20069132 10.2119/molmed.2009.00149
502. Kim BC Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta Type II receptor expression J. Cell Physiol. 2003 195 331 336 10.1002/jcp.10301 12704642
Kim, B. C. et al. Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta Type II receptor expression. J. Cell Physiol. 195, 331–336 (2003).12704642 10.1002/jcp.10301
503. Cowin AJ Effect of healing on the expression of transforming growth factor beta(s) and their receptors in chronic venous leg ulcers J. Invest Dermatol 2001 117 1282 1289 10.1046/j.0022-202x.2001.01501.x 11710945
Cowin, A. J. et al. Effect of healing on the expression of transforming growth factor beta(s) and their receptors in chronic venous leg ulcers. J. Invest Dermatol 117, 1282–1289 (2001).11710945 10.1046/j.0022-202x.2001.01501.x
504. Bitar MS Labbad ZN Transforming growth factor-beta and insulin-like growth factor-I in relation to diabetes-induced impairment of wound healing J. Surg. Res 1996 61 113 119 10.1006/jsre.1996.0090 8769952
Bitar, M. S. & Labbad, Z. N. Transforming growth factor-beta and insulin-like growth factor-I in relation to diabetes-induced impairment of wound healing. J. Surg. Res 61, 113–119 (1996).8769952 10.1006/jsre.1996.0090
505. Jude EB Blakytny R Bulmer J Boulton AJ Ferguson MW Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers Diabet. Med 2002 19 440 447 10.1046/j.1464-5491.2002.00692.x 12060054
Jude, E. B., Blakytny, R., Bulmer, J., Boulton, A. J. & Ferguson, M. W. Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet. Med 19, 440–447 (2002).12060054 10.1046/j.1464-5491.2002.00692.x
506. Liu J Regenerative phenotype in mice with a point mutation in transforming growth factor beta type I receptor (TGFBR1) Proc. Natl Acad. Sci. USA 2011 108 14560 14565 10.1073/pnas.1111056108 21841138
Liu, J. et al. Regenerative phenotype in mice with a point mutation in transforming growth factor beta type I receptor (TGFBR1). Proc. Natl Acad. Sci. USA 108, 14560–14565 (2011).21841138 10.1073/pnas.1111056108
507. Tredget EB Transforming growth factor-beta and its effect on reepithelialization of partial-thickness ear wounds in transgenic mice Wound Repair Regen. 2005 13 61 67 10.1111/j.1067-1927.2005.130108.x 15659037
Tredget, E. B. et al. Transforming growth factor-beta and its effect on reepithelialization of partial-thickness ear wounds in transgenic mice. Wound Repair Regen. 13, 61–67 (2005).15659037 10.1111/j.1067-1927.2005.130108.x
508. Chan T Development, characterization, and wound healing of the keratin 14 promoted transforming growth factor-beta1 transgenic mouse Wound Repair Regen. 2002 10 177 187 10.1046/j.1524-475X.2002.11101.x 12100379
Chan, T. et al. Development, characterization, and wound healing of the keratin 14 promoted transforming growth factor-beta1 transgenic mouse. Wound Repair Regen. 10, 177–187 (2002).12100379 10.1046/j.1524-475X.2002.11101.x
509. Brown RL Ormsby I Doetschman TC Greenhalgh DG Wound healing in the transforming growth factor-beta-deficient mouse Wound Repair Regen. 1995 3 25 36 10.1046/j.1524-475X.1995.30108.x 17168860
Brown, R. L., Ormsby, I., Doetschman, T. C. & Greenhalgh, D. G. Wound healing in the transforming growth factor-beta-deficient mouse. Wound Repair Regen. 3, 25–36 (1995).17168860 10.1046/j.1524-475X.1995.30108.x
510. Crowe MJ Doetschman T Greenhalgh DG Delayed wound healing in immunodeficient TGF-beta 1 knockout mice J. Invest Dermatol 2000 115 3 11 10.1046/j.1523-1747.2000.00010.x 10886500
Crowe, M. J., Doetschman, T. & Greenhalgh, D. G. Delayed wound healing in immunodeficient TGF-beta 1 knockout mice. J. Invest Dermatol 115, 3–11 (2000).10886500 10.1046/j.1523-1747.2000.00010.x
511. Amendt C Mann A Schirmacher P Blessing M Resistance of keratinocytes to TGFbeta-mediated growth restriction and apoptosis induction accelerates re-epithelialization in skin wounds J. Cell Sci. 2002 115 2189 2198 10.1242/jcs.115.10.2189 11973359
Amendt, C., Mann, A., Schirmacher, P. & Blessing, M. Resistance of keratinocytes to TGFbeta-mediated growth restriction and apoptosis induction accelerates re-epithelialization in skin wounds. J. Cell Sci. 115, 2189–2198 (2002).11973359 10.1242/jcs.115.10.2189
512. Owens P Engelking E Han G Haeger SM Wang XJ Epidermal Smad4 deletion results in aberrant wound healing Am. J. Pathol. 2010 176 122 133 10.2353/ajpath.2010.090081 19959815
Owens, P., Engelking, E., Han, G., Haeger, S. M. & Wang, X. J. Epidermal Smad4 deletion results in aberrant wound healing. Am. J. Pathol. 176, 122–133 (2010).19959815 10.2353/ajpath.2010.090081
513. Ashcroft GS Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response Nat. Cell Biol. 1999 1 260 266 10.1038/12971 10559937
Ashcroft, G. S. et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat. Cell Biol. 1, 260–266 (1999).10559937 10.1038/12971
514. Ghahary A Shen YJ Scott PG Tredget EE Immunolocalization of TGF-beta 1 in human hypertrophic scar and normal dermal tissues Cytokine 1995 7 184 190 10.1006/cyto.1995.1025 7780038
Ghahary, A., Shen, Y. J., Scott, P. G. & Tredget, E. E. Immunolocalization of TGF-beta 1 in human hypertrophic scar and normal dermal tissues. Cytokine 7, 184–190 (1995).7780038 10.1006/cyto.1995.1025
515. Schmid P Itin P Cherry G Bi C Cox DA Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar Am. J. Pathol. 1998 152 485 493 9466575
Schmid, P., Itin, P., Cherry, G., Bi, C. & Cox, D. A. Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar. Am. J. Pathol. 152, 485–493 (1998).9466575
516. Wang R Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells Wound Repair Regen. 2000 8 128 137 10.1046/j.1524-475x.2000.00128.x 10810039
Wang, R. et al. Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. Wound Repair Regen. 8, 128–137 (2000).10810039 10.1046/j.1524-475x.2000.00128.x
517. Chin GS Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts Plast. Reconstr. Surg. 2001 108 423 429 10.1097/00006534-200108000-00022 11496185
Chin, G. S. et al. Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast. Reconstr. Surg. 108, 423–429 (2001).11496185 10.1097/00006534-200108000-00022
518. Xia W Phan TT Lim IJ Longaker MT Yang GP Complex epithelial-mesenchymal interactions modulate transforming growth factor-beta expression in keloid-derived cells Wound Repair Regen. 2004 12 546 556 10.1111/j.1067-1927.2004.012507.x 15453837
Xia, W., Phan, T. T., Lim, I. J., Longaker, M. T. & Yang, G. P. Complex epithelial-mesenchymal interactions modulate transforming growth factor-beta expression in keloid-derived cells. Wound Repair Regen. 12, 546–556 (2004).15453837 10.1111/j.1067-1927.2004.012507.x
519. Younai S Modulation of collagen synthesis by transforming growth factor-beta in keloid and hypertrophic scar fibroblasts Ann. Plast. Surg. 1994 33 148 151 10.1097/00000637-199408000-00005 7979045
Younai, S. et al. Modulation of collagen synthesis by transforming growth factor-beta in keloid and hypertrophic scar fibroblasts. Ann. Plast. Surg. 33, 148–151 (1994).7979045 10.1097/00000637-199408000-00005
520. Chodon T Sugihara T Igawa HH Funayama E Furukawa H Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance Am. J. Pathol. 2000 157 1661 1669 10.1016/S0002-9440(10)64803-1 11073825
Chodon, T., Sugihara, T., Igawa, H. H., Funayama, E. & Furukawa, H. Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Am. J. Pathol. 157, 1661–1669 (2000).11073825 10.1016/S0002-9440(10)64803-1
521. Colwell AS Phan TT Kong W Longaker MT Lorenz PH Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation Plast. Reconstr. Surg. 2005 116 1387 1390 10.1097/01.prs.0000182343.99694.28 16217483
Colwell, A. S., Phan, T. T., Kong, W., Longaker, M. T. & Lorenz, P. H. Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation. Plast. Reconstr. Surg. 116, 1387–1390 (2005). discussion 1391-1382.16217483 10.1097/01.prs.0000182343.99694.28
522. Bettinger DA Yager DR Diegelmann RF Cohen IK The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis Plast. Reconstr. Surg. 1996 98 827 833 10.1097/00006534-199610000-00012 8823022
Bettinger, D. A., Yager, D. R., Diegelmann, R. F. & Cohen, I. K. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast. Reconstr. Surg. 98, 827–833 (1996).8823022 10.1097/00006534-199610000-00012
523. Fujiwara M Muragaki Y Ooshima A Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity Arch. Dermatol Res 2005 297 161 169 10.1007/s00403-005-0596-2 16184401
Fujiwara, M., Muragaki, Y. & Ooshima, A. Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity. Arch. Dermatol Res 297, 161–169 (2005).16184401 10.1007/s00403-005-0596-2
524. Hoyt DG Lazo JS Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice J. Pharm. Exp. Ther. 1988 246 765 771
Hoyt, D. G. & Lazo, J. S. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. J. Pharm. Exp. Ther. 246, 765–771 (1988).
525. Westergren-Thorsson G Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats J. Clin. Invest 1993 92 632 637 10.1172/JCI116631 7688761
Westergren-Thorsson, G. et al. Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats. J. Clin. Invest 92, 632–637 (1993).7688761 10.1172/JCI116631
526. Broekelmann TJ Limper AH Colby TV McDonald JA Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis Proc. Natl Acad. Sci. USA 1991 88 6642 6646 10.1073/pnas.88.15.6642 1862087
Broekelmann, T. J., Limper, A. H., Colby, T. V. & McDonald, J. A. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl Acad. Sci. USA 88, 6642–6646 (1991).1862087 10.1073/pnas.88.15.6642
527. Coker RK Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung Thorax 2001 56 549 556 11413354
Coker, R. K. et al. Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung. Thorax 56, 549–556 (2001).11413354
528. Corrin B Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders Histopathology 1994 24 145 150 10.1111/j.1365-2559.1994.tb01293.x 8181807
Corrin, B. et al. Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 24, 145–150 (1994).8181807 10.1111/j.1365-2559.1994.tb01293.x
529. Utsugi M C-Jun-NH2-terminal kinase mediates expression of connective tissue growth factor induced by transforming growth factor-beta1 in human lung fibroblasts Am. J. Respir. Cell Mol. Biol. 2003 28 754 761 10.1165/rcmb.4892 12760970
Utsugi, M. et al. C-Jun-NH2-terminal kinase mediates expression of connective tissue growth factor induced by transforming growth factor-beta1 in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 28, 754–761 (2003).12760970 10.1165/rcmb.4892
530. Togami K Yamaguchi K Chono S Tada H Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-β(1) in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in idiopathic pulmonary fibrosis J. Pharm. Toxicol. Methods 2017 86 19 27 10.1016/j.vascn.2017.02.023
Togami, K., Yamaguchi, K., Chono, S. & Tada, H. Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-β(1) in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in idiopathic pulmonary fibrosis. J. Pharm. Toxicol. Methods 86, 19–27 (2017).10.1016/j.vascn.2017.02.023
531. Roy SG Nozaki Y Phan SH Regulation of alpha-smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts Int J. Biochem Cell Biol. 2001 33 723 734 10.1016/S1357-2725(01)00041-3 11390280
Roy, S. G., Nozaki, Y. & Phan, S. H. Regulation of alpha-smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts. Int J. Biochem Cell Biol. 33, 723–734 (2001).11390280 10.1016/S1357-2725(01)00041-3
532. Kim KK Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix Proc. Natl Acad. Sci. USA 2006 103 13180 13185 10.1073/pnas.0605669103 16924102
Kim, K. K. et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA 103, 13180–13185 (2006).16924102 10.1073/pnas.0605669103
533. Lee CG Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis J. Exp. Med 2004 200 377 389 10.1084/jem.20040104 15289506
Lee, C. G. et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J. Exp. Med 200, 377–389 (2004).15289506 10.1084/jem.20040104
534. Sime PJ Xing Z Graham FL Csaky KG Gauldie J Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung J. Clin. Invest 1997 100 768 776 10.1172/JCI119590 9259574
Sime, P. J., Xing, Z., Graham, F. L., Csaky, K. G. & Gauldie, J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest 100, 768–776 (1997).9259574 10.1172/JCI119590
535. D’Alessandro-Gabazza CN Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis Am. J. Respir. Cell Mol. Biol. 2012 46 397 406 10.1165/rcmb.2011-0158OC 22033267
D’Alessandro-Gabazza, C. N. et al. Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 46, 397–406 (2012).22033267 10.1165/rcmb.2011-0158OC
536. Li M Epithelium-specific deletion of TGF-β receptor type II protects mice from bleomycin-induced pulmonary fibrosis J. Clin. Invest 2011 121 277 287 10.1172/JCI42090 21135509
Li, M. et al. Epithelium-specific deletion of TGF-β receptor type II protects mice from bleomycin-induced pulmonary fibrosis. J. Clin. Invest 121, 277–287 (2011).21135509 10.1172/JCI42090
537. Xu L Transforming growth factor β3 attenuates the development of radiation-induced pulmonary fibrosis in mice by decreasing fibrocyte recruitment and regulating IFN-γ/IL-4 balance Immunol. Lett. 2014 162 27 33 10.1016/j.imlet.2014.06.010 24996042
Xu, L. et al. Transforming growth factor β3 attenuates the development of radiation-induced pulmonary fibrosis in mice by decreasing fibrocyte recruitment and regulating IFN-γ/IL-4 balance. Immunol. Lett. 162, 27–33 (2014).24996042 10.1016/j.imlet.2014.06.010
538. Zhao J Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice Am. J. Physiol. Lung Cell Mol. Physiol. 2002 282 L585 L593 10.1152/ajplung.00151.2001 11839555
Zhao, J. et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L585–L593 (2002).11839555 10.1152/ajplung.00151.2001
539. Nakao A Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice J. Clin. Invest 1999 104 5 11 10.1172/JCI6094 10393693
Nakao, A. et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J. Clin. Invest 104, 5–11 (1999).10393693 10.1172/JCI6094
540. Yamamoto T Expression of transforming growth factor-beta isoforms in human glomerular diseases Kidney Int 1996 49 461 469 10.1038/ki.1996.65 8821830
Yamamoto, T. et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 49, 461–469 (1996).8821830 10.1038/ki.1996.65
541. Shihab FS Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts J. Am. Soc. Nephrol. 1995 6 286 294 10.1681/ASN.V62286 7579098
Shihab, F. S. et al. Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. J. Am. Soc. Nephrol. 6, 286–294 (1995).7579098 10.1681/ASN.V62286
542. Yoshioka K Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys Lab Invest 1993 68 154 163 8441250
Yoshioka, K. et al. Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 68, 154–163 (1993).8441250
543. Iwano M Intraglomerular expression of transforming growth factor-beta 1 (TGF-beta 1) mRNA in patients with glomerulonephritis: quantitative analysis by competitive polymerase chain reaction Clin. Exp. Immunol. 1994 97 309 314 10.1111/j.1365-2249.1994.tb06086.x 8050182
Iwano, M. et al. Intraglomerular expression of transforming growth factor-beta 1 (TGF-beta 1) mRNA in patients with glomerulonephritis: quantitative analysis by competitive polymerase chain reaction. Clin. Exp. Immunol. 97, 309–314 (1994).8050182 10.1111/j.1365-2249.1994.tb06086.x
544. Grande J Melder D Zinsmeister A Killen P Transforming growth factor-beta 1 induces collagen IV gene expression in NIH-3T3 cells Lab Invest 1993 69 387 395 8231107
Grande, J., Melder, D., Zinsmeister, A. & Killen, P. Transforming growth factor-beta 1 induces collagen IV gene expression in NIH-3T3 cells. Lab Invest 69, 387–395 (1993).8231107
545. Nakamura T Miller D Ruoslahti E Border WA Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1 Kidney Int 1992 41 1213 1221 10.1038/ki.1992.183 1614036
Nakamura, T., Miller, D., Ruoslahti, E. & Border, W. A. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. Kidney Int 41, 1213–1221 (1992).1614036 10.1038/ki.1992.183
546. Kagami S Transforming growth factor-beta (TGF-beta) stimulates the expression of beta1 integrins and adhesion by rat mesangial cells Exp. Cell Res 1996 229 1 6 10.1006/excr.1996.0336 8940242
Kagami, S. et al. Transforming growth factor-beta (TGF-beta) stimulates the expression of beta1 integrins and adhesion by rat mesangial cells. Exp. Cell Res 229, 1–6 (1996).8940242 10.1006/excr.1996.0336
547. Okuda S Languino LR Ruoslahti E Border WA Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix J. Clin. Invest 1990 86 453 462 10.1172/JCI114731 2200803
Okuda, S., Languino, L. R., Ruoslahti, E. & Border, W. A. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J. Clin. Invest 86, 453–462 (1990).2200803 10.1172/JCI114731
548. Marti HP Lee L Kashgarian M Lovett DH Transforming growth factor-beta 1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase Am. J. Pathol. 1994 144 82 94 8291614
Marti, H. P., Lee, L., Kashgarian, M. & Lovett, D. H. Transforming growth factor-beta 1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am. J. Pathol. 144, 82–94 (1994).8291614
549. Zeisberg M Maeshima Y Mosterman B Kalluri R Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells Am. J. Pathol. 2002 160 2001 2008 10.1016/S0002-9440(10)61150-9 12057905
Zeisberg, M., Maeshima, Y., Mosterman, B. & Kalluri, R. Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am. J. Pathol. 160, 2001–2008 (2002).12057905 10.1016/S0002-9440(10)61150-9
550. Yang J Liu Y Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis Am. J. Pathol. 2001 159 1465 1475 10.1016/S0002-9440(10)62533-3 11583974
Yang, J. & Liu, Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am. J. Pathol. 159, 1465–1475 (2001).11583974 10.1016/S0002-9440(10)62533-3
551. Kopp JB Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease Lab Invest 1996 74 991 1003 8667617
Kopp, J. B. et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 74, 991–1003 (1996).8667617
552. Mozes MM Böttinger EP Jacot TA Kopp JB Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice J. Am. Soc. Nephrol. 1999 10 271 280 10.1681/ASN.V102271 10215326
Mozes, M. M., Böttinger, E. P., Jacot, T. A. & Kopp, J. B. Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice. J. Am. Soc. Nephrol. 10, 271–280 (1999).10215326 10.1681/ASN.V102271
553. Nagy P Schaff Z Lapis K Immunohistochemical detection of transforming growth factor-beta 1 in fibrotic liver diseases Hepatology 1991 14 269 273 10.1002/hep.1840140211 1713566
Nagy, P., Schaff, Z. & Lapis, K. Immunohistochemical detection of transforming growth factor-beta 1 in fibrotic liver diseases. Hepatology 14, 269–273 (1991).1713566 10.1002/hep.1840140211
554. Castilla A Prieto J Fausto N Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy N. Engl. J. Med 1991 324 933 940 10.1056/NEJM199104043241401 1900574
Castilla, A., Prieto, J. & Fausto, N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N. Engl. J. Med 324, 933–940 (1991).1900574 10.1056/NEJM199104043241401
555. Czaja MJ In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis J. Cell Biol. 1989 108 2477 2482 10.1083/jcb.108.6.2477 2500447
Czaja, M. J. et al. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J. Cell Biol. 108, 2477–2482 (1989).2500447 10.1083/jcb.108.6.2477
556. Sakaguchi E Th1 down-regulation at the single-lymphocyte level in HCV-related liver cirrhosis and the effect of TGF-beta on Th1 response: possible implications for the development of hepatoma Hepatol. Res 2002 24 282 10.1016/S1386-6346(02)00090-6 12393030
Sakaguchi, E. et al. Th1 down-regulation at the single-lymphocyte level in HCV-related liver cirrhosis and the effect of TGF-beta on Th1 response: possible implications for the development of hepatoma. Hepatol. Res 24, 282 (2002).12393030 10.1016/S1386-6346(02)00090-6
557. Ueberham E Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis Hepatology 2003 37 1067 1078 10.1053/jhep.2003.50196 12717387
Ueberham, E. et al. Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology 37, 1067–1078 (2003).12717387 10.1053/jhep.2003.50196
558. Sanderson N Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions Proc. Natl Acad. Sci. USA 1995 92 2572 2576 10.1073/pnas.92.7.2572 7708687
Sanderson, N. et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc. Natl Acad. Sci. USA 92, 2572–2576 (1995).7708687 10.1073/pnas.92.7.2572
559. El-Youssef M Mu Y Huang L Stellmach V Crawford SE Increased expression of transforming growth factor-beta1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell J. Pediatr. Gastroenterol. Nutr. 1999 28 386 392 10204502
El-Youssef, M., Mu, Y., Huang, L., Stellmach, V. & Crawford, S. E. Increased expression of transforming growth factor-beta1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell. J. Pediatr. Gastroenterol. Nutr. 28, 386–392 (1999).10204502
560. Teekakirikul P Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β J. Clin. Invest 2010 120 3520 3529 10.1172/JCI42028 20811150
Teekakirikul, P. et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J. Clin. Invest 120, 3520–3529 (2010).20811150 10.1172/JCI42028
561. Kania G Heart-infiltrating prominin-1+/CD133+ progenitor cells represent the cellular source of transforming growth factor beta-mediated cardiac fibrosis in experimental autoimmune myocarditis Circ. Res 2009 105 462 470 10.1161/CIRCRESAHA.109.196287 19628793
Kania, G. et al. Heart-infiltrating prominin-1+/CD133+ progenitor cells represent the cellular source of transforming growth factor beta-mediated cardiac fibrosis in experimental autoimmune myocarditis. Circ. Res 105, 462–470 (2009).19628793 10.1161/CIRCRESAHA.109.196287
562. Zhao W Zhao T Chen Y Ahokas RA Sun Y Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats Mol. Cell Biochem 2008 317 43 50 10.1007/s11010-008-9803-8 18581202
Zhao, W., Zhao, T., Chen, Y., Ahokas, R. A. & Sun, Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol. Cell Biochem 317, 43–50 (2008).18581202 10.1007/s11010-008-9803-8
563. Lijnen PJ Petrov VV Fagard RH Induction of cardiac fibrosis by transforming growth factor-beta(1) Mol. Genet Metab. 2000 71 418 435 10.1006/mgme.2000.3032 11001836
Lijnen, P. J., Petrov, V. V. & Fagard, R. H. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol. Genet Metab. 71, 418–435 (2000).11001836 10.1006/mgme.2000.3032
564. Kuwahara F Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats Circulation 2002 106 130 135 10.1161/01.CIR.0000020689.12472.E0 12093782
Kuwahara, F. et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106, 130–135 (2002).12093782 10.1161/01.CIR.0000020689.12472.E0
565. Sakata Y Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor Basic Res Cardiol. 2008 103 60 68 10.1007/s00395-007-0689-5 18034274
Sakata, Y. et al. Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol. 103, 60–68 (2008).18034274 10.1007/s00395-007-0689-5
566. Hagler MA TGF-β signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves Cardiovasc Res 2013 99 175 184 10.1093/cvr/cvt083 23554457
Hagler, M. A. et al. TGF-β signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves. Cardiovasc Res 99, 175–184 (2013).23554457 10.1093/cvr/cvt083
567. Spriewald BM Ensminger SM Billing JS Morris PJ Wood KJ Increased expression of transforming growth factor-beta and eosinophil infiltration is associated with the development of transplant arteriosclerosis in long-term surviving cardiac allografts Transplantation 2003 76 1105 1111 10.1097/01.TP.0000076467.83192.42 14557761
Spriewald, B. M., Ensminger, S. M., Billing, J. S., Morris, P. J. & Wood, K. J. Increased expression of transforming growth factor-beta and eosinophil infiltration is associated with the development of transplant arteriosclerosis in long-term surviving cardiac allografts. Transplantation 76, 1105–1111 (2003).14557761 10.1097/01.TP.0000076467.83192.42
568. Bobik A Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development Circulation 1999 99 2883 2891 10.1161/01.CIR.99.22.2883 10359732
Bobik, A. et al. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation 99, 2883–2891 (1999).10359732 10.1161/01.CIR.99.22.2883
569. Li J Endothelial Cell Apoptosis Induces TGF-β Signaling-Dependent Host Endothelial-Mesenchymal Transition to Promote Transplant Arteriosclerosis Am. J. Transpl. 2015 15 3095 3111 10.1111/ajt.13406
Li, J. et al. Endothelial Cell Apoptosis Induces TGF-β Signaling-Dependent Host Endothelial-Mesenchymal Transition to Promote Transplant Arteriosclerosis. Am. J. Transpl. 15, 3095–3111 (2015).10.1111/ajt.13406
570. Chang SH Transforming growth factor-β-mediated CD44/STAT3 signaling contributes to the development of atrial fibrosis and fibrillation Basic Res Cardiol. 2017 112 58 10.1007/s00395-017-0647-9 28871329
Chang, S. H. et al. Transforming growth factor-β-mediated CD44/STAT3 signaling contributes to the development of atrial fibrosis and fibrillation. Basic Res Cardiol. 112, 58 (2017).28871329 10.1007/s00395-017-0647-9
571. Seeland U Myocardial fibrosis in transforming growth factor-beta(1) (TGF-beta(1)) transgenic mice is associated with inhibition of interstitial collagenase Eur. J. Clin. Invest 2002 32 295 303 10.1046/j.1365-2362.2002.00985.x 12027867
Seeland, U. et al. Myocardial fibrosis in transforming growth factor-beta(1) (TGF-beta(1)) transgenic mice is associated with inhibition of interstitial collagenase. Eur. J. Clin. Invest 32, 295–303 (2002).12027867 10.1046/j.1365-2362.2002.00985.x
572. Cucoranu I NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts Circ. Res 2005 97 900 907 10.1161/01.RES.0000187457.24338.3D 16179589
Cucoranu, I. et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ. Res 97, 900–907 (2005).16179589 10.1161/01.RES.0000187457.24338.3D
573. Blyszczuk P Transforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis Eur. Heart J. 2017 38 1413 1425 27099262
Blyszczuk, P. et al. Transforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis. Eur. Heart J. 38, 1413–1425 (2017).27099262
574. Song S Foxm1 is a critical driver of TGF-β-induced EndMT in endothelial cells through Smad2/3 and binds to the Snail promoter J. Cell Physiol. 2019 234 9052 9064 10.1002/jcp.27583 30378114
Song, S. et al. Foxm1 is a critical driver of TGF-β-induced EndMT in endothelial cells through Smad2/3 and binds to the Snail promoter. J. Cell Physiol. 234, 9052–9064 (2019).30378114 10.1002/jcp.27583
575. Zeisberg EM Endothelial-to-mesenchymal transition contributes to cardiac fibrosis Nat. Med 2007 13 952 961 10.1038/nm1613 17660828
Zeisberg, E. M. et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med 13, 952–961 (2007).17660828 10.1038/nm1613
576. Varga J Rosenbloom J Jimenez SA Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts Biochem J. 1987 247 597 604 10.1042/bj2470597 3501287
Varga, J., Rosenbloom, J. & Jimenez, S. A. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J. 247, 597–604 (1987).3501287 10.1042/bj2470597
577. Goto K Development and progression of immobilization-induced skin fibrosis through overexpression of transforming growth factor-ß1 and hypoxic conditions in a rat knee joint contracture model Connect Tissue Res 2017 58 586 596 10.1080/03008207.2017.1284823 28121187
Goto, K. et al. Development and progression of immobilization-induced skin fibrosis through overexpression of transforming growth factor-ß1 and hypoxic conditions in a rat knee joint contracture model. Connect Tissue Res 58, 586–596 (2017).28121187 10.1080/03008207.2017.1284823
578. Zhang X Roles of TGF-β/Smad signaling pathway in pathogenesis and development of gluteal muscle contracture Connect Tissue Res 2015 56 9 17 10.3109/03008207.2014.964400 25207745
Zhang, X. et al. Roles of TGF-β/Smad signaling pathway in pathogenesis and development of gluteal muscle contracture. Connect Tissue Res 56, 9–17 (2015).25207745 10.3109/03008207.2014.964400
579. Yoshikawa H Role of TGF-beta1 in the development of pancreatic fibrosis in Otsuka Long-Evans Tokushima Fatty rats Am. J. Physiol. Gastrointest. Liver Physiol. 2002 282 G549 G558 10.1152/ajpgi.00323.2001 11842006
Yoshikawa, H. et al. Role of TGF-beta1 in the development of pancreatic fibrosis in Otsuka Long-Evans Tokushima Fatty rats. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G549–G558 (2002).11842006 10.1152/ajpgi.00323.2001
580. Vogelmann R Ruf D Wagner M Adler G Menke A Effects of fibrogenic mediators on the development of pancreatic fibrosis in a TGF-beta1 transgenic mouse model Am. J. Physiol. Gastrointest. Liver Physiol. 2001 280 G164 G172 10.1152/ajpgi.2001.280.1.G164 11123210
Vogelmann, R., Ruf, D., Wagner, M., Adler, G. & Menke, A. Effects of fibrogenic mediators on the development of pancreatic fibrosis in a TGF-beta1 transgenic mouse model. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G164–G172 (2001).11123210 10.1152/ajpgi.2001.280.1.G164
581. Van Laethem JL Robberecht P Résibois A Devière J Transforming growth factor beta promotes development of fibrosis after repeated courses of acute pancreatitis in mice Gastroenterology 1996 110 576 582 10.1053/gast.1996.v110.pm8566606 8566606
Van Laethem, J. L., Robberecht, P., Résibois, A. & Devière, J. Transforming growth factor beta promotes development of fibrosis after repeated courses of acute pancreatitis in mice. Gastroenterology 110, 576–582 (1996).8566606 10.1053/gast.1996.v110.pm8566606
582. Shek FW Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis Am. J. Pathol. 2002 160 1787 1798 10.1016/S0002-9440(10)61125-X 12000730
Shek, F. W. et al. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am. J. Pathol. 160, 1787–1798 (2002).12000730 10.1016/S0002-9440(10)61125-X
583. Yao JC TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche J. Clin. Invest 2022 132 e154092 10.1172/JCI154092 35439167
Yao, J. C. et al. TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche. J. Clin. Invest 132, e154092 (2022).35439167 10.1172/JCI154092
584. Ponce CC de Lourdes FCM Ihara SS Silva MR The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis Med Oncol. 2012 29 2337 2344 10.1007/s12032-011-0144-1 22200991
Ponce, C. C., de Lourdes, F. C. M., Ihara, S. S. & Silva, M. R. The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis. Med Oncol. 29, 2337–2344 (2012).22200991 10.1007/s12032-011-0144-1
585. Shen M Liu X Zhang H Guo SW Transforming growth factor β1 signaling coincides with epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis in mice Hum. Reprod. 2016 31 355 369 26689216
Shen, M., Liu, X., Zhang, H. & Guo, S. W. Transforming growth factor β1 signaling coincides with epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis in mice. Hum. Reprod. 31, 355–369 (2016).26689216
586. Koski H Konttinen YT Gu XH Hietanen J Malmström M Transforming growth factor beta 2 in labial salivary glands in Sjögren’s syndrome Ann. Rheum. Dis. 1995 54 744 747 10.1136/ard.54.9.744 7495347
Koski, H., Konttinen, Y. T., Gu, X. H., Hietanen, J. & Malmström, M. Transforming growth factor beta 2 in labial salivary glands in Sjögren’s syndrome. Ann. Rheum. Dis. 54, 744–747 (1995).7495347 10.1136/ard.54.9.744
587. di Mola FF Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn’s disease Ann. Surg. 1999 229 67 75 10.1097/00000658-199901000-00009 9923802
di Mola, F. F. et al. Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn’s disease. Ann. Surg. 229, 67–75 (1999).9923802 10.1097/00000658-199901000-00009
588. Gómez-Bernal F Transforming growth factor beta 1 is associated with subclinical carotid atherosclerosis in patients with systemic lupus erythematosus Arthritis Res Ther. 2023 25 64 10.1186/s13075-023-03046-2 37069672
Gómez-Bernal, F. et al. Transforming growth factor beta 1 is associated with subclinical carotid atherosclerosis in patients with systemic lupus erythematosus. Arthritis Res Ther. 25, 64 (2023).37069672 10.1186/s13075-023-03046-2
589. Liu B Aberrant TGF-β1 signaling contributes to the development of primary biliary cirrhosis in murine model World J. Gastroenterol. 2013 19 5828 5836 10.3748/wjg.v19.i35.5828 24124327
Liu, B. et al. Aberrant TGF-β1 signaling contributes to the development of primary biliary cirrhosis in murine model. World J. Gastroenterol. 19, 5828–5836 (2013).24124327 10.3748/wjg.v19.i35.5828
590. Chida T Critical role of CREBH-mediated induction of transforming growth factor β2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells Hepatology 2017 66 1430 1443 10.1002/hep.29319 28621467
Chida, T. et al. Critical role of CREBH-mediated induction of transforming growth factor β2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells. Hepatology 66, 1430–1443 (2017).28621467 10.1002/hep.29319
591. Mehta AK Doherty T Broide D Croft M Tumor necrosis factor family member LIGHT acts with IL-1β and TGF-β to promote airway remodeling during rhinovirus infection Allergy 2018 73 1415 1424 10.1111/all.13390 29315623
Mehta, A. K., Doherty, T., Broide, D. & Croft, M. Tumor necrosis factor family member LIGHT acts with IL-1β and TGF-β to promote airway remodeling during rhinovirus infection. Allergy 73, 1415–1424 (2018).29315623 10.1111/all.13390
592. Ahodantin J Type I interferons and TGF-β cooperate to induce liver fibrosis during HIV-1 infection under antiretroviral therapy JCI Insight 2022 7 e152738 10.1172/jci.insight.152738 35639478
Ahodantin, J. et al. Type I interferons and TGF-β cooperate to induce liver fibrosis during HIV-1 infection under antiretroviral therapy. JCI Insight 7, e152738 (2022).35639478 10.1172/jci.insight.152738
593. Huang L CD8+ T cells with high TGF‑β1 expression cause lymph node fibrosis following HIV infection Mol. Med Rep. 2018 18 77 86 29749506
Huang, L. et al. CD8+ T cells with high TGF‑β1 expression cause lymph node fibrosis following HIV infection. Mol. Med Rep. 18, 77–86 (2018).29749506
594. Kulkarni AB Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death Proc. Natl Acad. Sci. USA 1993 90 770 774 10.1073/pnas.90.2.770 8421714
Kulkarni, A. B. et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA 90, 770–774 (1993).8421714 10.1073/pnas.90.2.770
595. Kulkarni AB Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders Am. J. Pathol. 1995 146 264 275 7856732
Kulkarni, A. B. et al. Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am. J. Pathol. 146, 264–275 (1995).7856732
596. Dang H SLE-like autoantibodies and Sjögren’s syndrome-like lymphoproliferation in TGF-beta knockout mice J. Immunol. 1995 155 3205 3212 10.4049/jimmunol.155.6.3205 7673733
Dang, H. et al. SLE-like autoantibodies and Sjögren’s syndrome-like lymphoproliferation in TGF-beta knockout mice. J. Immunol. 155, 3205–3212 (1995).7673733 10.4049/jimmunol.155.6.3205
597. Laouar Y TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis Proc. Natl Acad. Sci. USA 2008 105 10865 10870 10.1073/pnas.0805058105 18669656
Laouar, Y. et al. TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 105, 10865–10870 (2008).18669656 10.1073/pnas.0805058105
598. Hahm KB Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease Gut 2001 49 190 198 10.1136/gut.49.2.190 11454793
Hahm, K. B. et al. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 49, 190–198 (2001).11454793 10.1136/gut.49.2.190
599. Schramm C Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice Am. J. Physiol. Gastrointest. Liver Physiol. 2003 284 G525 G535 10.1152/ajpgi.00286.2002 12466145
Schramm, C. et al. Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G525–G535 (2003).12466145 10.1152/ajpgi.00286.2002
600. Ramalingam R Dendritic cell-specific disruption of TGF-beta receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity J. Immunol. 2012 189 3878 3893 10.4049/jimmunol.1201029 22972928
Ramalingam, R. et al. Dendritic cell-specific disruption of TGF-beta receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J. Immunol. 189, 3878–3893 (2012).22972928 10.4049/jimmunol.1201029
601. Ihara S TGF-beta Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota J. Immunol. 2016 196 4603 4613 10.4049/jimmunol.1502548 27183608
Ihara, S. et al. TGF-beta Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota. J. Immunol. 196, 4603–4613 (2016).27183608 10.4049/jimmunol.1502548
602. Gorelik L Flavell RA Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease Immunity 2000 12 171 181 10.1016/S1074-7613(00)80170-3 10714683
Gorelik, L. & Flavell, R. A. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171–181 (2000).10714683 10.1016/S1074-7613(00)80170-3
603. Turner JA Regulatory T Cell-Derived TGF-β1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity Immunity 2020 53 1202 1214.e1206 10.1016/j.immuni.2020.10.002 33086036
Turner, J. A. et al. Regulatory T Cell-Derived TGF-β1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity. Immunity 53, 1202–1214.e1206 (2020).33086036 10.1016/j.immuni.2020.10.002
604. Hahm KB Loss of TGF-beta signaling contributes to autoimmune pancreatitis J. Clin. Invest 2000 105 1057 1065 10.1172/JCI8337 10772650
Hahm, K. B. et al. Loss of TGF-beta signaling contributes to autoimmune pancreatitis. J. Clin. Invest 105, 1057–1065 (2000).10772650 10.1172/JCI8337
605. Gómez-Bernal F Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients Biomolecules 2022 13 73 10.3390/biom13010073 36671458
Gómez-Bernal, F. et al. Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients. Biomolecules 13, 73 (2022).36671458 10.3390/biom13010073
606. Manolova I Gerenova J Ivanova M Serum levels of transforming growth factor-β1 (TGF-β1) in patients with systemic lupus erythematosus and Hashimoto’s thyroiditis Eur. Cytokine Netw. 2013 24 69 74 10.1684/ecn.2013.0331 23614931
Manolova, I., Gerenova, J. & Ivanova, M. Serum levels of transforming growth factor-β1 (TGF-β1) in patients with systemic lupus erythematosus and Hashimoto’s thyroiditis. Eur. Cytokine Netw. 24, 69–74 (2013).23614931 10.1684/ecn.2013.0331
607. Becker-Merok A Eilertsen G Nossent JC Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease J. Rheumatol. 2010 37 2039 2045 10.3899/jrheum.100180 20682675
Becker-Merok, A., Eilertsen, G. & Nossent, J. C. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J. Rheumatol. 37, 2039–2045 (2010).20682675 10.3899/jrheum.100180
608. Lomelí-Nieto JA Transforming growth factor beta isoforms and TGF-βR1 and TGF-βR2 expression in systemic sclerosis patients Clin. Exp. Med 2023 23 471 481 10.1007/s10238-022-00841-0 35643962
Lomelí-Nieto, J. A. et al. Transforming growth factor beta isoforms and TGF-βR1 and TGF-βR2 expression in systemic sclerosis patients. Clin. Exp. Med 23, 471–481 (2023).35643962 10.1007/s10238-022-00841-0
609. Dziadzio M Smith RE Abraham DJ Black CM Denton CP Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score Rheumatol. (Oxf.) 2005 44 1518 1524 10.1093/rheumatology/kei088
Dziadzio, M., Smith, R. E., Abraham, D. J., Black, C. M. & Denton, C. P. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatol. (Oxf.) 44, 1518–1524 (2005).10.1093/rheumatology/kei088
610. Kulozik M Hogg A Lankat-Buttgereit B Krieg T Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis J. Clin. Invest 1990 86 917 922 10.1172/JCI114793 1697606
Kulozik, M., Hogg, A., Lankat-Buttgereit, B. & Krieg, T. Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J. Clin. Invest 86, 917–922 (1990).1697606 10.1172/JCI114793
611. Kubo M Ihn H Yamane K Tamaki K Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis J. Rheumatol. 2002 29 2558 2564 12465152
Kubo, M., Ihn, H., Yamane, K. & Tamaki, K. Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J. Rheumatol. 29, 2558–2564 (2002).12465152
612. Taketazu F Enhanced expression of transforming growth factor-beta s and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis Lab Invest 1994 70 620 630 8196359
Taketazu, F. et al. Enhanced expression of transforming growth factor-beta s and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis. Lab Invest 70, 620–630 (1994).8196359
613. Szekanecz Z Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease Clin. Immunol. Immunopathol. 1995 76 187 194 10.1006/clin.1995.1114 7614737
Szekanecz, Z. et al. Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin. Immunol. Immunopathol. 76, 187–194 (1995).7614737 10.1006/clin.1995.1114
614. Mieliauskaite D Venalis P Dumalakiene I Venalis A Distler J Relationship between serum levels of TGF-beta1 and clinical parameters in patients with rheumatoid arthritis and Sjögren’s syndrome secondary to rheumatoid arthritis Autoimmunity 2009 42 356 358 10.1080/08916930902831977 19811300
Mieliauskaite, D., Venalis, P., Dumalakiene, I., Venalis, A. & Distler, J. Relationship between serum levels of TGF-beta1 and clinical parameters in patients with rheumatoid arthritis and Sjögren’s syndrome secondary to rheumatoid arthritis. Autoimmunity 42, 356–358 (2009).19811300 10.1080/08916930902831977
615. He J Clinical significance of the expression levels of serum transforming growth factor-β and CXC type chemokine ligand 13 in primary Sjogren’s syndrome patients Clin. Rheumatol. 2023 42 3283 3288 10.1007/s10067-023-06783-6 37755549
He, J. et al. Clinical significance of the expression levels of serum transforming growth factor-β and CXC type chemokine ligand 13 in primary Sjogren’s syndrome patients. Clin. Rheumatol. 42, 3283–3288 (2023).37755549 10.1007/s10067-023-06783-6
616. Ogawa N Analysis of transforming growth factor beta and other cytokines in autoimmune exocrinopathy (Sjögren’s syndrome) J. Interferon Cytokine Res 1995 15 759 767 10.1089/jir.1995.15.759 8536103
Ogawa, N. et al. Analysis of transforming growth factor beta and other cytokines in autoimmune exocrinopathy (Sjögren’s syndrome). J. Interferon Cytokine Res 15, 759–767 (1995).8536103 10.1089/jir.1995.15.759
617. Kader HA Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn’s disease and ulcerative colitis patients in remission versus active disease Am. J. Gastroenterol. 2005 100 414 423 10.1111/j.1572-0241.2005.40819.x 15667502
Kader, H. A. et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn’s disease and ulcerative colitis patients in remission versus active disease. Am. J. Gastroenterol. 100, 414–423 (2005).15667502 10.1111/j.1572-0241.2005.40819.x
618. Kanazawa S VEGF, basic-FGF, and TGF-beta in Crohn’s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation Am. J. Gastroenterol. 2001 96 822 828 11280558
Kanazawa, S. et al. VEGF, basic-FGF, and TGF-beta in Crohn’s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am. J. Gastroenterol. 96, 822–828 (2001).11280558
619. Babyatsky MW Rossiter G Podolsky DK Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease Gastroenterology 1996 110 975 984 10.1053/gast.1996.v110.pm8613031 8613031
Babyatsky, M. W., Rossiter, G. & Podolsky, D. K. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110, 975–984 (1996).8613031 10.1053/gast.1996.v110.pm8613031
620. Stadnicki A Machnik G Klimacka-Nawrot E Wolanska-Karut A Labuzek K Transforming growth factor-beta1 and its receptors in patients with ulcerative colitis Int Immunopharmacol. 2009 9 761 766 10.1016/j.intimp.2009.02.014 19285572
Stadnicki, A., Machnik, G., Klimacka-Nawrot, E., Wolanska-Karut, A. & Labuzek, K. Transforming growth factor-beta1 and its receptors in patients with ulcerative colitis. Int Immunopharmacol. 9, 761–766 (2009).19285572 10.1016/j.intimp.2009.02.014
621. Wiercińska-Drapało A Flisiak R Prokopowicz D Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1 Cytokine 2001 14 343 346 10.1006/cyto.2001.0901 11497495
Wiercińska-Drapało, A., Flisiak, R. & Prokopowicz, D. Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1. Cytokine 14, 343–346 (2001).11497495 10.1006/cyto.2001.0901
622. Chowdhury A Fukuda R Fukumoto S Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients J. Gastroenterol. 1996 31 353 360 10.1007/BF02355024 8726826
Chowdhury, A., Fukuda, R. & Fukumoto, S. Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients. J. Gastroenterol. 31, 353–360 (1996).8726826 10.1007/BF02355024
623. Bayer EM Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity J. Hepatol. 1998 28 803 811 10.1016/S0168-8278(98)80230-4 9625315
Bayer, E. M. et al. Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J. Hepatol. 28, 803–811 (1998).9625315 10.1016/S0168-8278(98)80230-4
624. Sakaguchi K Serum level of transforming growth factor-beta1 (TGF-beta1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis Hepatogastroenterology 2004 51 1780 1783 15532825
Sakaguchi, K. et al. Serum level of transforming growth factor-beta1 (TGF-beta1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis. Hepatogastroenterology 51, 1780–1783 (2004).15532825
625. Vural P Degirmencioglu S Erden S Gelincik A The relationship between transforming growth factor-beta1, vascular endothelial growth factor, nitric oxide and Hashimoto’s thyroiditis Int Immunopharmacol. 2009 9 212 215 10.1016/j.intimp.2008.11.003 19028605
Vural, P., Degirmencioglu, S., Erden, S. & Gelincik, A. The relationship between transforming growth factor-beta1, vascular endothelial growth factor, nitric oxide and Hashimoto’s thyroiditis. Int Immunopharmacol. 9, 212–215 (2009).19028605 10.1016/j.intimp.2008.11.003
626. Akinci B Hashimoto’s thyroiditis, but not treatment of hypothyroidism, is associated with altered TGF-beta1 levels Arch. Med Res 2008 39 397 401 10.1016/j.arcmed.2007.12.001 18375250
Akinci, B. et al. Hashimoto’s thyroiditis, but not treatment of hypothyroidism, is associated with altered TGF-beta1 levels. Arch. Med Res 39, 397–401 (2008).18375250 10.1016/j.arcmed.2007.12.001
627. Ohtsuka K Gray JD Stimmler MM Toro B Horwitz DA Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus J. Immunol. 1998 160 2539 2545 10.4049/jimmunol.160.5.2539 9498800
Ohtsuka, K., Gray, J. D., Stimmler, M. M., Toro, B. & Horwitz, D. A. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 160, 2539–2545 (1998).9498800 10.4049/jimmunol.160.5.2539
628. Del Zotto B TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn’s disease and ulcerative colitis Clin. Exp. Immunol. 2003 134 120 126 10.1046/j.1365-2249.2003.02250.x 12974764
Del Zotto, B. et al. TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn’s disease and ulcerative colitis. Clin. Exp. Immunol. 134, 120–126 (2003).12974764 10.1046/j.1365-2249.2003.02250.x
629. Ohtsuka K Gray JD Stimmler MM Horwitz DA The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity Lupus 1999 8 90 94 10.1191/096120399678847489 10192501
Ohtsuka, K., Gray, J. D., Stimmler, M. M. & Horwitz, D. A. The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity. Lupus 8, 90–94 (1999).10192501 10.1191/096120399678847489
630. Kotlarz D Human TGF-β1 deficiency causes severe inflammatory bowel disease and encephalopathy Nat. Genet 2018 50 344 348 10.1038/s41588-018-0063-6 29483653
Kotlarz, D. et al. Human TGF-β1 deficiency causes severe inflammatory bowel disease and encephalopathy. Nat. Genet 50, 344–348 (2018).29483653 10.1038/s41588-018-0063-6
631. Bai B Molecular mechanism of the TGF‑β/Smad7 signaling pathway in ulcerative colitis Mol. Med Rep. 2022 25 116 10.3892/mmr.2022.12632 35137923
Bai, B. et al. Molecular mechanism of the TGF‑β/Smad7 signaling pathway in ulcerative colitis. Mol. Med Rep. 25, 116 (2022).35137923 10.3892/mmr.2022.12632
632. Elbeldi-Ferchiou A Resistance to exogenous TGF-β effects in patients with systemic lupus erythematosus J. Clin. Immunol. 2011 31 574 583 10.1007/s10875-011-9531-9 21503670
Elbeldi-Ferchiou, A. et al. Resistance to exogenous TGF-β effects in patients with systemic lupus erythematosus. J. Clin. Immunol. 31, 574–583 (2011).21503670 10.1007/s10875-011-9531-9
633. Naviglio S Severe inflammatory bowel disease associated with congenital alteration of transforming growth factor beta signaling J. Crohns Colitis 2014 8 770 774 10.1016/j.crohns.2014.01.013 24486179
Naviglio, S. et al. Severe inflammatory bowel disease associated with congenital alteration of transforming growth factor beta signaling. J. Crohns Colitis 8, 770–774 (2014).24486179 10.1016/j.crohns.2014.01.013
634. Peres RS TGF-β signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis J. Autoimmun. 2018 90 49 58 10.1016/j.jaut.2018.01.004 29426578
Peres, R. S. et al. TGF-β signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis. J. Autoimmun. 90, 49–58 (2018).29426578 10.1016/j.jaut.2018.01.004
635. Rekik R Impaired TGF-β signaling in patients with active systemic lupus erythematosus is associated with an overexpression of IL-22 Cytokine 2018 108 182 189 10.1016/j.cyto.2018.04.011 29684755
Rekik, R. et al. Impaired TGF-β signaling in patients with active systemic lupus erythematosus is associated with an overexpression of IL-22. Cytokine 108, 182–189 (2018).29684755 10.1016/j.cyto.2018.04.011
636. Yalcin AD Bisgin A Gorczynski RM IL-8, IL-10, TGF-β, and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment Mediators Inflamm. 2012 2012 720976 10.1155/2012/720976 23316107
Yalcin, A. D., Bisgin, A. & Gorczynski, R. M. IL-8, IL-10, TGF-β, and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm. 2012, 720976 (2012).23316107 10.1155/2012/720976
637. Yamaguchi M Sputum levels of transforming growth factor-beta1 in asthma: relation to clinical and computed tomography findings J. Investig. Allergol. Clin. Immunol. 2008 18 202 206 18564632
Yamaguchi, M. et al. Sputum levels of transforming growth factor-beta1 in asthma: relation to clinical and computed tomography findings. J. Investig. Allergol. Clin. Immunol. 18, 202–206 (2008).18564632
638. Manuyakorn W Serum TGF-beta1 in atopic asthma Asian Pac. J. Allergy Immunol. 2008 26 185 189 19317336
Manuyakorn, W. et al. Serum TGF-beta1 in atopic asthma. Asian Pac. J. Allergy Immunol. 26, 185–189 (2008).19317336
639. Redington AE Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid Am. J. Respir. Crit. Care Med 1997 156 642 647 10.1164/ajrccm.156.2.9605065 9279252
Redington, A. E. et al. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. Am. J. Respir. Crit. Care Med 156, 642–647 (1997).9279252 10.1164/ajrccm.156.2.9605065
640. Balzar S Increased TGF-beta2 in severe asthma with eosinophilia J. Allergy Clin. Immunol. 2005 115 110 117 10.1016/j.jaci.2004.09.034 15637555
Balzar, S. et al. Increased TGF-beta2 in severe asthma with eosinophilia. J. Allergy Clin. Immunol. 115, 110–117 (2005).15637555 10.1016/j.jaci.2004.09.034
641. Torrego A Hew M Oates T Sukkar M Fan Chung K Expression and activation of TGF-beta isoforms in acute allergen-induced remodelling in asthma Thorax 2007 62 307 313 10.1136/thx.2006.063487 17251317
Torrego, A., Hew, M., Oates, T., Sukkar, M. & Fan Chung, K. Expression and activation of TGF-beta isoforms in acute allergen-induced remodelling in asthma. Thorax 62, 307–313 (2007).17251317 10.1136/thx.2006.063487
642. Vignola AM Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis Am. J. Respir. Crit. Care Med 1997 156 591 599 10.1164/ajrccm.156.2.9609066 9279245
Vignola, A. M. et al. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med 156, 591–599 (1997).9279245 10.1164/ajrccm.156.2.9609066
643. Jiang K Changes in interleukin-17 and transforming growth factor beta 1 levels in serum and bronchoalveolar lavage fluid and their clinical significance among children with asthma Transl. Pediatr. 2013 2 154 159 26835311
Jiang, K. et al. Changes in interleukin-17 and transforming growth factor beta 1 levels in serum and bronchoalveolar lavage fluid and their clinical significance among children with asthma. Transl. Pediatr. 2, 154–159 (2013).26835311
644. Vignola AM Release of transforming growth factor-beta (TGF-beta) and fibronectin by alveolar macrophages in airway diseases Clin. Exp. Immunol. 1996 106 114 119 10.1046/j.1365-2249.1996.d01-811.x 8870708
Vignola, A. M. et al. Release of transforming growth factor-beta (TGF-beta) and fibronectin by alveolar macrophages in airway diseases. Clin. Exp. Immunol. 106, 114–119 (1996).8870708 10.1046/j.1365-2249.1996.d01-811.x
645. Minshall EM Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma Am. J. Respir. Cell Mol. Biol. 1997 17 326 333 10.1165/ajrcmb.17.3.2733 9308919
Minshall, E. M. et al. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 17, 326–333 (1997).9308919 10.1165/ajrcmb.17.3.2733
646. Ohno I Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation Am. J. Respir. Cell Mol. Biol. 1996 15 404 409 10.1165/ajrcmb.15.3.8810646 8810646
Ohno, I. et al. Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation. Am. J. Respir. Cell Mol. Biol. 15, 404–409 (1996).8810646 10.1165/ajrcmb.15.3.8810646
647. Xie S Sukkar MB Issa R Khorasani NM Chung KF Mechanisms of induction of airway smooth muscle hyperplasia by transforming growth factor-beta Am. J. Physiol. Lung Cell Mol. Physiol. 2007 293 L245 L253 10.1152/ajplung.00068.2007 17468136
Xie, S., Sukkar, M. B., Issa, R., Khorasani, N. M. & Chung, K. F. Mechanisms of induction of airway smooth muscle hyperplasia by transforming growth factor-beta. Am. J. Physiol. Lung Cell Mol. Physiol. 293, L245–L253 (2007).17468136 10.1152/ajplung.00068.2007
648. Berger P Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis Faseb j. 2003 17 2139 2141 10.1096/fj.03-0041fje 14500550
Berger, P. et al. Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. Faseb j. 17, 2139–2141 (2003).14500550 10.1096/fj.03-0041fje
649. Janulaityte I Januskevicius A Kalinauskaite-Zukauske V Bajoriuniene I Malakauskas K In Vivo Allergen-Activated Eosinophils Promote Collagen I and Fibronectin Gene Expression in Airway Smooth Muscle Cells via TGF-β1 Signaling Pathway in Asthma Int J. Mol. Sci. 2020 21 1837 10.3390/ijms21051837 32155894
Janulaityte, I., Januskevicius, A., Kalinauskaite-Zukauske, V., Bajoriuniene, I. & Malakauskas, K. In Vivo Allergen-Activated Eosinophils Promote Collagen I and Fibronectin Gene Expression in Airway Smooth Muscle Cells via TGF-β1 Signaling Pathway in Asthma. Int J. Mol. Sci. 21, 1837 (2020).32155894 10.3390/ijms21051837
650. Januskevicius A Eosinophils enhance WNT-5a and TGF-β1 genes expression in airway smooth muscle cells and promote their proliferation by increased extracellular matrix proteins production in asthma BMC Pulm. Med 2016 16 94 10.1186/s12890-016-0254-9 27297409
Januskevicius, A. et al. Eosinophils enhance WNT-5a and TGF-β1 genes expression in airway smooth muscle cells and promote their proliferation by increased extracellular matrix proteins production in asthma. BMC Pulm. Med 16, 94 (2016).27297409 10.1186/s12890-016-0254-9
651. Bottoms SE Howell JE Reinhardt AK Evans IC McAnulty RJ Tgf-Beta isoform specific regulation of airway inflammation and remodelling in a murine model of asthma PLoS One 2010 5 e9674 10.1371/journal.pone.0009674 20300191
Bottoms, S. E., Howell, J. E., Reinhardt, A. K., Evans, I. C. & McAnulty, R. J. Tgf-Beta isoform specific regulation of airway inflammation and remodelling in a murine model of asthma. PLoS One 5, e9674 (2010).20300191 10.1371/journal.pone.0009674
652. Gagliardo R The role of transforming growth factor-β1 in airway inflammation of childhood asthma Int J. Immunopathol. Pharm. 2013 26 725 738 10.1177/039463201302600316
Gagliardo, R. et al. The role of transforming growth factor-β1 in airway inflammation of childhood asthma. Int J. Immunopathol. Pharm. 26, 725–738 (2013).10.1177/039463201302600316
653. Eusebio M Kraszula L Kupczyk M Kuna P Pietruczuk M The effects of interleukin-10 or TGF-beta on anti-CD3/CD28 induced activation of CD8+CD28- and CD8+CD28+ T cells in allergic asthma J. Biol. Regul. Homeost. Agents 2013 27 681 692 24152837
Eusebio, M., Kraszula, L., Kupczyk, M., Kuna, P. & Pietruczuk, M. The effects of interleukin-10 or TGF-beta on anti-CD3/CD28 induced activation of CD8+CD28- and CD8+CD28+ T cells in allergic asthma. J. Biol. Regul. Homeost. Agents 27, 681–692 (2013).24152837
654. Hung CH Altered pattern of monocyte differentiation and monocyte-derived TGF-β1 in severe asthma Sci. Rep. 2018 8 919 10.1038/s41598-017-19105-z 29343695
Hung, C. H. et al. Altered pattern of monocyte differentiation and monocyte-derived TGF-β1 in severe asthma. Sci. Rep. 8, 919 (2018).29343695 10.1038/s41598-017-19105-z
655. Ma Y Immunization against TGF-β1 reduces collagen deposition but increases sustained inflammation in a murine asthma model Hum. Vaccin Immunother. 2016 12 1876 1885 26901684
Ma, Y. et al. Immunization against TGF-β1 reduces collagen deposition but increases sustained inflammation in a murine asthma model. Hum. Vaccin Immunother. 12, 1876–1885 (2016).26901684
656. Scherf W Burdach S Hansen G Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model Eur. J. Immunol. 2005 35 198 206 10.1002/eji.200425209 15593298
Scherf, W., Burdach, S. & Hansen, G. Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model. Eur. J. Immunol. 35, 198–206 (2005).15593298 10.1002/eji.200425209
657. Luo X In vivo disruption of TGF-beta signaling by Smad7 in airway epithelium alleviates allergic asthma but aggravates lung carcinogenesis in mouse PLoS One 2010 5 e10149 10.1371/journal.pone.0010149 20405019
Luo, X. et al. In vivo disruption of TGF-beta signaling by Smad7 in airway epithelium alleviates allergic asthma but aggravates lung carcinogenesis in mouse. PLoS One 5, e10149 (2010).20405019 10.1371/journal.pone.0010149
658. Gao P Functional effects of TGF-β1 on mesenchymal stem cell mobilization in cockroach allergen-induced asthma J. Immunol. 2014 192 4560 4570 10.4049/jimmunol.1303461 24711618
Gao, P. et al. Functional effects of TGF-β1 on mesenchymal stem cell mobilization in cockroach allergen-induced asthma. J. Immunol. 192, 4560–4570 (2014).24711618 10.4049/jimmunol.1303461
659. Nemeth K Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma Proc. Natl Acad. Sci. USA 2010 107 5652 5657 10.1073/pnas.0910720107 20231466
Nemeth, K. et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc. Natl Acad. Sci. USA 107, 5652–5657 (2010).20231466 10.1073/pnas.0910720107
660. Musiol S TGF-β1 Drives Inflammatory Th Cell But Not Treg Cell Compartment Upon Allergen Exposure Front Immunol. 2021 12 763243 10.3389/fimmu.2021.763243 35069535
Musiol, S. et al. TGF-β1 Drives Inflammatory Th Cell But Not Treg Cell Compartment Upon Allergen Exposure. Front Immunol. 12, 763243 (2021).35069535 10.3389/fimmu.2021.763243
661. Whitehead GS A neutrophil/TGF-β axis limits the pathogenicity of allergen-specific CD4+ T cells JCI Insight 2022 7 e150251 10.1172/jci.insight.150251 35191395
Whitehead, G. S. et al. A neutrophil/TGF-β axis limits the pathogenicity of allergen-specific CD4+ T cells. JCI Insight 7, e150251 (2022).35191395 10.1172/jci.insight.150251
662. Yang ZC Transforming growth factor-β1 induces bronchial epithelial cells to mesenchymal transition by activating the Snail pathway and promotes airway remodeling in asthma Mol. Med Rep. 2013 8 1663 1668 10.3892/mmr.2013.1728 24126595
Yang, Z. C. et al. Transforming growth factor-β1 induces bronchial epithelial cells to mesenchymal transition by activating the Snail pathway and promotes airway remodeling in asthma. Mol. Med Rep. 8, 1663–1668 (2013).24126595 10.3892/mmr.2013.1728
663. Hackett TL Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1 Am. J. Respir. Crit. Care Med 2009 180 122 133 10.1164/rccm.200811-1730OC 19406982
Hackett, T. L. et al. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1. Am. J. Respir. Crit. Care Med 180, 122–133 (2009).19406982 10.1164/rccm.200811-1730OC
664. Stumm CL Lung remodeling in a mouse model of asthma involves a balance between TGF-β1 and BMP-7 PLoS One 2014 9 e95959 10.1371/journal.pone.0095959 24781156
Stumm, C. L. et al. Lung remodeling in a mouse model of asthma involves a balance between TGF-β1 and BMP-7. PLoS One 9, e95959 (2014).24781156 10.1371/journal.pone.0095959
665. Wnuk D Enhanced asthma-related fibroblast to myofibroblast transition is the result of profibrotic TGF-β/Smad2/3 pathway intensification and antifibrotic TGF-β/Smad1/5/(8)9 pathway impairment Sci. Rep. 2020 10 16492 10.1038/s41598-020-73473-7 33020537
Wnuk, D. et al. Enhanced asthma-related fibroblast to myofibroblast transition is the result of profibrotic TGF-β/Smad2/3 pathway intensification and antifibrotic TGF-β/Smad1/5/(8)9 pathway impairment. Sci. Rep. 10, 16492 (2020).33020537 10.1038/s41598-020-73473-7
666. Ciprandi G De Amici M Tosca M Marseglia G Serum transforming growth factor-beta levels depend on allergen exposure in allergic rhinitis Int Arch. Allergy Immunol. 2010 152 66 70 10.1159/000260085 19940507
Ciprandi, G., De Amici, M., Tosca, M. & Marseglia, G. Serum transforming growth factor-beta levels depend on allergen exposure in allergic rhinitis. Int Arch. Allergy Immunol. 152, 66–70 (2010).19940507 10.1159/000260085
667. Salib RJ Kumar S Wilson SJ Howarth PH Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis J. Allergy Clin. Immunol. 2004 114 799 806 10.1016/j.jaci.2004.07.010 15480318
Salib, R. J., Kumar, S., Wilson, S. J. & Howarth, P. H. Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis. J. Allergy Clin. Immunol. 114, 799–806 (2004).15480318 10.1016/j.jaci.2004.07.010
668. Salib RJ Transforming growth factor-beta gene expression studies in nasal mucosal biopsies in naturally occurring allergic rhinitis Ann. R. Coll. Surg. Engl. 2007 89 563 573 10.1308/003588407X202164 18201469
Salib, R. J. Transforming growth factor-beta gene expression studies in nasal mucosal biopsies in naturally occurring allergic rhinitis. Ann. R. Coll. Surg. Engl. 89, 563–573 (2007).18201469 10.1308/003588407X202164
669. Ouyang Y Nakao A Han D Zhang L Transforming growth factor-β1 promotes nasal mucosal mast cell chemotaxis in murine experimental allergic rhinitis ORL J. Otorhinolaryngol. Relat. Spec. 2012 74 117 123 10.1159/000328587 22433901
Ouyang, Y., Nakao, A., Han, D. & Zhang, L. Transforming growth factor-β1 promotes nasal mucosal mast cell chemotaxis in murine experimental allergic rhinitis. ORL J. Otorhinolaryngol. Relat. Spec. 74, 117–123 (2012).22433901 10.1159/000328587
670. Ouyang Y TGF-beta signaling may play a role in the development of goblet cell hyperplasia in a mouse model of allergic rhinitis Allergol. Int 2010 59 313 319 10.2332/allergolint.10-SC-0172 20495338
Ouyang, Y. et al. TGF-beta signaling may play a role in the development of goblet cell hyperplasia in a mouse model of allergic rhinitis. Allergol. Int 59, 313–319 (2010).20495338 10.2332/allergolint.10-SC-0172
671. Wang M Gu Z Yang J Zhao H Cao Z Changes among TGF-β1(+) Breg cells and helper T cell subsets in a murine model of allergic rhinitis with prolonged OVA challenge Int Immunopharmacol. 2019 69 347 357 10.1016/j.intimp.2019.01.009 30776643
Wang, M., Gu, Z., Yang, J., Zhao, H. & Cao, Z. Changes among TGF-β1(+) Breg cells and helper T cell subsets in a murine model of allergic rhinitis with prolonged OVA challenge. Int Immunopharmacol. 69, 347–357 (2019).30776643 10.1016/j.intimp.2019.01.009
672. Yang M Yang C Mine Y Multiple T cell epitope peptides suppress allergic responses in an egg allergy mouse model by the elicitation of forkhead box transcription factor 3- and transforming growth factor-beta-associated mechanisms Clin. Exp. Allergy 2010 40 668 678 10.1111/j.1365-2222.2009.03442.x 20082619
Yang, M., Yang, C. & Mine, Y. Multiple T cell epitope peptides suppress allergic responses in an egg allergy mouse model by the elicitation of forkhead box transcription factor 3- and transforming growth factor-beta-associated mechanisms. Clin. Exp. Allergy 40, 668–678 (2010).20082619 10.1111/j.1365-2222.2009.03442.x
673. Barletta B Probiotic VSL#3-induced TGF-β ameliorates food allergy inflammation in a mouse model of peanut sensitization through the induction of regulatory T cells in the gut mucosa Mol. Nutr. Food Res 2013 57 2233 2244 10.1002/mnfr.201300028 23943347
Barletta, B. et al. Probiotic VSL#3-induced TGF-β ameliorates food allergy inflammation in a mouse model of peanut sensitization through the induction of regulatory T cells in the gut mucosa. Mol. Nutr. Food Res 57, 2233–2244 (2013).23943347 10.1002/mnfr.201300028
674. Pérez-Machado MA Reduced transforming growth factor-beta1-producing T cells in the duodenal mucosa of children with food allergy Eur. J. Immunol. 2003 33 2307 2315 10.1002/eji.200323308 12884306
Pérez-Machado, M. A. et al. Reduced transforming growth factor-beta1-producing T cells in the duodenal mucosa of children with food allergy. Eur. J. Immunol. 33, 2307–2315 (2003).12884306 10.1002/eji.200323308
675. Park HH TGF-β secreted by human umbilical cord blood-derived mesenchymal stem cells ameliorates atopic dermatitis by inhibiting secretion of TNF-α and IgE Stem Cells 2020 38 904 916 10.1002/stem.3183 32277785
Park, H. H. et al. TGF-β secreted by human umbilical cord blood-derived mesenchymal stem cells ameliorates atopic dermatitis by inhibiting secretion of TNF-α and IgE. Stem Cells 38, 904–916 (2020).32277785 10.1002/stem.3183
676. Sumiyoshi K Transforming growth factor-beta1 suppresses atopic dermatitis-like skin lesions in NC/Nga mice Clin. Exp. Allergy 2002 32 309 314 10.1046/j.1365-2222.2002.01221.x 11929498
Sumiyoshi, K. et al. Transforming growth factor-beta1 suppresses atopic dermatitis-like skin lesions in NC/Nga mice. Clin. Exp. Allergy 32, 309–314 (2002).11929498 10.1046/j.1365-2222.2002.01221.x
677. Kim HS Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF-β1 alleviate atopic dermatitis by reducing mast cell degranulation Stem Cells 2015 33 1254 1266 10.1002/stem.1913 25522163
Kim, H. S. et al. Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF-β1 alleviate atopic dermatitis by reducing mast cell degranulation. Stem Cells 33, 1254–1266 (2015).25522163 10.1002/stem.1913
678. Lee HJ Lee HP Ha SJ Byun DG Kim JW Spontaneous expression of mRNA for IL-10, GM-CSF, TGF-beta, TGF-alpha, and IL-6 in peripheral blood mononuclear cells from atopic dermatitis Ann. Allergy Asthma Immunol. 2000 84 553 558 10.1016/S1081-1206(10)62522-7 10831012
Lee, H. J., Lee, H. P., Ha, S. J., Byun, D. G. & Kim, J. W. Spontaneous expression of mRNA for IL-10, GM-CSF, TGF-beta, TGF-alpha, and IL-6 in peripheral blood mononuclear cells from atopic dermatitis. Ann. Allergy Asthma Immunol. 84, 553–558 (2000).10831012 10.1016/S1081-1206(10)62522-7
679. Peng WM Maintz L Allam JP Novak N Attenuated TGF-β1 responsiveness of dendritic cells and their precursors in atopic dermatitis Eur. J. Immunol. 2013 43 1374 1382 10.1002/eji.201242955 23436698
Peng, W. M., Maintz, L., Allam, J. P. & Novak, N. Attenuated TGF-β1 responsiveness of dendritic cells and their precursors in atopic dermatitis. Eur. J. Immunol. 43, 1374–1382 (2013).23436698 10.1002/eji.201242955
680. Shafi, T. et al. Investigating dysregulation of TGF-β1/SMAD3 signaling in Atopic Dermatitis: A Molecular and Immunohistochemical Analysis. Clin. Exp. Immunol.10.1093/cei/uxad130 (2023).
681. Akbarshahi H Sam A Chen C Rosendahl AH Andersson R Early activation of pulmonary TGF-β1/Smad2 signaling in mice with acute pancreatitis-associated acute lung injury Mediat. Inflamm. 2014 2014 148029 10.1155/2014/148029
Akbarshahi, H., Sam, A., Chen, C., Rosendahl, A. H. & Andersson, R. Early activation of pulmonary TGF-β1/Smad2 signaling in mice with acute pancreatitis-associated acute lung injury. Mediat. Inflamm. 2014, 148029 (2014).10.1155/2014/148029
682. Hori Y Macrophage-derived transforming growth factor-beta1 induces hepatocellular injury via apoptosis in rat severe acute pancreatitis Surgery 2000 127 641 649 10.1067/msy.2000.105499 10840359
Hori, Y. et al. Macrophage-derived transforming growth factor-beta1 induces hepatocellular injury via apoptosis in rat severe acute pancreatitis. Surgery 127, 641–649 (2000).10840359 10.1067/msy.2000.105499
683. van Laethem JL Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitis Gastroenterology 1995 108 1873 1881 10.1016/0016-5085(95)90152-3 7768393
van Laethem, J. L. et al. Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitis. Gastroenterology 108, 1873–1881 (1995).7768393 10.1016/0016-5085(95)90152-3
684. Kanamaru Y Blockade of TGF-beta signaling in T cells prevents the development of experimental glomerulonephritis J. Immunol. 2001 166 2818 2823 10.4049/jimmunol.166.4.2818 11160349
Kanamaru, Y. et al. Blockade of TGF-beta signaling in T cells prevents the development of experimental glomerulonephritis. J. Immunol. 166, 2818–2823 (2001).11160349 10.4049/jimmunol.166.4.2818
685. Kitamura M Sütö T Yokoo T Shimizu F Fine LG Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells J. Immunol. 1996 156 2964 2971 10.4049/jimmunol.156.8.2964 8609417
Kitamura, M., Sütö, T., Yokoo, T., Shimizu, F. & Fine, L. G. Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J. Immunol. 156, 2964–2971 (1996).8609417 10.4049/jimmunol.156.8.2964
686. Zhang W Staphylococcus aureus Infection Initiates Hypoxia-Mediated Transforming Growth Factor-β1 Upregulation to Trigger Osteomyelitis mSystems 2022 7 e0038022 10.1128/msystems.00380-22 35852344
Zhang, W. et al. Staphylococcus aureus Infection Initiates Hypoxia-Mediated Transforming Growth Factor-β1 Upregulation to Trigger Osteomyelitis. mSystems 7, e0038022 (2022).35852344 10.1128/msystems.00380-22
687. Brandes ME Allen JB Ogawa Y Wahl SM Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals J. Clin. Invest 1991 87 1108 1113 10.1172/JCI115073 1999490
Brandes, M. E., Allen, J. B., Ogawa, Y. & Wahl, S. M. Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J. Clin. Invest 87, 1108–1113 (1991).1999490 10.1172/JCI115073
688. Yan J Obesity- and aging-induced excess of central transforming growth factor-β potentiates diabetic development via an RNA stress response Nat. Med 2014 20 1001 1008 10.1038/nm.3616 25086906
Yan, J. et al. Obesity- and aging-induced excess of central transforming growth factor-β potentiates diabetic development via an RNA stress response. Nat. Med 20, 1001–1008 (2014).25086906 10.1038/nm.3616
689. Weiss R Lifshitz V Frenkel D TGF-β1 affects endothelial cell interaction with macrophages and T cells leading to the development of cerebrovascular amyloidosis Brain Behav. Immun. 2011 25 1017 1024 10.1016/j.bbi.2010.11.012 21112386
Weiss, R., Lifshitz, V. & Frenkel, D. TGF-β1 affects endothelial cell interaction with macrophages and T cells leading to the development of cerebrovascular amyloidosis. Brain Behav. Immun. 25, 1017–1024 (2011).21112386 10.1016/j.bbi.2010.11.012
690. Grammas P Ovase R Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer’s disease brain Am. J. Pathol. 2002 160 1583 1587 10.1016/S0002-9440(10)61105-4 12000710
Grammas, P. & Ovase, R. Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer’s disease brain. Am. J. Pathol. 160, 1583–1587 (2002).12000710 10.1016/S0002-9440(10)61105-4
691. Rendón-Ramirez EJ TGF-β Blood Levels Distinguish Between Influenza A (H1N1)pdm09 Virus Sepsis and Sepsis due to Other Forms of Community-Acquired Pneumonia Viral Immunol. 2015 28 248 254 10.1089/vim.2014.0123 25923384
Rendón-Ramirez, E. J. et al. TGF-β Blood Levels Distinguish Between Influenza A (H1N1)pdm09 Virus Sepsis and Sepsis due to Other Forms of Community-Acquired Pneumonia. Viral Immunol. 28, 248–254 (2015).25923384 10.1089/vim.2014.0123
692. Carlson CM Transforming growth factor-β: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis PLoS Pathog. 2010 6 e1001136 10.1371/journal.ppat.1001136 20949074
Carlson, C. M. et al. Transforming growth factor-β: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog. 6, e1001136 (2010).20949074 10.1371/journal.ppat.1001136
693. Furuya Y Prevention of Influenza Virus-Induced Immunopathology by TGF-β Produced during Allergic Asthma PLoS Pathog. 2015 11 e1005180 10.1371/journal.ppat.1005180 26407325
Furuya, Y. et al. Prevention of Influenza Virus-Induced Immunopathology by TGF-β Produced during Allergic Asthma. PLoS Pathog. 11, e1005180 (2015).26407325 10.1371/journal.ppat.1005180
694. Richer MJ Straka N Fang D Shanina I Horwitz MS Regulatory T-cells protect from type 1 diabetes after induction by coxsackievirus infection in the context of transforming growth factor-beta Diabetes 2008 57 1302 1311 10.2337/db07-1460 18268045
Richer, M. J., Straka, N., Fang, D., Shanina, I. & Horwitz, M. S. Regulatory T-cells protect from type 1 diabetes after induction by coxsackievirus infection in the context of transforming growth factor-beta. Diabetes 57, 1302–1311 (2008).18268045 10.2337/db07-1460
695. Shi Y Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway Circulation 2010 121 2624 2634 10.1161/CIRCULATIONAHA.109.893248 20530002
Shi, Y. et al. Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway. Circulation 121, 2624–2634 (2010).20530002 10.1161/CIRCULATIONAHA.109.893248
696. Beckham JD Tuttle K Tyler KL Reovirus activates transforming growth factor beta and bone morphogenetic protein signaling pathways in the central nervous system that contribute to neuronal survival following infection J. Virol. 2009 83 5035 5045 10.1128/JVI.02433-08 19279118
Beckham, J. D., Tuttle, K. & Tyler, K. L. Reovirus activates transforming growth factor beta and bone morphogenetic protein signaling pathways in the central nervous system that contribute to neuronal survival following infection. J. Virol. 83, 5035–5045 (2009).19279118 10.1128/JVI.02433-08
697. Stanifer ML Reovirus intermediate subviral particles constitute a strategy to infect intestinal epithelial cells by exploiting TGF-β dependent pro-survival signaling Cell Microbiol 2016 18 1831 1845 10.1111/cmi.12626 27279006
Stanifer, M. L. et al. Reovirus intermediate subviral particles constitute a strategy to infect intestinal epithelial cells by exploiting TGF-β dependent pro-survival signaling. Cell Microbiol 18, 1831–1845 (2016).27279006 10.1111/cmi.12626
698. Chen Y Mechanism of exosomes from adipose-derived mesenchymal stem cells on sepsis-induced acute lung injury by promoting TGF-β secretion in macrophages Surgery 2023 174 1208 1219 10.1016/j.surg.2023.06.017 37612209
Chen, Y. et al. Mechanism of exosomes from adipose-derived mesenchymal stem cells on sepsis-induced acute lung injury by promoting TGF-β secretion in macrophages. Surgery 174, 1208–1219 (2023).37612209 10.1016/j.surg.2023.06.017
699. Sanfilippo AM Furuya Y Roberts S Salmon SL Metzger DW Allergic Lung Inflammation Reduces Tissue Invasion and Enhances Survival from Pulmonary Pneumococcal Infection in Mice, Which Correlates with Increased Expression of Transforming Growth Factor β1 and SiglecF(low) Alveolar Macrophages Infect. Immun. 2015 83 2976 2983 10.1128/IAI.00142-15 25964474
Sanfilippo, A. M., Furuya, Y., Roberts, S., Salmon, S. L. & Metzger, D. W. Allergic Lung Inflammation Reduces Tissue Invasion and Enhances Survival from Pulmonary Pneumococcal Infection in Mice, Which Correlates with Increased Expression of Transforming Growth Factor β1 and SiglecF(low) Alveolar Macrophages. Infect. Immun. 83, 2976–2983 (2015).25964474 10.1128/IAI.00142-15
700. Wang B Induction of TGF-beta1 and TGF-beta1-dependent predominant Th17 differentiation by group A streptococcal infection Proc. Natl Acad. Sci. USA 2010 107 5937 5942 10.1073/pnas.0904831107 20231435
Wang, B. et al. Induction of TGF-beta1 and TGF-beta1-dependent predominant Th17 differentiation by group A streptococcal infection. Proc. Natl Acad. Sci. USA 107, 5937–5942 (2010).20231435 10.1073/pnas.0904831107
701. Nakane A Transforming growth factor beta is protective in host resistance against Listeria monocytogenes infection in mice Infect. Immun. 1996 64 3901 3904 10.1128/iai.64.9.3901-3904.1996 8751946
Nakane, A. et al. Transforming growth factor beta is protective in host resistance against Listeria monocytogenes infection in mice. Infect. Immun. 64, 3901–3904 (1996).8751946 10.1128/iai.64.9.3901-3904.1996
702. Zhong Y Cantwell A Dube PH Transforming growth factor beta and CD25 are important for controlling systemic dissemination following Yersinia enterocolitica infection of the gut Infect. Immun. 2010 78 3716 3725 10.1128/IAI.00203-10 20584975
Zhong, Y., Cantwell, A. & Dube, P. H. Transforming growth factor beta and CD25 are important for controlling systemic dissemination following Yersinia enterocolitica infection of the gut. Infect. Immun. 78, 3716–3725 (2010).20584975 10.1128/IAI.00203-10
703. Shao X Rivera J Niang R Casadevall A Goldman DL A dual role for TGF-beta1 in the control and persistence of fungal pneumonia J. Immunol. 2005 175 6757 6763 10.4049/jimmunol.175.10.6757 16272332
Shao, X., Rivera, J., Niang, R., Casadevall, A. & Goldman, D. L. A dual role for TGF-beta1 in the control and persistence of fungal pneumonia. J. Immunol. 175, 6757–6763 (2005).16272332 10.4049/jimmunol.175.10.6757
704. Omer FM Riley EM Transforming growth factor beta production is inversely correlated with severity of murine malaria infection J. Exp. Med 1998 188 39 48 10.1084/jem.188.1.39 9653082
Omer, F. M. & Riley, E. M. Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. J. Exp. Med 188, 39–48 (1998).9653082 10.1084/jem.188.1.39
705. Namangala B Sugimoto C Inoue N Effects of exogenous transforming growth factor beta on Trypanosoma congolense infection in mice Infect. Immun. 2007 75 1878 1885 10.1128/IAI.01452-06 17261602
Namangala, B., Sugimoto, C. & Inoue, N. Effects of exogenous transforming growth factor beta on Trypanosoma congolense infection in mice. Infect. Immun. 75, 1878–1885 (2007).17261602 10.1128/IAI.01452-06
706. Buzoni-Gatel D Murine ileitis after intracellular parasite infection is controlled by TGF-beta-producing intraepithelial lymphocytes Gastroenterology 2001 120 914 924 10.1053/gast.2001.22432a 11231945
Buzoni-Gatel, D. et al. Murine ileitis after intracellular parasite infection is controlled by TGF-beta-producing intraepithelial lymphocytes. Gastroenterology 120, 914–924 (2001).11231945 10.1053/gast.2001.22432a
707. Cekanaviciute E Astrocytic TGF-β signaling limits inflammation and reduces neuronal damage during central nervous system Toxoplasma infection J. Immunol. 2014 193 139 149 10.4049/jimmunol.1303284 24860191
Cekanaviciute, E. et al. Astrocytic TGF-β signaling limits inflammation and reduces neuronal damage during central nervous system Toxoplasma infection. J. Immunol. 193, 139–149 (2014).24860191 10.4049/jimmunol.1303284
708. Zhao M The Effect of TGF-β on Treg Cells in Adverse Pregnancy Outcome upon Toxoplasma gondii Infection Front Microbiol 2017 8 901 10.3389/fmicb.2017.00901 28603517
Zhao, M. et al. The Effect of TGF-β on Treg Cells in Adverse Pregnancy Outcome upon Toxoplasma gondii Infection. Front Microbiol 8, 901 (2017).28603517 10.3389/fmicb.2017.00901
709. Xu X TGF-β1 improving abnormal pregnancy outcomes induced by Toxoplasma gondii infection: Regulating NKG2D/DAP10 and killer subset of decidual NK cells Cell Immunol. 2017 317 9 17 10.1016/j.cellimm.2017.04.004 28438315
Xu, X. et al. TGF-β1 improving abnormal pregnancy outcomes induced by Toxoplasma gondii infection: Regulating NKG2D/DAP10 and killer subset of decidual NK cells. Cell Immunol. 317, 9–17 (2017).28438315 10.1016/j.cellimm.2017.04.004
710. Heitmann L TGF-β-responsive myeloid cells suppress type 2 immunity and emphysematous pathology after hookworm infection Am. J. Pathol. 2012 181 897 906 10.1016/j.ajpath.2012.05.032 22901754
Heitmann, L. et al. TGF-β-responsive myeloid cells suppress type 2 immunity and emphysematous pathology after hookworm infection. Am. J. Pathol. 181, 897–906 (2012).22901754 10.1016/j.ajpath.2012.05.032
711. Wu HP Plasma transforming growth factor-beta1 level in patients with severe community-acquired pneumonia and association with disease severity J. Formos. Med Assoc. 2009 108 20 27 10.1016/S0929-6646(09)60028-0 19181604
Wu, H. P. et al. Plasma transforming growth factor-beta1 level in patients with severe community-acquired pneumonia and association with disease severity. J. Formos. Med Assoc. 108, 20–27 (2009).19181604 10.1016/S0929-6646(09)60028-0
712. de Pablo R Sepsis-induced acute respiratory distress syndrome with fatal outcome is associated to increased serum transforming growth factor beta-1 levels Eur. J. Intern Med 2012 23 358 362 10.1016/j.ejim.2011.10.001 22560386
de Pablo, R. et al. Sepsis-induced acute respiratory distress syndrome with fatal outcome is associated to increased serum transforming growth factor beta-1 levels. Eur. J. Intern Med 23, 358–362 (2012).22560386 10.1016/j.ejim.2011.10.001
713. Gauthier T TGF-β uncouples glycolysis and inflammation in macrophages and controls survival during sepsis Sci. Signal 2023 16 eade0385 10.1126/scisignal.ade0385 37552767
Gauthier, T. et al. TGF-β uncouples glycolysis and inflammation in macrophages and controls survival during sepsis. Sci. Signal 16, eade0385 (2023).37552767 10.1126/scisignal.ade0385
714. Ahmad S Choudhry MA Shankar R Sayeed MM Transforming growth factor-beta negatively modulates T-cell responses in sepsis FEBS Lett. 1997 402 213 218 10.1016/S0014-5793(96)01535-9 9037198
Ahmad, S., Choudhry, M. A., Shankar, R. & Sayeed, M. M. Transforming growth factor-beta negatively modulates T-cell responses in sepsis. FEBS Lett. 402, 213–218 (1997).9037198 10.1016/S0014-5793(96)01535-9
715. Lowrance JH O’Sullivan FX Caver TE Waegell W Gresham HD Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice J. Exp. Med 1994 180 1693 1703 10.1084/jem.180.5.1693 7964455
Lowrance, J. H., O’Sullivan, F. X., Caver, T. E., Waegell, W. & Gresham, H. D. Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J. Exp. Med 180, 1693–1703 (1994).7964455 10.1084/jem.180.5.1693
716. Li N Influenza viral neuraminidase primes bacterial coinfection through TGF-β-mediated expression of host cell receptors Proc. Natl Acad. Sci. USA 2015 112 238 243 10.1073/pnas.1414422112 25535343
Li, N. et al. Influenza viral neuraminidase primes bacterial coinfection through TGF-β-mediated expression of host cell receptors. Proc. Natl Acad. Sci. USA 112, 238–243 (2015).25535343 10.1073/pnas.1414422112
717. Zhang M TGF-β1 promoted the infection of bovine mammary epithelial cells by Staphylococcus aureus through increasing expression of cells’ fibronectin and integrin β1 Vet. Microbiol 2019 237 108420 10.1016/j.vetmic.2019.108420 31585649
Zhang, M. et al. TGF-β1 promoted the infection of bovine mammary epithelial cells by Staphylococcus aureus through increasing expression of cells’ fibronectin and integrin β1. Vet. Microbiol 237, 108420 (2019).31585649 10.1016/j.vetmic.2019.108420
718. Owyang SY Dendritic cell-derived TGF-β mediates the induction of mucosal regulatory T-cell response to Helicobacter infection essential for maintenance of immune tolerance in mice Helicobacter 2020 25 e12763 10.1111/hel.12763 33025641
Owyang, S. Y. et al. Dendritic cell-derived TGF-β mediates the induction of mucosal regulatory T-cell response to Helicobacter infection essential for maintenance of immune tolerance in mice. Helicobacter 25, e12763 (2020).33025641 10.1111/hel.12763
719. Beswick EJ Pinchuk IV Earley RB Schmitt DA Reyes VE Role of gastric epithelial cell-derived transforming growth factor beta in reduced CD4+ T cell proliferation and development of regulatory T cells during Helicobacter pylori infection Infect. Immun. 2011 79 2737 2745 10.1128/IAI.01146-10 21482686
Beswick, E. J., Pinchuk, I. V., Earley, R. B., Schmitt, D. A. & Reyes, V. E. Role of gastric epithelial cell-derived transforming growth factor beta in reduced CD4+ T cell proliferation and development of regulatory T cells during Helicobacter pylori infection. Infect. Immun. 79, 2737–2745 (2011).21482686 10.1128/IAI.01146-10
720. Liu Y Islam EA Jarvis GA Gray-Owen SD Russell MW Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms Mucosal. Immunol. 2012 5 320 331 10.1038/mi.2012.12 22354319
Liu, Y., Islam, E. A., Jarvis, G. A., Gray-Owen, S. D. & Russell, M. W. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms. Mucosal. Immunol. 5, 320–331 (2012).22354319 10.1038/mi.2012.12
721. Balkhi MY Sinha A Natarajan K Dominance of CD86, transforming growth factor- beta 1, and interleukin-10 in Mycobacterium tuberculosis secretory antigen-activated dendritic cells regulates T helper 1 responses to mycobacterial antigens J. Infect. Dis. 2004 189 1598 1609 10.1086/383328 15116295
Balkhi, M. Y., Sinha, A. & Natarajan, K. Dominance of CD86, transforming growth factor- beta 1, and interleukin-10 in Mycobacterium tuberculosis secretory antigen-activated dendritic cells regulates T helper 1 responses to mycobacterial antigens. J. Infect. Dis. 189, 1598–1609 (2004).15116295 10.1086/383328
722. Roberts T Beyers N Aguirre A Walzl G Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta, and interleukin-4 mRNA levels J. Infect. Dis. 2007 195 870 878 10.1086/511277 17299718
Roberts, T., Beyers, N., Aguirre, A. & Walzl, G. Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta, and interleukin-4 mRNA levels. J. Infect. Dis. 195, 870–878 (2007).17299718 10.1086/511277
723. Denney L Branchett W Gregory LG Oliver RA Lloyd CM Epithelial-derived TGF-β1 acts as a pro-viral factor in the lung during influenza A infection Mucosal. Immunol. 2018 11 523 535 10.1038/mi.2017.77 29067998
Denney, L., Branchett, W., Gregory, L. G., Oliver, R. A. & Lloyd, C. M. Epithelial-derived TGF-β1 acts as a pro-viral factor in the lung during influenza A infection. Mucosal. Immunol. 11, 523–535 (2018).29067998 10.1038/mi.2017.77
724. Thomas BJ Transforming growth factor-beta enhances rhinovirus infection by diminishing early innate responses Am. J. Respir. Cell Mol. Biol. 2009 41 339 347 10.1165/rcmb.2008-0316OC 19168696
Thomas, B. J. et al. Transforming growth factor-beta enhances rhinovirus infection by diminishing early innate responses. Am. J. Respir. Cell Mol. Biol. 41, 339–347 (2009).19168696 10.1165/rcmb.2008-0316OC
725. Lewis GM Macal M Hesser CR Zuñiga EI Constitutive but not inducible attenuation of transforming growth factor β signaling increases natural killer cell responses without directly affecting dendritic cells early after persistent viral infection J. Virol. 2015 89 3343 3355 10.1128/JVI.03076-14 25589641
Lewis, G. M., Macal, M., Hesser, C. R. & Zuñiga, E. I. Constitutive but not inducible attenuation of transforming growth factor β signaling increases natural killer cell responses without directly affecting dendritic cells early after persistent viral infection. J. Virol. 89, 3343–3355 (2015).25589641 10.1128/JVI.03076-14
726. Marcoe JP TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy Nat. Immunol. 2012 13 843 850 10.1038/ni.2388 22863752
Marcoe, J. P. et al. TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat. Immunol. 13, 843–850 (2012).22863752 10.1038/ni.2388
727. Kekow J Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection Proc. Natl Acad. Sci. USA 1990 87 8321 8325 10.1073/pnas.87.21.8321 1700428
Kekow, J. et al. Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc. Natl Acad. Sci. USA 87, 8321–8325 (1990).1700428 10.1073/pnas.87.21.8321
728. Kekow J Transforming growth factor-beta and suppression of humoral immune responses in HIV infection J. Clin. Invest 1991 87 1010 1016 10.1172/JCI115059 1999481
Kekow, J. et al. Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J. Clin. Invest 87, 1010–1016 (1991).1999481 10.1172/JCI115059
729. Bedke N Transforming growth factor-beta promotes rhinovirus replication in bronchial epithelial cells by suppressing the innate immune response PLoS One 2012 7 e44580 10.1371/journal.pone.0044580 22970254
Bedke, N. et al. Transforming growth factor-beta promotes rhinovirus replication in bronchial epithelial cells by suppressing the innate immune response. PLoS One 7, e44580 (2012).22970254 10.1371/journal.pone.0044580
730. Grunwell JR TGF-β1 Suppresses the Type I IFN Response and Induces Mitochondrial Dysfunction in Alveolar Macrophages J. Immunol. 2018 200 2115 2128 10.4049/jimmunol.1701325 29427413
Grunwell, J. R. et al. TGF-β1 Suppresses the Type I IFN Response and Induces Mitochondrial Dysfunction in Alveolar Macrophages. J. Immunol. 200, 2115–2128 (2018).29427413 10.4049/jimmunol.1701325
731. Witkowski M Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells Nature 2021 600 295 301 10.1038/s41586-021-04142-6 34695836
Witkowski, M. et al. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature 600, 295–301 (2021).34695836 10.1038/s41586-021-04142-6
732. Moriuchi M Moriuchi H Cell-type-dependent effect of transforming growth factor beta, a major cytokine in breast milk, on human immunodeficiency virus type 1 infection of mammary epithelial MCF-7 cells or macrophages J. Virol. 2004 78 13046 13052 10.1128/JVI.78.23.13046-13052.2004 15542656
Moriuchi, M. & Moriuchi, H. Cell-type-dependent effect of transforming growth factor beta, a major cytokine in breast milk, on human immunodeficiency virus type 1 infection of mammary epithelial MCF-7 cells or macrophages. J. Virol. 78, 13046–13052 (2004).15542656 10.1128/JVI.78.23.13046-13052.2004
733. Yim LY Transforming Growth Factor β Signaling Promotes HIV-1 Infection in Activated and Resting Memory CD4(+) T Cells J. Virol. 2023 97 e0027023 10.1128/jvi.00270-23 37042759
Yim, L. Y. et al. Transforming Growth Factor β Signaling Promotes HIV-1 Infection in Activated and Resting Memory CD4(+) T Cells. J. Virol. 97, e0027023 (2023).37042759 10.1128/jvi.00270-23
734. Cheung KW α(4)β(7)(+) CD4(+) Effector/Effector Memory T Cells Differentiate into Productively and Latently Infected Central Memory T Cells by Transforming Growth Factor β1 during HIV-1 Infection J. Virol. 2018 92 e01510 e01517 10.1128/JVI.01510-17 29386290
Cheung, K. W. et al. α(4)β(7)(+) CD4(+) Effector/Effector Memory T Cells Differentiate into Productively and Latently Infected Central Memory T Cells by Transforming Growth Factor β1 during HIV-1 Infection. J. Virol. 92, e01510–e01517 (2018).29386290 10.1128/JVI.01510-17
735. Moriuchi M Moriuchi H Transforming growth factor-beta enhances human T-cell leukemia virus type I infection J. Med Virol. 2002 67 427 430 10.1002/jmv.10074 12116037
Moriuchi, M. & Moriuchi, H. Transforming growth factor-beta enhances human T-cell leukemia virus type I infection. J. Med Virol. 67, 427–430 (2002).12116037 10.1002/jmv.10074
736. Lin W HIV increases HCV replication in a TGF-beta1-dependent manner Gastroenterology 2008 134 803 811 10.1053/j.gastro.2008.01.005 18325393
Lin, W. et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 134, 803–811 (2008).18325393 10.1053/j.gastro.2008.01.005
737. Trinh QD TGF-β1 Promotes Zika Virus Infection in Immortalized Human First-Trimester Trophoblasts via the Smad Pathway Cells 2022 11 3026 10.3390/cells11193026 36230987
Trinh, Q. D. et al. TGF-β1 Promotes Zika Virus Infection in Immortalized Human First-Trimester Trophoblasts via the Smad Pathway. Cells 11, 3026 (2022).36230987 10.3390/cells11193026
738. Pham NTK The Epithelial-to-Mesenchymal Transition-Like Process Induced by TGF-β1 Enhances Rubella Virus Binding and Infection in A549 Cells via the Smad Pathway Microorganisms 2021 9 662 10.3390/microorganisms9030662 33806778
Pham, N. T. K. et al. The Epithelial-to-Mesenchymal Transition-Like Process Induced by TGF-β1 Enhances Rubella Virus Binding and Infection in A549 Cells via the Smad Pathway. Microorganisms 9, 662 (2021).33806778 10.3390/microorganisms9030662
739. Flynn RJ Mulcahy G The roles of IL-10 and TGF-beta in controlling IL-4 and IFN-gamma production during experimental Fasciola hepatica infection Int J. Parasitol. 2008 38 1673 1680 10.1016/j.ijpara.2008.05.008 18597757
Flynn, R. J. & Mulcahy, G. The roles of IL-10 and TGF-beta in controlling IL-4 and IFN-gamma production during experimental Fasciola hepatica infection. Int J. Parasitol. 38, 1673–1680 (2008).18597757 10.1016/j.ijpara.2008.05.008
740. Pang N TGF-β/Smad signaling pathway regulates Th17/Treg balance during Echinococcus multilocularis infection Int Immunopharmacol. 2014 20 248 257 10.1016/j.intimp.2014.02.038 24631515
Pang, N. et al. TGF-β/Smad signaling pathway regulates Th17/Treg balance during Echinococcus multilocularis infection. Int Immunopharmacol. 20, 248–257 (2014).24631515 10.1016/j.intimp.2014.02.038
741. Barbosa BF IL10, TGF beta1, and IFN gamma modulate intracellular signaling pathways and cytokine production to control Toxoplasma gondii infection in BeWo trophoblast cells Biol. Reprod. 2015 92 82 10.1095/biolreprod.114.124115 25673564
Barbosa, B. F. et al. IL10, TGF beta1, and IFN gamma modulate intracellular signaling pathways and cytokine production to control Toxoplasma gondii infection in BeWo trophoblast cells. Biol. Reprod. 92, 82 (2015).25673564 10.1095/biolreprod.114.124115
742. Barral-Netto M Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism Science 1992 257 545 548 10.1126/science.1636092 1636092
Barral-Netto, M. et al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257, 545–548 (1992).1636092 10.1126/science.1636092
743. Walther M Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection Immunity 2005 23 287 296 10.1016/j.immuni.2005.08.006 16169501
Walther, M. et al. Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity 23, 287–296 (2005).16169501 10.1016/j.immuni.2005.08.006
744. Tsutsui N Kamiyama T Transforming growth factor beta-induced failure of resistance to infection with blood-stage Plasmodium chabaudi in mice Infect. Immun. 1999 67 2306 2311 10.1128/IAI.67.5.2306-2311.1999 10225888
Tsutsui, N. & Kamiyama, T. Transforming growth factor beta-induced failure of resistance to infection with blood-stage Plasmodium chabaudi in mice. Infect. Immun. 67, 2306–2311 (1999).10225888 10.1128/IAI.67.5.2306-2311.1999
745. Akhurst RJ Fee F Balmain A Localized production of TGF-beta mRNA in tumour promoter-stimulated mouse epidermis Nature 1988 331 363 365 10.1038/331363a0 3422343
Akhurst, R. J., Fee, F. & Balmain, A. Localized production of TGF-beta mRNA in tumour promoter-stimulated mouse epidermis. Nature 331, 363–365 (1988).3422343 10.1038/331363a0
746. Cui W Concerted action of TGF-beta 1 and its type II receptor in control of epidermal homeostasis in transgenic mice Genes Dev. 1995 9 945 955 10.1101/gad.9.8.945 7774812
Cui, W. et al. Concerted action of TGF-beta 1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Dev. 9, 945–955 (1995).7774812 10.1101/gad.9.8.945
747. Fowlis DJ Cui W Johnson SA Balmain A Akhurst RJ Altered epidermal cell growth control in vivo by inducible expression of transforming growth factor beta 1 in the skin of transgenic mice Cell Growth Differ. 1996 7 679 687 8732677
Fowlis, D. J., Cui, W., Johnson, S. A., Balmain, A. & Akhurst, R. J. Altered epidermal cell growth control in vivo by inducible expression of transforming growth factor beta 1 in the skin of transgenic mice. Cell Growth Differ. 7, 679–687 (1996).8732677
748. Boulanger CA Smith GH Reducing mammary cancer risk through premature stem cell senescence Oncogene 2001 20 2264 2272 10.1038/sj.onc.1204312 11402321
Boulanger, C. A. & Smith, G. H. Reducing mammary cancer risk through premature stem cell senescence. Oncogene 20, 2264–2272 (2001).11402321 10.1038/sj.onc.1204312
749. Siegel PM Shu W Cardiff RD Muller WJ Massagué J Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis Proc. Natl Acad. Sci. USA 2003 100 8430 8435 10.1073/pnas.0932636100 12808151
Siegel, P. M., Shu, W., Cardiff, R. D., Muller, W. J. & Massagué, J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl Acad. Sci. USA 100, 8430–8435 (2003).12808151 10.1073/pnas.0932636100
750. Weeks BH He W Olson KL Wang XJ Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis Cancer Res 2001 61 7435 7443 11606377
Weeks, B. H., He, W., Olson, K. L. & Wang, X. J. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. Cancer Res 61, 7435–7443 (2001).11606377
751. Gobbi H Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia J. Natl Cancer Inst. 1999 91 2096 2101 10.1093/jnci/91.24.2096 10601380
Gobbi, H. et al. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J. Natl Cancer Inst. 91, 2096–2101 (1999).10601380 10.1093/jnci/91.24.2096
752. Goudie DR Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1 Nat. Genet 2011 43 365 369 10.1038/ng.780 21358634
Goudie, D. R. et al. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat. Genet 43, 365–369 (2011).21358634 10.1038/ng.780
753. Goudie D Multiple Self-Healing Squamous Epithelioma (MSSE): A Digenic Trait Associated with Loss of Function Mutations in TGFBR1 and Variants at a Second Linked Locus on the Long Arm of Chromosome 9 Genes (Basel) 2020 11 1410 10.3390/genes11121410 33256177
Goudie, D. Multiple Self-Healing Squamous Epithelioma (MSSE): A Digenic Trait Associated with Loss of Function Mutations in TGFBR1 and Variants at a Second Linked Locus on the Long Arm of Chromosome 9. Genes (Basel) 11, 1410 (2020).33256177 10.3390/genes11121410
754. Lu SL HNPCC associated with germline mutation in the TGF-beta type II receptor gene Nat. Genet 1998 19 17 18 10.1038/ng0598-17 9590282
Lu, S. L. et al. HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nat. Genet 19, 17–18 (1998).9590282 10.1038/ng0598-17
755. Woodford-Richens K Analysis of genetic and phenotypic heterogeneity in juvenile polyposis Gut 2000 46 656 660 10.1136/gut.46.5.656 10764709
Woodford-Richens, K. et al. Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut 46, 656–660 (2000).10764709 10.1136/gut.46.5.656
756. Howe JR The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations J. Med Genet 2004 41 484 491 10.1136/jmg.2004.018598 15235019
Howe, J. R. et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J. Med Genet 41, 484–491 (2004).15235019 10.1136/jmg.2004.018598
757. Engle SJ Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis Cancer Res 1999 59 3379 3386 10416598
Engle, S. J. et al. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59, 3379–3386 (1999).10416598
758. Glick AB Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion Proc. Natl Acad. Sci. USA 1993 90 6076 6080 10.1073/pnas.90.13.6076 7687059
Glick, A. B. et al. Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc. Natl Acad. Sci. USA 90, 6076–6080 (1993).7687059 10.1073/pnas.90.13.6076
759. Forrester E Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis Cancer Res 2005 65 2296 2302 10.1158/0008-5472.CAN-04-3272 15781643
Forrester, E. et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 65, 2296–2302 (2005).15781643 10.1158/0008-5472.CAN-04-3272
760. Muñoz NM Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation Cancer Res 2006 66 9837 9844 10.1158/0008-5472.CAN-06-0890 17047044
Muñoz, N. M. et al. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 66, 9837–9844 (2006).17047044 10.1158/0008-5472.CAN-06-0890
761. Ijichi H Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression Genes Dev. 2006 20 3147 3160 10.1101/gad.1475506 17114585
Ijichi, H. et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev. 20, 3147–3160 (2006).17114585 10.1101/gad.1475506
762. Lu SL Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma Genes Dev. 2006 20 1331 1342 10.1101/gad.1413306 16702406
Lu, S. L. et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 20, 1331–1342 (2006).16702406 10.1101/gad.1413306
763. Bian Y Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway Cancer Res 2009 69 5918 5926 10.1158/0008-5472.CAN-08-4623 19584284
Bian, Y. et al. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res 69, 5918–5926 (2009).19584284 10.1158/0008-5472.CAN-08-4623
764. Guasch G Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia Cancer Cell 2007 12 313 327 10.1016/j.ccr.2007.08.020 17936557
Guasch, G. et al. Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 12, 313–327 (2007).17936557 10.1016/j.ccr.2007.08.020
765. Go C Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGFbetaRII Oncogene 2000 19 3623 3631 10.1038/sj.onc.1203701 10951568
Go, C. et al. Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGFbetaRII. Oncogene 19, 3623–3631 (2000).10951568 10.1038/sj.onc.1203701
766. Amendt C Schirmacher P Weber H Blessing M Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development Oncogene 1998 17 25 34 10.1038/sj.onc.1202161 9671311
Amendt, C., Schirmacher, P., Weber, H. & Blessing, M. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17, 25–34 (1998).9671311 10.1038/sj.onc.1202161
767. Kanzler S Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis Oncogene 2001 20 5015 5024 10.1038/sj.onc.1204544 11526486
Kanzler, S. et al. Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene 20, 5015–5024 (2001).11526486 10.1038/sj.onc.1204544
768. Hahm KB Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice Aliment Pharm. Ther. 2002 16 115 127 10.1046/j.1365-2036.16.s2.3.x
Hahm, K. B. et al. Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment Pharm. Ther. 16, 115–127 (2002).10.1046/j.1365-2036.16.s2.3.x
769. Biswas S Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer Cancer Res 2004 64 4687 4692 10.1158/0008-5472.CAN-03-3255 15256431
Biswas, S. et al. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 64, 4687–4692 (2004).15256431 10.1158/0008-5472.CAN-03-3255
770. Gorska AE Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation Am. J. Pathol. 2003 163 1539 1549 10.1016/S0002-9440(10)63510-9 14507660
Gorska, A. E. et al. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am. J. Pathol. 163, 1539–1549 (2003).14507660 10.1016/S0002-9440(10)63510-9
771. Zhu Y Richardson JA Parada LF Graff JM Smad3 mutant mice develop metastatic colorectal cancer Cell 1998 94 703 714 10.1016/S0092-8674(00)81730-4 9753318
Zhu, Y., Richardson, J. A., Parada, L. F. & Graff, J. M. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94, 703–714 (1998).9753318 10.1016/S0092-8674(00)81730-4
772. Wolfraim LA Loss of Smad3 in acute T-cell lymphoblastic leukemia N. Engl. J. Med 2004 351 552 559 10.1056/NEJMoa031197 15295048
Wolfraim, L. A. et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N. Engl. J. Med 351, 552–559 (2004).15295048 10.1056/NEJMoa031197
773. Takaku K Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice Cancer Res 1999 59 6113 6117 10626800
Takaku, K. et al. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res 59, 6113–6117 (1999).10626800
774. Bardeesy N Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer Genes Dev. 2006 20 3130 3146 10.1101/gad.1478706 17114584
Bardeesy, N. et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 20, 3130–3146 (2006).17114584 10.1101/gad.1478706
775. Alberici P Smad4 haploinsufficiency in mouse models for intestinal cancer Oncogene 2006 25 1841 1851 10.1038/sj.onc.1209226 16288217
Alberici, P. et al. Smad4 haploinsufficiency in mouse models for intestinal cancer. Oncogene 25, 1841–1851 (2006).16288217 10.1038/sj.onc.1209226
776. Xu X Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice Oncogene 2000 19 1868 1874 10.1038/sj.onc.1203504 10773876
Xu, X. et al. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 19, 1868–1874 (2000).10773876 10.1038/sj.onc.1203504
777. Braun L Dürst M Mikumo R Crowley A Robinson M Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor-beta: implications for the control of papillomavirus infection Mol. Carcinog. 1992 6 100 111 10.1002/mc.2940060205 1326988
Braun, L., Dürst, M., Mikumo, R., Crowley, A. & Robinson, M. Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor-beta: implications for the control of papillomavirus infection. Mol. Carcinog. 6, 100–111 (1992).1326988 10.1002/mc.2940060205
778. Souza RF A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms Gastroenterology 1997 112 40 45 10.1016/S0016-5085(97)70217-8 8978341
Souza, R. F. et al. A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms. Gastroenterology 112, 40–45 (1997).8978341 10.1016/S0016-5085(97)70217-8
779. Kim BG Smad4 signalling in T cells is required for suppression of gastrointestinal cancer Nature 2006 441 1015 1019 10.1038/nature04846 16791201
Kim, B. G. et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441, 1015–1019 (2006).16791201 10.1038/nature04846
780. Matsuzaki K Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma Hepatology 2007 46 48 57 10.1002/hep.21672 17596875
Matsuzaki, K. et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 46, 48–57 (2007).17596875 10.1002/hep.21672
781. Achyut BR Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling PLoS Genet 2013 9 e1003251 10.1371/journal.pgen.1003251 23408900
Achyut, B. R. et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet 9, e1003251 (2013).23408900 10.1371/journal.pgen.1003251
782. Glick AB Weinberg WC Wu IH Quan W Yuspa SH Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb Cancer Res 1996 56 3645 3650 8706000
Glick, A. B., Weinberg, W. C., Wu, I. H., Quan, W. & Yuspa, S. H. Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res 56, 3645–3650 (1996).8706000
783. Katakura Y Nakata E Miura T Shirahata S Transforming growth factor beta triggers two independent-senescence programs in cancer cells Biochem Biophys. Res Commun. 1999 255 110 115 10.1006/bbrc.1999.0129 10082664
Katakura, Y., Nakata, E., Miura, T. & Shirahata, S. Transforming growth factor beta triggers two independent-senescence programs in cancer cells. Biochem Biophys. Res Commun. 255, 110–115 (1999).10082664 10.1006/bbrc.1999.0129
784. Bhowmick NA TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia Science 2004 303 848 851 10.1126/science.1090922 14764882
Bhowmick, N. A. et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848–851 (2004).14764882 10.1126/science.1090922
785. Moustakas A Kardassis D Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members Proc. Natl Acad. Sci. USA 1998 95 6733 6738 10.1073/pnas.95.12.6733 9618481
Moustakas, A. & Kardassis, D. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc. Natl Acad. Sci. USA 95, 6733–6738 (1998).9618481 10.1073/pnas.95.12.6733
786. Kang SH Rapid induction of p21WAF1 but delayed down-regulation of Cdc25A in the TGF-beta-induced cell cycle arrest of gastric carcinoma cells Br. J. Cancer 1999 80 1144 1149 10.1038/sj.bjc.6690478 10376964
Kang, S. H. et al. Rapid induction of p21WAF1 but delayed down-regulation of Cdc25A in the TGF-beta-induced cell cycle arrest of gastric carcinoma cells. Br. J. Cancer 80, 1144–1149 (1999).10376964 10.1038/sj.bjc.6690478
787. Damdinsuren B TGF-beta1-induced cell growth arrest and partial differentiation is related to the suppression of Id1 in human hepatoma cells Oncol. Rep. 2006 15 401 408 16391861
Damdinsuren, B. et al. TGF-beta1-induced cell growth arrest and partial differentiation is related to the suppression of Id1 in human hepatoma cells. Oncol. Rep. 15, 401–408 (2006).16391861
788. Hishikawa K Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7 J. Biol. Chem. 1999 274 37461 37466 10.1074/jbc.274.52.37461 10601320
Hishikawa, K. et al. Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J. Biol. Chem. 274, 37461–37466 (1999).10601320 10.1074/jbc.274.52.37461
789. Zhang H Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma Oncogene 2006 25 6101 6112 10.1038/sj.onc.1209634 16682950
Zhang, H. et al. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene 25, 6101–6112 (2006).16682950 10.1038/sj.onc.1209634
790. Kim SG Transforming growth factor-beta 1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells Mol. Biol. Cell 2004 15 420 434 10.1091/mbc.e03-04-0201 14595120
Kim, S. G. et al. Transforming growth factor-beta 1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells. Mol. Biol. Cell 15, 420–434 (2004).14595120 10.1091/mbc.e03-04-0201
791. Jang CW TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase Nat. Cell Biol. 2002 4 51 58 10.1038/ncb731 11740493
Jang, C. W. et al. TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat. Cell Biol. 4, 51–58 (2002).11740493 10.1038/ncb731
792. David CJ TGF-β Tumor Suppression through a Lethal EMT Cell 2016 164 1015 1030 10.1016/j.cell.2016.01.009 26898331
David, C. J. et al. TGF-β Tumor Suppression through a Lethal EMT. Cell 164, 1015–1030 (2016).26898331 10.1016/j.cell.2016.01.009
793. Tachibana I Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells J. Clin. Invest 1997 99 2365 2374 10.1172/JCI119418 9153278
Tachibana, I. et al. Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. J. Clin. Invest 99, 2365–2374 (1997).9153278 10.1172/JCI119418
794. Kim BC Mamura M Choi KS Calabretta B Kim SJ Transforming growth factor beta 1 induces apoptosis through cleavage of BAD in a Smad3-dependent mechanism in FaO hepatoma cells Mol. Cell Biol. 2002 22 1369 1378 10.1128/MCB.22.5.1369-1378.2002 11839804
Kim, B. C., Mamura, M., Choi, K. S., Calabretta, B. & Kim, S. J. Transforming growth factor beta 1 induces apoptosis through cleavage of BAD in a Smad3-dependent mechanism in FaO hepatoma cells. Mol. Cell Biol. 22, 1369–1378 (2002).11839804 10.1128/MCB.22.5.1369-1378.2002
795. Chipuk JE Bhat M Hsing AY Ma J Danielpour D Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells J. Biol. Chem. 2001 276 26614 26621 10.1074/jbc.M100913200 11320089
Chipuk, J. E., Bhat, M., Hsing, A. Y., Ma, J. & Danielpour, D. Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J. Biol. Chem. 276, 26614–26621 (2001).11320089 10.1074/jbc.M100913200
796. Spender LC TGF-beta induces apoptosis in human B cells by transcriptional regulation of BIK and BCL-XL Cell Death Differ. 2009 16 593 602 10.1038/cdd.2008.183 19136942
Spender, L. C. et al. TGF-beta induces apoptosis in human B cells by transcriptional regulation of BIK and BCL-XL. Cell Death Differ. 16, 593–602 (2009).19136942 10.1038/cdd.2008.183
797. Ohgushi M Transforming growth factor beta-dependent sequential activation of Smad, Bim, and caspase-9 mediates physiological apoptosis in gastric epithelial cells Mol. Cell Biol. 2005 25 10017 10028 10.1128/MCB.25.22.10017-10028.2005 16260615
Ohgushi, M. et al. Transforming growth factor beta-dependent sequential activation of Smad, Bim, and caspase-9 mediates physiological apoptosis in gastric epithelial cells. Mol. Cell Biol. 25, 10017–10028 (2005).16260615 10.1128/MCB.25.22.10017-10028.2005
798. Saltzman A Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation Exp. Cell Res 1998 242 244 254 10.1006/excr.1998.4096 9665822
Saltzman, A. et al. Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp. Cell Res 242, 244–254 (1998).9665822 10.1006/excr.1998.4096
799. Kanamaru C Yasuda H Fujita T Involvement of Smad proteins in TGF-beta and activin A-induced apoptosis and growth inhibition of liver cells Hepatol. Res 2002 23 211 219 10.1016/S1386-6346(01)00175-9 12076717
Kanamaru, C., Yasuda, H. & Fujita, T. Involvement of Smad proteins in TGF-beta and activin A-induced apoptosis and growth inhibition of liver cells. Hepatol. Res 23, 211–219 (2002).12076717 10.1016/S1386-6346(01)00175-9
800. Bakhshayesh M Zaker F Hashemi M Katebi M Solaimani M TGF- β1-mediated apoptosis associated with SMAD-dependent mitochondrial Bcl-2 expression Clin. Lymphoma Myeloma Leuk. 2012 12 138 143 10.1016/j.clml.2011.12.001 22297256
Bakhshayesh, M., Zaker, F., Hashemi, M., Katebi, M. & Solaimani, M. TGF- β1-mediated apoptosis associated with SMAD-dependent mitochondrial Bcl-2 expression. Clin. Lymphoma Myeloma Leuk. 12, 138–143 (2012).22297256 10.1016/j.clml.2011.12.001
801. Cui W Kemp CJ Duffie E Balmain A Akhurst RJ Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53null mice is prognostic for a high risk of malignant conversion Cancer Res 1994 54 5831 5836 7954410
Cui, W., Kemp, C. J., Duffie, E., Balmain, A. & Akhurst, R. J. Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53null mice is prognostic for a high risk of malignant conversion. Cancer Res 54, 5831–5836 (1994).7954410
802. Cui W TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice Cell 1996 86 531 542 10.1016/S0092-8674(00)80127-0 8752208
Cui, W. et al. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531–542 (1996).8752208 10.1016/S0092-8674(00)80127-0
803. Capocasale RJ Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sézary patients Proc. Natl Acad. Sci. USA 1995 92 5501 5505 10.1073/pnas.92.12.5501 7777538
Capocasale, R. J. et al. Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sézary patients. Proc. Natl Acad. Sci. USA 92, 5501–5505 (1995).7777538 10.1073/pnas.92.12.5501
804. Kadin ME Loss of receptors for transforming growth factor beta in human T-cell malignancies Proc. Natl Acad. Sci. USA 1994 91 6002 6006 10.1073/pnas.91.13.6002 8016105
Kadin, M. E. et al. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc. Natl Acad. Sci. USA 91, 6002–6006 (1994).8016105 10.1073/pnas.91.13.6002
805. Fukai Y Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma Int J. Cancer 2003 104 161 166 10.1002/ijc.10929 12569570
Fukai, Y. et al. Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J. Cancer 104, 161–166 (2003).12569570 10.1002/ijc.10929
806. Tanaka S Mori M Mafune K Ohno S Sugimachi K A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma Br. J. Cancer 2000 82 1557 1560 10789724
Tanaka, S., Mori, M., Mafune, K., Ohno, S. & Sugimachi, K. A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma. Br. J. Cancer 82, 1557–1560 (2000).10789724
807. Souza RF Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasms Hum. Cell 1996 9 229 236 9183654
Souza, R. F. et al. Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasms. Hum. Cell 9, 229–236 (1996).9183654
808. Myeroff LL A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability Cancer Res 1995 55 5545 5547 7585631
Myeroff, L. L. et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55, 5545–5547 (1995).7585631
809. Grady WM Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas Cancer Res 1998 58 3101 3104 9679977
Grady, W. M. et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58, 3101–3104 (1998).9679977
810. Salovaara R Frequent loss of SMAD4/DPC4 protein in colorectal cancers Gut 2002 51 56 59 10.1136/gut.51.1.56 12077092
Salovaara, R. et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 51, 56–59 (2002).12077092 10.1136/gut.51.1.56
811. Takagi Y Somatic alterations of the DPC4 gene in human colorectal cancers in vivo Gastroenterology 1996 111 1369 1372 10.1053/gast.1996.v111.pm8898652 8898652
Takagi, Y. et al. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 111, 1369–1372 (1996).8898652 10.1053/gast.1996.v111.pm8898652
812. Goggins M Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas Cancer Res 1998 58 5329 5332 9850059
Goggins, M. et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 58, 5329–5332 (1998).9850059
813. Venkatasubbarao K Novel mutations in the polyadenine tract of the transforming growth factor beta type II receptor gene are found in a subpopulation of human pancreatic adenocarcinomas Genes Chromosomes Cancer 1998 22 138 144 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y 9598801
Venkatasubbarao, K. et al. Novel mutations in the polyadenine tract of the transforming growth factor beta type II receptor gene are found in a subpopulation of human pancreatic adenocarcinomas. Genes Chromosomes Cancer 22, 138–144 (1998).9598801 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y
814. Imai Y Tsurutani N Oda H Inoue T Ishikawa T Genetic instability and mutation of the TGF-beta-receptor-II gene in ampullary carcinomas Int J. Cancer 1998 76 407 411 10.1002/(SICI)1097-0215(19980504)76:3<407::AID-IJC19>3.0.CO;2-7 9579579
Imai, Y., Tsurutani, N., Oda, H., Inoue, T. & Ishikawa, T. Genetic instability and mutation of the TGF-beta-receptor-II gene in ampullary carcinomas. Int J. Cancer 76, 407–411 (1998).9579579 10.1002/(SICI)1097-0215(19980504)76:3<407::AID-IJC19>3.0.CO;2-7
815. Lazzereschi D Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein Cancer Res 1997 57 2071 2076 9158007
Lazzereschi, D. et al. Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein. Cancer Res 57, 2071–2076 (1997).9158007
816. Kim IY Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients Clin. Cancer Res 1998 4 1625 1630 9676836
Kim, I. Y. et al. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin. Cancer Res 4, 1625–1630 (1998).9676836
817. Guo Y Jacobs SC Kyprianou N Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer Int J. Cancer 1997 71 573 579 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.0.CO;2-D 9178810
Guo, Y., Jacobs, S. C. & Kyprianou, N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J. Cancer 71, 573–579 (1997).9178810 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.0.CO;2-D
818. Gobbi H Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas Histopathology 2000 36 168 177 10.1046/j.1365-2559.2000.00841.x 10672063
Gobbi, H. et al. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology 36, 168–177 (2000).10672063 10.1046/j.1365-2559.2000.00841.x
819. Lynch MA Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma Cancer Res 1998 58 4227 4232 9766642
Lynch, M. A. et al. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res 58, 4227–4232 (1998).9766642
820. Chen T Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases Int J. Cancer 2001 93 653 661 10.1002/ijc.1381 11477574
Chen, T. et al. Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases. Int J. Cancer 93, 653–661 (2001).11477574 10.1002/ijc.1381
821. Wang D Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck Carcinogenesis 1997 18 2285 2290 10.1093/carcin/18.11.2285 9395234
Wang, D. et al. Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis 18, 2285–2290 (1997).9395234 10.1093/carcin/18.11.2285
822. Qiu W Schönleben F Li X Su GH Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4 Cancer Lett. 2007 245 163 170 10.1016/j.canlet.2006.01.003 16478646
Qiu, W., Schönleben, F., Li, X. & Su, G. H. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett. 245, 163–170 (2007).16478646 10.1016/j.canlet.2006.01.003
823. Xie W Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis Oncol. Res 2003 14 61 73 10.3727/000000003108748612 14649540
Xie, W. et al. Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol. Res 14, 61–73 (2003).14649540 10.3727/000000003108748612
824. Sun L Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells J. Biol. Chem. 1994 269 26449 26455 10.1016/S0021-9258(18)47215-8 7929366
Sun, L. et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem. 269, 26449–26455 (1994).7929366 10.1016/S0021-9258(18)47215-8
825. Steiner MS & Barrack, E. R. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro Mol. Endocrinol. 1992 6 15 25 1738367
Steiner, M. S. & Barrack, E. R. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol. Endocrinol. 6, 15–25 (1992).1738367
826. Chang HL Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells Cancer Res 1993 53 4391 4398 8364935
Chang, H. L. et al. Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 53, 4391–4398 (1993).8364935
827. Kleeff J The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer Oncogene 1999 18 5363 5372 10.1038/sj.onc.1202909 10498890
Kleeff, J. et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18, 5363–5372 (1999).10498890 10.1038/sj.onc.1202909
828. Datto MB Hu PP Kowalik TF Yingling J Wang XF The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B Mol. Cell Biol. 1997 17 2030 2037 10.1128/MCB.17.4.2030 9121451
Datto, M. B., Hu, P. P., Kowalik, T. F., Yingling, J. & Wang, X. F. The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Mol. Cell Biol. 17, 2030–2037 (1997).9121451 10.1128/MCB.17.4.2030
829. Missero C Ramon y Cajal, S. & Dotto, G. P. Escape from transforming growth factor beta control and oncogene cooperation in skin tumor development Proc. Natl Acad. Sci. USA 1991 88 9613 9617 10.1073/pnas.88.21.9613 1946376
Missero, C. Ramon y Cajal, S. & Dotto, G. P. Escape from transforming growth factor beta control and oncogene cooperation in skin tumor development. Proc. Natl Acad. Sci. USA 88, 9613–9617 (1991).1946376 10.1073/pnas.88.21.9613
830. Kurokawa M The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3 Nature 1998 394 92 96 10.1038/27945 9665135
Kurokawa, M. et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 394, 92–96 (1998).9665135 10.1038/27945
831. Alexandrow MG Kawabata M Aakre M Moses HL Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1 Proc. Natl Acad. Sci. USA 1995 92 3239 3243 10.1073/pnas.92.8.3239 7724545
Alexandrow, M. G., Kawabata, M., Aakre, M. & Moses, H. L. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc. Natl Acad. Sci. USA 92, 3239–3243 (1995).7724545 10.1073/pnas.92.8.3239
832. Schlegel NC Id2 suppression of p15 counters TGF-beta-mediated growth inhibition of melanoma cells Pigment Cell Melanoma Res 2009 22 445 453 10.1111/j.1755-148X.2009.00571.x 19368689
Schlegel, N. C. et al. Id2 suppression of p15 counters TGF-beta-mediated growth inhibition of melanoma cells. Pigment Cell Melanoma Res 22, 445–453 (2009).19368689 10.1111/j.1755-148X.2009.00571.x
833. Ewen ME Oliver CJ Sluss HK Miller SJ Peeper D S. p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest Genes Dev. 1995 9 204 217 10.1101/gad.9.2.204 7851794
Ewen, M. E., Oliver, C. J., Sluss, H. K., Miller, S. J. & Peeper, D. S. p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest. Genes Dev. 9, 204–217 (1995).7851794 10.1101/gad.9.2.204
834. Kretzschmar M Doody J Timokhina I Massague J A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras Genes Dev. 1999 13 804 816 10.1101/gad.13.7.804 10197981
Kretzschmar, M., Doody, J., Timokhina, I. & Massague, J. A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev. 13, 804–816 (1999).10197981 10.1101/gad.13.7.804
835. Dalal BI Keown PA Greenberg AH Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma Am. J. Pathol. 1993 143 381 389 8393616
Dalal, B. I., Keown, P. A. & Greenberg, A. H. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am. J. Pathol. 143, 381–389 (1993).8393616
836. Walker RA Dearing SJ Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast Eur. J. Cancer 1992 28 641 644 10.1016/S0959-8049(05)80116-9 1317202
Walker, R. A. & Dearing, S. J. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur. J. Cancer 28, 641–644 (1992).1317202 10.1016/S0959-8049(05)80116-9
837. Friess H Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival Gastroenterology 1993 105 1846 1856 10.1016/0016-5085(93)91084-U 8253361
Friess, H. et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105, 1846–1856 (1993).8253361 10.1016/0016-5085(93)91084-U
838. Wagner M Kleeff J Friess H Büchler MW Korc M Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer Pancreas 1999 19 370 376 10.1097/00006676-199911000-00008 10547197
Wagner, M., Kleeff, J., Friess, H., Büchler, M. W. & Korc, M. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas 19, 370–376 (1999).10547197 10.1097/00006676-199911000-00008
839. Tateishi M The progression of invasiveness regarding the role of transforming growth factor beta receptor type II in gastric cancer Eur. J. Surg. Oncol. 2000 26 377 380 10.1053/ejso.1999.0902 10873359
Tateishi, M. et al. The progression of invasiveness regarding the role of transforming growth factor beta receptor type II in gastric cancer. Eur. J. Surg. Oncol. 26, 377–380 (2000).10873359 10.1053/ejso.1999.0902
840. Welch DR Fabra A Nakajima M Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential Proc. Natl Acad. Sci. USA 1990 87 7678 7682 10.1073/pnas.87.19.7678 2217201
Welch, D. R., Fabra, A. & Nakajima, M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Natl Acad. Sci. USA 87, 7678–7682 (1990).2217201 10.1073/pnas.87.19.7678
841. Tang B TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression J. Clin. Invest 2003 112 1116 1124 10.1172/JCI200318899 14523048
Tang, B. et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J. Clin. Invest 112, 1116–1124 (2003).14523048 10.1172/JCI200318899
842. Oft M Heider KH Beug H TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis Curr. Biol. 1998 8 1243 1252 10.1016/S0960-9822(07)00533-7 9822576
Oft, M., Heider, K. H. & Beug, H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 8, 1243–1252 (1998).9822576 10.1016/S0960-9822(07)00533-7
843. Han G Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis J. Clin. Invest 2005 115 1714 1723 10.1172/JCI24399 15937546
Han, G. et al. Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J. Clin. Invest 115, 1714–1723 (2005).15937546 10.1172/JCI24399
844. Caulín C Scholl FG Frontelo P Gamallo C Quintanilla M Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-beta 1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype Cell Growth Differ. 1995 6 1027 1035 8547217
Caulín, C., Scholl, F. G., Frontelo, P., Gamallo, C. & Quintanilla, M. Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-beta 1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype. Cell Growth Differ. 6, 1027–1035 (1995).8547217
845. Cheng JC Auersperg N Leung PC TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells PLoS One 2012 7 e42436 10.1371/journal.pone.0042436 22905131
Cheng, J. C., Auersperg, N. & Leung, P. C. TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells. PLoS One 7, e42436 (2012).22905131 10.1371/journal.pone.0042436
846. Qiao B Johnson NW Gao J Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta1 is Snail family-dependent and correlates with matrix metalloproteinase-2 and -9 expressions Int J. Oncol. 2010 37 663 668 20664935
Qiao, B., Johnson, N. W. & Gao, J. Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta1 is Snail family-dependent and correlates with matrix metalloproteinase-2 and -9 expressions. Int J. Oncol. 37, 663–668 (2010).20664935
847. Vincent T A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition Nat. Cell Biol. 2009 11 943 950 10.1038/ncb1905 19597490
Vincent, T. et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat. Cell Biol. 11, 943–950 (2009).19597490 10.1038/ncb1905
848. Arrick BA Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1 J. Cell Biol. 1992 118 715 726 10.1083/jcb.118.3.715 1639853
Arrick, B. A. et al. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1. J. Cell Biol. 118, 715–726 (1992).1639853 10.1083/jcb.118.3.715
849. Tu WH The loss of TGF-beta signaling promotes prostate cancer metastasis Neoplasia 2003 5 267 277 10.1016/S1476-5586(03)80058-1 12869309
Tu, W. H. et al. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia 5, 267–277 (2003).12869309 10.1016/S1476-5586(03)80058-1
850. Huntley SP Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination Int J. Cancer 2004 110 170 176 10.1002/ijc.20111 15069677
Huntley, S. P. et al. Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination. Int J. Cancer 110, 170–176 (2004).15069677 10.1002/ijc.20111
851. Hoosein NM Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1 Exp. Cell Res 1989 181 442 453 10.1016/0014-4827(89)90101-8 2538337
Hoosein, N. M. et al. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1. Exp. Cell Res 181, 442–453 (1989).2538337 10.1016/0014-4827(89)90101-8
852. Takaku K Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes Cell 1998 92 645 656 10.1016/S0092-8674(00)81132-0 9506519
Takaku, K. et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92, 645–656 (1998).9506519 10.1016/S0092-8674(00)81132-0
853. Lewis MP Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells Br. J. Cancer 2004 90 822 832 10.1038/sj.bjc.6601611 14970860
Lewis, M. P. et al. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br. J. Cancer 90, 822–832 (2004).14970860 10.1038/sj.bjc.6601611
854. Stuelten CH Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer PLoS One 2010 5 e9832 10.1371/journal.pone.0009832 20352126
Stuelten, C. H. et al. Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One 5, e9832 (2010).20352126 10.1371/journal.pone.0009832
855. Löhr M Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma Cancer Res 2001 61 550 555 11212248
Löhr, M. et al. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res 61, 550–555 (2001).11212248
856. Igarashi A Okochi H Bradham DM Grotendorst GR Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair Mol. Biol. Cell 1993 4 637 645 10.1091/mbc.4.6.637 8374172
Igarashi, A., Okochi, H., Bradham, D. M. & Grotendorst, G. R. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell 4, 637–645 (1993).8374172 10.1091/mbc.4.6.637
857. Chantry D Turner M Abney E Feldmann M Modulation of cytokine production by transforming growth factor-beta J. Immunol. 1989 142 4295 4300 10.4049/jimmunol.142.12.4295 2542408
Chantry, D., Turner, M., Abney, E. & Feldmann, M. Modulation of cytokine production by transforming growth factor-beta. J. Immunol. 142, 4295–4300 (1989).2542408 10.4049/jimmunol.142.12.4295
858. Sieuwerts AM Klijn JG Henzen-Logmans SC Foekens JA Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro Breast Cancer Res Treat. 1999 55 9 20 10.1023/A:1006190729866 10472775
Sieuwerts, A. M., Klijn, J. G., Henzen-Logmans, S. C. & Foekens, J. A. Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro. Breast Cancer Res Treat. 55, 9–20 (1999).10472775 10.1023/A:1006190729866
859. Cheng N Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks Oncogene 2005 24 5053 5068 10.1038/sj.onc.1208685 15856015
Cheng, N. et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 24, 5053–5068 (2005).15856015 10.1038/sj.onc.1208685
860. Zeisberg EM Potenta S Xie L Zeisberg M Kalluri R Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts Cancer Res 2007 67 10123 10128 10.1158/0008-5472.CAN-07-3127 17974953
Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M. & Kalluri, R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67, 10123–10128 (2007).17974953 10.1158/0008-5472.CAN-07-3127
861. Go C Li P Wang XJ Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis Cancer Res 1999 59 2861 2868 10383147
Go, C., Li, P. & Wang, X. J. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis. Cancer Res 59, 2861–2868 (1999).10383147
862. Ueki N Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth Biochim Biophys. Acta 1992 1137 189 196 10.1016/0167-4889(92)90201-L 1384712
Ueki, N. et al. Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys. Acta 1137, 189–196 (1992).1384712 10.1016/0167-4889(92)90201-L
863. Padua D TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4 Cell 2008 133 66 77 10.1016/j.cell.2008.01.046 18394990
Padua, D. et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66–77 (2008).18394990 10.1016/j.cell.2008.01.046
864. Haak-Frendscho M Wynn TA Czuprynski CJ Paulnock D Transforming growth factor-beta 1 inhibits activation of macrophage cell line RAW 264.7 for cell killing Clin. Exp. Immunol. 1990 82 404 410 10.1111/j.1365-2249.1990.tb05461.x 2242621
Haak-Frendscho, M., Wynn, T. A., Czuprynski, C. J. & Paulnock, D. Transforming growth factor-beta 1 inhibits activation of macrophage cell line RAW 264.7 for cell killing. Clin. Exp. Immunol. 82, 404–410 (1990).2242621 10.1111/j.1365-2249.1990.tb05461.x
865. Torre-Amione G A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance Proc. Natl Acad. Sci. USA 1990 87 1486 1490 10.1073/pnas.87.4.1486 2137615
Torre-Amione, G. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc. Natl Acad. Sci. USA 87, 1486–1490 (1990).2137615 10.1073/pnas.87.4.1486
866. Donkor MK Sarkar A Li MO Tgf-β1 produced by activated CD4(+) T Cells Antagonizes T Cell Surveillance of Tumor Development Oncoimmunology 2012 1 162 171 10.4161/onci.1.2.18481 22720237
Donkor, M. K., Sarkar, A. & Li, M. O. Tgf-β1 produced by activated CD4(+) T Cells Antagonizes T Cell Surveillance of Tumor Development. Oncoimmunology 1, 162–171 (2012).22720237 10.4161/onci.1.2.18481
867. Sarkar A Donkor MK Li MO T cell- but not tumor cell-produced TGF-β1 promotes the development of spontaneous mammary cancer Oncotarget 2011 2 1339 1351 10.18632/oncotarget.403 22248703
Sarkar, A., Donkor, M. K. & Li, M. O. T cell- but not tumor cell-produced TGF-β1 promotes the development of spontaneous mammary cancer. Oncotarget 2, 1339–1351 (2011).22248703 10.18632/oncotarget.403
868. Arteaga CL Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression J. Clin. Invest 1993 92 2569 2576 10.1172/JCI116871 7504687
Arteaga, C. L. et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest 92, 2569–2576 (1993).7504687 10.1172/JCI116871
869. Ghiringhelli F Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation J. Exp. Med 2005 202 919 929 10.1084/jem.20050463 16186184
Ghiringhelli, F. et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med 202, 919–929 (2005).16186184 10.1084/jem.20050463
870. Hsiao YW Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression Cancer Immunol. Immunother. 2008 57 1091 1104 10.1007/s00262-007-0446-5 18259750
Hsiao, Y. W. et al. Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol. Immunother. 57, 1091–1104 (2008).18259750 10.1007/s00262-007-0446-5
871. Czarniecki CW Chiu HH Wong GH McCabe SM Palladino MA Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells J. Immunol. 1988 140 4217 4223 10.4049/jimmunol.140.12.4217 3131428
Czarniecki, C. W., Chiu, H. H., Wong, G. H., McCabe, S. M. & Palladino, M. A. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J. Immunol. 140, 4217–4223 (1988).3131428 10.4049/jimmunol.140.12.4217
872. Ma D Niederkorn JY Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis Immunology 1995 86 263 269 7490128
Ma, D. & Niederkorn, J. Y. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 86, 263–269 (1995).7490128
873. Bogdahn U Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study Neuro Oncol. 2011 13 132 142 10.1093/neuonc/noq142 20980335
Bogdahn, U. et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 13, 132–142 (2011).20980335 10.1093/neuonc/noq142
874. Niu NK Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study Drug Des. Devel Ther. 2015 9 4441 4470 26300629
Niu, N. K. et al. Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study. Drug Des. Devel Ther. 9, 4441–4470 (2015).26300629
875. Yang Z Preparation, characterization, and in-vitro cytotoxicity of nanoliposomes loaded with anti-tubercular drugs and TGF-β1 siRNA for improving spinal tuberculosis therapy BMC Infect. Dis. 2022 22 824 10.1186/s12879-022-07791-8 36348467
Yang, Z. et al. Preparation, characterization, and in-vitro cytotoxicity of nanoliposomes loaded with anti-tubercular drugs and TGF-β1 siRNA for improving spinal tuberculosis therapy. BMC Infect. Dis. 22, 824 (2022).36348467 10.1186/s12879-022-07791-8
876. Guoyou Z Modulation of transforming growth factor-beta1 production by vector-based RNAi in hypertrophic scar fibroblasts: a therapeutic potential strategy for hypertrophic scar J. Dermatol Sci. 2007 48 67 70 10.1016/j.jdermsci.2007.06.009 17683912
Guoyou, Z. et al. Modulation of transforming growth factor-beta1 production by vector-based RNAi in hypertrophic scar fibroblasts: a therapeutic potential strategy for hypertrophic scar. J. Dermatol Sci. 48, 67–70 (2007).17683912 10.1016/j.jdermsci.2007.06.009
877. Loiselle AE Development of antisense oligonucleotide (ASO) technology against Tgf-β signaling to prevent scarring during flexor tendon repair J. Orthop. Res 2015 33 859 866 10.1002/jor.22890 25761254
Loiselle, A. E. et al. Development of antisense oligonucleotide (ASO) technology against Tgf-β signaling to prevent scarring during flexor tendon repair. J. Orthop. Res 33, 859–866 (2015).25761254 10.1002/jor.22890
878. Jeong HS Effect of antisense TGF-beta1 oligodeoxynucleotides in streptozotocin- induced diabetic rat kidney J. Korean Med Sci. 2004 19 374 383 10.3346/jkms.2004.19.3.374 15201503
Jeong, H. S. et al. Effect of antisense TGF-beta1 oligodeoxynucleotides in streptozotocin- induced diabetic rat kidney. J. Korean Med Sci. 19, 374–383 (2004).15201503 10.3346/jkms.2004.19.3.374
879. Isaka Y Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction Kidney Int 2000 58 1885 1892 10.1111/j.1523-1755.2000.00360.x 11044208
Isaka, Y. et al. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 58, 1885–1892 (2000).11044208 10.1111/j.1523-1755.2000.00360.x
880. Han DC Hoffman BB Hong SW Guo J Ziyadeh FN Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice Am. J. Physiol. Ren. Physiol. 2000 278 F628 F634 10.1152/ajprenal.2000.278.4.F628
Han, D. C., Hoffman, B. B., Hong, S. W., Guo, J. & Ziyadeh, F. N. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am. J. Physiol. Ren. Physiol. 278, F628–F634 (2000).10.1152/ajprenal.2000.278.4.F628
881. Akagi Y Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis Kidney Int 1996 50 148 155 10.1038/ki.1996.297 8807583
Akagi, Y. et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 50, 148–155 (1996).8807583 10.1038/ki.1996.297
882. Giaccone G A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer Eur. J. Cancer 2015 51 2321 2329 10.1016/j.ejca.2015.07.035 26283035
Giaccone, G. et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur. J. Cancer 51, 2321–2329 (2015).26283035 10.1016/j.ejca.2015.07.035
883. Olivares J Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine Clin. Cancer Res 2011 17 183 192 10.1158/1078-0432.CCR-10-2195 21208907
Olivares, J. et al. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin. Cancer Res 17, 183–192 (2011).21208907 10.1158/1078-0432.CCR-10-2195
884. Senzer N Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer Mol. Ther. 2012 20 679 686 10.1038/mt.2011.269 22186789
Senzer, N. et al. Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer. Mol. Ther. 20, 679–686 (2012).22186789 10.1038/mt.2011.269
885. Rocconi RP Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer Gynecol. Oncol. 2021 161 676 680 10.1016/j.ygyno.2021.03.009 33715892
Rocconi, R. P. et al. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecol. Oncol. 161, 676–680 (2021).33715892 10.1016/j.ygyno.2021.03.009
886. Martin CJ Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape Sci. Transl. Med 2020 12 eaay8456 10.1126/scitranslmed.aay8456 32213632
Martin, C. J. et al. Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci. Transl. Med 12, eaay8456 (2020).32213632 10.1126/scitranslmed.aay8456
887. Welsh BT Nonclinical Development of SRK-181: An Anti-Latent TGFbeta1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors Int J. Toxicol. 2021 40 226 241 10.1177/1091581821998945 33739172
Welsh, B. T. et al. Nonclinical Development of SRK-181: An Anti-Latent TGFbeta1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors. Int J. Toxicol. 40, 226–241 (2021).33739172 10.1177/1091581821998945
888. Li A Selective targeting of GARP-LTGFbeta axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8(+) T cell antitumor immunity J. Immunother. Cancer 2022 10 e005433 10.1136/jitc-2022-005433 36096533
Li, A. et al. Selective targeting of GARP-LTGFbeta axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8(+) T cell antitumor immunity. J. Immunother. Cancer 10, e005433 (2022).36096533 10.1136/jitc-2022-005433
889. Elez E Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial Ann. Oncol. 2015 26 132 140 10.1093/annonc/mdu474 25319061
Elez, E. et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann. Oncol. 26, 132–140 (2015).25319061 10.1093/annonc/mdu474
890. Hussain M Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer Clin. Cancer Res 2016 22 3192 3200 10.1158/1078-0432.CCR-15-2512 26839144
Hussain, M. et al. Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin. Cancer Res 22, 3192–3200 (2016).26839144 10.1158/1078-0432.CCR-15-2512
891. Khanna D STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease J. Rheumatol. 2021 48 1295 1298 10.3899/jrheum.191365 33004536
Khanna, D. et al. STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease. J. Rheumatol. 48, 1295–1298 (2021).33004536 10.3899/jrheum.191365
892. Uhl W Zuhlsdorf M Koernicke T Forssmann U Kovar A Safety, tolerability, and pharmacokinetics of the novel alphav-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses Invest N. Drugs 2014 32 347 354 10.1007/s10637-013-0038-5
Uhl, W., Zuhlsdorf, M., Koernicke, T., Forssmann, U. & Kovar, A. Safety, tolerability, and pharmacokinetics of the novel alphav-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Invest N. Drugs 32, 347–354 (2014).10.1007/s10637-013-0038-5
893. Manegold C Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer Invest N. Drugs 2013 31 175 182 10.1007/s10637-012-9842-6
Manegold, C. et al. Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Invest N. Drugs 31, 175–182 (2013).10.1007/s10637-012-9842-6
894. Vansteenkiste J Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO) Ann. Oncol. 2015 26 1734 1740 10.1093/annonc/mdv219 25939894
Vansteenkiste, J. et al. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Ann. Oncol. 26, 1734–1740 (2015).25939894 10.1093/annonc/mdv219
895. Vermorken JB Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part) Ann. Oncol. 2014 25 682 688 10.1093/annonc/mdu003 24567516
Vermorken, J. B. et al. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Ann. Oncol. 25, 682–688 (2014).24567516 10.1093/annonc/mdu003
896. Stupp R Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J. Clin. Oncol. 2010 28 2712 2718 10.1200/JCO.2009.26.6650 20439646
Stupp, R. et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 2712–2718 (2010).20439646 10.1200/JCO.2009.26.6650
897. Reardon DA Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J. Clin. Oncol. 2008 26 5610 5617 10.1200/JCO.2008.16.7510 18981465
Reardon, D. A. et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26, 5610–5617 (2008).18981465 10.1200/JCO.2008.16.7510
898. Nabors LB A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) Cancer 2012 118 5601 5607 10.1002/cncr.27585 22517399
Nabors, L. B. et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 118, 5601–5607 (2012).22517399 10.1002/cncr.27585
899. Gilbert MR Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery J. Neurooncol 2012 106 147 153 10.1007/s11060-011-0650-1 21739168
Gilbert, M. R. et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J. Neurooncol 106, 147–153 (2012).21739168 10.1007/s11060-011-0650-1
900. MacDonald TJ Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children’s Oncology Group Neuro Oncol. 2013 15 1438 1444 10.1093/neuonc/not058 24014381
MacDonald, T. J. et al. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol. 15, 1438–1444 (2013).24014381 10.1093/neuonc/not058
901. Nabors LB Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study Neuro Oncol. 2015 17 708 717 10.1093/neuonc/nou356 25762461
Nabors, L. B. et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 17, 708–717 (2015).25762461 10.1093/neuonc/nou356
902. Khasraw M Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial J. Neurooncol 2016 128 163 171 10.1007/s11060-016-2094-0 26935578
Khasraw, M. et al. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. J. Neurooncol 128, 163–171 (2016).26935578 10.1007/s11060-016-2094-0
903. Stupp R Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol. 2014 15 1100 1108 10.1016/S1470-2045(14)70379-1 25163906
Stupp, R. et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1100–1108 (2014).25163906 10.1016/S1470-2045(14)70379-1
904. Kim KB A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma Melanoma Res 2012 22 294 301 10.1097/CMR.0b013e32835312e4 22668797
Kim, K. B. et al. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res 22, 294–301 (2012).22668797 10.1097/CMR.0b013e32835312e4
905. Friess H A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer BMC Cancer 2006 6 285 10.1186/1471-2407-6-285 17156477
Friess, H. et al. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6, 285 (2006).17156477 10.1186/1471-2407-6-285
906. Bradley DA Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium Invest N. Drugs 2011 29 1432 1440 10.1007/s10637-010-9420-8
Bradley, D. A. et al. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest N. Drugs 29, 1432–1440 (2011).10.1007/s10637-010-9420-8
907. Alva A Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium Invest N. Drugs 2012 30 749 757 10.1007/s10637-010-9573-5
Alva, A. et al. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest N. Drugs 30, 749–757 (2012).10.1007/s10637-010-9573-5
908. Li C Increased activation of latent TGF-β1 by αVβ3 in human Crohn’s disease and fibrosis in TNBS colitis can be prevented by cilengitide Inflamm. Bowel Dis. 2013 19 2829 2839 10.1097/MIB.0b013e3182a8452e 24051933
Li, C. et al. Increased activation of latent TGF-β1 by αVβ3 in human Crohn’s disease and fibrosis in TNBS colitis can be prevented by cilengitide. Inflamm. Bowel Dis. 19, 2829–2839 (2013).24051933 10.1097/MIB.0b013e3182a8452e
909. Bagnato GL Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis Clin. Sci. (Lond.) 2018 132 231 242 10.1042/CS20171426 29237724
Bagnato, G. L. et al. Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis. Clin. Sci. (Lond.) 132, 231–242 (2018).29237724 10.1042/CS20171426
910. MacDonald WJ Broad spectrum integrin inhibitor GLPG-0187 bypasses immune evasion in colorectal cancer by TGF-β signaling mediated downregulation of PD-L1 Am. J. Cancer Res 2023 13 2938 2947 37559982
MacDonald, W. J. et al. Broad spectrum integrin inhibitor GLPG-0187 bypasses immune evasion in colorectal cancer by TGF-β signaling mediated downregulation of PD-L1. Am. J. Cancer Res 13, 2938–2947 (2023).37559982
911. Verschleiser B Pan-integrin inhibitor GLPG-0187 promotes T-cell killing of mismatch repair-deficient colorectal cancer cells by suppression of SMAD/TGF-β signaling Am. J. Cancer Res 2023 13 2878 2885 37559992
Verschleiser, B. et al. Pan-integrin inhibitor GLPG-0187 promotes T-cell killing of mismatch repair-deficient colorectal cancer cells by suppression of SMAD/TGF-β signaling. Am. J. Cancer Res 13, 2878–2885 (2023).37559992
912. Belmadani S A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II Am. J. Pathol. 2007 171 777 789 10.2353/ajpath.2007.070056 17640965
Belmadani, S. et al. A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am. J. Pathol. 171, 777–789 (2007).17640965 10.2353/ajpath.2007.070056
913. Ruschkowski BA Thrombospondin-1 Plays a Major Pathogenic Role in Experimental and Human Bronchopulmonary Dysplasia Am. J. Respir. Crit. Care Med 2022 205 685 699 10.1164/rccm.202104-1021OC 35021035
Ruschkowski, B. A. et al. Thrombospondin-1 Plays a Major Pathogenic Role in Experimental and Human Bronchopulmonary Dysplasia. Am. J. Respir. Crit. Care Med 205, 685–699 (2022).35021035 10.1164/rccm.202104-1021OC
914. Song S Sestrin2 remedies podocyte injury via orchestrating TSP-1/TGF-β1/Smad3 axis in diabetic kidney disease Cell Death Dis. 2022 13 663 10.1038/s41419-022-05120-0 35908070
Song, S. et al. Sestrin2 remedies podocyte injury via orchestrating TSP-1/TGF-β1/Smad3 axis in diabetic kidney disease. Cell Death Dis. 13, 663 (2022).35908070 10.1038/s41419-022-05120-0
915. Xie XS LSKL, a peptide antagonist of thrombospondin-1, attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction Arch. Pharm. Res 2010 33 275 284 10.1007/s12272-010-0213-6 20195829
Xie, X. S. et al. LSKL, a peptide antagonist of thrombospondin-1, attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction. Arch. Pharm. Res 33, 275–284 (2010).20195829 10.1007/s12272-010-0213-6
916. Lu A Miao M Schoeb TR Agarwal A Murphy-Ullrich JE Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy Am. J. Pathol. 2011 178 2573 2586 10.1016/j.ajpath.2011.02.039 21641382
Lu, A., Miao, M., Schoeb, T. R., Agarwal, A. & Murphy-Ullrich, J. E. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am. J. Pathol. 178, 2573–2586 (2011).21641382 10.1016/j.ajpath.2011.02.039
917. Zhang Y P2Y4/TSP-1/TGF-β1/pSmad2/3 pathway contributes to acute generalized seizures induced by kainic acid Brain Res Bull. 2019 149 106 119 10.1016/j.brainresbull.2019.04.004 31005663
Zhang, Y. et al. P2Y4/TSP-1/TGF-β1/pSmad2/3 pathway contributes to acute generalized seizures induced by kainic acid. Brain Res Bull. 149, 106–119 (2019).31005663 10.1016/j.brainresbull.2019.04.004
918. Liao F LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats Exp. Ther. Med 2016 12 2537 2543 10.3892/etm.2016.3640 27698755
Liao, F. et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp. Ther. Med 12, 2537–2543 (2016).27698755 10.3892/etm.2016.3640
919. Jiang N Blockade of thrombospondin-1 ameliorates high glucose-induced peritoneal fibrosis through downregulation of TGF-β1/Smad3 signaling pathway J. Cell Physiol. 2020 235 364 379 10.1002/jcp.28976 31236971
Jiang, N. et al. Blockade of thrombospondin-1 ameliorates high glucose-induced peritoneal fibrosis through downregulation of TGF-β1/Smad3 signaling pathway. J. Cell Physiol. 235, 364–379 (2020).31236971 10.1002/jcp.28976
920. Narmada BC Chia SM Tucker-Kellogg L Yu H HGF regulates the activation of TGF-β1 in rat hepatocytes and hepatic stellate cells J. Cell Physiol. 2013 228 393 401 10.1002/jcp.24143 22718393
Narmada, B. C., Chia, S. M., Tucker-Kellogg, L. & Yu, H. HGF regulates the activation of TGF-β1 in rat hepatocytes and hepatic stellate cells. J. Cell Physiol. 228, 393–401 (2013).22718393 10.1002/jcp.24143
921. Kondou H A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo J. Hepatol. 2003 39 742 748 10.1016/S0168-8278(03)00377-5 14568256
Kondou, H. et al. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. J. Hepatol. 39, 742–748 (2003).14568256 10.1016/S0168-8278(03)00377-5
922. Xu X Investigating the potential of LSKL peptide as a novel hypertrophic scar treatment Biomed. Pharmacother. 2020 124 109824 10.1016/j.biopha.2020.109824 31972355
Xu, X. et al. Investigating the potential of LSKL peptide as a novel hypertrophic scar treatment. Biomed. Pharmacother. 124, 109824 (2020).31972355 10.1016/j.biopha.2020.109824
923. Kuroki H Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model Br. J. Surg. 2015 102 813 825 10.1002/bjs.9765 25866938
Kuroki, H. et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br. J. Surg. 102, 813–825 (2015).25866938 10.1002/bjs.9765
924. Lu A Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma Am. J. Pathol. 2016 186 678 690 10.1016/j.ajpath.2015.11.003 26801735
Lu, A. et al. Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma. Am. J. Pathol. 186, 678–690 (2016).26801735 10.1016/j.ajpath.2015.11.003
925. Fu PY Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis Carcinogenesis 2020 41 950 960 10.1093/carcin/bgz171 31587040
Fu, P. Y. et al. Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis. Carcinogenesis 41, 950–960 (2020).31587040 10.1093/carcin/bgz171
926. Gu J Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop J. Exp. Clin. Cancer Res 2022 41 259 10.1186/s13046-022-02471-6 36008860
Gu, J. et al. Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop. J. Exp. Clin. Cancer Res 41, 259 (2022).36008860 10.1186/s13046-022-02471-6
927. Daniel C Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo Am. J. Pathol. 2003 163 1185 1192 10.1016/S0002-9440(10)63478-5 12937160
Daniel, C. et al. Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am. J. Pathol. 163, 1185–1192 (2003).12937160 10.1016/S0002-9440(10)63478-5
928. Agin M Yucel A Gumus M Yuksekkaya HA Tumgor G The Effect of Enteral Nutrition Support Rich in TGF-β in the Treatment of Inflammatory Bowel Disease in Childhood Med. (Kaunas.) 2019 55 620
Agin, M., Yucel, A., Gumus, M., Yuksekkaya, H. A. & Tumgor, G. The Effect of Enteral Nutrition Support Rich in TGF-β in the Treatment of Inflammatory Bowel Disease in Childhood. Med. (Kaunas.) 55, 620 (2019).
929. Fell JM Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease Aliment Pharm. Ther. 2000 14 281 289 10.1046/j.1365-2036.2000.00707.x
Fell, J. M. et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharm. Ther. 14, 281–289 (2000).10.1046/j.1365-2036.2000.00707.x
930. Hartman C Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn’s disease Isr. Med Assoc. J. 2008 10 503 507 18751627
Hartman, C. et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn’s disease. Isr. Med Assoc. J. 10, 503–507 (2008).18751627
931. Ferreira TMR Effect of Oral Nutrition Supplements and TGF-β2 on Nutrition and Inflammatory Patterns in Patients With Active Crohn’s Disease Nutr. Clin. Pr. 2020 35 885 893 10.1002/ncp.10448
Ferreira, T. M. R. et al. Effect of Oral Nutrition Supplements and TGF-β2 on Nutrition and Inflammatory Patterns in Patients With Active Crohn’s Disease. Nutr. Clin. Pr. 35, 885–893 (2020).10.1002/ncp.10448
932. Borrelli O Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial Clin. Gastroenterol. Hepatol. 2006 4 744 753 10.1016/j.cgh.2006.03.010 16682258
Borrelli, O. et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. 4, 744–753 (2006).16682258 10.1016/j.cgh.2006.03.010
933. Pigneur B Mucosal Healing and Bacterial Composition in Response to Enteral Nutrition Vs Steroid-based Induction Therapy-A Randomised Prospective Clinical Trial in Children With Crohn’s Disease J. Crohns Colitis 2019 13 846 855 10.1093/ecco-jcc/jjy207 30541015
Pigneur, B. et al. Mucosal Healing and Bacterial Composition in Response to Enteral Nutrition Vs Steroid-based Induction Therapy-A Randomised Prospective Clinical Trial in Children With Crohn’s Disease. J. Crohns Colitis 13, 846–855 (2019).30541015 10.1093/ecco-jcc/jjy207
934. Beaupel N Preoperative oral polymeric diet enriched with transforming growth factor-beta 2 (Modulen) could decrease postoperative morbidity after surgery for complicated ileocolonic Crohn’s disease Scand. J. Gastroenterol. 2017 52 5 10 10.1080/00365521.2016.1221994 27553420
Beaupel, N. et al. Preoperative oral polymeric diet enriched with transforming growth factor-beta 2 (Modulen) could decrease postoperative morbidity after surgery for complicated ileocolonic Crohn’s disease. Scand. J. Gastroenterol. 52, 5–10 (2017).27553420 10.1080/00365521.2016.1221994
935. Okamoto A Suppression of serum IgE response and systemic anaphylaxis in a food allergy model by orally administered high-dose TGF-beta Int Immunol. 2005 17 705 712 10.1093/intimm/dxh250 15837712
Okamoto, A. et al. Suppression of serum IgE response and systemic anaphylaxis in a food allergy model by orally administered high-dose TGF-beta. Int Immunol. 17, 705–712 (2005).15837712 10.1093/intimm/dxh250
936. Rekima A Long-term reduction in food allergy susceptibility in mice by combining breastfeeding-induced tolerance and TGF-β-enriched formula after weaning Clin. Exp. Allergy 2017 47 565 576 10.1111/cea.12864 27883236
Rekima, A. et al. Long-term reduction in food allergy susceptibility in mice by combining breastfeeding-induced tolerance and TGF-β-enriched formula after weaning. Clin. Exp. Allergy 47, 565–576 (2017).27883236 10.1111/cea.12864
937. Penttila I Effects of transforming growth factor-beta and formula feeding on systemic immune responses to dietary beta-lactoglobulin in allergy-prone rats Pediatr. Res 2006 59 650 655 10.1203/01.pdr.0000203149.75465.74 16627876
Penttila, I. Effects of transforming growth factor-beta and formula feeding on systemic immune responses to dietary beta-lactoglobulin in allergy-prone rats. Pediatr. Res 59, 650–655 (2006).16627876 10.1203/01.pdr.0000203149.75465.74
938. Verhasselt V Neonatal tolerance under breastfeeding influence: the presence of allergen and transforming growth factor-beta in breast milk protects the progeny from allergic asthma J. Pediatr. 2010 156 S16 S20 10.1016/j.jpeds.2009.11.015 20105659
Verhasselt, V. Neonatal tolerance under breastfeeding influence: the presence of allergen and transforming growth factor-beta in breast milk protects the progeny from allergic asthma. J. Pediatr. 156, S16–S20 (2010).20105659 10.1016/j.jpeds.2009.11.015
939. Morita Y TGF-β Concentration in Breast Milk is Associated With the Development of Eczema in Infants Front Pediatr. 2018 6 162 10.3389/fped.2018.00162 29911097
Morita, Y. et al. TGF-β Concentration in Breast Milk is Associated With the Development of Eczema in Infants. Front Pediatr. 6, 162 (2018).29911097 10.3389/fped.2018.00162
940. Saarinen KM Vaarala O Klemetti P Savilahti E Transforming growth factor-beta1 in mothers’ colostrum and immune responses to cows’ milk proteins in infants with cows’ milk allergy J. Allergy Clin. Immunol. 1999 104 1093 1098 10.1016/S0091-6749(99)70094-1 10550758
Saarinen, K. M., Vaarala, O., Klemetti, P. & Savilahti, E. Transforming growth factor-beta1 in mothers’ colostrum and immune responses to cows’ milk proteins in infants with cows’ milk allergy. J. Allergy Clin. Immunol. 104, 1093–1098 (1999).10550758 10.1016/S0091-6749(99)70094-1
941. Ferguson MW Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies Lancet 2009 373 1264 1274 10.1016/S0140-6736(09)60322-6 19362676
Ferguson, M. W. et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 373, 1264–1274 (2009).19362676 10.1016/S0140-6736(09)60322-6
942. So K Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial Plast. Reconstr. Surg. 2011 128 163 172 10.1097/PRS.0b013e318217429b 21701333
So, K. et al. Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial. Plast. Reconstr. Surg. 128, 163–172 (2011).21701333 10.1097/PRS.0b013e318217429b
943. Bush J Scar-improving efficacy of avotermin administered into the wound margins of skin incisions as evaluated by a randomized, double-blind, placebo-controlled, phase II clinical trial Plast. Reconstr. Surg. 2010 126 1604 1615 10.1097/PRS.0b013e3181ef8e66 21042116
Bush, J. et al. Scar-improving efficacy of avotermin administered into the wound margins of skin incisions as evaluated by a randomized, double-blind, placebo-controlled, phase II clinical trial. Plast. Reconstr. Surg. 126, 1604–1615 (2010).21042116 10.1097/PRS.0b013e3181ef8e66
944. McCollum PT Randomized phase II clinical trial of avotermin versus placebo for scar improvement Br. J. Surg. 2011 98 925 934 10.1002/bjs.7438 21618480
McCollum, P. T. et al. Randomized phase II clinical trial of avotermin versus placebo for scar improvement. Br. J. Surg. 98, 925–934 (2011).21618480 10.1002/bjs.7438
945. Robson MC Safety and effect of transforming growth factor-beta(2) for treatment of venous stasis ulcers Wound Repair Regen. 1995 3 157 167 10.1046/j.1524-475X.1995.30207.x 17173644
Robson, M. C. et al. Safety and effect of transforming growth factor-beta(2) for treatment of venous stasis ulcers. Wound Repair Regen. 3, 157–167 (1995).17173644 10.1046/j.1524-475X.1995.30207.x
946. Wang X Demineralized bone matrix combined bone marrow mesenchymal stem cells, bone morphogenetic protein-2 and transforming growth factor-β3 gene promoted pig cartilage defect repair PLoS One 2014 9 e116061 10.1371/journal.pone.0116061 25545777
Wang, X. et al. Demineralized bone matrix combined bone marrow mesenchymal stem cells, bone morphogenetic protein-2 and transforming growth factor-β3 gene promoted pig cartilage defect repair. PLoS One 9, e116061 (2014).25545777 10.1371/journal.pone.0116061
947. Luo Z Mechano growth factor (MGF) and transforming growth factor (TGF)-β3 functionalized silk scaffolds enhance articular hyaline cartilage regeneration in rabbit model Biomaterials 2015 52 463 475 10.1016/j.biomaterials.2015.01.001 25818452
Luo, Z. et al. Mechano growth factor (MGF) and transforming growth factor (TGF)-β3 functionalized silk scaffolds enhance articular hyaline cartilage regeneration in rabbit model. Biomaterials 52, 463–475 (2015).25818452 10.1016/j.biomaterials.2015.01.001
948. Kuruvilla AP Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice Proc. Natl Acad. Sci. USA 1991 88 2918 2921 10.1073/pnas.88.7.2918 2011600
Kuruvilla, A. P. et al. Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc. Natl Acad. Sci. USA 88, 2918–2921 (1991).2011600 10.1073/pnas.88.7.2918
949. Srivastava V Khanna M Sharma S Kumar B Resolution of immune response by recombinant transforming growth factor-beta (rTGF-β) during influenza A virus infection Indian J. Med Res 2012 136 641 648 23168705
Srivastava, V., Khanna, M., Sharma, S. & Kumar, B. Resolution of immune response by recombinant transforming growth factor-beta (rTGF-β) during influenza A virus infection. Indian J. Med Res 136, 641–648 (2012).23168705
950. Morris JC Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma PLoS One 2014 9 e90353 10.1371/journal.pone.0090353 24618589
Morris, J. C. et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 9, e90353 (2014).24618589 10.1371/journal.pone.0090353
951. Formenti SC Focal Irradiation and Systemic TGFbeta Blockade in Metastatic Breast Cancer Clin. Cancer Res 2018 24 2493 2504 10.1158/1078-0432.CCR-17-3322 29476019
Formenti, S. C. et al. Focal Irradiation and Systemic TGFbeta Blockade in Metastatic Breast Cancer. Clin. Cancer Res 24, 2493–2504 (2018).29476019 10.1158/1078-0432.CCR-17-3322
952. Rice LM Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients J. Clin. Invest 2015 125 2795 2807 10.1172/JCI77958 26098215
Rice, L. M. et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J. Clin. Invest 125, 2795–2807 (2015).26098215 10.1172/JCI77958
953. Trachtman H A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis Kidney Int 2011 79 1236 1243 10.1038/ki.2011.33 21368745
Trachtman, H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79, 1236–1243 (2011).21368745 10.1038/ki.2011.33
954. Lacouture ME Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008) Cancer Immunol. Immunother. 2015 64 437 446 10.1007/s00262-015-1653-0 25579378
Lacouture, M. E. et al. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol. Immunother. 64, 437–446 (2015).25579378 10.1007/s00262-015-1653-0
955. Bauer TM Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors J. Immunother. Cancer 2023 11 e007353 10.1136/jitc-2023-007353 38030303
Bauer, T. M. et al. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. J. Immunother. Cancer 11, e007353 (2023).38030303 10.1136/jitc-2023-007353
956. Denton CP Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192 Arthritis Rheum. 2007 56 323 333 10.1002/art.22289 17195236
Denton, C. P. et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56, 323–333 (2007).17195236 10.1002/art.22289
957. Voelker J Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy J. Am. Soc. Nephrol. 2017 28 953 962 10.1681/ASN.2015111230 27647855
Voelker, J. et al. Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy. J. Am. Soc. Nephrol. 28, 953–962 (2017).27647855 10.1681/ASN.2015111230
958. Mascarenhas J A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis Clin. Cancer Res 2023 29 3622 3632 10.1158/1078-0432.CCR-23-0276 37439808
Mascarenhas, J. et al. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis. Clin. Cancer Res 29, 3622–3632 (2023).37439808 10.1158/1078-0432.CCR-23-0276
959. Li Y Neutralization of excessive levels of active TGF-β1 reduces MSC recruitment and differentiation to mitigate peritendinous adhesion Bone Res 2023 11 24 10.1038/s41413-023-00252-1 37156778
Li, Y. et al. Neutralization of excessive levels of active TGF-β1 reduces MSC recruitment and differentiation to mitigate peritendinous adhesion. Bone Res 11, 24 (2023).37156778 10.1038/s41413-023-00252-1
960. Lu L The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation J. Am. Coll. Surg. 2005 201 391 397 10.1016/j.jamcollsurg.2005.03.032 16125072
Lu, L. et al. The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J. Am. Coll. Surg. 201, 391–397 (2005).16125072 10.1016/j.jamcollsurg.2005.03.032
961. Wang L Aberrant Transforming Growth Factor-β Activation Recruits Mesenchymal Stem Cells During Prostatic Hyperplasia Stem Cells Transl. Med 2017 6 394 404 10.5966/sctm.2015-0411 28191756
Wang, L. et al. Aberrant Transforming Growth Factor-β Activation Recruits Mesenchymal Stem Cells During Prostatic Hyperplasia. Stem Cells Transl. Med 6, 394–404 (2017).28191756 10.5966/sctm.2015-0411
962. Deng S Zhang H Han W Guo C Deng C Transforming Growth Factor-β-Neutralizing Antibodies Improve Alveolarization in the Oxygen-Exposed Newborn Mouse Lung J. Interferon Cytokine Res 2019 39 106 116 10.1089/jir.2018.0080 30657417
Deng, S., Zhang, H., Han, W., Guo, C. & Deng, C. Transforming Growth Factor-β-Neutralizing Antibodies Improve Alveolarization in the Oxygen-Exposed Newborn Mouse Lung. J. Interferon Cytokine Res 39, 106–116 (2019).30657417 10.1089/jir.2018.0080
963. Nelson CA Inhibiting TGF-β activity improves respiratory function in mdx mice Am. J. Pathol. 2011 178 2611 2621 10.1016/j.ajpath.2011.02.024 21641384
Nelson, C. A. et al. Inhibiting TGF-β activity improves respiratory function in mdx mice. Am. J. Pathol. 178, 2611–2621 (2011).21641384 10.1016/j.ajpath.2011.02.024
964. Cook JR Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome Arterioscler Thromb. Vasc. Biol. 2015 35 911 917 10.1161/ATVBAHA.114.305150 25614286
Cook, J. R. et al. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome. Arterioscler Thromb. Vasc. Biol. 35, 911–917 (2015).25614286 10.1161/ATVBAHA.114.305150
965. Wang X Aberrant TGF-β activation in bone tendon insertion induces enthesopathy-like disease J. Clin. Invest 2018 128 846 860 10.1172/JCI96186 29355842
Wang, X. et al. Aberrant TGF-β activation in bone tendon insertion induces enthesopathy-like disease. J. Clin. Invest 128, 846–860 (2018).29355842 10.1172/JCI96186
966. Becerikli M TGF-beta pathway inhibition as the therapeutic acceleration of diabetic bone regeneration J. Orthop. Res 2022 40 1810 1826 10.1002/jor.25212 34775640
Becerikli, M. et al. TGF-beta pathway inhibition as the therapeutic acceleration of diabetic bone regeneration. J. Orthop. Res 40, 1810–1826 (2022).34775640 10.1002/jor.25212
967. Sahbani K Cardozo CP Bauman WA Tawfeek HA Inhibition of TGF-β Signaling Attenuates Disuse-induced Trabecular Bone Loss After Spinal Cord Injury in Male Mice Endocrinology 2022 163 bqab230 10.1210/endocr/bqab230 34791098
Sahbani, K., Cardozo, C. P., Bauman, W. A. & Tawfeek, H. A. Inhibition of TGF-β Signaling Attenuates Disuse-induced Trabecular Bone Loss After Spinal Cord Injury in Male Mice. Endocrinology 163, bqab230 (2022).34791098 10.1210/endocr/bqab230
968. Grafe I Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta Nat. Med 2014 20 670 675 10.1038/nm.3544 24793237
Grafe, I. et al. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta. Nat. Med 20, 670–675 (2014).24793237 10.1038/nm.3544
969. Wahl SM Allen JB Costa GL Wong HL Dasch JR Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta J. Exp. Med 1993 177 225 230 10.1084/jem.177.1.225 8418203
Wahl, S. M., Allen, J. B., Costa, G. L., Wong, H. L. & Dasch, J. R. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J. Exp. Med 177, 225–230 (1993).8418203 10.1084/jem.177.1.225
970. Xie L Systemic neutralization of TGF-β attenuates osteoarthritis Ann. N. Y Acad. Sci. 2016 1376 53 64 10.1111/nyas.13000 26837060
Xie, L. et al. Systemic neutralization of TGF-β attenuates osteoarthritis. Ann. N. Y Acad. Sci. 1376, 53–64 (2016).26837060 10.1111/nyas.13000
971. Ferreira RR In Chagas disease, transforming growth factor beta neutralization reduces Trypanosoma cruzi infection and improves cardiac performance Front Cell Infect. Microbiol 2022 12 1017040 10.3389/fcimb.2022.1017040 36530434
Ferreira, R. R. et al. In Chagas disease, transforming growth factor beta neutralization reduces Trypanosoma cruzi infection and improves cardiac performance. Front Cell Infect. Microbiol 12, 1017040 (2022).36530434 10.3389/fcimb.2022.1017040
972. Ravi R Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy Nat. Commun. 2018 9 741 10.1038/s41467-017-02696-6 29467463
Ravi, R. et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy. Nat. Commun. 9, 741 (2018).29467463 10.1038/s41467-017-02696-6
973. Paz-Ares L Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial J. Thorac. Oncol. 2020 15 1210 1222 10.1016/j.jtho.2020.03.003 32173464
Paz-Ares, L. et al. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J. Thorac. Oncol. 15, 1210–1222 (2020).32173464 10.1016/j.jtho.2020.03.003
974. Kang YK Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFbeta and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer Clin. Cancer Res 2020 26 3202 3210 10.1158/1078-0432.CCR-19-3806 32299818
Kang, Y. K. et al. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFbeta and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. Clin. Cancer Res 26, 3202–3210 (2020).32299818 10.1158/1078-0432.CCR-19-3806
975. Yoo C Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer J. Immunother. Cancer 2020 8 e000564 10.1136/jitc-2020-000564 32461347
Yoo, C. et al. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer. J. Immunother. Cancer 8, e000564 (2020).32461347 10.1136/jitc-2020-000564
976. Redman JM Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-beta blockade in HPV-unrelated head and neck cancer J. Clin. Invest 2022 132 e161400 10.1172/JCI161400 35727629
Redman, J. M. et al. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-beta blockade in HPV-unrelated head and neck cancer. J. Clin. Invest 132, e161400 (2022).35727629 10.1172/JCI161400
977. Strauss J Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFbeta, in Advanced Solid Tumors Clin. Cancer Res 2018 24 1287 1295 10.1158/1078-0432.CCR-17-2653 29298798
Strauss, J. et al. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFbeta, in Advanced Solid Tumors. Clin. Cancer Res 24, 1287–1295 (2018).29298798 10.1158/1078-0432.CCR-17-2653
978. Wu ZH Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy Cancers (Basel) 2022 14 4964 10.3390/cancers14194964 36230887
Wu, Z. H. et al. Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy. Cancers (Basel) 14, 4964 (2022).36230887 10.3390/cancers14194964
979. Chen X Secretion of bispecific protein of anti-PD-1 fused with TGF-beta trap enhances antitumor efficacy of CAR-T cell therapy Mol. Ther. Oncolyt. 2021 21 144 157 10.1016/j.omto.2021.03.014
Chen, X. et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-beta trap enhances antitumor efficacy of CAR-T cell therapy. Mol. Ther. Oncolyt. 21, 144–157 (2021).10.1016/j.omto.2021.03.014
980. Fukushima K The use of an antifibrosis agent to improve muscle recovery after laceration Am. J. Sports Med 2001 29 394 402 10.1177/03635465010290040201 11476375
Fukushima, K. et al. The use of an antifibrosis agent to improve muscle recovery after laceration. Am. J. Sports Med 29, 394–402 (2001).11476375 10.1177/03635465010290040201
981. Ruehle MA Decorin-supplemented collagen hydrogels for the co-delivery of bone morphogenetic protein-2 and microvascular fragments to a composite bone-muscle injury model with impaired vascularization Acta Biomater. 2019 93 210 221 10.1016/j.actbio.2019.01.045 30685477
Ruehle, M. A. et al. Decorin-supplemented collagen hydrogels for the co-delivery of bone morphogenetic protein-2 and microvascular fragments to a composite bone-muscle injury model with impaired vascularization. Acta Biomater. 93, 210–221 (2019).30685477 10.1016/j.actbio.2019.01.045
982. Ahmed Z Decorin blocks scarring and cystic cavitation in acute and induces scar dissolution in chronic spinal cord wounds Neurobiol. Dis. 2014 64 163 176 10.1016/j.nbd.2013.12.008 24384090
Ahmed, Z. et al. Decorin blocks scarring and cystic cavitation in acute and induces scar dissolution in chronic spinal cord wounds. Neurobiol. Dis. 64, 163–176 (2014).24384090 10.1016/j.nbd.2013.12.008
983. Qiu SS Dotor J Hontanilla B Effect of P144® (Anti-TGF-β) in an “In Vivo” Human Hypertrophic Scar Model in Nude Mice PLoS One 2015 10 e0144489 10.1371/journal.pone.0144489 26720517
Qiu, S. S., Dotor, J. & Hontanilla, B. Effect of P144® (Anti-TGF-β) in an “In Vivo” Human Hypertrophic Scar Model in Nude Mice. PLoS One 10, e0144489 (2015).26720517 10.1371/journal.pone.0144489
984. Arce C Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome Arterioscler Thromb. Vasc. Biol. 2021 41 e440 e452 10.1161/ATVBAHA.121.316496 34162229
Arce, C. et al. Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome. Arterioscler Thromb. Vasc. Biol. 41, e440–e452 (2021).34162229 10.1161/ATVBAHA.121.316496
985. Li L Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction Am. J. Physiol. Heart Circ. Physiol. 2009 297 H1504 H1513 10.1152/ajpheart.00194.2009 19684189
Li, L. et al. Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction. Am. J. Physiol. Heart Circ. Physiol. 297, H1504–H1513 (2009).19684189 10.1152/ajpheart.00194.2009
986. Yan W Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways Hum. Gene Ther. 2009 20 1190 1200 10.1089/hum.2008.204 19697998
Yan, W. et al. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum. Gene Ther. 20, 1190–1200 (2009).19697998 10.1089/hum.2008.204
987. Hermida N A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats Cardiovasc Res 2009 81 601 609 10.1093/cvr/cvn315 19019833
Hermida, N. et al. A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 81, 601–609 (2009).19019833 10.1093/cvr/cvn315
988. Nili N Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function: potential mechanism for inhibition of intimal hyperplasia after balloon angioplasty Am. J. Pathol. 2003 163 869 878 10.1016/S0002-9440(10)63447-5 12937128
Nili, N. et al. Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function: potential mechanism for inhibition of intimal hyperplasia after balloon angioplasty. Am. J. Pathol. 163, 869–878 (2003).12937128 10.1016/S0002-9440(10)63447-5
989. Recalde S Transforming growth factor-β inhibition decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides Invest Ophthalmol. Vis. Sci. 2011 52 7090 7097 10.1167/iovs.11-7300 21810978
Recalde, S. et al. Transforming growth factor-β inhibition decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides. Invest Ophthalmol. Vis. Sci. 52, 7090–7097 (2011).21810978 10.1167/iovs.11-7300
990. Aojula A Diffusion tensor imaging with direct cytopathological validation: characterisation of decorin treatment in experimental juvenile communicating hydrocephalus Fluids Barriers CNS 2016 13 9 10.1186/s12987-016-0033-2 27246837
Aojula, A. et al. Diffusion tensor imaging with direct cytopathological validation: characterisation of decorin treatment in experimental juvenile communicating hydrocephalus. Fluids Barriers CNS 13, 9 (2016).27246837 10.1186/s12987-016-0033-2
991. Botfield H Decorin prevents the development of juvenile communicating hydrocephalus Brain 2013 136 2842 2858 10.1093/brain/awt203 23983032
Botfield, H. et al. Decorin prevents the development of juvenile communicating hydrocephalus. Brain 136, 2842–2858 (2013).23983032 10.1093/brain/awt203
992. Murillo-Cuesta S Transforming growth factor β1 inhibition protects from noise-induced hearing loss Front Aging Neurosci. 2015 7 32 25852546
Murillo-Cuesta, S. et al. Transforming growth factor β1 inhibition protects from noise-induced hearing loss. Front Aging Neurosci. 7, 32 (2015).25852546
993. Border WA Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease Nature 1992 360 361 364 10.1038/360361a0 1280332
Border, W. A. et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360, 361–364 (1992).1280332 10.1038/360361a0
994. Juárez P Soluble betaglycan reduces renal damage progression in db/db mice Am. J. Physiol. Ren. Physiol. 2007 292 F321 F329 10.1152/ajprenal.00264.2006
Juárez, P. et al. Soluble betaglycan reduces renal damage progression in db/db mice. Am. J. Physiol. Ren. Physiol. 292, F321–F329 (2007).10.1152/ajprenal.00264.2006
995. Baltanás A A synthetic peptide from transforming growth factor-β1 type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats Antioxid. Redox Signal 2013 19 1607 1618 10.1089/ars.2012.4653 23350688
Baltanás, A. et al. A synthetic peptide from transforming growth factor-β1 type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats. Antioxid. Redox Signal 19, 1607–1618 (2013).23350688 10.1089/ars.2012.4653
996. Li D TGF-β1 peptide-based inhibitor P144 ameliorates renal fibrosis after ischemia-reperfusion injury by modulating alternatively activated macrophages Cell Prolif. 2022 55 e13299 10.1111/cpr.13299 35762283
Li, D. et al. TGF-β1 peptide-based inhibitor P144 ameliorates renal fibrosis after ischemia-reperfusion injury by modulating alternatively activated macrophages. Cell Prolif. 55, e13299 (2022).35762283 10.1111/cpr.13299
997. Zhang Y McCormick LL Gilliam AC Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma J. Invest Dermatol 2003 121 713 719 10.1046/j.1523-1747.2003.12517.x 14632186
Zhang, Y., McCormick, L. L. & Gilliam, A. C. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J. Invest Dermatol 121, 713–719 (2003).14632186 10.1046/j.1523-1747.2003.12517.x
998. Jang YO Effect of Function-Enhanced Mesenchymal Stem Cells Infected With Decorin-Expressing Adenovirus on Hepatic Fibrosis Stem Cells Transl. Med 2016 5 1247 1256 10.5966/sctm.2015-0323 27365486
Jang, Y. O. et al. Effect of Function-Enhanced Mesenchymal Stem Cells Infected With Decorin-Expressing Adenovirus on Hepatic Fibrosis. Stem Cells Transl. Med 5, 1247–1256 (2016).27365486 10.5966/sctm.2015-0323
999. Kolb M Margetts PJ Sime PJ Gauldie J Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung Am. J. Physiol. Lung Cell Mol. Physiol. 2001 280 L1327 L1334 10.1152/ajplung.2001.280.6.L1327 11350814
Kolb, M., Margetts, P. J., Sime, P. J. & Gauldie, J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am. J. Physiol. Lung Cell Mol. Physiol. 280, L1327–L1334 (2001).11350814 10.1152/ajplung.2001.280.6.L1327
1000. Ezquerro IJ A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury Cytokine 2003 22 12 20 10.1016/S1043-4666(03)00101-7 12946101
Ezquerro, I. J. et al. A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 22, 12–20 (2003).12946101 10.1016/S1043-4666(03)00101-7
1001. Hirsch CS Ellner JJ Blinkhorn R Toossi Z In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta Proc. Natl Acad. Sci. USA 1997 94 3926 3931 10.1073/pnas.94.8.3926 9108081
Hirsch, C. S., Ellner, J. J., Blinkhorn, R. & Toossi, Z. In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta. Proc. Natl Acad. Sci. USA 94, 3926–3931 (1997).9108081 10.1073/pnas.94.8.3926
1002. Bandyopadhyay A Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft Cancer Res 2002 62 4690 4695 12183427
Bandyopadhyay, A. et al. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 62, 4690–4695 (2002).12183427
1003. Liu Z An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation Hum. Gene Ther. 2017 28 667 680 10.1089/hum.2017.033 28530155
Liu, Z. et al. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation. Hum. Gene Ther. 28, 667–680 (2017).28530155 10.1089/hum.2017.033
1004. Zhang W Efficacy of an Oncolytic Adenovirus Driven by a Chimeric Promoter and Armed with Decorin Against Renal Cell Carcinoma Hum. Gene Ther. 2020 31 651 663 10.1089/hum.2019.352 32216478
Zhang, W. et al. Efficacy of an Oncolytic Adenovirus Driven by a Chimeric Promoter and Armed with Decorin Against Renal Cell Carcinoma. Hum. Gene Ther. 31, 651–663 (2020).32216478 10.1089/hum.2019.352
1005. Yang Y Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases Hum. Gene Ther. 2015 26 813 825 10.1089/hum.2015.098 26467629
Yang, Y. et al. Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases. Hum. Gene Ther. 26, 813–825 (2015).26467629 10.1089/hum.2015.098
1006. Narayan V PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial Nat. Med 2022 28 724 734 10.1038/s41591-022-01726-1 35314843
Narayan, V. et al. PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med 28, 724–734 (2022).35314843 10.1038/s41591-022-01726-1
1007. Wang FL TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer Cancer Immunol. Immunother. 2007 56 1785 1793 10.1007/s00262-007-0322-3 17473921
Wang, F. L. et al. TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer. Cancer Immunol. Immunother. 56, 1785–1793 (2007).17473921 10.1007/s00262-007-0322-3
1008. Tian F Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice Cancer Lett. 2008 271 333 341 10.1016/j.canlet.2008.06.025 18675506
Tian, F. et al. Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice. Cancer Lett. 271, 333–341 (2008).18675506 10.1016/j.canlet.2008.06.025
1009. Reid RR Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-beta receptor II J. Plast. Reconstr. Aesthet. Surg. 2007 60 64 72 10.1016/j.bjps.2005.12.026 17126268
Reid, R. R. et al. Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-beta receptor II. J. Plast. Reconstr. Aesthet. Surg. 60, 64–72 (2007). discussion 73-64.17126268 10.1016/j.bjps.2005.12.026
1010. Santini V Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes Clin. Cancer Res 2019 25 6976 6985 10.1158/1078-0432.CCR-19-1338 31481511
Santini, V. et al. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin. Cancer Res 25, 6976–6985 (2019).31481511 10.1158/1078-0432.CCR-19-1338
1011. Nadal E A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer BMC Cancer 2023 23 708 10.1186/s12885-023-11153-1 37507657
Nadal, E. et al. A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. BMC Cancer 23, 708 (2023).37507657 10.1186/s12885-023-11153-1
1012. Kelley RK A Phase 2 Study of Galunisertib (TGF-beta1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Clin. Transl. Gastroenterol. 2019 10 e00056 10.14309/ctg.0000000000000056 31295152
Kelley, R. K. et al. A Phase 2 Study of Galunisertib (TGF-beta1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clin. Transl. Gastroenterol. 10, e00056 (2019).31295152 10.14309/ctg.0000000000000056
1013. Faivre S Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma Liver Int 2019 39 1468 1477 10.1111/liv.14113 30963691
Faivre, S. et al. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int 39, 1468–1477 (2019).30963691 10.1111/liv.14113
1014. Yamazaki T Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial Lancet Oncol. 2022 23 1189 1200 10.1016/S1470-2045(22)00446-6 35952709
Yamazaki, T. et al. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol. 23, 1189–1200 (2022).35952709 10.1016/S1470-2045(22)00446-6
1015. Melisi D Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer Br. J. Cancer 2018 119 1208 1214 10.1038/s41416-018-0246-z 30318515
Melisi, D. et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br. J. Cancer 119, 1208–1214 (2018).30318515 10.1038/s41416-018-0246-z
1016. Wick A Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma Invest N. Drugs 2020 38 1570 1579 10.1007/s10637-020-00910-9
Wick, A. et al. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Invest N. Drugs 38, 1570–1579 (2020).10.1007/s10637-020-00910-9
1017. Brandes AA A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma Neuro Oncol. 2016 18 1146 1156 10.1093/neuonc/now009 26902851
Brandes, A. A. et al. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol. 18, 1146–1156 (2016).26902851 10.1093/neuonc/now009
1018. Kovacs RJ Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study Cardiovasc Toxicol. 2015 15 309 323 10.1007/s12012-014-9297-4 25488804
Kovacs, R. J. et al. Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 15, 309–323 (2015).25488804 10.1007/s12012-014-9297-4
1019. Tolcher AW A phase 1 study of anti-TGFbeta receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors Cancer Chemother. Pharm. 2017 79 673 680 10.1007/s00280-017-3245-5
Tolcher, A. W. et al. A phase 1 study of anti-TGFbeta receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother. Pharm. 79, 673–680 (2017).10.1007/s00280-017-3245-5
1020. Suzuki E A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection Cancer Res 2007 67 2351 2359 10.1158/0008-5472.CAN-06-2389 17332368
Suzuki, E. et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67, 2351–2359 (2007).17332368 10.1158/0008-5472.CAN-06-2389
1021. Uhl M SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo Cancer Res 2004 64 7954 7961 10.1158/0008-5472.CAN-04-1013 15520202
Uhl, M. et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64, 7954–7961 (2004).15520202 10.1158/0008-5472.CAN-04-1013
1022. Tanaka H Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity Oncol. Rep. 2010 24 1637 1643 10.3892/or_00001028 21042762
Tanaka, H. et al. Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol. Rep. 24, 1637–1643 (2010).21042762 10.3892/or_00001028
1023. Halder SK Beauchamp RD Datta PK A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers Neoplasia 2005 7 509 521 10.1593/neo.04640 15967103
Halder, S. K., Beauchamp, R. D. & Datta, P. K. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 7, 509–521 (2005).15967103 10.1593/neo.04640
1024. Lee JE Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer Biomed. Pharmacother. 2023 162 114716 10.1016/j.biopha.2023.114716 37086509
Lee, J. E. et al. Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer. Biomed. Pharmacother. 162, 114716 (2023).37086509 10.1016/j.biopha.2023.114716
1025. Zhang P The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment Biomaterials 2022 284 121518 10.1016/j.biomaterials.2022.121518 35462305
Zhang, P. et al. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials 284, 121518 (2022).35462305 10.1016/j.biomaterials.2022.121518
1026. Chen J TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer Pharm. Res 2023 40 689 699 10.1007/s11095-022-03461-1 36539669
Chen, J. et al. TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer. Pharm. Res 40, 689–699 (2023).36539669 10.1007/s11095-022-03461-1
1027. Fu K SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model Arterioscler Thromb. Vasc. Biol. 2008 28 665 671 10.1161/ATVBAHA.107.158030 18202322
Fu, K. et al. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb. Vasc. Biol. 28, 665–671 (2008).18202322 10.1161/ATVBAHA.107.158030
1028. Engebretsen KV Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5 J. Mol. Cell Cardiol. 2014 76 148 157 10.1016/j.yjmcc.2014.08.008 25169971
Engebretsen, K. V. et al. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. J. Mol. Cell Cardiol. 76, 148–157 (2014).25169971 10.1016/j.yjmcc.2014.08.008
1029. Atis M Targeting the blood-brain barrier disruption in hypertension by ALK5/TGF-Β type I receptor inhibitor SB-431542 and dynamin inhibitor dynasore Brain Res 2022 1794 148071 10.1016/j.brainres.2022.148071 36058283
Atis, M. et al. Targeting the blood-brain barrier disruption in hypertension by ALK5/TGF-Β type I receptor inhibitor SB-431542 and dynamin inhibitor dynasore. Brain Res 1794, 148071 (2022).36058283 10.1016/j.brainres.2022.148071
1030. Wu D TGF-β1-PML SUMOylation-peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) form a positive feedback loop to regulate cardiac fibrosis J. Cell Physiol. 2019 234 6263 6273 10.1002/jcp.27357 30246389
Wu, D. et al. TGF-β1-PML SUMOylation-peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) form a positive feedback loop to regulate cardiac fibrosis. J. Cell Physiol. 234, 6263–6273 (2019).30246389 10.1002/jcp.27357
1031. Ha KB EW-7197 Attenuates the Progression of Diabetic Nephropathy in db/db Mice through Suppression of Fibrogenesis and Inflammation Endocrinol. Metab. (Seoul.) 2022 37 96 111 10.3803/EnM.2021.1305 35255604
Ha, K. B. et al. EW-7197 Attenuates the Progression of Diabetic Nephropathy in db/db Mice through Suppression of Fibrogenesis and Inflammation. Endocrinol. Metab. (Seoul.) 37, 96–111 (2022).35255604 10.3803/EnM.2021.1305
1032. Nassar K A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy Exp. Eye Res 2014 123 72 86 10.1016/j.exer.2014.04.006 24742493
Nassar, K. et al. A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy. Exp. Eye Res 123, 72–86 (2014).24742493 10.1016/j.exer.2014.04.006
1033. Maeda S Hayashi M Komiya S Imamura T Miyazono K Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells Embo j. 2004 23 552 563 10.1038/sj.emboj.7600067 14749725
Maeda, S., Hayashi, M., Komiya, S., Imamura, T. & Miyazono, K. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. Embo j. 23, 552–563 (2004).14749725 10.1038/sj.emboj.7600067
1034. Lee AJ Sustained Delivery of SB-431542, a Type I Transforming Growth Factor Beta-1 Receptor Inhibitor, to Prevent Arthrofibrosis Tissue Eng. Part A 2021 27 1411 1421 10.1089/ten.tea.2021.0029 33752445
Lee, A. J. et al. Sustained Delivery of SB-431542, a Type I Transforming Growth Factor Beta-1 Receptor Inhibitor, to Prevent Arthrofibrosis. Tissue Eng. Part A 27, 1411–1421 (2021).33752445 10.1089/ten.tea.2021.0029
1035. Anscher MS Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury Int J. Radiat. Oncol. Biol. Phys. 2008 71 829 837 10.1016/j.ijrobp.2008.02.046 18411002
Anscher, M. S. et al. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int J. Radiat. Oncol. Biol. Phys. 71, 829–837 (2008).18411002 10.1016/j.ijrobp.2008.02.046
1036. Park SA EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling Cell Mol. Life Sci. 2015 72 2023 2039 10.1007/s00018-014-1798-6 25487606
Park, S. A. et al. EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling. Cell Mol. Life Sci. 72, 2023–2039 (2015).25487606 10.1007/s00018-014-1798-6
1037. Alyoussef A Blocking TGF-β type 1 receptor partially reversed skin tissue damage in experimentally induced atopic dermatitis in mice Cytokine 2018 106 45 53 10.1016/j.cyto.2018.02.025 29549723
Alyoussef, A. Blocking TGF-β type 1 receptor partially reversed skin tissue damage in experimentally induced atopic dermatitis in mice. Cytokine 106, 45–53 (2018).29549723 10.1016/j.cyto.2018.02.025
1038. Binabaj MM EW-7197 prevents ulcerative colitis-associated fibrosis and inflammation J. Cell Physiol. 2019 234 11654 11661 10.1002/jcp.27823 30478959
Binabaj, M. M. et al. EW-7197 prevents ulcerative colitis-associated fibrosis and inflammation. J. Cell Physiol. 234, 11654–11661 (2019).30478959 10.1002/jcp.27823
1039. Ko HK The role of transforming growth factor-β2 in cigarette smoke-induced lung inflammation and injury Life Sci. 2023 320 121539 10.1016/j.lfs.2023.121539 36870385
Ko, H. K. et al. The role of transforming growth factor-β2 in cigarette smoke-induced lung inflammation and injury. Life Sci. 320, 121539 (2023).36870385 10.1016/j.lfs.2023.121539
1040. Waghabi MC Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas’ disease Antimicrob. Agents Chemother. 2009 53 4694 4701 10.1128/AAC.00580-09 19738024
Waghabi, M. C. et al. Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas’ disease. Antimicrob. Agents Chemother. 53, 4694–4701 (2009).19738024 10.1128/AAC.00580-09
1041. Waghabi MC SB-431542, a transforming growth factor beta inhibitor, impairs Trypanosoma cruzi infection in cardiomyocytes and parasite cycle completion Antimicrob. Agents Chemother. 2007 51 2905 2910 10.1128/AAC.00022-07 17526757
Waghabi, M. C. et al. SB-431542, a transforming growth factor beta inhibitor, impairs Trypanosoma cruzi infection in cardiomyocytes and parasite cycle completion. Antimicrob. Agents Chemother. 51, 2905–2910 (2007).17526757 10.1128/AAC.00022-07
1042. Mezger MC Inhibitors of Activin Receptor-like Kinase 5 Interfere with SARS-CoV-2 S-Protein Processing and Spike-Mediated Cell Fusion via Attenuation of Furin Expression Viruses 2022 14 1308 10.3390/v14061308 35746781
Mezger, M. C. et al. Inhibitors of Activin Receptor-like Kinase 5 Interfere with SARS-CoV-2 S-Protein Processing and Spike-Mediated Cell Fusion via Attenuation of Furin Expression. Viruses 14, 1308 (2022).35746781 10.3390/v14061308
1043. Xiao YQ Liu K Shen JF Xu GT Ye W SB-431542 inhibition of scar formation after filtration surgery and its potential mechanism Invest Ophthalmol. Vis. Sci. 2009 50 1698 1706 10.1167/iovs.08-1675 19098325
Xiao, Y. Q., Liu, K., Shen, J. F., Xu, G. T. & Ye, W. SB-431542 inhibition of scar formation after filtration surgery and its potential mechanism. Invest Ophthalmol. Vis. Sci. 50, 1698–1706 (2009).19098325 10.1167/iovs.08-1675
1044. Hasegawa T Nakao A Sumiyoshi K Tsuchihashi H Ogawa H SB-431542 inhibits TGF-beta-induced contraction of collagen gel by normal and keloid fibroblasts J. Dermatol Sci. 2005 39 33 38 10.1016/j.jdermsci.2005.01.013 15978417
Hasegawa, T., Nakao, A., Sumiyoshi, K., Tsuchihashi, H. & Ogawa, H. SB-431542 inhibits TGF-beta-induced contraction of collagen gel by normal and keloid fibroblasts. J. Dermatol Sci. 39, 33–38 (2005).15978417 10.1016/j.jdermsci.2005.01.013
1045. Soleimani A Novel oral transforming growth factor-β signaling inhibitor potently inhibits postsurgical adhesion band formation J. Cell Physiol. 2020 235 1349 1357 10.1002/jcp.29053 31313829
Soleimani, A. et al. Novel oral transforming growth factor-β signaling inhibitor potently inhibits postsurgical adhesion band formation. J. Cell Physiol. 235, 1349–1357 (2020).31313829 10.1002/jcp.29053
1046. Monteleone G Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease Mol. Ther. 2012 20 870 876 10.1038/mt.2011.290 22252452
Monteleone, G. et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease. Mol. Ther. 20, 870–876 (2012).22252452 10.1038/mt.2011.290
1047. Monteleone G Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease N. Engl. J. Med 2015 372 1104 1113 10.1056/NEJMoa1407250 25785968
Monteleone, G. et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N. Engl. J. Med 372, 1104–1113 (2015).25785968 10.1056/NEJMoa1407250
1048. Sands BE Mongersen (GED-0301) for Active Crohn’s Disease: Results of a Phase 3 Study Am. J. Gastroenterol. 2020 115 738 745 10.14309/ajg.0000000000000493 31850931
Sands, B. E. et al. Mongersen (GED-0301) for Active Crohn’s Disease: Results of a Phase 3 Study. Am. J. Gastroenterol. 115, 738–745 (2020).31850931 10.14309/ajg.0000000000000493
1049. Huo, D., Bi, X. Y., Zeng, J. L., Dai, D. M. & Dong, X. L. Drugs targeting TGF-β/Notch interaction attenuate hypertrophic scar formation by optic atrophy 1-mediated mitochondrial fusion. Mol. Cell Biochem.10.1007/s11010-023-04912-y (2023).
1050. Zhang C Mitomycin C induces pulmonary vascular endothelial-to-mesenchymal transition and pulmonary veno-occlusive disease via Smad3-dependent pathway in rats Br. J. Pharm. 2021 178 217 235 10.1111/bph.15314
Zhang, C. et al. Mitomycin C induces pulmonary vascular endothelial-to-mesenchymal transition and pulmonary veno-occlusive disease via Smad3-dependent pathway in rats. Br. J. Pharm. 178, 217–235 (2021).10.1111/bph.15314
1051. Meng J Treatment of Hypertensive Heart Disease by Targeting Smad3 Signaling in Mice Mol. Ther. Methods Clin. Dev. 2020 18 791 802 10.1016/j.omtm.2020.08.003 32953930
Meng, J. et al. Treatment of Hypertensive Heart Disease by Targeting Smad3 Signaling in Mice. Mol. Ther. Methods Clin. Dev. 18, 791–802 (2020).32953930 10.1016/j.omtm.2020.08.003
1052. Liu S Suppression of TGFβR-Smad3 pathway alleviates the syrinx induced by syringomyelia Cell Biosci. 2023 13 98 10.1186/s13578-023-01048-w 37248485
Liu, S. et al. Suppression of TGFβR-Smad3 pathway alleviates the syrinx induced by syringomyelia. Cell Biosci. 13, 98 (2023).37248485 10.1186/s13578-023-01048-w
1053. Ji X Specific Inhibitor of Smad3 (SIS3) Attenuates Fibrosis, Apoptosis, and Inflammation in Unilateral Ureteral Obstruction Kidneys by Inhibition of Transforming Growth Factor β (TGF-β)/Smad3 Signaling Med Sci. Monit. 2018 24 1633 1641 10.12659/MSM.909236 29555895
Ji, X. et al. Specific Inhibitor of Smad3 (SIS3) Attenuates Fibrosis, Apoptosis, and Inflammation in Unilateral Ureteral Obstruction Kidneys by Inhibition of Transforming Growth Factor β (TGF-β)/Smad3 Signaling. Med Sci. Monit. 24, 1633–1641 (2018).29555895 10.12659/MSM.909236
1054. Zhang Y Meng XM Huang XR Lan HY The preventive and therapeutic implication for renal fibrosis by targetting TGF-β/Smad3 signaling Clin. Sci. (Lond.) 2018 132 1403 1415 10.1042/CS20180243 29875262
Zhang, Y., Meng, X. M., Huang, X. R. & Lan, H. Y. The preventive and therapeutic implication for renal fibrosis by targetting TGF-β/Smad3 signaling. Clin. Sci. (Lond.) 132, 1403–1415 (2018).29875262 10.1042/CS20180243
1055. Pan W SIS3 suppresses osteoclastogenesis and ameliorates bone loss in ovariectomized mice by modulating Nox4-dependent reactive oxygen species Biochem Pharm. 2022 195 114846 10.1016/j.bcp.2021.114846 34801525
Pan, W. et al. SIS3 suppresses osteoclastogenesis and ameliorates bone loss in ovariectomized mice by modulating Nox4-dependent reactive oxygen species. Biochem Pharm. 195, 114846 (2022).34801525 10.1016/j.bcp.2021.114846
1056. Shou J SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice Biochem Biophys. Res Commun. 2018 503 757 762 10.1016/j.bbrc.2018.06.072 29913150
Shou, J. et al. SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice. Biochem Biophys. Res Commun. 503, 757–762 (2018).29913150 10.1016/j.bbrc.2018.06.072
1057. Rudnik M Elevated Fibronectin Levels in Profibrotic CD14(+) Monocytes and CD14(+) Macrophages in Systemic Sclerosis Front Immunol. 2021 12 642891 10.3389/fimmu.2021.642891 34504485
Rudnik, M. et al. Elevated Fibronectin Levels in Profibrotic CD14(+) Monocytes and CD14(+) Macrophages in Systemic Sclerosis. Front Immunol. 12, 642891 (2021).34504485 10.3389/fimmu.2021.642891
1058. Xiang W Inhibition of SMAD3 effectively reduces ADAMTS-5 expression in the early stages of osteoarthritis BMC Musculoskelet. Disord. 2023 24 130 10.1186/s12891-022-05949-8 36803799
Xiang, W. et al. Inhibition of SMAD3 effectively reduces ADAMTS-5 expression in the early stages of osteoarthritis. BMC Musculoskelet. Disord. 24, 130 (2023).36803799 10.1186/s12891-022-05949-8
1059. He H Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling Int J. Biol. Sci. 2024 20 200 217 10.7150/ijbs.87820 38164169
He, H. et al. Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling. Int J. Biol. Sci. 20, 200–217 (2024).38164169 10.7150/ijbs.87820
1060. He H Smad3 Mediates Diabetic Dyslipidemia and Fatty Liver in db/db Mice by Targeting PPARδ Int J. Mol. Sci. 2023 24 11396 10.3390/ijms241411396 37511155
He, H. et al. Smad3 Mediates Diabetic Dyslipidemia and Fatty Liver in db/db Mice by Targeting PPARδ. Int J. Mol. Sci. 24, 11396 (2023).37511155 10.3390/ijms241411396
1061. Wu CP SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines Cancer Lett. 2018 433 259 272 10.1016/j.canlet.2018.07.004 30026175
Wu, C. P. et al. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Lett. 433, 259–272 (2018).30026175 10.1016/j.canlet.2018.07.004
1062. Chihara Y A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells Breast Cancer Res Treat. 2017 166 55 68 10.1007/s10549-017-4382-6 28702892
Chihara, Y. et al. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells. Breast Cancer Res Treat. 166, 55–68 (2017).28702892 10.1007/s10549-017-4382-6
1063. Conidi A van den Berghe V Huylebroeck D Aptamers and their potential to selectively target aspects of EGF, Wnt/beta-catenin and TGFbeta-smad family signaling Int J. Mol. Sci. 2013 14 6690 6719 10.3390/ijms14046690 23531534
Conidi, A., van den Berghe, V. & Huylebroeck, D. Aptamers and their potential to selectively target aspects of EGF, Wnt/beta-catenin and TGFbeta-smad family signaling. Int J. Mol. Sci. 14, 6690–6719 (2013).23531534 10.3390/ijms14046690
1064. Lim SK Hoffmann FM Smad4 cooperates with lymphoid enhancer-binding factor 1/T cell-specific factor to increase c-myc expression in the absence of TGF-beta signaling Proc. Natl Acad. Sci. USA 2006 103 18580 18585 10.1073/pnas.0604773103 17132729
Lim, S. K. & Hoffmann, F. M. Smad4 cooperates with lymphoid enhancer-binding factor 1/T cell-specific factor to increase c-myc expression in the absence of TGF-beta signaling. Proc. Natl Acad. Sci. USA 103, 18580–18585 (2006).17132729 10.1073/pnas.0604773103
1065. Zhao BM Hoffmann FM Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA Mol. Biol. Cell 2006 17 3819 3831 10.1091/mbc.e05-10-0990 16775010
Zhao, B. M. & Hoffmann, F. M. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol. Biol. Cell 17, 3819–3831 (2006).16775010 10.1091/mbc.e05-10-0990
1066. Huang C Expression, purification, and functional characterization of recombinant PTD-SARA Acta Biochim Biophys. Sin. (Shanghai) 2011 43 110 117 10.1093/abbs/gmq122 21266541
Huang, C. et al. Expression, purification, and functional characterization of recombinant PTD-SARA. Acta Biochim Biophys. Sin. (Shanghai) 43, 110–117 (2011).21266541 10.1093/abbs/gmq122
1067. Ji WP Dong Y Targeting Yes-associated Protein with Evolved Peptide Aptamers to Disrupt TGF-beta Signaling Pathway: Therapeutic Implication for Bone Tumor Mol. Inf. 2015 34 771 777 10.1002/minf.201500063
Ji, W. P. & Dong, Y. Targeting Yes-associated Protein with Evolved Peptide Aptamers to Disrupt TGF-beta Signaling Pathway: Therapeutic Implication for Bone Tumor. Mol. Inf. 34, 771–777 (2015).10.1002/minf.201500063
1068. Cheifetz S Heterodimeric transforming growth factor beta. Biological properties and interaction with three types of cell surface receptors J. Biol. Chem. 1988 263 10783 10789 10.1016/S0021-9258(18)38039-6 2899081
Cheifetz, S. et al. Heterodimeric transforming growth factor beta. Biological properties and interaction with three types of cell surface receptors. J. Biol. Chem. 263, 10783–10789 (1988).2899081 10.1016/S0021-9258(18)38039-6
1069. Goumans MJ Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors Embo j. 2002 21 1743 1753 10.1093/emboj/21.7.1743 11927558
Goumans, M. J. et al. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. Embo j. 21, 1743–1753 (2002).11927558 10.1093/emboj/21.7.1743
1070. van den Bosch MH Canonical Wnt signaling skews TGF-β signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8 Cell Signal 2014 26 951 958 10.1016/j.cellsig.2014.01.021 24463008
van den Bosch, M. H. et al. Canonical Wnt signaling skews TGF-β signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8. Cell Signal 26, 951–958 (2014).24463008 10.1016/j.cellsig.2014.01.021
1071. Pannu J Nakerakanti S Smith E ten Dijke P Trojanowska M Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways J. Biol. Chem. 2007 282 10405 10413 10.1074/jbc.M611742200 17317656
Pannu, J., Nakerakanti, S., Smith, E., ten Dijke, P. & Trojanowska, M. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J. Biol. Chem. 282, 10405–10413 (2007).17317656 10.1074/jbc.M611742200
1072. Bharathy S Xie W Yingling JM Reiss M Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype Cancer Res 2008 68 1656 1666 10.1158/0008-5472.CAN-07-5089 18339844
Bharathy, S., Xie, W., Yingling, J. M. & Reiss, M. Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype. Cancer Res 68, 1656–1666 (2008).18339844 10.1158/0008-5472.CAN-07-5089
1073. Daly AC Randall RA Hill CS Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth Mol. Cell Biol. 2008 28 6889 6902 10.1128/MCB.01192-08 18794361
Daly, A. C., Randall, R. A. & Hill, C. S. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol. Cell Biol. 28, 6889–6902 (2008).18794361 10.1128/MCB.01192-08
1074. Hussein YM Mohamed RH El-Shahawy EE Alzahrani SS Interaction between TGF-β1 (869C/T) polymorphism and biochemical risk factor for prediction of disease progression in rheumatoid arthritis Gene 2014 536 393 397 10.1016/j.gene.2013.11.042 24315820
Hussein, Y. M., Mohamed, R. H., El-Shahawy, E. E. & Alzahrani, S. S. Interaction between TGF-β1 (869C/T) polymorphism and biochemical risk factor for prediction of disease progression in rheumatoid arthritis. Gene 536, 393–397 (2014).24315820 10.1016/j.gene.2013.11.042
1075. Nakao E Elevated Plasma Transforming Growth Factor β1 Levels Predict the Development of Hypertension in Normotensives: The 14-Year Follow-Up Study Am. J. Hypertens. 2017 30 808 814 10.1093/ajh/hpx053 28575138
Nakao, E. et al. Elevated Plasma Transforming Growth Factor β1 Levels Predict the Development of Hypertension in Normotensives: The 14-Year Follow-Up Study. Am. J. Hypertens. 30, 808–814 (2017).28575138 10.1093/ajh/hpx053
1076. Kanzler S Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta J. Viral Hepat. 2001 8 430 437 10.1046/j.1365-2893.2001.00314.x 11703574
Kanzler, S. et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J. Viral Hepat. 8, 430–437 (2001).11703574 10.1046/j.1365-2893.2001.00314.x
1077. Wei Y Tian Q Zhao X Wang X Serum transforming growth factor beta 3 predicts future development of nonalcoholic fatty liver disease Int J. Clin. Exp. Med 2015 8 4545 4550 26064382
Wei, Y., Tian, Q., Zhao, X. & Wang, X. Serum transforming growth factor beta 3 predicts future development of nonalcoholic fatty liver disease. Int J. Clin. Exp. Med 8, 4545–4550 (2015).26064382
1078. Wu CY Li L Zhang LH Detection of serum MCP-1 and TGF-β1 in polymyositis/dermatomyositis patients and its significance Eur. J. Med Res 2019 24 12 10.1186/s40001-019-0368-7 30764873
Wu, C. Y., Li, L. & Zhang, L. H. Detection of serum MCP-1 and TGF-β1 in polymyositis/dermatomyositis patients and its significance. Eur. J. Med Res 24, 12 (2019).30764873 10.1186/s40001-019-0368-7
1079. Boix F A high concentration of TGF-β correlates with opportunistic infection in liver and kidney transplantation Hum. Immunol. 2021 82 414 421 10.1016/j.humimm.2021.03.007 33814194
Boix, F. et al. A high concentration of TGF-β correlates with opportunistic infection in liver and kidney transplantation. Hum. Immunol. 82, 414–421 (2021).33814194 10.1016/j.humimm.2021.03.007
1080. Leppäpuska IM Low TGF-β1 in Wound Exudate Predicts Surgical Site Infection After Axillary Lymph Node Dissection J. Surg. Res 2021 267 302 308 10.1016/j.jss.2021.05.039 34175584
Leppäpuska, I. M. et al. Low TGF-β1 in Wound Exudate Predicts Surgical Site Infection After Axillary Lymph Node Dissection. J. Surg. Res 267, 302–308 (2021).34175584 10.1016/j.jss.2021.05.039
1081. Capuano A Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis Arthritis Rheum. 2006 54 3633 3639 10.1002/art.22192 17075808
Capuano, A. et al. Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis Rheum. 54, 3633–3639 (2006).17075808 10.1002/art.22192
1082. Daïen CI TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis Jt. Bone Spine 2012 79 471 475 10.1016/j.jbspin.2011.10.007
Daïen, C. I. et al. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Jt. Bone Spine 79, 471–475 (2012).10.1016/j.jbspin.2011.10.007
1083. Sambuelli A Serum transforming growth factor-beta1 levels increase in response to successful anti-inflammatory therapy in ulcerative colitis Aliment Pharm. Ther. 2000 14 1443 1449 10.1046/j.1365-2036.2000.00861.x
Sambuelli, A. et al. Serum transforming growth factor-beta1 levels increase in response to successful anti-inflammatory therapy in ulcerative colitis. Aliment Pharm. Ther. 14, 1443–1449 (2000).10.1046/j.1365-2036.2000.00861.x
1084. Rodrigues-Junior DM Circulating extracellular vesicle-associated TGFβ3 modulates response to cytotoxic therapy in head and neck squamous cell carcinoma Carcinogenesis 2019 40 1452 1461 31436806
Rodrigues-Junior, D. M. et al. Circulating extracellular vesicle-associated TGFβ3 modulates response to cytotoxic therapy in head and neck squamous cell carcinoma. Carcinogenesis 40, 1452–1461 (2019).31436806
1085. Scarpa M TGF-beta1 and IGF-1 production and recurrence of Crohn’s disease after ileo-colonic resection J. Surg. Res 2009 152 26 34 10.1016/j.jss.2008.04.014 19027918
Scarpa, M. et al. TGF-beta1 and IGF-1 production and recurrence of Crohn’s disease after ileo-colonic resection. J. Surg. Res 152, 26–34 (2009).19027918 10.1016/j.jss.2008.04.014
1086. Scarpa M TGF-beta1 and IGF-1 and anastomotic recurrence of Crohn’s disease after ileo-colonic resection J. Gastrointest. Surg. 2008 12 1981 1990 10.1007/s11605-008-0641-5 18704594
Scarpa, M. et al. TGF-beta1 and IGF-1 and anastomotic recurrence of Crohn’s disease after ileo-colonic resection. J. Gastrointest. Surg. 12, 1981–1990 (2008).18704594 10.1007/s11605-008-0641-5
1087. Memon AA Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism J. Thromb. Thrombolysis 2014 38 348 354 10.1007/s11239-013-1047-0 24402195
Memon, A. A. et al. Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism. J. Thromb. Thrombolysis 38, 348–354 (2014).24402195 10.1007/s11239-013-1047-0
1088. Mattey DL Nixon N Dawes PT Kerr J Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis Ann. Rheum. Dis. 2005 64 1190 1194 10.1136/ard.2004.031674 15695537
Mattey, D. L., Nixon, N., Dawes, P. T. & Kerr, J. Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis. Ann. Rheum. Dis. 64, 1190–1194 (2005).15695537 10.1136/ard.2004.031674
1089. Watanabe Y Transforming Growth Factor-β1 as a Predictor for the Development of Hepatocellular Carcinoma: A Nested Case-Controlled Study EBioMedicine 2016 12 68 71 10.1016/j.ebiom.2016.09.001 27614396
Watanabe, Y. et al. Transforming Growth Factor-β1 as a Predictor for the Development of Hepatocellular Carcinoma: A Nested Case-Controlled Study. EBioMedicine 12, 68–71 (2016).27614396 10.1016/j.ebiom.2016.09.001
1090. Ikeguchi M Iwamoto A Taniguchi K Katano K Hirooka Y The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma J. Exp. Clin. Cancer Res 2005 24 415 421 16270528
Ikeguchi, M., Iwamoto, A., Taniguchi, K., Katano, K. & Hirooka, Y. The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma. J. Exp. Clin. Cancer Res 24, 415–421 (2005).16270528
1091. Wu X Development of a TGF-β signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma Front Oncol. 2023 13 1124080 10.3389/fonc.2023.1124080 36776317
Wu, X. et al. Development of a TGF-β signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma. Front Oncol. 13, 1124080 (2023).36776317 10.3389/fonc.2023.1124080
